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« Comment se fait une vie? Quelle est la part des circonstances, de la nécessité, du hasard, des 
choix et des initiatives du sujet? » 
 
“How is a life formed? How much of it is made up by circumstance, how much by necessity, how 
much by chance, and how much by the subject’s own options and personal initiatives?” 
 
Simone de Beauvoir, Tout compte fait (1972) 
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Abstract 
Background: The relationships between human papillomavirus (HPV) and HIV, in an African 
context are limited. Given the large number of women living with HIV (WLHIV) accessing 
antiretroviral therapy (ART), it is important to establish associations of HIV-related factors with 
high-risk (HR)-HPV and cervical intraepithelial neoplasia (CIN).  
Design: Prospective cohort of WLHIV attending HIV treatment centres in Ouagadougou, Burkina 
Faso (BF) and Johannesburg, South Africa (SA).  
Methods: At baseline and endline (median 16 months), cervical samples and biopsies were 
analyzed for HPV genotyping (InnoLiPA) and by histology. HPV serology targeting 15 HPV types (12 
HR) was by multiplexed pseudovirion-based serological assay. Methylation of a human gene 
EPB41L3 and HPV16 was measured by pyrosequencing. Logistic regression was used to estimate 
associations of HIV-related factors with HR-HPV and CIN2+ outcomes.  
Results: Among 1238 enrolled WLHIV (BF=615; SA=623) HR-HPV prevalence was 59.1% in BF and 
79.1% in SA. CIN2+ prevalence was 5.8% in BF and 22.5% in SA. Prolonged ART use (>2 years) was 
associated with lower HR-HPV prevalence in BF and lower CIN2+ prevalence compared to short-
duration ART users and ART-naïve participants in SA.  
Among 963 (77.8%) women seen at endline, HR-HPV persistence was 41.1% in BF and 30.2% in SA; 
CIN2+ incidence over 16-months was 1.2% in BF and 5.8% in SA. HR-HPV persistence was lower 
among those with prolonged ART compared to ART-naïve and short-duration ART users. CIN2+ 
incidence was reduced among women on ART in SA.  
HPV seroprevalence and seropersistence were high (93% and 95%, respectively).  Seroconversion 
was 23.1%, and was higher among recent ART users (≤2 years) and among those with type-specific 
DNA persistence compared to those who cleared infection.  
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The human gene EPB41L3 showed elevated methylation in CIN2+ compared to ≤CIN1 (Mann 
Whitney U p=<0.001) at baseline. Higher methylation levels were found among recent ART users 
(≤2 years) and women with CD4 ≤200 cells/mm3.  
 
Conclusion: WLHIV in BF and SA have high rates of HR-HPV and CIN2+, and WLHIV in SA have higher 
CIN2+, linked with poorer control of HIV and higher frequency of cofactors for HR-HPV and CIN2+. 
Prolonged and effective ART is important in controlling HR-HPV and the development of CIN2+. 
WLHIV are infected with multiple HR-HPV types and there is limited evidence that HPV antibodies 
protect against same-type reinfection. WLHIV may benefit from vaccination using a multivalent 
vaccine. DNA methylation of a tumour suppressor gene EPB41L3 is elevated among women with 
CIN2+ and shows promise as a biomarker test for CIN2+ prediction among WLHIV.  
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1 INTRODUCTION 
1.1 Background and Rationale for the thesis 
Invasive cervical cancer (ICC) is the most common female cancer in low and middle-income 
countries [1], where 85% of the estimated 500,000 global annual cases occur [1, 2] and is the leading 
cause of cancer deaths among African women [3]. Cervical intraepithelial neoplasia (CIN) is an early 
stage of cancer of the cervix, which is curable if detected early. There is international consensus 
that persistent infection by HPV types designated as high-risk (HR), including genotypes 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, is necessary for the development of squamous intraepithelial 
lesions (SIL) and cervical intraepithelial neoplasia (CIN) [4, 5]. SIL of low or high grade represent 
abnormal growth of squamous epithelial cells in a cytology reading, while CIN grades 1 to 3 describe 
the proportion and thickness of abnormal cells in a cervical biopsy section.    
Cervical cancer incidence and mortality have declined in many high-income countries over the past 
40 years as a result of widespread routine screening, treatment of precancerous lesions and 
improved socioeconomic status [6]. HPV vaccines targeting HR types associated with ICC 
(HPV16/18/31/33/45/52/58) and two low risk types implicated in anogenital warts (HPV 6 and 11) are 
licensed for use among girls from the age of nine years, and are widely implemented in high-income 
settings. However, ICC incidence and mortality remains high in low and middle-income countries 
(LIMC), where few have organised screening services and HPV vaccination programmes in place. 
Furthermore, the availability of services for the management of ICC is limited due to lack of skilled 
staff, surgical equipment and radiation facilities [3].  
The Sub-Saharan African (SSA) region has both the highest incidence of ICC and the highest 
prevalence of HIV (Figure 1.1). ICC ranks as one of the most common neoplasms among women 
living with HIV (WLHIV) and is considered an AIDS-defining illness [7, 8]. Opportunities for control, 
early detection and prevention of HPV and related cervical neoplasia among WLHIV are available, 
although they are limited or inadequately implemented.     
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Figure 1.1. HIV prevalence among women aged 15-49 years (red) and age-standardised incidence 
of cervical cancer (blue) worldwide (panel A) and in Africa (panel B) 
                             
                 
Cervical cancer incidence rates from IARC GLOBOCAN 2012 [9]; prevalence of HIV from UNAIDS, 2015 [10]; *ASR=Age-standardised rate 
 
With the advent of the antiretroviral therapy (ART) era, the incidence of other AIDS-defining 
cancers has decreased, however the impact on cervical cancer and its precursor lesions is less clear. 
In a recent systematic review of observational studies evaluating the incidence of malignancies 
before and after the introduction of ART in people with HIV/AIDS, the risk for the development of 
Kaposi's sarcoma decreased by 70% (Risk Ratio [RR]=0.30, 95% Confidence Interval [CI]: 0.28-0.33) 
and 48% for non-Hodgkin's lymphoma (RR=0.52, 95% CI: 0.48-0.56), but a 1.5-fold increased risk was 
observed for invasive cervical cancer (RR=1.46, 95% CI: 1.09-1.94)[11].  As ART becomes more widely 
available in Africa, longer survival times may increase the rates of cervical cancer as many women 
remain susceptible to HR-HPV acquisition and persistence and consequently are at an increased 
risk for CIN or SIL incidence and progression. Given the large number of WLHIV now accessing ART 
in Africa, it is important to establish the impact that ART and other HIV-related factors have on the 
 
(B) 
 
(A) 
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natural history of HPV infection and CIN progression, as this may influence cervical cancer control 
strategies.  
Current HPV vaccines offer potential for cervical cancer prevention by targeting the HR-HPV types 
associated with ICC. Although there are no data yet available on HPV vaccine efficacy among HIV-
positive persons, HPV vaccines have been reported to be safe and immunogenic in HIV-positive 
children, female adolescents and adults [12]. Recent meta-analyses have shown that the HPV types 
associated with high-grade SIL (≥HSIL) and ICC are similar among WLHIV and HIV-negative women 
[13, 14]. However, data on HPV genotypes associated with CIN grade 2 and 3 (CIN2/3) are limited 
among WLHIV in SSA settings. It is important to assess the distribution of HPV genotypes in cervical 
precursor lesions of WLHIV, in order to establish the potential impact of HPV vaccination on this 
population.   
Furthermore, the seroepidemiology of a wide range of vaccine types and evaluation of current and 
past exposure has seldom been estimated among WLHIV, particularly in SSA. There is also no 
information on antibody responses to natural infection observed longitudinally among WLHIV. An 
improved understanding of 1.) exposure to vaccine-related HPV types, and 2.) whether past 
exposure protects against same-type re-infection would be useful to understand the value of HPV 
vaccines in this population.  
Finally, there is a need for better biomarkers for earlier detection of CIN grade 2 and higher (CIN2+), 
in order to avoid late stage development and subsequent expensive colposcopy/biopsy and 
treatment, particularly in low resource settings [1]. Epigenetic mechanisms, such as DNA 
methylation of human genes and the HPV virus itself have recently been shown to distinguish non-
progressive HPV infections from those that progress to cancer among HIV-negative women [15, 
16]. DNA methylation has rarely been studied among WLHIV [17], and its association with CIN2+, 
and the influence of HIV-related factors has never before been prospectively evaluated.  
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Study 3 Study 1 Study 2 
1.2 Aims and Objectives of the Thesis 
Aims 
In a cohort of women living with HIV-1 enrolled in the HARP (HPV in Africa Research Partnership) 
study in Burkina Faso and South Africa and followed-up over 18 months, I aim to evaluate the 
influence of HIV-related factors (ART, CD4+ cell count and HIV-1 plasma viral load [PVL]) and other 
known risk factors on the epidemiology of HR-HPV and high-grade cervical intraepithelial neoplasia 
(CIN2+) (STUDY 1); to evaluate the prevalence, incidence and persistence of HPV vaccines types 
and their association with CIN2+ (STUDY 2) and to investigate the association of human gene and 
HPV DNA methylation markers with CIN2+ (STUDY 3).   
Each study addresses the value of different control measures that could be used in the pathway 
from HPV infection to CIN2+ as depicted in the box below, including: the prevention of HR-HPV 
infection through HPV vaccination (STUDY 2), control of HR-HPV infection and lesion development 
in part through ART use and control of other cofactors, including sexually transmitted infections 
(STIs) (STUDY 1) and detection of CIN2+ once established (STUDY 3).  
 
 
 
 
 
 
HPV 
vaccination
Prevention 
of 
infection Known RF 
(STIs, hormonal 
contraception) 
HIV factors (ART, 
CD4+, HIV-1 PVL 
Control of 
infection 
and 
precursor 
lesions
DNA 
methylation
Human gene 
& HPV
Screening 
for early 
detection
Normal
HR-HPV Incident 
infection
HR-HPV 
Persistence
Incident CIN2+
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Specific Objectives 
Two systematic reviews will be performed with the following objectives (summarised in Table 
1.1):  
1.1 To evaluate the association of ART with HR-HPV prevalence, and with cervical lesion 
prevalence, incidence, progression and regression (Chapter 3) 
1.2 To summarise the association of DNA methylation (of human genes and HPV16) with cervical 
intraepithelial lesions and invasive cervical cancer (Chapter 4) 
Three studies will be conducted to address the following objectives (summarised in Table 1.1):  
 
STUDY 1 (Chapters 6 and 7) 
Using cross-sectional and prospective data collected in the HARP study, this study will describe:  
 
[Chapter 6]: 
2.1 the prevalence and persistence of HR-HPV infection;  
2.2 the prevalence and incidence of CIN2+;  
2.3 the associations of HR-HPV and CIN2+ prevalence with socio-demographic, behavioural and 
sexual behavioural factors, and other STIs; 
[Chapter 7]:   
2.4 the associations of HR-HPV prevalence and persistence, and CIN2+ prevalence and incidence 
with HIV-related factors (ART, CD4+ cell count, HIV-1 PVL).  
 
 
 
 
6 
 
 
 
STUDY 2 (Chapters 8 and 9) 
Using cross-sectional and prospective data collected in the HARP study, this study will describe: 
[Chapter 8]:  
3.1 the prevalence, incidence and persistence of individual HPV genotypes;  
3.2 their association with prevalent and incident CIN grade 2 and higher (CIN2+), and persistent 
and regressed CIN2+;  
3.3 the associations of specific HPV types with ART, CD4+ cell count and HIV-1 PVL. 
Using cross-sectional and prospective data collected in the HARP study (in South Africa only), this 
study will describe [Chapter 9]:   
3.4 the seroprevalence of HPV types and association with socio-demographic, behavioural and 
sexual behavioural factors, and other STIs;  
3.5 HPV type seroincidence and seroconversion and determinants, including HPV DNA status at 
baseline and endline, HIV-related factors and other known risk factors;  
3.6 the risk of type specific reinfection according to same type seropositive at baseline. 
 
STUDY 3 (Chapter 10) 
In a nested case-control study using samples collected at baseline and endline from among the 
HARP participants, this study will: 
4.1 determine the association of baseline methylation of a human gene EPB41L3 and HPV16 with 
prevalent CIN2+, and EPB41L3 baseline and endline methylation with incident CIN2+; 
4.2 determine whether EPB41L3 methylation levels at enrolment are influenced by HIV related 
factors (ART, CD4+ cell count, HIV-1 PVL), and other risk factors; 
4.3 monitor the change in EPB41L3 methylation levels over time among CIN2/3 that persist or 
regress.  
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Table 1.1 Project summary 
Objective Outcomes Key exposure Chapter and 
manuscript 
SYSTEMATIC REVIEWS 
1.1 To evaluate the association of ART 
with HR-HPV prevalence, and with 
cervical lesion prevalence, incidence, 
progression and regression 
 HR-HPV prevalence 
 HSIL+/CIN2+ prevalence 
 SIL incidence 
 SIL progression 
 SIL regression 
ART  Chapter 3 
 
[PAPER 1] 
1.2 To summarise the association of DNA 
methylation (human genes and HPV16) 
with cervical intraepithelial lesions and 
invasive cervical cancer 
 CIN2+ DNA methylation of 
human genes and 
HPV16 
Chapter 4 
STUDY 1: Epidemiology of HPV infection and cervical lesions in WLHIV in Burkina Faso and South Africa over 16 months  
2.1 
To describe the prevalence and 
persistence of HR-HPV  
 HR-HPV prevalence 
 HR-HPV persistence 
n/a Chapter 6 
 
[PAPER 2] 
2.2 
To describe the prevalence and 
incidence of CIN2+ 
 CIN2+ prevalence 
 CIN2+ Incidence 
n/a 
2.3 
To evaluate socio-demographic, sex 
behaviour risk factors, and other STIs 
for HR-HPV prevalence and CIN2+ 
prevalence   
 HR-HPV prevalence 
 CIN2+ prevalence 
Known risk factors for 
HR-HPV and CIN2+  
Chapter 6 
2.4 To evaluate the association of HPV 
prevalence and persistence with HIV-
related risk factors  
 HR-HPV prevalence 
 HR-HPV persistence 
ART 
CD4+ cell count 
HIV-1 PVL 
Chapter 7 
 
[PAPER 2] 
To evaluate the association of CIN2+ 
prevalence and incidence with HIV-
related risk factors 
 CIN2+ prevalence 
 CIN2+ Incidence 
ART 
CD4+ cell count 
HIV-1 PVL 
STUDY 2: HPV type specific infection and serodynamics among WLHIV in Burkina Faso and South Africa over 16 months 
3.1 To describe the prevalence, incidence 
and persistence of individual 
genotypes  
 Prevalence, incidence and 
persistence of individual 
genotypes 
n/a Chapter 8 
 
[PAPER 3] 
3.2 
To assess the associations of prevalent 
HPV genotypes with prevalent CIN2+ 
 CIN2+ prevalence Prevalent HPV 
genotypes  
To assess the associations of persistent 
HPV genotypes with incident CIN2+. 
 CIN2+ incidence Persistent HPV 
genotypes  
3.3 
To evaluate the association of 
individual HPV genotype prevalence 
with HIV-related risk factors 
 Prevalence of individual 
genotypes 
ART 
CD4+ cell count 
HIV-1 PVL 
(sub analysis in South Africa only) 
3.4 To describe the seroprevalence of HPV 
genotypes and its determinants 
 HPV type-specific (and 
combined) seroprevalence 
n/a Chapter 9 
 
[PAPER 4] 3.5 To describe type-specific HPV 
seroincidence and seroconversion and 
its determinants 
 Type-specific HPV 
seroconversion 
ART 
CD4+ cell count 
HIV-1 PVL 
3.6 Risk of type-specific re-infection 
following same-type seropositivity at 
baseline 
 Type-specific DNA 
incidence 
Same-type seropositive 
at baseline 
STUDY 3: Association of DNA methylation with prevalent and incident CIN2+ among WLHIV in Burkina Faso and South Africa 
4.1 To determine the association of DNA 
methylation of a human gene EPB41L3 
and HPV16 with CIN2+ prevalence  
 CIN2+ prevalence  EPB41L3 methylation at 
baseline 
Chapter 10 
 
[PAPER 5] 
To determine the association of 
baseline and endline EPB41L3 DNA 
methylation with CIN2+ incidence  
 CIN2+ incidence  EPB41L3 methylation at 
baseline and endline 
4.2 To evaluate the role of HIV-related and 
other risk factors on the EPB41L3 DNA 
methylation at enrolment 
 ‘High’ EPB41L3 DNA 
methylation 
ART 
CD4+ cell count 
HIV-1 PVL 
4.3 
To monitor the change in EPB41L3 DNA 
methylation levels over time among 
CIN2+ that progress vs. regress 
 CIN2+ progression 
 CIN2+ regression 
EPB41L3 methylation at 
baseline and endline 
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1.3 Structure of the thesis 
The thesis is organised in 4 distinct sub-sections, as depicted below.  
 
 
 
This thesis starts in Chapter 1 by providing the rationale and a summary of the aims and objectives 
of this research, as well as the role of the candidate in the research activities.  
Chapters 2, 3 and 4 are review chapters setting out what is already known of HPV and related 
cervical disease in WLHIV. Chapter 2 provides an overview of the epidemiology of HPV infection 
and related cervical disease among WLHIV in comparison to HIV-negative women. This chapter also 
summarises data on cervical cancer incidence globally, as well as in the Sub-Saharan Africa (SSA) 
region, and more specifically in Burkina Faso and South Africa, the two countries which this 
research is set. In order to put this research in context in the two countries, Chapter 2 also provides 
a brief overview of the two countries using demographic and economic data from the World Bank, 
HIV related information using indicators from UNAIDS and finally details on cervical cancer 
screening strategies and HPV vaccination programmes in each of these two countries. 
On reviewing the literature on the associations of HIV-related factors such as ART and CD4+ count 
on HPV infection and related cervical lesions, the data was found to be limited and often conflicting 
and inconsistent. Therefore, Chapter 3 is a systematic review and meta-analysis of data for the 
association of ART on HPV and cervical lesions. The literature on DNA methylation makers 
associated with cervical lesions was similarly heterogeneous and Chapter 4 is a systematic review 
on this topic. The findings of these reviews helped to identify the main research gaps which inform 
the objectives of this research and help put the research findings in this thesis into context.  
Chp.1 Chp.2 Chp.3 Chp.4 Chp.5 Chp.6 Chp.7 Chp.8 Chp.9 Chp.10 Chp.11
Chapters 1-4: 
 
 Introduction and literature 
reviews (Chp 2, 3, 4) 
 Overview of Burkina Faso 
and South Africa (Chp 2) 
Chapters 5 and 6: 
 
 Methodology (Chp 5) 
 Description of study 
participants (Chp 6) 
Chapters 7-10: 
 
 STUDY 1 (Chp 6, 7) 
 STUDY 2 (Chp 8,9) 
 STUDY 3 (Chp 10)  
Chapter 11:  
 
 Discussion  
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Chapter 5 summarises the methodologies used as part of this research thesis, and provides a full 
description of the HARP study design and methods within which this thesis is nested.  
Chapter 6 provides a summary of the HARP study participants at enrolment and at the follow-up. 
This includes a description of the socio-demographic and behavioural factors, sexual behaviour, 
STI screening results, cervical screening history and HIV-related factors. It also describes the HR-
HPV prevalence, incidence and persistence, and CIN2+ prevalence and incidence in these 
populations.  
Chapters 6 to 10 are dedicated to the analyses of this data. Each chapter focusses on different steps 
in the pathway from HPV acquistion to cervical lesion progression. Chapter 6 investigates the 
association of known risk factors (socio-demographic,  behavioural, sexual behaviour, STIs) on HR-
HPV prevalence, incidence, persistence and clearance and CIN2+ prevalence and incidence, while  
Chapter 7 investigates the association of HIV-related factors (ART, CD4+ cell count and HIV-1 PVL) 
on the these outcomes.   
In order to understand the potential impact of HPV vaccines on high-grade cervical lesions, Chapter 
8 describes the prevalence, incidence and persistence of individual HPV genotypes and 
investigates their association with CIN2+ prevalence and incidence. In order to understand past 
exposure of WLHIV to HPV infection and the serodynamics of HPV infection among WLHIV, 
Chapter 9 describes the type-specific seroprevalence of HPV genotypes, the seroconversion rates 
at follow-up following infection at baseline and re-infection rate among those with type-specific 
antibodies at follow-up. This chapter also investigates the association of HIV-related factors, such 
as ART, CD4+ cell count and HIV-1 PVL, with HPV seroconversion.    
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Finally, in order to further understand the role of epigenetic markers such as human gene DNA 
methylation on the natural history of lesion progression, Chapter 10 investigates the association of 
human gene EPB41L3 and HPV16 methylation with CIN2+ prevalence and incidence and explores 
EPB41L3 methylation changes over time among those that develop incident lesion, those that 
progress and spontaneously regress.  
The final section of this thesis, Chapter 11, summarises the key research findings and discusses the 
public health implications in the context of screening and vaccination.    
1.4 Role of the Candidate 
This PhD was undertaken part-time as a staff member at LSHTM. My salary was funded through a 
combination of sources –the European Union (EU) FP7 programme and the Medical Research 
Council (MRC) PHINDS programme, within which the individual research studies of this thesis are 
embedded. My role in each of these projects is detailed below, and summarised in Table 1.2.  
  
HARP (HPV in Africa Research Partnership) EU FP7 Framework funding (grant No. HEALTH-2010-F2-
265396) 
As part of the HARP study, I acted as the study coordinator between 2010 and 2014, and worked 
closely with the Chief Investigator (Prof Philippe Mayaud) and the study statistician (Prof Helen 
Weiss) at LSHTM and the local study investigators in Burkina Faso (Prof Nicolas Meda), South Africa 
(Prof Sinead Delany-Moretlwe) and France (Dr Michel Segondy and Prof Nicolas Nagot) during the 
finalization of the study research protocol, Informed Consent Forms (ICFs), Case Report Forms 
(CRFs) and Standard Operating Procedures (SOPs). I have monitored and reported on the progress 
of enrolment and retention of participants throughout the study period, and monitored and 
reported on any Adverse Events related to the study procedures, in liaison with an External Clinical 
Monitor. I have undertaken site visits to ensure good research and implementation according to 
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Good Clinical Practice (GCP) standards. I was involved in the development of the analysis plans for 
the cross-sectional and longitudinal studies for the HPV and CIN related analyses.  
 
HPV vaccination among WLHIV study  - (funded by UK MRC, PHINDS scheme, Grant PH01/14-39) 
This study was undertaken between March to September 2015. As part of this study, I worked with 
infectious disease modellers at Imperial College and provided them with HPV type-specific 
infection data from the HARP study for estimation of genotype attribution to CIN2+ in order to 
model the potential impact of HPV vaccines among WLHIV in South Africa. In addition to this, 
serology samples from the HARP participants were sent to the pathology laboratory of Prof Joakim 
Dillner at Karolinska Institute, Stockholm, Sweden, for HPV serology testing to measure the past 
exposure of HPV types in this population. I was involved in the study design and co-wrote the 
proposal with the PI Prof Philippe Mayaud and co-Investigator Prof Sinead Delany-Moretlwe.  
 
DNA methylation study 
From July to September 2015, I performed the DNA methylation assays using cervical samples from 
the HARP participants, at the laboratory of Prof Attila Lorincz at the Wolfson Institute of 
Preventive Medicine, Queen Mary University of London (QMUL).  
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Table 1.2. Candidate’s role in the thesis 
Study  Candidate’s Role 
Paper 1 (Chapter 4): Antiretroviral therapy, 
high-risk human papillomavirus and cervical 
intraepithelial neoplasia: a systematic review 
and meta-analysis  
 
 Study design: HK conceptualised the study together with PM and SDS, and HK developed the research protocol 
 Ethical approval: none required 
 Data extraction and cleaning: HK extracted all data, and 25% of all data was blindly extracted by HW  
 Statistical analysis and interpretation: HK performed all analyses with input from HW and YBM 
 Final manuscript: HK wrote first draft with contributions from PM, SDS, HW and YBM 
 Status of manuscript: Re-submitted following Reviewer comments with Lancet HIV 
Paper 2 (Chapters 6 and 7): Epidemiology of 
High-risk Human Papillomavirus and Cervical 
Lesions in African women living with HIV/AIDS: 
Effect of Anti-Retroviral Therapy   
 
 Study design: HARP investigators designed the HARP study: PM, SDM, NM, HW, MS, NN 
 Ethical approval: PM, SDS and NM applied and gained ethical approval from the Ministry of Health in Burkina Faso, the Witwatersrand University in 
South Africa, and the London School of Hygiene and Tropical Medicine  (LSHTM) 
 Study coordination: HK acted as the international study coordinator and worked closely with local study coordinators BS and AC 
 Data extraction and cleaning: Data management teams in local sites performed data entry and quality checks. HK monitored data entry monthly 
 Statistical analysis and interpretation: HK performed all analyses with input from HW and CG 
 Final manuscript: HK wrote first draft with contributions from PM, HW, SDM, MS, NN 
 Status of manuscript: Accepted and published in AIDS (November 2016) 
Paper 3 (Chapter 8): Associations of human 
papillomavirus (HPV) genotypes with high 
grade cervical lesions in a cohort of women 
living with HIV/AIDS in Africa 
 
 Study design: HARP investigators designed the HARP study: PM, SD, NM, HW, MS, NN 
 Ethical approval: PM, SDS and NM applied and gained ethical approval from the Ministry of Health in Burkina Faso, the Witwatersrand University in 
South Africa, and the LSHTM  
 Study coordination: HK acted as the international study coordinator and worked closely with local study coordinators BS and AC 
 Data extraction and cleaning: Data management teams in local sites performed data entry and quality checks. HK monitored data entry monthly 
 Statistical analysis and interpretation: HK performed all analyses with input from HW and CG 
 Final manuscript: HK wrote first draft with contributions from PM, HW, SDM, MS, NN  
 Status of manuscript: Accepted and published in PLoS One (March 2017) 
Paper 4 (Chapter 9): Type-specific serologic 
responses to human papillomaviruses among 
women living with HIV in South Africa: 
seroprevalence, seroconversion and risk of re-
infection 
 
 Study design: HK, PM and SDM wrote the proposal and submitted to MRC PHINDS; use of HARP samples for HPV serology  
 Ethical approval: HK, PM, SDM gained ethical approval from the Witwatersrand University in South Africa, and the LSHTM 
 Data extraction and cleaning: HK received data from KI, extracted and cleaned data for entry in HARP database 
 Laboratory testing: HF performed all laboratory testing at KI 
 Statistical analysis and interpretation: HK performed all analyses with input from HW and HF 
 Final manuscript: HK wrote first draft with contributions from PM, HW, JD and HF  
 Status of manuscript: Co-author review 
Paper 5 (Chapter 10): Associations of EPB41L3 
DNA methylation with cervical lesions in 
women living with HIV-1 in Burkina Faso and 
South Africa  
 
 Study design: HK conceptualised the study together with PM and AL, and HK developed the research protocol 
 Ethical approval: HK, NM and SDM gained ethical approval from the Ministry of Health in Burkina Faso, the Witwatersrand University in South Africa, 
and the LSHTM  
 Laboratory testing: HK performed all laboratory testing with assistance from RW and NV at QMUL 
 Data extraction and cleaning: HK conducted all data entry and cleaning  
 Statistical analysis and interpretation: HK performed all analyses with input from AL  
 Final manuscript: HK wrote first draft with contributions from AL, PM, MS  
 Status of manuscript: Co-author review 
PM=Philippe Mayaud; SDS=Silvia de Sanjose; HW=Helen Weiss; YBM=Yolanda Buenevente-Moreno;  SDM=Sinead Delany-Moretlwe; NM=Nicolas Meda; MS=Michel Segondy; NN=Nicolas Nagot; CG=Clare 
Gilham;  BS=Bernard Sawadogo; AC=Admire Chikandiwa; KI-Karolinska Institute, Sweden; JD=Joakim Dillner; HF=Helena Faust; AL=Attila Lorincz; RW=Rhian Warman; NV=Natasa Vasiljevic
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1.5 Collaborating institutions and the HARP study 
This study is nested within a larger prospective study which aimed to evaluate cervical cancer 
screening strategies among WLHIV. This EU-funded study called HARP (HPV in Africa Research 
Partnership) was undertaken in two African countries – Burkina Faso and South Africa - with 
different HIV epidemics, burdens of HPV infection and cervical cancer, and approaches to 
screening for cervical cancer. This allows the findings to be extended to a range of countries and 
settings in the region.  The HARP study, including its methodology, is described in detail in Chapter 
5, but is briefly described here.  
The HARP study evaluated cervical cancer screening strategies against histological (CIN) and 
cytological (SIL) endpoints in a cohort of 1238 WLHIV (two thirds of whom were taking ART) in 
Burkina Faso and South Africa. The objective of HARP was to improve cervical cancer prevention 
programmes for WLHIV in South Africa and Burkina Faso, by evaluating the effectiveness and cost-
effectiveness of alternative screening strategies, and by developing algorithms leading to earlier 
detection and management of cervical cancer in these high-risk populations.  
The HARP study was conducted at one study site in each country, and consisted of three interlinked 
sub-studies: 
 A cross-sectional study of HPV and cervical neoplasia screening among HIV-1 seropositive 
women attending HIV care centres in Burkina Faso and South Africa.  
 A prospective cohort study of HIV-1 seropositive women recruited in Study 1 including women 
without advanced histological lesions (≤CIN1), and women with CIN2+ up to 18 months (which 
was reduced to 16 months because of project constraints). 
 A health economics and modelling study using data from the cross sectional and cohort studies 
to determine cost-effectiveness of the various screening strategies in preventing cervical 
cancer cases.  
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This thesis used secondary quantitative longitudinal data collected between December 2011 and 
August 2014 recorded during participant visits to the local clinics in Burkina Faso and South Africa 
as part of the HARP study and stored in the HARP database at the LSHTM. Histological 
measurements, in addition to data on HPV genotyping data, socio-demogepahic, behavioural, sex 
behaviour, STI screening results and HIV related factors, such as ART status, ART duration, CD4+ 
cell count and HIV-1 PVL were used during the analysis (Chapters 6, 7 and 8).   
As part of a connected study to inform the development of an HPV vaccine study among WLHIV in 
South Africa and funded by the UK MRC PHINDS programme, analyses were later performed using 
serum collected from the HARP study participants for HPV serology performed at the Karolinska 
Institute in Stockholm, Sweden (Chapter 9).  
A collaboration between LSHTM and Queen Mary University of London (QMUL) involved the use 
of HARP cervical specimens for DNA methylation analysis (Chapter 10).  
The timeline of HARP activities and PhD activities is summarised in Figure 1.2.
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Figure 1.2. Time line of PhD and HARP study  
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1.6 Academic Support 
My supervisor is Prof Philippe Mayaud, Professor of Infectious Diseases & Reproductive Health at 
LSHTM and was PI of the HARP study. He has considerable research experience in the field of 
epidemiology and control of HIV and STIs in developing countries. He has successfully supervised 
over 10 PhD candidates.  
Prof Helen Weiss, PhD, Professor in Epidemiology at LSHTM provided statistical overview. She has 
designed and analysed many epidemiological studies and trials of HIV prevention and was a Co-PI 
on the HARP study. She has collaborated with Prof Mayaud on many HIV/STI intervention trials. 
She has supervised 7 PhD students.  
The Scientific Advisory Board was formed of the following people:  
Dr Michel Segondy, PhD, is Associate Professor at the Faculty of Medicine and University Hospital 
and is the head of the Virology Laboratory at CHU Arnaud de Villeneuve, University of Montpellier 
(UM-1), France and was a Co-Investigator in HARP. He was responsible for overseeing the testing 
and quality control of HPV genotyping testing, and HPV variant testing and analysis. He advised on 
the virological aspects and analyses of this study.  
Prof Silvia de Sanjose, MD, PhD is Chief of the Cancer Epidemiology Research Programme at Institut 
Català Oncologia, Barcelona, Spain. She is a leading researcher on studies of cancer-associated 
infectious diseases. She was a member of the International Scientific Advisory Group for the HARP 
study and has been closely involved and advised on the study progress over its duration. Prof de 
Sanjose inspired and was co-responsible for the conceptualisation of the meta-analysis on the 
association of ART with HR-HPV and cervical lesion outcomes (PAPER 1).  
Prof Attila Lorincz, PhD, Professor of Molecular Epidemiology is a molecular biologist at Queen 
Mary University of London (QMUL) recognized for his research in human diagnostics and the 
natural history of HPV infections. He invited me to work in his laboratory at QMUL and supervised 
the work on DNA methylation assays.  
17 
 
 
 
Prof Sinead Delany-Moretlwe, MD, PhD, is Director of Research at Wits RHI, University of the 
Witwatersrand, Johannesburg, South Africa and was Co-PI on HARP. She provided scientific 
supervision in South Africa, ensured that local ethical approvals were obtained, and reviewed 
results and provided guidance as required. Prof Nicolas Meda, MD, PhD, is Director of the ANRS 
HIV research site, CRIS, University of Ouagadougou, Burkina Faso, and was a Co-PI on HARP. He 
provided scientific supervision in Burkina Faso, ensured that local ethical approvals were obtained, 
and reviewed results and provided guidance as required. 
 
1.7 Ethical clearance 
Ethical approval was granted by the Ministry of Health in Burkina Faso (no. 2012-12-089), the 
Witwatersrand University in South Africa (no. 110707), and the London School of Hygiene and 
Tropical Medicine (no. 7400) [PAPERS 2 and 3] with supplementary approvals for serology [PAPER 
4] and DNA methylation analysis [PAPER 5]. 
 
1.8 Funding 
This research was conducted as a staff member at the London School of Hygiene and Tropical 
Medicine, and salary costs were covered through a combination of funding from the European 
Commission (EC) 7th Framework Programme under grant agreement No. HEALTH-2010-F2-265396 
and the UK Medical Research Council (MRC) PHINDS scheme (PH01/14-39).  
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1.9 Publications and conference presentations resulting from this PhD 
 
PUBLICATIONS 
PUBLISHED:  
 PAPER 2 (CHAPTERS 6 AND 7)  
Kelly HA, Sawadogo B, Chikandiwa A, Segondy M, Gilham C, Lompo O, Omar T, Didelot 
MN, Nagot N, Meda N, Weiss HA, Delany-Moretlwe S, Mayaud P; HARP Study Group. 
Epidemiology of High-risk Human Papillomavirus and Cervical Lesions in African women 
living with HIV/AIDS: Effect of Anti-Retroviral Therapy. AIDS. 2017 Jan 14;31(2):273-285. doi: 
10.1097/QAD.0000000000001301.  
 PAPER 3 (CHAPTER 8)  
Kelly HA, Ngou J, Chikandiwa A, Sawadogo B, Gilham C, Omar T, Lompo O, Doutre S, Meda 
N, Weiss HA, Delany-Moretlwe S, Segondy M and Mayaud P for the HARP Study Group. 
Associations of human papillomavirus (HPV) genotypes with high-grade cervical lesions in 
a cohort of women living with HIV/AIDS in Africa PLoS One. 2017 Mar 23;12(3):e0174117. doi: 
10.1371/journal.pone.0174117  
UNDER REVIEW:  
 PAPER 1 (CHAPTER 3)  
Kelly HA, Weiss HA, Benavente-Moreno Y, De Sanjose S, Mayaud P. Antiretroviral therapy, 
high-risk human papillomavirus and cervical intraepithelial neoplasia: a systematic review 
and meta-analysis [RESUBMITTED FOLLOWING PEER REVIEW WITH LANCET HIV] 
 PAPER 4 (CHAPTER 9) 
Kelly HA, Faust H, Chikandiwa A, Ngou J, Helen Weiss, Segondy M, Dillner J, Delany-
Moretlwe S, Mayaud P. Type-specific serologic responses of human papillomavirus among 
women living with HIV in South Africa: seroprevalence, seroconversion and risk of re-
infection [CO-AUTHORS REVIEW] 
 PAPER 5 (CHAPTER 10) 
Kelly HA, Warman R, Segondy M, Chikandiwa A, Sawadogo B, Vasiljevic N, Scibor-
Bentkowska D, Meda N, Weiss HA, Delany-Moretlwe S, Mayaud P, Lorincz A.  Associations 
of DNA methylation of EPB41L3 and HPV16 with cervical lesions in women living with HIV in 
Burkina Faso and South Africa [CO-AUTHORS REVIEW] 
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CONFERENCE PROCEEDINGS 
European Research Organisation on Genital Infection and Neoplasia (EUROGIN 2012) Prague, 
Czech Republic (8-11 July 2012) 
 Kelly H, Muzah B, Sawadogo B, Didelot M, Michelow P, Lompo O, Doutre S, Gilham C, Von 
Knorring N, Zan S, Delany S, Omar T, Meda N, Drabo J, Weiss H, Legood R, Nagot N, Segondy 
M, Costes V, Mayaud P. Prospective evaluation of cervical screening methods in HIV positive 
women in Africa (HARP study): baseline results (oral presentation; number FC 6-2)  
 
STI & AIDS World Congress 2013 in Vienna, Austria (14 to 17 July 2013) 
 Kelly H, Ngou J, Sawadogo B, Muzah B, Gilham C, Nagot N, Meda N, Delany S, Segondy M, 
Mayaud P. HPV genotype distribution in HIV-positive African women and associations with 
high grade histological lesions by CD4+ count (poster)  
 
7eme Alliance Francophone des Acteur de sante contre le VIH et les infections virales (AFRAVIH 
2014) in Montpellier, France (27 to 30 April 2014) 
 Kelly H, Ngou J, Chikandiwa A, Sawadogo B, Weiss H, Omar T, Lompo O, Nagot N, Meda, 
N, Delany S, Segondy M, Mayaud P. Distribution des génotypes du HPV et associations avec 
les lésions histologiques du col utérin chez les femmes africaines séropositives au VIH-1 
(Poster; number Po M6.32)  
 Kelly H, Ngou J, Chikandiwa A, Sawadogo B, Weiss H, Omar T, Lompo O, Nagot N, Meda, 
N, Delany S, Segondy M, Mayaud P. Importance du contrôle immunitaire et virologique sur 
le risque de lésions cervicales intraépitheliales néoplasiques de haut grade (CIN2+) et 
d’infection par HPV à haut-risque (hr-HPV) chez les femmes africaines infectées par le VIH-
1 (Poster; number Po M6.34)  
 
7th Association Francophone pour l’Etude des Infections á Papillomavirus et Polyomavirus (AFFIP 
2014) in Sète, France (29 September to 1 October 2014) –travel bursary awarded for attendance 
 Kelly H, Warman R, Segondy M, Chikandiwa A, Sawadogo B, Vasiljevic N, Scibor-
Bentkowska D, Meda N, Weiss HA, Delany-Moretlwe S, Mayaud P, Lorincz A.  Méthylation 
de l'ADN des cellules hôtes parmi des femmes africaines infectées par le VIH avec ou sans 
lésions du col utérin (oral presentation)  
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30th International Papillomavirus Conference 2016, in Lisbon, Portugal (17-21 September 2016) –
travel bursary awarded for attendance 
 Kelly H, Ngou J, Chikandiwa A, Sawadogo B, Gilham C, Didelot MN, Omar T, Lompo O, Weiss 
H, Nagot N, Meda, N, Delany S, Segondy M , Mayaud P. Persistence and incidence of high-
risk HPV associated with CIN2+ among African women living with HIV-1 (oral presentation; 
number HPV15-0792) 
 Kelly H, Warman R, Segondy M, Chikandiwa A, Sawadogo B, Vasiljevic N, Scibor-
Bentkowska D, Meda N, Weiss HA, Delany-Moretlwe S, Mayaud P, Lorincz A.  Association 
of DNA methylation of EPB41L3 human gene with CIN2+ and HIV-related factors in African 
women living with HIV (poster; number HPV15-0794) 
 
8eme Conference Internationale Francophone VIH/Hepatites AFRAVIH 2016, Brussels, Belgium (20-
23 April 2016) –travel bursary awarded for attendance 
 Kelly H, Ngou J, Omar T, Lompo O, Gilham C,  Magooa-Mahalpe P, Djigma F, 
Sawadogo B, Chikandiwa A, Didelot MN,  Meda N, Nagot N,  Weiss HA, Delany-Moretlwe 
S, Segondy M,  Mayaud P.  Infections HPV et lésions cervicales chez les femmes VIH+ en 
Afrique subsaharienne : données issues des études transversale et longitudinale du projet 
HARP (oral presentation ; number S11.01) 
 Kelly H, Warman R, Segondy M, Chikandiwa A, Sawadogo B, Vasiljevic N, Scibor-
Bentkowska D, Meda N, Weiss HA, Delany-Moretlwe S, Mayaud P, Lorincz A.  Méthylation 
de l'ADN des cellules hôtes chez des femmes africaines infectées par le VIH avec ou sans 
lésions du col utérin (poster; number PV254) 
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2 LITERATURE REVIEW 
 
2.1 Anogenital HPV and associations with cervical lesions 
The link between a sexually transmitted agent and invasive cervical cancer (ICC) was first 
postulated in 1842 when an Italian physician noted a high frequency of cervical cancer among 
married women, widows and prostitutes, but was a rare occurrence among virgins and nuns [18, 
19]. Later epidemiological studies reported the sexual behaviour of a woman and that of her male 
partner was associated with the risk of ICC [20-23]. ICC was often found to co-exist with other 
sexually transmitted infections (STIs), and studies in the 1960s reported a strong association of 
Herpes Simplex Virus Type 2 (HSV-2) antibodies with ICC [24-26]. However, a large prospective 
study among women in former Czechoslovakia found no association between HSV-2 antibodies 
and CIN development [27, 28]. In the meantime, the HPV virus was reported to be localised in 
cervical tumour tissue using a nucleic acid hybridization technique in the 1970s [29, 30] and later 
prospective studies demonstrated the presence of persistent HPV DNA precedes cervical lesion 
development [31, 32]. HPV DNA detection in cervical biopsies using polymerase chain reaction 
(PCR)-based tests in the 1990s confirmed that HPV was an aetiological agent of ICC [33, 34].  
A recent meta-analysis of cross-sectional HR-HPV type distribution among 369,186 women and 423 
studies worldwide [35] found that HPV prevalence among women with atypical squamous cells of 
undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), high-grade 
squamous intraepithelial lesion (HSIL) was 12.4%, 52.5%, 75.7% and 85.4%, respectively, and among 
women with cervical intraepithelial neoplasia grade 1 (CIN1), CIN2, CIN3 and ICC was 73.4%, 85.6%, 
92.6% and 89.4%, respectively (Figure 2.1). Even though it is reported that HPV is a necessary cause 
of ICC [34, 36], it is not uncommon to find patients with ICC being HPV negative. In their review of 
10,575 biopsies of invasive cervical cancer from around the world [37], De SanJose et al (2010) 
found that only 85% were positive for any HPV and the authors suggest this could be the result of 
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samples used (cervical swab vs. cervical biopsy) as it may be plausible that HPV infection may no 
longer be detectable from the cervical mucosa whilst having caused lesions.  
Figure 2.1. Prevalence of human papillomavirus (HPV) DNA among cytological normal women 
(A) and by cervical disease grade and region (B) 
(A)                                                                           (B) 
  
(A) from [1] and (B) from [35] Abbreviations; ASCUS: atypical squamous cells of undetermined significance; LSIL: low-grade squamous 
intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; CIN: cervical intraepithelial neoplasia; ICC: invasive cervical 
cancer. 
 
 
 
2.2 Invasive cervical cancer  
ICC is the most common female cancer in low and middle-income countries [1], where 85% of the 
estimated 500,000 global annual cases occur [1, 2] (Figure 2.2) and is the leading cause of cancer 
deaths among African women [3]. This is likely due to the lack of organised screening services for 
the prevention and detection of disease, and with the limited resources to manage and treat 
cervical disease when detected.  
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Figure 2.2. Incidence of and mortality from cancers (in thousands) among women in 2012 
 
From [9] 
 
ICC is also one of the most common cancers in women living with HIV (WLHIV) [7], and ranks as 
one of the most common neoplasms among WLHIV and is considered an AIDS-defining illness [8]. 
In the African region the prevalence of both ICC and HIV are high (Figure 1.1).  CIN is an early stage 
of cancer of the cervix which is curable. Persistent infection with high-risk human papillomavirus 
(HR-HPV) genotypes (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) is necessary for the 
development of squamous intraepithelial lesions (SIL) and CIN [5, 33].  
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2.3 HPV virus structure  
HPV is a relatively small virus (8kb) containing a circular double-stranded DNA (Figure 2.3). The 
virus is organized into three regions; the non-coding upstream regulator region (URR) which 
controls gene expression; an early (E) region with the open reading frame (ORF) encoding genes 
involved in viral replication and cell transformation (E6, E7, E1, E2, E4, E5); and a late (L) region 
encoding the L1 and L2 capsid proteins which self-assemble to form the virion [38]. 
HPV is classified into genotypes based on L1 capsid protein. There are over 100 HPV genotypes 
identified; 40 of these are genital and 15 are oncogenic, or high-risk given their association with 
anogenital neoplasia. The genital HPV types are classified by the International Agency for Research 
on Cancer (IARC) according to the magnitude of their association with ICC. HR-HPV types include 
the types that are ‘carcinogenic to humans’ (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) and 
‘probable carcinogenic’ (HPV68) [4]. The ‘possible carcinogenic’ types include HPV26, 53, 66, 69, 
70, 73, and 82 and other known low-risk types include HPV6, 11, 40, 43, 44, 54, 71, and 74.  
Figure 2.3. HPV16 genome organization  
From [39] 
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2.4 The natural history of HPV and cervical lesions 
The squamocolumnar junction (SCJ) is the junction between the squamous epithelium and the 
columnar epithelium of the cervix (Figure 2.4). The location of the SCJ on the cervix varies over a 
woman’s lifetime and is dependent on age, hormonal status, oral contraceptive use, birth trauma 
and pregnancy [40]. Cervical lesions develop in the area of the cervix called the Transformation 
Zone (TZ, Figure 2.4), which is an area of high cellular turnover, as columnar cells change into 
squamous cells. It is located fully on the outer cervix in teenage girls and moves higher into the 
endocervical canal in older women with decreasing levels of oestrogen. 
Cervical ectopy, or ectropion is defined as the presence of everted endocervical columnar 
epithelium on the extocervix. It is a normal occurrence in a woman’s life, but when the columnar 
epithelium extends into the vaginal fornix, there is disruption of the mucosa which can result in 
squamous metaplasia and is associated with abnormal transformation in ICC.  
Figure 2.4. Cervical Squamocolumnar junction (SCJ) and the Transformation Zone (TZ) in mid-
later reproductive stage (30’s age range) 
 
Image from http://www.prn.org/images/uploads/Palefsky-fig3-680.gif 
 
The pathway from HPV infection to ICC is depicted in Figure 2.5 and summarised here. Two 
terminologies are used to determine stages of cervical neoplasia. Cytological results are reported 
using the Bethesda nomenclature: low-grade and high-grade squamous intraepithelial lesions (LSIL 
Endocervix 
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and HSIL, respectively) [41]; histological results are reported using the 3-tier Cervical Intraepithelial 
Neoplasia (CIN1-3) classification system [42].  
The HPV virus is dependent on a complete programme of keratinocyte differentiation [43, 44]. It 
infects keratinocytes, and enters the cell to attach to the basement membrane if there is a 
microabrasion on the surface of the cervix, which can occur through trauma during sexual 
intercourse, vaginal cleansing or drying and if the cervix is inflamed as a result of other sexually 
transmitted infections (STIs). In the normal cervix, the epithelial stem cell divides along the 
basement membrane and matures vertically through epithelium without further division, a process 
which can take 12-48 hours. The virus and cell replicate together and the viral genome remains in 
the basal layer at low copy number (~100 copies per cell). HPV viral replication is accompanied by 
the expression of 'early' proteins E1 and E2 in the basal layers. During this phase, the oncoproteins 
E6 and E7 are tightly controlled. The viral lifecycle goes through successive stages of genome 
amplification, virus assembly and virus release. As the host cell stops dividing, it begins to 
differentiate into a mature keratinocyte. The dividing cell population expands vertically and the 
virus activates all genes and the copy number increases to the thousands. This is called a productive 
infection, LSIL or CIN1 and can be cleared with an effective immune response.  A shift in virus 
expression patterns to oncogene expression (E6 and E7) leads to unregulated viral DNA replication 
in non-cycling host cells, brought about through the suppression of normal cell cycle checkpoints. 
This promotes cell proliferation and delay differentiation, and this is defined as a precursor lesion 
(HSIL/CIN2 or 3), which can be managed if detected or can spontaneously regress. As infected cells 
differentiate into squamous cells, the E4 protein, and the late proteins L1 and L2 (which form the 
capsid), are expressed. Viral capsids are shed into the genital tract within desquamated epithelial 
cells. In rare events, the HPV virus integrates into the host genome, which causes deletion or 
disruption of E2 gene but retains E6, E7 and the URR. These cells show increasing genomic 
instability and a greater probability of acquiring genomic abnormalities which drives malignant 
transformation and invasion [39].   
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Figure 2.5. HPV-mediated progression to cervical cancer   
Adapted from [44, 45] 
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2.5 HPV immune evasion mechanisms   
The HPV virus has several mechanisms through which it successfully manages to evade detection 
from the immune response, primarily linked to the differentiation of the target cell, the 
keratinocyte [39, 46, 47]:   
i. Viral lifecycle occurs entirely within epithelium 
The HPV viral lifecycle occurs entirely within the stratified epithelium far from the sites of immune 
activity. It infects and multiplies within differentiating keratinocytes which have a short life span 
and are destined for death by natural causes and desquamation away from sites of immune 
activity. Because there is no cytolysis resulting from viral replication, the infected cell is not a target 
of the host immune response and there is no opportunity for the Antigen Presenting Cell (APC) to 
present the antigens to the immune system. The early proteins are produced in the basal layer and 
late proteins in the distal layer, and so are not detected by the Langerhans cells, which are the APCs 
of the squamous epithelium and reside in the parabasal and lower suprabasal layers of the 
squamous epithelium. This allows for long periods of uninterrupted viral replication.   
ii. Absence of viraemia 
There is no blood-borne (viraemic) phase of the HPV lifecycle and the infection is not spread 
systemically, and so it remains unexposed to the immune system outside the epithelium, allowing 
the virus to persist in the cervical tissue.  
iii. Absence of inflammation  
There is no virus-induced death and no inflammation, and there appears to be little or no release 
of pro-inflammatory cytokines that are necessary for activation and migration of the Langerhans 
cells and macrophages and the recruitment of effector T-lymphocyte cells. During normal turnover 
of cervical epithelial cells, dying cells are detected by Langerhans cells, which subsequently release 
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immunosuppressive cytokines (TGF-ß, IL-10 and IL-13). Dendritic cells (DCs) transiting from 
epithelium to lymph nodes require maturation to deliver antigen to T-cells in order to trigger a 
positive immune response. To do this, the DCs require co-stimulation by other co-factors (B7) 
which in turn requires release of inflammatory cytokines. Because the HPV virus does not need to 
destroy the host cell, it does not trigger inflammation or inflammatory cytokines.  
iv. The viral proteins cause local immunosuppression  
HPV downregulates the expression of interferon 1 genes (IFN-α and IFN-β) which have antiviral, 
antiproliferative and immunostimulatory properties and act as a bridge between the innate and 
humoral immune responses [39]. HPV oncoproteins E6 and E7 can directly inhibit these antiviral 
pathways in the cell. In this way, E6 and E7 maintain the keratinocyte in the cell cycle.  
v. Oncoprotein evasion  
E7 is located in the nucleus where Langerhans cells cannot gain access. HPV16 E7 also displays 
similarity to several human proteins, which might be a reason for the limited immunogenicity of 
HPV16 E7 [47].  
 
2.6 Immune response to natural infection 
These immune evasion mechanisms allow the HPV virus to persist. However not all infections 
persist and the majority of immuno-competent women clear infection [48].  Prospective studies of 
incident and prevalent infections among young women have shown that up to half of infections 
clear within 6 months and approximately 90% clear within 2 years after acquisition [49, 50].  
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2.6.1 Innate immune response to HPV infection 
The innate immune response is the first line of recognition and defence against viral infection. The 
role of the innate immune response to HPV infection is still poorly understood, but current 
evidence is summarised here, and illustrated in Figure 2.6.  
Detection of virus  
Although keratinocytes are not classic immune cells, they can act as APCs for presentation of 
antigen in association with the Major Histocompatability Complex (MHC) class 1. Keratinocytes are 
also able to secrete pro-inflammatory cytokines and chemokines and can activate CD4+ and CD8+ 
T-cells [51]. The double stranded DNA and L1 and L2 capsids of the HPV virion can trigger signalling 
through Toll-like receptors (TLR), which are a class of proteins involved in the recognition of 
foreign pathogens [52] (Figure 2.6).  A greater expression of Toll-like receptors (TLR2, 3, 7, 8 and 
9) has been reported after incident HPV16 infection compared to before infection and this 
expression was found to be significantly associated with subsequent clearance within 4 months 
[53]. Virus capsid entry is usually an activating signal for APCs of the squamous epithelia, the 
Langerhans cells.  
Immune response to infection  
Once virus is detected, the APCs secrete cytokines to promote a T-cell response to HPV infection 
[54]. Two longitudinal studies have shown that IFN-γ mRNA expression in both cervical cytobrush 
[55] and cervical biopsy [56] specimens was associated with HPV clearance. IFN-γ is expressed by 
Natural Killer (NK) cells and activated T-cells which in turn are stimulated by the cytokines IFN-α, 
IL-12 and IL-18 produced by the infected cells or activated APCs (Figure 2.6).  
Women who clear infection are more likely to have detectable levels of IFN-γ, indicative of a Th1 
immune response compared to those whose infections persist [55]. A Th2 response (IL-4 and IL-
10) is more likely among those whose infections progress to precursor lesions [57](Table 2.1).  
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Immunohistochemical studies have shown that regression of anogenital warts (AGW) is 
accompanied by an infiltration of mononuclear cells (CD4+, CD8+, CD56+, macrophages) into the 
lesion and increased expression of Th1 cytokines (IL-2, IL-12, IFN-γ, TNF-α). A 12-month prospective 
study of histologically confirmed CIN1 lesions found that lesion regression was strongly correlated 
with CD8+ and CD56+ T-cells [58].  
Figure 2.6. Detection and response to HPV by host immune response  
 
(A) Resting uninfected keratinocyte; (B) Detection of foreign DNA by infected keratinocyte and professional Antigen Presenting Cells 
(APCs) and signalling through Toll-like receptors; (C) Activation of  Natural Killer (NK) cells and T-lymphocytes by cytokines secreted 
from professional APCs and infected cells; (D) IFN-y secretion by NK cells and activated T-cells; (E) Activation of infected keratinocyte 
by IFN-y ; (F) Increased surface expression of MHC I and II, CD40, ICAM and CXCL9-11 on infected keratinocyte; (F) this attracts 
activated Th1 cells (CD4+, CD8+, macrophages) ; IFN-γR=IFN-γ Receptor 
 
Immune response to cervical precursor lesions 
CIN2/3 lesions appear to be characterised by a reduction in the Th1 immune response, but an 
increase in the Th2 immune response. Previous studies have shown that in comparison to normal 
or CIN1 biopsy specimens, CIN2/3 biopsy specimens contained lower levels of IFN-γ mRNA [59] and 
contained increased numbers of immune cells from both the acquired and innate immune 
response in the stroma (CD4+ and CD8+ T-lymphocytes, macrophages, mast cells, B-cells, 
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neutrophils and NK cells) and in the dysplastic epithelium (CD4+ T-cells, macrophages and NK cells) 
[60-62].  
Table 2.1. Th1 and Th2 cytokine responses for HPV transient infection and HPV persistence and 
CIN2/3 
Response Function HPV transient 
infection 
HPV 
persistence 
CIN2/3 
lesions 
Th1 immune 
response 
Cell-mediated immunity -proinflammatory responses 
responsible for killing intracellular pathogens and for 
perpetuating autoimmune response 
  
IFN-γ Activate cytotoxic T lymphocyte and NK cell mediated 
cytolytic functions that have been proposed to provide 
effective antitumour defence mechanisms 
↑ ↓ 
IL-2 Proliferation and activation of T- and B-cells; Induces the 
transformation of NK cells into lymphokine activated killer 
cells that have been associated with improved capacity to 
destroy tumour cells 
↑  
IL-12 Activates cytotoxic T lymphocyte and NK cell mediated 
cytolytic functions that have been proposed to provide 
effective antitumour defence mechanisms 
↑  
TNF-α Binds 2 cell surface receptors: TNF receptor 1 and TNF receptor 
2, activating multiple signalling pathways involved in antiviral 
activities, growth arrest, cell proliferation, differentiation or 
apoptosis, depending on cell type and GF availability 
↑ ↓ 
Th2 immune 
response 
Humoral immunity, inhibition of inflammation    
IL-4 Inhibits Cell Mediated Immune responses   ↑ 
IL-10 Inhibition of cytokine production; Tumour derived IL-10 
suggested to modulate antitumor responses by inhibiting 
tumour antigen presentation by professional and non 
professional APCs; it is possible that IL-10 suppresses 
expression of MHC class 1 expression preventing tumour 
antigen presentation to CD8+ CTLS 
 ↑ 
↑=increase in levels; ↓=decrease in levels; [63] 
 
 
2.6.2 Adaptive immune response to HPV infection  
Antigen-specific T-cell responses are weak and often transient [39] and there is still uncertainty 
about whether antibodies to HPV L1, elicited by natural infection, are partially protective against 
re-infection by the same HPV type.  Detectable serum neutralising antibody responses to L1 are 
type specific [64]. Comparisons between sero-epidemiological studies are difficult due to the use 
of different serological assays, and the lack of a reference serum for establishing cut-off values 
[65]. The pseudovirion-based neutralization assay (PBNA) is the “gold standard” for detection of 
HPV antibodies and international reference sera are available for HPV16 and HPV18 (WHO LabNet) 
33 
 
 
 
[66, 67]. The competitive Luminex immunoassay (cLIA; Merck), the virus-like-particle (VLP)-based 
multiplex immunoassay (VLP-MIA; GlaxoSmithKline), and the in situ purified glutathione S-
transferase L1-based MIA (GST-L1-MIA) are the most widely used assays for seroprevalence studies 
in several countries and trials.  
Seronversion following incident infection 
Seroconversion has been previously shown to be dependent on time following incident infection.  
Carter et al [68] enrolled 588 HIV-negative college-attending women aged 18-20 years in a 
prospective study over a mean 31 months follow-up with average time between visits of 4.8 
months. The authors report that 60%, 54% and 69% of women seroconverted for HPV-16, -18 or -6, 
respectively within 18 months of incident DNA detection. HPV6 seroconversion coincided with DNA 
detection but HPV16 seroconversion occurred between 6 to 12 months after DNA detection, with 
the highest rate of seroconversion occurring 7-8 months after DNA detection.  
Furthermore, HPV16 and HPV18 antibodies were more likely to persist compared to HPV6 
antibodies and women with persistent HPV16 and HPV18 infections (DNA positive at more than 1 
consecutive visit) were more likely to seroconvert, but there were some women with persistent 
DNA who never seroconverted. In contrast, HPV6 seroconversion was the same, irrespective of 
HPV6 DNA persistence or clearance.  
Baseline seropositivity and risk of same-type re-infection  
A recent meta-analysis [69] of 14 studies among >24,000 individuals (90% women) investigating 
whether antibodies against HPV16 and 18 were protective against type-specific re-infection found 
that HPV16 antibodies acquired through natural infection were associated with a 35% (pooled Risk 
Ratio [RR]=0.65, 95%CI: 0.50-0.80) decreased risk of subsequent cervical HPV16 infection, while 
HPV18 antibodies were associated with a 30% (pooled RR=0.70, 95%CI: 0.43-0.98) decreased risk of 
subsequent HPV18 infection.  
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Furthermore, Safaeian et al have shown that antibody generated in natural infections is protective 
against re-infection but protection was antibody titre-dependent in a study among Costa-Rican 
women aged 18-25 years in the control group of a community-based, randomized HPV16/18 vaccine 
trial [70]. The women were negative for HPV16/18 DNA at enrolment and followed up annually for 
a median 4 years. The study found that women who were HPV16-seropositive at enrolment with 
HPV16 antibody titres in the highest tertile (≥66 percentile point; ≥60 Elisa Units/mL) had a 50% 
decreased risk of subsequent HPV16 infection compared to HPV-16 seronegative women 
(aRR=0.50, 95%CI: 0.26-0.86, adjusted for age, education, marital status, lifetime number of sexual 
partners, and smoking) [70]. Similarly women with HPV18 antibody in the highest tertile (≥28 
EU/mL) at enrolment had a 64% reduced risk of subsequent HPV18 infection (aRR=0.36, 95%CI: 0.14-
0.76). These findings were not found among women whose antibodies titres were in the low 
tertiles for both HPV16 and 18.    
 
2.7 Risk factors associated with the natural history of HPV: from HPV acquisition to 
ICC    
A framework for the study of risk factors that influence the pathway from HPV acquisition to 
persistence and the development of CIN and ICC includes two groups of factors, corresponding to 
the key stages in HPV natural history:  
i.) socio-demographic and behavioural factors which determine the acquisition of HR-HPV 
infection; and  
ii.) biological factors which determine the persistence of infection and cervical precursor 
lesion development/carcinogenesis.  
Figure 2.7 presents a conceptual framework of risk factors for HR-HPV acquisition, persistence and 
development of cervical lesions, based on a framework designed for the analysis and 
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interpretation of risk factors in demographic studies and more recently used in for studies for HIV 
transmission [71]. This framework links the socio-demographic factors (underlying determinants) 
on the left of the diagram with the health outcome on the right. The underlying determinants 
(socio-demographic factors) influence the proximate determinants which have both behavioural, 
and biological components; those, in turn, determine the health outcomes/stages (HR-HPV 
acquisition, persistence and cervical lesion development). In the case of HPV, the risk factors can 
vary according to the stage of the HPV life cycle; some risk factors are associated with only one 
stage of the life cycle (e.g. condom use reduces HR-HPV acquisition) and others are associated with  
more than one stage (e.g. hormonal contraception can influence acquisition of infection as well as 
promote carcinogenesis).  
Published evidence has so far focused on the association of risk factors with ICC, despite the fact 
that some risk factors are associated with an increased risk in HR-HPV acquisition as well as 
persistence. Indeed, a separate group of risk factors could be considered for the progression of 
high-grade cervical lesions to ICC (in addition to groups i.) and ii.) above), although, some of 
biological risk factors considered in group ii.) above, also apply to this stage of the pathway.  
Where data is available on HR-HPV outcomes, these are given (there were no meta-analyses 
investigating these associations on SIL or CIN outcomes). The associations reviewed here, 
summarized in Table 2.2, are based on i.) the epidemiological evidence currently available on the 
association of the risk factor with HR-HPV infection and/or ICC, and ii.) the biological plausibility for 
this association. The summarised evidence satisfied five of the nine elements of the classical 
epidemiological Bradford-Hill criteria for establishing causality between risk factors and health 
outcomes [72]. Data from meta-analyses investigating the association of the risk factors with the 
outcome (HR-HPV acquisition or persistence and/or ICC) were used where available as this shows 
the consistency of the association. The strength of the association (effect estimate) between the risk 
factor and the outcome is summarised in Table 2.2. Prospective studies (evidence of termporality), 
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and those that report a dose-response relationship (biological gradient) between a risk and the 
outcome (e.g. smoking frequency, duration of hormonal contraceptive use) are presented where 
available. Finally, the biological plausibility of an association between the risk factor and the 
outcome is briefly discussed.   
2.7.1 Socio-demographic factors  
Age 
Epidemiological evidence 
The relationship between age and HPV prevalence is similar worldwide with the highest prevalence 
among women <25 years and a decline at older ages [73, 74]. In Europe and North America, young 
women <25 years have very high rates (20-30%) which decrease to very low levels over the age of 
45 years (<5%). In Africa and Asia, HPV prevalence remains ≥10% among older age groups (>45 
years), and in Latin America and the Caribbean, there is a decline and an increase again in middle-
aged women [75]. The peak transmission of HPV infections is typically among young women 
following sexual debut [76] because HPV is highly prevalent in younger age groups, and is easily 
transmitted [77]. Several studies which examined the influence of age on persistence of infection 
and risk of CIN2+ have reported that for prevalently-detected infections, the risk of HPV 
persistence and CIN3 increases with older age [49, 78-80] but newly acquired infections were 
cleared as quickly by older women as by younger women [49]. 
Biological plausibility  
Cervical ectopy, which is more likely among young women has been shown to increase the risk of 
acquisition of other STIs [81], including HPV [82, 83]. The single layer columnar epithelium, 
indicative of ectopy, is a weak physical barrier and may facilitate entry of HPV and other STIs. 
Furthermore, oral contraceptive use - another risk factor for HPV infection, which is frequently 
used among younger women- can increase the likelihood of ectopy [84].  
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Table 2.2. Summary of risk factors associated with the natural history for HPV infection and cervical cancer  
Outcome Risk factor Risk exposure Comparison group N studies Effect Estimate (95%CI) Reference 
HR-HPV incidence Circumcision status of 
male partner 
Circumcised Uncircumcised 1 IRR=0.77 (0.63-0.93)  [85] 
HPV persistence Age ≥30 years 17-24 years 1 aOR=5.2 (1.5-1.8) [79] 
25-29 years 17-24 years 1 aOR=1.4 (1.4-4.8) [79] 
HPV clearance Smoking Ever Never 1 HR=0.51 (0.30-0.88) [86] 
HPV Prevalence Age Peak prevalence ≤25 years 
(% prevalence variable by geographic region) 
134 Not presented [74] 
HPV Prevalence Trichomonas vaginalis Positive Negative 1 aOR=4.1 (1.7-9.8) [87] 
HPV Prevalence Bacterial vaginosis Positive Negative 12 OR=1.43 (1.11-1.84) [88] 
HPV prevalence HIV Seropositive Seronegative  Refer to Table 2.3  
       
ICC Smoking  Ever Never 7 OR=2.2 (1.5-3.2) [89] 
Age at first sexual 
intercourse 
≤16 years ≥21 years 9 OR=2.31 (1.85-2.87) [90] 
Age at first pregnancy <17 years ≥25 years 25 aRR=1.77 (1.42-2.23) [91] 
Parity ≥7 FTP 1-2 FTP 25 aRR=1.76 (1.53-2.02) [91] 
Oral contraception 5-9 years Never 28 RR=1.3 (1.0-1.9) [92] 
≥10 years Never  RR=2.5 (1.6-3.9) [92] 
Injectable 
contraception 
<5 years Never 3 RR=1.0 (0.9–1.2) [92] 
≥5 years Never  RR=1.2 (1.0-1.6) [92] 
Chlamydia trachomatis Positive  Negative 22 aOR=1.76 (1.03-3.01) [93, 94] 
Trichomonas vaginalis Positive  Negative 2 aRR=1.93 (1.22-2.65) [95] 
Herpes simplex virus-2 Positive  Negative 7 aOR=1.96 (1.24-3.09) [96] 
HIV Seropositive Seronegative  Refer to Table 2.3  
Updated from [97]; a=adjusted; IRR=Incidence Rate Ratio; OR=Odds Ratio; HR=Hazard Ratio; RR=Relative Risk; FTP=full term pregnancy 
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Figure 2.7 Conceptual framework for the analysis of factors affecting the epidemiology and natural history (prevalence, incidence, persistence and 
clearance) of HPV and development and progression of cervical lesions 
 
 Adapted from [71]  
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2.7.2 Behavioural factors  
Smoking  
Epidemiological evidence 
Compared to HPV-positive women who never smoked, HPV-positive women who have ever 
smoked tobacco have a 4.6 (95%CI: 0.9-22.9), 2.2 (95%CI: 1.4-3.4) and 2.2 (95%CI: 1.5-3.2) increased 
odds of CIN2/3, CIN3 and CIS/ICC, respectively (Table 2.2)  [86, 89, 98-103]. The amount of smoking 
(number of cigarettes per day) and duration of smoking history were also shown to increase the 
odds of CIS/ICC [89]. Ever having smoked was found to be associated with a 49% reduction in HPV 
clearance in a cohort study of 346 HIV-negative women aged 18-35 years in the US [86]. 
Biological plausibility  
Tobacco smoke contains known carcinogens such as polycyclic aromatic hydrocarbons that could 
have a direct transformation effect on the cervix [98]. It is also known to suppress the immune 
response by reducing the number of Langerhans cells and other immune markers [89], thereby 
allowing HPV to persist and cervical lesion to develop [86, 104].   
 
2.7.3 Sexual behaviour 
Age at first pregnancy and parity  
Epidemiological evidence 
In a review of 25 epidemiological studies which included individual data on 11,161 women with ICC, 
5,402 women with CIN3/carcinoma in situ (CIS) and 33,542 women without cervical carcinoma [91], 
multiparous women (≥7 full-term pregnancies [FTP]) had a 2-fold (aRR=1.76, 95%CI: 1.53-2.02, 
adjusted for age at first FTP) increased risk of ICC compared to women who had 1-2 FTP (Table 2.2). 
This association was not observed for CIN3/CIS. In a case-control study of 702 HIV-negative women 
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in Uganda, women with 10 or more children had a 7-fold increased risk of ICC compared to women 
with fewer than 4 pregnancies [105].  
A younger age at FTP was also associated with a 2-fold increased risk of ICC (<17 years vs. ≥25 years: 
aRR=1.77, 95%CI: 1.42-2.23, adjusted for number of FTP) and CIN3/CIS (aRR=1.78, 95%CI: 1.26-2.51) in 
[91]. Both associations persisted even after adjustment for lifetime number of sex partners (LTSP), 
age at first sexual intercourse (AFSI) and history of screening, and when restricted to HPV-positive 
women only. The finding that number of FTP and age at FTP were not associated with HR-HPV 
positivity among the control group further confirms contribution of these factors to ICC 
development. However, this may be indicative of early HPV infection, which may have initiated 
cervical lesion pathway but may be undetected at time of ICC detection.  
Biological plausibility  
The increase in ICC risk among women with younger age at first pregnancy may be attributed to 
cervical trauma during delivery, which can result in cervical ectopy, thereby increasing exposure of 
the SCJ to HPV infection [91]. High concentrations of oestrogen and progesterone during 
pregnancy could facilitate cervical carcinogenesis, a mechanism similar to that reported for 
hormonal contraceptive users. Immunosuppression during pregnancy can also facilitate 
acquisition and persistence of HPV [106].  
 
Age at first sexual intercourse and number of lifetime sex partners 
Epidemiological evidence 
A second review assessed the association of AFSI with ICC using a pooled analysis of case-control 
studies among 3,583 women from 8 developing countries [90]. The review shows that AFSI, age 
at first pregnancy (AFP) and age at first marriage (AFM) were highly interrelated. Compared with 
women with older AFSI (≥21 years), women with AFSI 17-20 years had a 1.8-fold (OR=1.80, 95%CI: 
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1.50-2.39) increased odds of ICC and women with AFSI ≤16 years has a 2.3-fold (OR=2.31, 95%CI: 1.85-
2.87; Table 2.2). 
Biological plausibility  
Early AFSI may be a surrogate marker for early HPV infection which may have persisted. Early AFSI 
has shown to be associated with riskier sexual behaviour, such as unprotected sex, a higher 
number of lifetime sex partners, or concurrent sex partners and a woman’s partner having multiple 
sex partners [90]. The peak transmission of HPV infections is typically among young women 
following sexual debut [76] and it has been suggested that the immature cervix during 
adolescence may be more susceptible to HPV acquisition and persistence [107]. 
 
2.7.4 Biological determinants 
Male circumcision 
Epidemiological evidence 
Previous studies in Uganda, South Africa and Kenya have shown that male circumcision is 
associated with lower HPV prevalence in both HIV-negative and HIV-positive men [108-113]. Male 
circumcision has been shown to decrease the risk of transmission of HPV from HIV-negative men 
to their female partners [85], however this has not been proven among HIV-positive men [114]. In 
Rakai, Uganda, 1,245 HIV-negative female partners of HIV-negative men enrolled in two 
randomised controlled trials of male circumcision were prospectively followed for 24 months. 
Female partners of men in the intervention group had 23% lower HR-HPV incidence compared to 
women in the control group (Incidence Rate Ratio [IRR] =0.77, 95%CI: 0.63-0.93; Table 2.2), and 
increased HR-HPV clearance (RR=1.12, 95%CI: 1.02-1.22). Male circumcision was also found to 
decrease the genital HPV viral load among both HIV-negative men [115] and their female partners 
[116] and others have reported that HPV viral load is predictive of HPV transmission between 
heterosexual partners [117].  
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Furthermore, among women with male partners with high-risk behaviour, the risk of ICC is reduced 
if male partners have been circumcised. In a pooled analysis of 1,913 couples enrolled a case-control 
study of determinants of ICC in South America, Asia and Europe [118], circumcised men were less 
likely to be HPV infected compared to uncircumcised men (aOR=0.37, 95%CI: 0.16-085, adjusted for 
AFSI and number of lifetime sex partners). Monogamous women whose male partners were 
circumcised and who engaged in risky sexual behaviour (i.e. had 6 or more sexual partners, or sex 
with prostitutes) had a 58% reduction in ICC (aOR=0.42, 95%CI: 0.23-0.79, adjusted for AFSI and 
number of lifetime sex partners) compared to monogamous female partners of uncircumcised 
men with similar high risk behaviour. This association was not observed when restricting analysis 
to men who did not engage in risky sexual behaviour. The reduction in risk among female partners 
of men with multiple sex partners suggests a decrease in the risk of acquisition of HR-HPV.   
Biological plausibility 
The reduction in HPV acquisition and ICC among women is linked to the reduction in transmission 
of HPV from male partners, which result from: a.) an overall reduction in HPV prevalence among 
men, and b.) reduction in likelihood of transmission from infected males to their female partners. 
Removal of the foreskin during male circumcision decreases the surface area vulnerable to HPV 
(and others STIs including HIV), and decreases the likelihood of mucosal trauma during intercourse. 
The glans of the circumcised penis has a thicker epithelium making it more resistant to abrasions 
and therefore less susceptible to HPV viral entry. In these men, the distal urethra is the only 
mucosal epithelium, which is known to contain relatively fewer HPV-related lesions [119].  
 
Hormonal contraception 
Epidemiological evidence 
Smith et al investigated the association of hormonal contraceptive use with ICC in a systematic 
review and meta-analysis of 28 cohort and case-control studies including a total of 12,531 women 
with ICC [92]. Compared with never users of oral contraceptives (OC), women taking OC for 
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durations of <5 years, 5-9 years and ≥10 years had increased risk of ICC with RRs of 1.1 (95%CI: 1.1-
1.2, adjusted for number of sexual partners, cervical screening, smoking, or use of barrier 
contraceptives), 1.6 (95%CI: 1.4-1.7) and 2.2 (95%CI: 1.9-2.4), irrespective of HPV infection. Among 
women with HPV infection, the respective RRs were 0.9 (95%CI: 0.7-1.2), 1.3 (95%CI: 1.0-1.9), and 2.5 
(95%CI: 1.6-3.9) for HPV positive women (Table 2.2). A more recent prospective study of 308,036 
women recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study 
and followed for a median 9 years [120] reported that prolonged duration of oral contraceptives 
use was associated with a significantly increased risk of both CIN3/carcinoma in situ (CIS) and ICC 
(HR=1.6 and HR=1.8 respectively for long term (≥15 years) use versus never use). 
The Smith et al meta-analysis [92] reported a weaker association for injectable contraception 
(which includes the progesterone-only norethisterone enanthate [NET-EN] and depot 
medroxyprogesterone acetate [DMPA]) use with ICC. Compared to never users, prolonged users 
(≥5 years) had 1.2- fold (RR=1.2, 95%CI: 1.0-1.6) increased risk of ICC (Table 2.2). No increased risk 
was observed among short-duration users (<5 years: RR=1.0, 95%CI: 0.9-1.2).  It should be noted 
however that their review was performed in 2003 and there were only 3 studies which provided 
data on injectable contraception. Injectable contraception use is increasing in SSA [121]; the 
prevalence of hormonal contraceptive use among married or in-union women aged 15-49 years in 
2015 was highest in Eastern Africa (31.1% in Malawi, 28.1% in Ethiopia and Rwanda), and Southern 
Africa (30.3% in South Africa and 27.5% in Namibia) [122]. Injectable contraceptives are highly 
effective, long lasting and easily reversible; a single dose is effective for months, which means 
fewer clinic visits and freedom from daily pills, which may be a reason for its popularity among 
WLHIV who may be on daily ART.  
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Biological plausibility  
Both oral and injectable contraception have been associated with increased risk of acquisition of 
HPV and other STIs [123-129]. Hormonal contraception influences the differentiation and 
maturation of the cervical epithelium which can lead to thinning of the mucosal epithelium and 
microtearing [123, 126-130], acting as portal of entry for HPV. DMPA has also been shown to modify 
the normal genital flora reducing the levels of hydrogen peroxide-producing lactobacillus in the 
vagina [131], associated with an increased risk of vaginal flora changes and bacterial vaginosis (BV), 
which in turn is linked to increased risk of HIV, and other STIs [132, 133]. Furthermore, hormonal 
contraceptives can regulate cytokine and immunoglobulin expression [134] which may facilitate 
HPV persistence. Both oestrogen and progesterone increase the expression of the HPV 
oncoproteins E6 and E7 linked to ICC development [135, 136] and there is evidence of oestrogen 
assisting in ICC development through oestrogen response elements found in the long-chain region 
of HPV16 [137]. DMPA users have been reported to have higher levels of HPV16 E7 DNA compared 
to non-DMPA users [138].  
Other Sexually Transmitted Infections (STIs) 
The presence of other STIs increases the risk of acquiring HPV, possibly due to disruption of the 
mucosal epithelial barrier caused by inflammation and ulceration, thereby facilitating entry of the 
HPV virus [139]. The disruption to immune responses can facilitate HPV persistence. The link with 
ICC is less clear, as STI positivity is a marker of past sexual behaviour, and may act as a confounder 
for HR-HPV infection.  However, several STIs induce inflammatory responses which are linked to 
HRHPV persistence and carcinogenesis, and these possibilities are reviewed here for selected 
pathogens, which have been better studied.  
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Herpes-simplex virus-2 (HSV-2) 
Herpes simplex type 2 virus (HSV-2) was originally thought to be an etiological agent for ICC as 
early case control studies found an association of HSV-2 antibodies with ICC [140]. However, larger 
prospective studies failed to confirm these findings [27, 28]. As HSV-2 is found to frequently co-
exist with HPV, it is thought that genital HSV-2 infection may facilitate HPV persistence and cervical 
lesion development [96].  
Epidemiological evidence 
The role of HSV-2 as a cofactor for ICC was investigated in a case-control study of 2,380 women 
from Africa, South America, Asia and Europe [96]. Among the HPV DNA-positive women, HSV-2 
seropositivity was associated with a 2-fold (aOR=1.96, 95%CI: 1.24 to 3.09) increased risk of 
squamous-cell carcinoma (SCC) after adjusting for age, study site, HPV DNA type, history of pap 
smear, and markers of sexual or reproductive behaviour which included number of FTP, number 
of sexual partners, AFSI, Chlamydia trachomatis seropositivity, and oral contraceptive use (Table 
2.2). As the analysis was restricted to those who were HPV DNA positive, the authors propose that 
genital HSV-2 may act in conjunction with HPV infection to modestly increase the risk of ICC.  
Biological plausibility  
As for HPV, HSV-2 can infect the cervical squamous epithelium at SCJ. Ulcerative HSV-2 lesions can 
facilitate HPV viral entry to the basal layer. Inflammation resulting from herpetic infections may 
interfere with targeted immune response to HPV infection by suppressing the T-helper cell-
mediated immune response [141, 142]. Furthermore, HSV-2 can induce the production of nitric 
oxide which has been shown to cause cellular DNA damage in HPV-infected cells [143]. Finally, HSV-
2 has been shown to facilitate HPV replication and integration of HPV DNA in infected host cells 
[144] and interfere with apoptosis [142], which may facilitate cervical lesion development and 
progression.  
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Chlamydia trachomatis 
Epidemiological evidence 
Chlamydia trachomatis infection has been shown to facilitate the entry and persistence of multiple 
HR-HPV types [145, 146] and has been suggested to be linked to the disruption of the immune 
response required to clear the virus [147]. The association of Chlamydia trachomatis as a cofactor 
for ICC has also been widely reported. A recent meta-analysis which examined the association 
between Chlamydia trachomatis and the risk of ICC [94] and included a total of 22 studies and 4,291 
ICC cases found a significant association between Chlamydia trachomatis and ICC (aOR = 1.76, 95%CI: 
1.03-3.01, adjusted for HPV and age; Table 2.2).  
Biological plausibility  
Genital Chlamydia trachomatis may cause chronic cervicitis and pelvic inflammatory disease. The 
biological plausibility for an increased risk in ICC associated with Chlamydia trachomatis may be 
linked to the inflammatory cytokine responses during infection which may lead to reactive 
oxidative metabolite production, causing DNA damage or modification, resulting in genetic 
instability, particularly if infection persists [93, 147, 148]. In vitro data show that Chlamydia 
trachomatis may inhibit cell apoptosis, or programmed cell death, resulting in unregulated cell 
proliferation [149].  
Trichomonas vaginalis 
Epidemiological evidence 
The link between Trichomonas vaginalis and ICC is less well studied. A systematic review dating 
from 1994 which included only 2 cohort studies investigating the association of Trichomonas 
vaginalis and ICC [95] reported a 2-fold (aRR=1.93, 95%CI: 1.22-2.65) increased risk of CIN1-3 among 
women positive for Trichomonas vaginalis, after adjustment for age, residence, past screening 
history and number of years since negative pap smear, number of sexual partners, HPV status and 
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duration of follow-up (Table 2.2).  A longitudinal cohort study among 19,114 women attending 
organized mass screening in Finland in 1985-1990 evaluated whether gynaecological infections 
other than human papillomavirus (HPV) were related to an increased risk of cervical neoplasia. 
Trichomonas vaginalis was associated with an increased risk (Standardized incidence ratios 
[SIR]=6.4, 95%CI: 3.7-10) of preinvasive lesions and invasive cancer combined, however it is unclear 
whether the authors adjusted for HPV detection in the analyses [150].   
Others have shown an increased risk of HR-HPV acquisition among 324 Tanzanian women positive 
for Trichomonas vaginalis (aOR=4.1, 95%CI: 1.7-9.8, adjusted for bacterial vaginosis and clinical pelvic 
inflammatory disease [87].  
Biological plausibility  
As the association of Trichomonas vaginalis with HPV and ICC has rarely been studied or reported, 
it remains unclear whether Trichomonas vaginalis generates any specific mechanism for HPV 
persistence or ICC development other than that reported for other STIs; that it may be a surrogate 
for HPV infection. However, Trichomonas vaginalis has shown to be associated with 
immunosuppression [151] and the presence of nitrosamines [152] in cervical discharge which may 
induce cervical epithelial cell transformation in the presence of oncogenic HPV infection [152-155]. 
It has also been shown to induce cervical epithelial atypia in mice [156] and to have promoter-
enhancing effects [157] which facilitate cervical lesion development. However, further 
epidemiological evidence is required to further investigate these effects.  
 
Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG) 
Although there is less evidence available on associations of Neisseria gonorrhoeae (NG) and 
Mycoplasma genitalium (MG) with HR-HPV and cervical lesions, HPV infection has been reported to 
be 4-fold higher among antenatal clinic attendees positive for NG compared to negative women 
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(aOR=4.46, 95%CI: 1.20-16.0) in Mwanza, Tanzania [158], but no such associations were reported 
for MG in a population of female sex workers (FSW) in Nairobi, Kenya [159].  
 
Bacterial vaginosis (BV) 
Epidemiological evidence 
Two recent meta-analyses investigated the association of BV on HPV infection and cervical 
precursor lesions. In a meta-analysis which included 12 studies (10 cross-sectional, 2 prospective) 
among 6,372 women [88], BV positivity was associated with a 1.4-fold (OR=1.43, 95%CI: 1.11-1.84) 
increased prevalence of cervical HPV (Table 2.2).  A separate prospective study in the US among 
1763 WLHIV and 493 HIV-negative women assessed semiannually for BV, TV and HPV found that 
women with BV at any time during follow-up had a higher risk of acquiring HPV (aOR=1.41, 95%CI: 
1.25-1.59, adjusted for LTSP) [160].  
A meta-analysis of the association of BV with cervical precursor lesions (defined as any of: LSIL, 
HSIL, CIN1, CIN2 or CIN3) included 17 cross-sectional and 2 incidence studies among over 10,000 
women and found a 1.5-fold increase in SIL (LSIL/HSIL) or CIN (CIN1-3) prevalence (SIL and CIN 
combined: OR=1.51, 95%CI: 1.24-1.83) among women with BV [161]. However, the authors report 
significant heterogeneity in the estimate, a wide range of OR was reported across the individual 
studies and while only 3 studies adjusted for HPV, markers of sexual behaviour and smoking, they 
yielded conflicting results on the association of BV and SIL/CIN prevalence.  
Biological plausibility  
BV is associated with changes in the physiochemical and immunological environment of the vagina. 
In BV-negative women, hydrogen peroxide-producing lactobacilli dominate the vaginal microflora 
and have a role in defence mechanisms [88]. BV results in the loss of these protective micro-
organisms and other changes in the vaginal milieu including changes in the production of cytokines 
such as IL-1β and IL-10 [162], which could facilitate the acquisition and persistence of other STI, 
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including HPV. Furthermore, BV-associated anaerobes release volatile amines which can form 
carcinogenic compounds such as nitrosamines in combination with nitrates, produced by nitrate 
reducing bacteria [163]. Others have shown that the local accumulation of nitrosamines during BV 
episodes may induce cervical epithelial cell transformation in the presence of oncogenic HPV 
infection [152-155]. Furthermore, the disrupted vaginal environment induced by BV is associated 
with alterations in the inflammatory cytokine profile which could promote cervical lesion 
development [162].  
 
Human immunodeficiency virus (HIV) 
The interrelations between HIV and HPV are bidirectional (Figure 2.8). Recent data has confirmed 
that HPV, like other STIs, facilitates the acquisition of HIV. Following on several observational 
studies, two systematic reviews have indicated that HPV infection confers a 2-fold increased risk of 
HIV acquisition in women and men [164, 165].  
Likewise, HIV seropositivity increases the risk of acquiring HPV and the subsequent 
immunosuppression increases the risk of HPV persistence and cervical lesion progression (Figure 
2.8). The associations of HIV-related factors (ART, CD4+ cell count and HIV-1 PVL) with HPV 
infection are discussed in more detail in the next section 2.8.   
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Figure 2.8. Factors associated with HPV infection and cervical lesion development among WLHIV 
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2.8 HPV and cervical intraepithelial neoplasia (CIN) among WLHIV 
The interactions between HIV, HPV and cervical lesions have long been a subject of research but 
full elucidation of the mechanisms of these interactions remain a challenge. Recent systematic 
reviews and meta-analyses have summarized the comparative data for HPV or HR-HPV prevalence 
and incidence of low and high-grade cervical lesions and ICC among WLHIV and HIV-negative 
women, and are summarized here and in Table 2.3. Data on longitudinal HPV or HR-HPV outcomes 
(incidence, clearance and persistence) are more limited and while there have been no formal 
review or meta-analyses comparing these outcomes among WLHIV and HIV-negative women, 
recent data is summarized.  
2.8.1 Effect of HIV on HPV infection epidemiology 
Previous systematic reviews have shown that WLHIV have a 2-fold higher prevalence of HPV 
compared to HIV-negative women (pooled prevalence=62.0% vs. 29.5%; pooled PR=1.97, 95%CI: 1.81-
2.15) [166], but among those with higher lesion grades (HSIL+) and ICC, HPV prevalence was similar, 
irrespective of HIV status [13, 14] (Table 2.3). However, the prevalence of multiple HPV was higher 
among WLHIV, irrespective of lesion grade. Four recent studies found that compared to HIV-
negative women, WLHIV had between 1.8- and 2.3-fold increased risk of HR-HPV incidence [167, 
168] and a 27-60% decreased likelihood of HR-HPV clearance [167, 169, 170].  
2.8.2 Effect of HIV on cervical lesion incidence and progression 
In a previous systematic review, WLHIV were reported to have a 4-fold increased prevalence of 
LSIL (pooled PR=3.63, 95%CI: 2.54-5.18) and HSIL (pooled PR=3.66, 95%CI: 2.55-5.25) compared to 
HIV-negative women [166]. In a large prospective study of 1,002 WLHIV and HIV-negative women 
in the US [171], WLHIV had a 5-fold increased risk of any SIL incidence (HR=4.50, 95%CI: 3.10-6.40) 
and HSIL incidence (HR=5.10, 95%CI: 1.90-14.20; [172, 173].   
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2.8.3 Effect of HIV on Invasive cervical cancer (ICC) 
A review of 8 linkage studies using HIV/AIDS and cancer registries between 2000 and 2007 [166] 
reported over a 6-fold increase in ICC incidence among WLHIV compared to HIV-negative women 
(pooled SIR=6.64, 95%CI: 3.35-13.14). There was a single study from SSA carried out between 1989-
2002 [174]; the authors report a 2.7-fold increased risk of ICC among WLHIV compared to HIV-
negative women (SIR=2.7, 95%CI: 1.8-4.0). An additional case-control analysis of cancer risk among 
4,399 women in Johannesburg and Soweto between 1995 to 2004, not included in the above meta-
analysis, found that HIV-1 infection was associated with an increased risk of ICC (aOR=1.6, 95%CI: 
1.3-2.0, adjusted for age, year of diagnosis, level of education and LTSP) [175].  
 
2.8.4 Factors associated with HPV and related cervical disease among WLHIV 
WLHIV have increased susceptibility to HPV infection and decreased ability to clear infection [176]. 
WLHIV have high rates of coinfection with HPV due to similar risk profiles for HIV and HPV 
acquisition, including early AFSI, multiple sex partners, low socioeconomic status, use of hormonal 
contraception and low use of barrier contraceptive methods [177]. Furthermore, both HIV and HPV 
infections elicit and thrive on viral and host factors that impair the immune system, thereby causing 
considerable co-morbidity [178]. The HIV-related factors influencing HPV infection and cervical 
lesion development are illustrated in Figure 2.8.   
The role of HIV-related factors such as ART status, CD4+ cell count and HIV plasma or genital RNA 
levels, on HPV infection and cervical lesion development was the subject of a manuscript written 
as part of this thesis [179], the key points of which are summarised here.  
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Table 2.3. Review of epidemiology data of HPV, HR-HPV and cervical lesion outcomes among 
WLHIV compared to HIV seronegative women 
Outcome N studies 
[N women] 
Percentage or No. Events Effect Estimate (95%CI) 
WLHIV HIV-
negative 
HPV prevalence [166] 29 [n=22,469] 62.0% 29.5% PRa 1.97 (1.81-2.15) 
HPV among cytology normal 
[13, 35] 
20 [n=5578] (HIV+) 
147 [n=266,671] (HIV-) 
36.3% 12.0% NR - 
HPV among HSIL+1 [13] 20 [n=5578] 84.1% 84.2% OR 1.00 (0.70-1.40) 
HPV among ICC [14] 21 [n=4616] 91.2% 89.6% PR 1.02 (0.96-1.08) 
      
Multiple HPV      
Multiple HR-HPV prevalence 
[180] 
10 [n=5,436] 22.7% 14.5% OR 2.41 (1.83-3.18) 
Multiple HPV among cytology 
normal [13] 
20 [n=5578] 11.9%    
Multiple HPV among HSIL+ 
[13] 
20 [n=5578] 41.1% 6.7% OR 9.30 (6.90-12.00) 
Multiple HPV among ICC [14] 21 [n=4616] 27.8% 15.9% PR 1.75 (1.18-2.58) 
      
Longitudinal outcomes      
HR-HPV Incidence       
[167] 1 [n=1073] NR NR aHR 2.28 (1.09–4.77) 
[168] 1 [n=1,284] 8.1 per  
100PY 
4.4 per 
100PY 
RR 1.80 (1.30-2.70) 
HR-HPV Clearance      
[167] 1 [n=1073] NR NR aHR 0.41 (0.25–0.65) 
[169] 1 [n=801] 37.3 per 
100PY 
62.0 per 
100PY 
aHR 0.58 (0.42-0.80) 
At 6-months follow-up [170] 1 [n=334] 59.0% 75.9% aHR 0.73 (0.52-1.01) 
      
HPV Persistence [181] 1 [n=805] 24.1% 3.9% aOR4 7.50 (3.60-16.0) 
      
Cervical lesions      
LSIL Prevalence [166] 8 [n=5,987] 14.6% 3.9% PRa 3.63 (2.54-5.18) 
HSIL Prevalence [166] 7 [n=5,577] 4.5% 2.0% PRa 3.66 (2.55-5.25) 
SIL Incidence [171] 3 [n=3,371] 8.9-11.5 per 
100YR 
2.2-2.6 per 
100PY 
HR 4.50 (3.10-6.40) 
HSIL incidence [171] 1 [n=1,002] 1.6 per  
100YR 
0.3 per 
100PY 
HR 5.10 (1.90-14.20) 
ICC Incidence [166] 8 [n=102,212] NR NR SIR 6.64 (3.35-13.14) 
a=adjusted; HR=Hazard Ratio; RR=Relative Risk; PY=person-years; SIR=Standardised Incidence Ratio for invasive cervical cancer in 
women with HIV or AIDS through cancer registry linkage studies; acrude Prevalence Ratio obtained from pool extracted data from 
[166]; 1estimates given for any HPV;  2Adjusted for study; 3adjusted for age, number of lifetime sex partners and ethnicity; 4adjusted for 
number of visits 
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CD4+ cell-count and HPV 
CD4+ cell count has been shown to be one of the strongest predictors of HR-HPV infection [182, 
183] and cervical lesion development [173] in multivariate analysis. 
HR-HPV prevalence has been shown to increase by 1.5- and 3-fold among those with low CD4+ cell 
count (<200 cells/µl) compared to high CD4+ cell count (≥500 cells/µl) [184-186].  A decrease of 
between 11% to 18% in HR-HPV prevalence per 100 cells/μl increase was observed in a cohort of 
WLHIV with no evidence of cervical lesions [187] and among women with evidence of cervical 
lesions [188], respectively. Few studies have reported the association of CD4+ cell count with HR-
HPV among ART users and ART-naïve separately.    
De Vuyst et al [186] reported that ART-naïve participants with CD4+ cell count <250 cells/µl had a 
higher HR-HPV prevalence compared to those with CD4+ cell count ≥500 cells/µl (PR=1.51, 95%CI: 
1.02-2.25) but no association was found among ART users, irrespective of duration on ART. 
Furthermore, Konopnicki et al [185] reported that a nadir CD4+ cell count <500 cells/µl was 
associated with a 3-fold increased risk of HR-HPV prevalence compared to those with CD4+ cell 
count ≥500 cells/µl.   
Although few studies have reported the association of CD4+ cell count with longitudinal HPV 
outcomes, high CD4+ cell count has been shown to be associated with increased clearance of any 
HPV, and decreased persistence of HR-HPV. Paramsothy et al reported a 10% increased likelihood 
of HPV clearance per 100 cells/µl increase in CD4+ cell count among women with normal (aHR=1.1, 
95%CI: 1.0-1.2) or ASCUS cytology  (aHR=1.1, 95%CI: 1.0-1.3) [189]. Furthermore, Lillo et al reported a 
marginal 8% decreased risk of HR-HPV persistence per 50 CD4+ cells/µl increase [190].  
Few studies have reported the impact of ART on specific HPV genotypes, and have tended to focus 
on HPV16/18 because of their greater importance in the aetiology of CIN and their supposed ability 
to escape immunological control [191]. Some studies, like Mane et al found that ART users had a 
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3.5-fold greater risk of HPV16 prevalence compared to ART-naïve individuals (aOR=3.47, 95%CI: 1.40-
8.59) [188], whilst Blitz et al reported that ART users had a 2-fold greater hazard risk of clearing 
HR-HPV types other than HV16/18 and had a non-significant decreased risk of HPV16 clearance [192]. 
In contrast, Lillo et al found that ART users had a 72% decreased risk of incident HPV16 and 18 
infections (aOR=0.28, 95%CI: 0.09-0.86), however the sample size was low in this study. Studies 
reporting the effect of CD4+ cell count on HPV16/18 infections have shown a clearer picture. Mane 
et al reported a 1.4-fold increased risk of prevalent HPV16 infection per 100 CD4+ cell decrease 
[188], while Blitz et al reported an almost 5-fold increased hazard risk of incident HPV16 among 
women with CD4+ cell count <200 cells/µl compared to those with CD4+ cell count >500 cells/µl 
(HR=4.82, 95%CI: 1.51-15.41), while no corresponding increase was observed for non-HPV16/18 types 
(HR=1.01, 95%CI: 0.39-2.60) [192]. 
CD4+ cell count and cervical lesions 
Several studies suggest that CD4+ cell count is one of the strongest predictors of SIL prevalence, 
incidence and progression. Compared to women with baseline or current high CD4+ cell count 
(≥500 cells/mm3), low CD4+ cell count (<200 cells/mm3) resulted in a 2-fold increased risk of cervical 
lesion prevalence [186, 193, 194], SIL incidence [195-197] and SIL progression [195, 197, 198]. Others 
have reported a 10% decreased hazard of SIL progression per 100 CD4 cells/mm3 increase [189, 199].  
In contrast, no study reported an association between baseline or current CD4+ cell count with the 
likelihood of SIL regression [192, 195, 197] but Paramsothy et al reported a marginal 10% increased 
hazard risk of SIL regression per 100 CD4+ cells/mm3 increase (aHR=1.1, 95%CI: 1.0-1.2) [189]. 
 Longitudinal studies have shown that in populations with controlled HIV disease (i.e,, with 
undetectable HIV PVL and CD4+ ≥350 cells/mm3), ART users present a similar risk of SIL incidence 
to ART-naïve with higher CD4+ cell counts [200] while ART use is most effective in the prevention 
of SIL incidence or progression at low CD4+ cell count. In South Africa, a 53% decreased risk in the 
rate of SIL incidence or progression was observed among ART users compared to ART-naïve 
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(incidence rate ratio [IRR]=0.47, 95%CI: 0.30-0.73) when the analysis was restricted to women with 
CD4+ <350 cells/mm3, but no association was observed among those with CD4+ cell count ≥350 
cells/mm3 [201].  
In contrast, cross-sectional studies report a significant association of low CD4+ with CIN2+ 
prevalence among ART-naïve but no association among ART users. De Vuyst et al have shown that 
ART-naïve Kenyan women with CD4+ cell count <250 cells/µl had a 4-fold increased risk of CIN2+ 
prevalence compared to those with CD4+ cell count ≥500 cells/μl (aOR=4.23, 95%CI: 1.27-14.07], but 
no association was observed among ART users, irrespective of duration on ART [186]. Similarly, 
Huchko et al also reported that ART-naïve women in Kenya with CD4+ count ≥500 cells/μl had a 
58% decreased risk of CIN2+ prevalence compared to those with <200 cells/μl  (aOR=0.42, 95%CI: 
0.22-0.80) but there was no association observed among ART users [193].  A major limitation of 
cross-sectional studies is the difficulty to disentangle the chronology of events, e.g. the timing of 
CIN incidence with regard to timing of ART initiation and nadir CD4+ cell count.  Several authors 
suggest that immune reconstitution by ART may not be established early enough after HPV 
infection to prevent or reverse the development of CIN2+ [186]. Huchko et al reported that nadir 
CD4+ count >500 cells/μl was associated with 40% reduction in CIN2+ detection compared to nadir 
CD4+ count <200 cells/μl (aOR=0.61, 95%CI: 0.38-0.97) [193]; while De Andrade et al showed that 
nadir CD4+ count ≥350 cells/μl was associated with greater than 80% decreased risk of CIN2+ 
compared to nadir CD4+ count <350 cells/μl (aPR=0.17, 95%CI: 0.04-0.67) [202]. 
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Antiretroviral therapy (ART) 
With the advent of the ART era, the incidence of other AIDS-defining cancers has decreased, 
however the impact on cervical cancer and its precursor lesions has been less clear. A recent meta-
analysis of observational studies evaluating the incidence of malignancies before and after the 
introduction of highly-active antiretroviral therapy (HAART) found that while the risk for the 
development of Kaposi's sarcoma and non-Hodgkin's lymphoma decreased by 70% (RR=0.30, 
95%CI: 0.28-0.33) and 48% (RR=0.52, 95%CI: 0.48-0.56), respectively, the incidence of invasive 
cervical cancer increased by 46% (RR=1.46, 95%CI: 1.09-1.94) after the introduction of HAART [11]. 
These opposing trends are depicted in a time-trend graph (Figure 2.9) between 1990 and 2015 
which compares numbers of WLHIV aged ≥15 years, sourced from UNAIDS [10] and the age-
standardized cervical cancer incidence in SSA sourced from cancer registries from the 
International Agency for Research on Cancer (IARC) [203]. Data on cervical cancer incidence is 
limited in SSA; only data from the general population of women in Uganda (Kyadondo County) 
between 1993 and 2007 is available. With the increased availability of ART from 2001 onwards 
(2004 in South Africa) and HIV prevention programmes in the region, the number of new 
infections is stabilizing and AIDS-related deaths are in decline and the total number of women 
living with HIV is increasing. Data from the general population of women in Uganda (Kyadondo 
County) and Harare, Zimbabwe between 1991 and 2010 however show a trend of increasing 
cervical cancer incidence.    
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Figure 2.9. Time-trends of numbers of women living with HIV (cumulative), new HIV infections 
(per year), AIDS-related deaths (per year) and numbers taking ART (cumulative), and age-
standardised cervical cancer incidence rates among women in Sub-Saharan African region   
 
WLHIV=women living with HIV; ASR=age-standardised incidence rate; data for variables WLHIV, new HIV infections, AIDS-related deaths 
and taking ART extracted from UNAIDS AIDSInfo [10]; data for Cervical cancer incidence ASR from Kyadondo County, Uganda extracted 
from IARC C15Plus Cancer Incidence Time Trends registry [203] and updated up to 2010 from [204]; data for Cervical cancer incidence 
ASR from Harare, Zimbabwe from [205] [no other country from Sub-Saharan Africa had sufficient data for set time period]  
 
Recently studies have shown that immediate ART reduces the risk of infection-related cancer 
during early HIV infection. The Strategic Timing of Antiretroviral Treatment (START) trial 
randomized HIV positive adults with a CD4+ count over 500 cells/mm3 to immediate combination 
ART initiation or deferral until CD4+ counts dropped below 350 cells/mm3 [206]. Immediate ART 
reduced the risk of infection-related cancers by 64% with greatest decreases observed for Kaposi's 
sarcoma and non-Hodgkin's lymphoma, but there were too few cases of cervical cancer t0 derive 
any meaningful associations.  
 The interactions of ART with HR-HPV and CIN are complex. ART increases potential exposure time 
to HR-HPV by decreasing mortality and increasing life expectancy of WLHIV. However, many 
individuals remain susceptible to HPV acquisition, persistence and incidence and progression of 
CIN or SIL, increasing the probability of accumulation of cellular genetic changes that increase the 
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likelihood of ICC [176, 207]. Improved survival among WLHIV may thus lead to increased cervical 
cancer rates [208]. Conversely, by decreasing HIV PVL, ART can restore mucosal immune 
competence to help clear HR-HPV and reduce the incidence of precursor lesions [209, 210]. 
Previous systematic reviews have explored the association of ART with HR-HPV and cervical lesions 
[173, 211, 212] but report conflicting results. Some studies show that “effective” ART (i.e. with high 
adherence, HIV viral suppression and immune reconstitution) over longer durations decreases HR-
HPV prevalence [184, 209, 213], by decreasing incidence [214, 215] and promoting clearance [209, 
214, 216].  ART has also been shown to reduce high-grade cytological SIL incidence [197] and 
progression [217, 218] especially among adherent users [214] and those with sustained HIV viral 
suppression [219]. However, other studies have reported no such benefits of ART on HR-HPV [188, 
220] or histological lesions [193, 213, 221-224], with some reporting a significant increased risk of 
CIN2+ among ART users [225]. Moreover, few longitudinal studies have reported the effect of ART 
and other HIV-related factors on the combined natural history of HR-HPV infection and histological 
cervical lesions. These observational studies differed with respect to study design, outcomes, 
timing of ART initiation and effectiveness of ART use, making it difficult to estimate the true effect 
of ART.  
Given that no meta-analysis has quantified the risk of HR-HPV and cervical lesions among ART users 
compared to ART-naive women, or considered other confounding factors, such as nadir CD4+ cell 
count and ART duration, one of the aims of this PhD was to  systematically review and summarise 
the literature on the association of ART with HR-HPV prevalence, and with cervical lesion 
prevalence, incidence, progression and regression, and to investigate the role of HIV-related co-
factors that might modify these associations, such as ART duration, timing of ART initiation and 
immune suppression and recovery. These findings are summarised and discussed in Chapter 3.   
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2.9 Control of HPV related cervical disease –screening and management  
Between 80-90% of confirmed ICC cases occur among women aged 35 years and older. In the SSA 
region, incidence rates rise steeply between the ages of 15-39 years and continues to rise among 
older age groups, and are particularly marked for the countries in which this study took place 
(Figure 2.10).  
Figure 2.10. Incidence of invasive cervical cancer, by age, in 2012  
 
Crude rate per 100,000 women. data from [9] 
The World Health Organisation (WHO) 2014 Cervical cancer screening guidelines recommend that 
screening should be performed at least once between the ages of 39-49 years, and this may be 
extended to women younger than 30 years if there is evidence of high risk for CIN2+ [226]. 
However, cervical cancer screening coverage, and linkage to care, is low in LMIC countries where 
infrastructure and personnel requirements for cervical screening and management put high 
demands on the health systems [227].   
The recommended cervical cancer screening methods include cervical cytology using the 
Papanicolaou method, Visual Inspection (VI) using acetic acid (VIA) or Lugol’s iodine (VILI) add HPV 
DNA based testing, which are briefly described here.  
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2.9.1 Screening tests  
Cytology  
Cytology based programmes have improved cervical cancer control in developed countries but 
implementation in developing countries is constrained by cost, lack of infrastructure and trained 
staff, and lag time between sample collection and availability of test result [228]. In a meta-analysis 
of studies evaluating performance of screening in Africa and India [229], cytology, whether using 
positive test result cut-offs of ≥ASCUS, ≥LSIL or ≥HSIL had poor sensitivity for the detection of 
CIN2+ (range: 42.6 for ≥HSIL to 57.0% for ≥ASCUS) and CIN3+ (range: 51.6-63.0%) but high specificity 
(range: 92.8-99.3% and 92.3-99.0% for CIN2+ and CIN3+, respectively) (Table 2.4).  
Visual Inspection  
Visual inspection using acetic acid (VIA) or Lugol’s iodine (VILI) is advantageous in low resource 
settings as it can be performed by trained midwifes and nurses, and requires simple tools to 
perform (speculum, acetic acetic acid, Lugol’s iodine, lamp). However, frequent training and 
supervision is required. In a meta-analysis of 21 studies from SSA and India among over 58,000 
women [228, 229], VIA showed good sensitivity for the detection of CIN2+ (range: 79.2-82.4%, Table 
2.4) and CIN3+ (82.9%) and good specificity (84.7%-87.4% and 84.2% for CIN2+ and CIN3+, 
respectively). VILI performed even better with higher sensitivity (CIN2+: 91.2-95.1%; CIN3+: 93.8%) 
and similar specificity (CIN2+: 84.5-87.2%; CIN3+: 83.8%). However sensitivity has been reported to 
be as low as 50% in other studies [230]. The wide variation in its performance is attributed to the 
subjective nature of test interpretation. High rates of positivity have resulted in over referral to 
colposcopy services and overtreatment [6]. Despite this, a single round of VIA screening has been 
associated with a 25-35% reduction in cervical cancer incidence, cervical cancer mortality and the 
frequency of CIN2+ lesions, in randomised-controlled trials in Thailand, Ghana and Zambia [231-
233]. In the absence of other adaptable cervical screening strategies in LMIC, VIA/VILI is a simple, 
inexpensive test for resource limited settings. A systematic review of 5 cross-sectional studies 
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which evaluated the performance of VIA and cytology for the detection of CIN2+ among WLHIV in 
Brazil, India, Kenya, Nigeria, South Africa, Tanzania, Thailand, Zambia and Zimbabwe [234] found 
that VIA sensitivity ranged from 65% to 80% and specificity ranged from 51% to 83%. Sensitivity of 
VIA was similar or better than that of cytology however VIA specificity was slightly lower. However, 
screening using VIA/VILI has also been shown increase detection and treatment rates among 
WLHIV in South Africa [227] as it allows for immediate treatment with cryotherapy. 
HPV DNA based tests 
Prior studies have shown that HPV DNA based screening allows for earlier diagnosis of high-grade 
CIN and is more effective in prevention of ICC [235]. A single round of the Digene Hybrid Capture 2 
(HC2) PCR based test which detects 13 HR-HPV types has shown to halve the rate of ICC (HR=0.47, 
95%CI: 0.32-0.69) and ICC-related mortality (HR=0.52, 95%CI: 0.33-0.83) compared to VIA among 
131,746 women aged 30-59 years in India [235].  
Point-of-care (POC) tests, such as the careHPV test (Qiagen) which is based on a simplification of 
the HC2 test platform, detects 14 HR-HPV types and is optimised for developing countries (shorter 
run time, portable batteries, longer shelf-life which does not require refrigeration) has shown good 
performance for the detection of CIN2+ in a large evaluation trial among 2,500 women in China 
[236]; careHPV had sensitivity of 90% for the detection of CIN2+ compared to 41% for VIA; and a 
specificity of 84% compared to 95% for VIA. 
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Table 2.4. Summary of 3 meta-analyses among the general population and 1 cross-sectional study among WLHIV assessing performance of cervical 
tests for CIN2+ and CIN3+ detection  
   CIN2+ 
 
CIN3+ 
Location 
and 
citation 
Test Test strategy N 
studies 
Sensitivity  % 
(95%CI) 
Specificity % 
(95%CI) 
Pooled CIN2+ 
Prevalence %  
(95%CI)  
N 
studies 
Sensitivity  % 
(95%CI) 
Specificity % 
(95%CI) 
Pooled CIN3+ 
Prevalence % 
(%, 95%CI)  
 
General population 
Worldwide 
[237] 
CareHPV Primary screening     1 87.0 (73.2-100.0) 86.1 (84.7-87.5) 1.0 (0.6-1.4) 
HC2a Primary screening 31 90.4 (88.0-92.8) 88.5 (87.0-90.0) 2.2 (1.8-2.6) 22 95.3 (93.3-97.3) 89.0 (87.2-90.8) 1.1 (0.8-1.3) 
 Triage ASCUS 39 90.4 (88.1-92.3) 58.3 (53.6-62.9) 12.0 (10.2-13.7) 17 93.7 (90.4-95.9) 52.3 (45.7-58.7) 6.8 (5.0-8.6) 
 Triage LSIL 24 95.4 (94.0-96.5) 27.8 (23.8-32.1) 21.3 (17.7-24.9) 14 96.4 (90.5-98.7) 23.7 (19.4-28.7) 8.9 (6.6-11.2) 
          
           
Africa and 
India [229] 
VIA Primary screening 11 79.2 (73.3-85.0) 84.7 (80.7-88.8) 2.3  11 82.9 (77.1-88.7) 84.2 (80.0-88.3) NR 
VILI 91.2 (87.8-94.6) 84.5 (81.3-87.8) 93.8 (90.6-97.1) 83.8 (80.5-87.1) 
≥ASCUS 57.0 (37.6-76.3) 92.8 (88.7-96.8) 63.0 (37.9-88.2) 92.3 (88.1-96.6) 
≥LSIL 51.2 (30.0-72.4) 94.9 (92.1-97.7) 56.1 (32.7-79.6) 94.5 (91.6-97.5) 
≥HSIL 42.6 (26.5-58.6) 99.3 (98.8-99.7) 51.6 (32.0-71.1) 99.0 (98.4-99.5) 
HC2 61.9 (56.2-67.7) 93.6 (92.4-94.8) 68.4 (61.5-75.4) 93.4 (92.2-94.6) 
           
Sub-
Saharan 
Africa [228] 
VIA Primary screening 10 82.4 (76.3-87.3) 87.4 (77.1-93.4) 3.3 (2.1-4.7)     
VILI 8 95.1 (90.1-97.7) 87.2 (78.1-92.8) 2.3 (1.5-3.3)     
HC2b 3 88.3 (73.1-95.5) 73.9 (50.7-88.7) 6.9 (1.7-15.2)     
           
           
WLHIV           
South 
Africac 
[238] 
VIA Primary screening 1 65.4 (59.7-76.1) 68.5 (65.3-71.7) 26.0 1 68.2 (59.3-77.2) 61.5 (58.6-64.4) 8.5 
≥ASCUS 94.8 (90.5-99.2) 35.6 (32.2-38.9)  99.9 (98.8-100.0) 29.6 (26.9-32.3)  
≥HSIL 75.8 (70.8-80.8) 83.4 (80.9-85.9)  94.5 (89.8-99.7) 72.7 (70.0-75.3)  
HC2 91.9 (88.5-95.3) 51.4 (48.0-54.8)  97.9 (95.0-100.0) 42.8 (39.8-45.7)  
HC2d Triage HSIL+ 96.6 (94.4-98.9) 17.3 (11.0-23.6)  97.8 (94.9-100.0) 10.4 (6.9-13.9)  
VIAe Triage HSIL+ 81.7 (77.0-86.5) 46.7 (38.4-55.1)  77.5 (69.3-85.8) 30.4 (25.1-35.6)  
≥HSILf VIA 81.9 (77.1-86.7) 72.2 (66.8-77.6)  96.1 (91.7-100.0) 53.6 (49.0-58.3)   
aHC2 as a second test; b2 studies used HC2, 1 used PCR; cthis study enrolled 1193 WLHIV in Johannesburg, South Africa; dHC2 as second test; eVIA as second test; fCytology HSIL+ as second test  
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2.9.2 Novel biomarkers for CIN2+ detection  
HPV testing may detect many transient infections, meaning that its specificity for high-grade CIN 
can be low. A recent review of HPV DNA based tests for the detection of cervical lesions reported 
that for a 10% increase in HR HPV prevalence, HR-HPV DNA based test specificity for CIN2+ 
detection decreased by 8.4% (95%CI: 8.0-8.8%) [239], which has important implications for HIV-
positive populations who have a high prevalence of HR-HPV. HC2 has shown to have high sensitivity 
for CIN2+ and CIN3+ among WLHIV, but poor specificity (Table 2.4) [238].  
Novel methods are therefore required to identify which HPV positive women need colposcopy 
referral or management, avoiding repeat tests/visits, which can result in substantial loss to follow-
up [240, 241].  
While infection with HR-HPV is necessary for the development of cervical lesions and cancer [35, 
37], other molecular changes occur with HR-HPV infection,  leading to subsequent  development 
of alterations  in the functions and abundance of gene products regulating oncogenesis, tumor 
suppression, DNA repair, apoptosis, metastasis and invasion, which are necessary for developing 
a malignant phenotype [242, 243]. Such alterations can result from DNA nucleotide mutations, 
structural genomic variations or epigenetic alterations, such as DNA methylation [244]. Aberrant 
DNA methylation is a potentially good early indicator of existing disease [245] and predictor for 
future development of disease [246].   
Human gene and HPV viral DNA methylation are novel biomarkers that may help distinguish non-
progressive HPV infections from those that progress to cancer. DNA methylation assays are now 
widely available for use in early detection of various cancers, including bladder, breast, colorectal, 
oesaphagal, gastric, head and neck, liver, lung and prostate cancers [246] and increased DNA 
methylation has more recently been shown to be associated with increasing persistence of HPV 
genotypes  [247-249] and severity of CIN lesions [15].  
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Methylation markers have seldom been tested among WLHIV. A combined panel of CADM1, MAL 
and MIR124-2 have previously shown good performance with an area under the receiver operating 
characteristic curve of 0.80 and 0.85 for the detection of CIN2 and CIN3, respectively among WLHIV 
in Nairobi, Kenya [17].  
The human gene EPB4L3 is a member of the band 4.1 protein superfamily, was originally identified 
as a tumour suppressor gene, which is down-regulated in lung adenocarcinoma [250]. EPB41L3 has 
been shown to be implicated in breast cancer [251], prostate cancer [252] and meningiomas [253] 
as a result of loss to its tumour suppressor activity. The performance of the human EPB41L3 has 
been previously shown to have reasonable sensitivity and specificity for the detection of CIN2/3 
relative to ≤CIN1 in the general population [254-256]. Three recent reviews [247-249] report 
methylation of different regions of the HPV16 genome and there are consistent reports of 
increased methylation of the L1 gene and high-grade cervical lesions. However, there are as yet no 
reports of the DNA methylation of EPB41L3 and HPV16 in the detection of CIN2/3 among WLHIV.  
There have been a wide range of studies on DNA methylation of human genes and the HPV virus 
for the detection of HPV related lesions. Many of these studies have looked at different human 
genes and HPV types, or different CpG sites within genes and the HPV virus [257], and it is therefore 
to understand the role of the different DNA methylation markers for detection of CIN2+. One of 
the aims of this PhD was to perform a systemic review of the literature on DNA methylation 
markers associated with CIN2+ among HIV-positive women. The review is extended to HIV-
negative women due to the relative scarcity of data among HIV-positive women. The review is 
summarised in Chapter 4.  
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2.10 Prevention of HPV infection: vaccination 
HPV vaccine type distribution among invasive cervical cancer (ICC) cases in HIV-negative and HIV-
positive women 
Infection with HR-HPV types 16 and 18 account for 70% of all cervical cancers and infection with an 
additional five types (31/33/45/52/58) account for >90% of cancers among HIV-negative women [73]. 
Vaccine manufacturers have designed a range of vaccines targeting HPV16 and 18 (combined in a 
bivalent and a quadrivalent vaccine, which also includes HPV6 and 11). The nonvalent vaccine, more 
recently available, includes the five additional HR types mentioned above (targeting 
HPV6/11/16/18/31/33/45/52/58). These vaccines have been extensively evaluated in HIV-negative 
populations [258], but there are as yet no efficacy data among WLHIV.  
A recent systematic review by investigators at International Agency for Research on Cancer (IARC) 
compared the HPV type distribution and the HPV vaccine type distribution in ICC biopsy and 
cervical cell specimens of 770 HIV-positive and 3846 HIV-negative women from 21 studies in 12 
African countries [14]. The authors report that the fraction of ICC attributable to the HPV types 
included in the current bivalent (HPV16/18) and nonavalent (HPV16/18/31/33/45/52/58) vaccines was 
similar among HIV-positive and HIV-negative women (bivalent: 61.7% and 67.3%; nonavalent: 88.9% 
and 89.5%, respectively). However, a non-negligible proportion of ICC from both HIV-positive and 
HIV-negative women were infected with non-vaccine types in the absence of any of the vaccine 
types (7.0% and 7.9% of ICC from HIV-positive and HIV-negative women, respectively), and this was 
highest for HPV35. These findings confirm that the currently available HPV vaccines could prevent 
a similar proportion of ICC cases in HIV-positive as in HIV-negative women.  
 
 
67 
 
 
 
2.10.1 HPV vaccinations among people living with HIV 
Although there is no direct data yet available on HPV vaccine efficacy among persons living with 
HIV (PLHIV) (Table 2.5), 2 recent reviews of trials of the bivalent (targeting HPV16 and -18) and 
quadrivalent (targeting HPV6/11/16/18) vaccines among PLHIV confirms that HPV vaccines are safe 
and immunogenic in children, female adolescents and adults (Table 2.5) [12, 259]. Seroconversion 
rates have been high in both ART users and ART naive vaccinees with high antibody titres sustained 
up to 12 months in both groups [260]. Antibody titres were comparable between HIV negative and 
ART users, but lower among ART-naïve patients [260, 261]. A recent meta-analysis of seropositivity 
studies among PLHIV following vaccination reported HPV antibody responses of 98% for HPV16 and 
94% for HPV18 following 3 doses of vaccination [259]. There are no data on safety, immunogenicity 
or efficacy of the more recently available nonavalent vaccine (targeting 7 HR types: 
HPV16/18/31/33/35/52/58 and the two LR types [HPV6/11]) among PLHIV to date. The nonavalent 
HPV vaccine offers greater scope for protection against a greater range of HPV types, important 
in a population with high levels of multiple HR infection. Given the high prevalence and incidence 
of HPV types other than HPV16/18 and high number of multiple HR-HPV infections in WLHIV, the 
nonavalent HPV vaccine has greater scope for potential prevention of diseases associated with 
these HPV types.  
Table 2.5. Summary outcomes of vaccine studies in target groups  
Outcome Young women 
Mid-adult 
women 
Young men Children  HIV+ 
Infection efficacy ✔ ✔ ✔ ✗ ✗ 
CIN2+ efficacy ✔ ✔ -  ✗ ✗ 
CIN3 efficacy ✔ ✗  - ✗ ✗ 
VIN/VIN 2/3 efficacy ✔ ✗  - ✗ ✗ 
Genital warts efficacy ✔ ✗ ✔ ✗ ✗ 
Anal infection efficacy ✔ ✗ ✔ ✗ ✗ 
AIN2+ efficacy ✗ ✗ ✔ ✗ ✗ 
Partial cross-protection infection ✔ ✗ ✗ ✗ ✗ 
Partial cross-protection CIN2+ ✔ ✗ ✗ ✗ ✗ 
Therapeutic efficacy None ✗ ✗ ✗ ✗ 
Immunogenicity  ✔ ✔ ✔  ✔ ✔ 
Safety No concerns No concerns No concerns No concerns No concerns 
Adapted from [12, 258]
68 
 
 
 
2.11 Country profiles 
 
The research in this PhD was performed among WLHIV in Burkina Faso (BF) and South Africa (SA), 
two countries with different burdens of HPV infection and cervical cancer, and different 
approaches to screening for cervical cancer.  The two countries also represent the spectrum of HIV 
infection (Figure 2.11), from relatively low prevalence in BF to high prevalence in SA, thereby 
providing useful case studies to determine the natural history HPV-related disease among WLHIV 
in different African contexts.   
 
Figure 2.11. HIV prevalence over time among women aged ≥15 years, 1990-2015 
  
Data extracted from UNAIDS AIDSInfo (2015) [10] 
2.11.1 Burkina Faso  
 
Burkina Faso has a total population of 18.1 million (Table 2.6). It is a country with a young 
demographic (46% are less than 15 years old). Life expectancy is 59 years, compared to 71 years 
worldwide.  Just under half (44%) of the population live below the poverty line of less than US$1.90 
a day.  
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Table 2.6. Demographic, sexual behavior and HIV-related factors in Burkina Faso and South 
Africa, 2012 
 Burkina Faso  South Africa  
 
  
   
Demographic factors   
Population, totala 18,105,570 54,956,920 
Population <15 years (%)a 45.6 29.0 
Life expectancy at birth, total (years) a 58.6 57.2 
Fertility rate (births/woman) a 5.7 2.41 
Population, female (% of total) a 50.4 50.8 
Population, female aged ≥15 yearsa 5, 040,000 19, 810, 000 
Urban population (% of total) a 29.9 64.8 
   
GDP per capita (current US$) a 589.8 5,724.0 
Poverty headcount ratio at national poverty lines (% of 
population) a,b 
40.1 53.8 
Poverty headcount ratio at $1.90 A DAY (2011 PPP)  
(% of population) a 
43.7 16.6 
   
Health service   
Health expenditure (% of GDP) a 5.0 8.8 
Number physicians/1000 population a,c 0.05 0.8 
Nurses/midwives/1000 population a,c 0.57 4.7 
   
HIV-related    
HIV prevalence among adults aged 15 to 49 years, %d 0.8 19.2 
HIV prevalence among young women (15-24 years) , %d 0.4 11.6 
HIV incidence rate among adults (15-49 years) d 0.05 1.44 
Number of adults  (≥15 years) living with HIVd 88,000 7,000,000 
Number of women (≥15 years) living with HIVd 53,000 4,000,000 
Number of deaths due to AIDS  (women ≥15 yrs) d 1,300 81,000 
Number of women (≥15 years) receiving ARTd 35,468 2,133,020 
   
HIV spending   
HIV spending from domestic public and international 
sources (US$)e 
49,000,000 1,880,000,000 
HIV spending from domestic public sources (%)e 7,780,061 (15.9%) 1,492,672,908 (79.4%) 
   
Cervical cancer estimates   
Cervical cancer incidence rate per 100,000 per year 
(age standardised)f 
23.3 31.7 
Mortality form cervical cancer rate per 100,000 per year 
(age standardised)f 
18.6 18.0 
Most frequent cancer among women 
(ranked by total # cases) f 
Cervix uteri Breast (followed by 
cervix uteri) 
Control and prevention measures   
HPV vaccination No Yes – school aged girls 
(started 2014) 
Primary cervical cancer screening modality Visual inspection 
 (with acetic acid or Lugol’s 
Iodine) 
Cervical cytology  
aWorld Bank (2015);  bNational poverty headcount ratio is the percentage of the population living below the national poverty lines. 
National estimates are based on population-weighted subgroup estimates from household surveys; in BF this is below CFA 82,672 
(US$165); cdata for Burkina Faso from 2010 at CIA:  https://www.cia.gov/library/publications/the-world-factbook/fields/2226.html and 
WHO: http://apps.who.int/iris/bitstream/10665/136973/1/ccsbrief_bfa_en.pdf; dUNAIDS (2015); eUNData, from 
http://data.un.org/Data.aspx?d=UNAIDS&f=inID%3A49  fHPV information Centre (2016), Institut Català d'Oncologia at 
http://www.hpvcentre.net 
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2.11.1.1 HIV control and Prevention 
In 1990, there were 78,000 women ≥15 years with HIV (prevalence of 3.6%). At the end of 2015, 
53,000 women ≥15 years were living with HIV (prevalence of 0.8%, Table 2.6), with the highest 
prevalence in the capital city of Ouagadougou (Centre Region, Figure 2.12). In the same year, there 
were 2,300 new infections and 1,300 AIDS-related deaths among women ≥15 years [10] (Figure 
2.13). By end-2015, 35,468 women aged ≥15 years were receiving ART (coverage of 66%) [10]. 
Figure 2.12. HIV Prevalence by region in Burkina Faso, 2010 DHS estimates [262] 
  
The first ARVs were made available in local private pharmacies from 1996 but their high cost was a 
significant barrier and this led to irrational use as most patients were able to afford only 
intermittent monotherapy or dual therapy [263]. Up until 2009, Burkina Faso was the exception to 
the trend in Africa of abolishing user fees for ART access. It had a direct out-of-pocket payment for 
ARVs at the point of care delivery, with subsidized payments for ARVs, laboratory tests and 
physician’s consultations, while the poorest received these services for free [264]. In 2005, the 
National AIDS Council decided that each HIV-infected person could have access to ART with an 
individual monthly income of CFA 5,000 (US$10), which was decreased to CFA 1,500 (US$3) in 2008. 
Patients identified as “worst off” would receive ART for free [264].  
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Figure 2.13. Time-trend analysis of HIV epidemic worldwide, in Sub-Saharan Africa, South Africa and Burkina Faso*  
 
  
 
*Data extracted from UNAIDS AIDSInfo (2015) [10]; (no data available on ART use before 2010)
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In 2015, 40% of the population lived on less than US$1.90 a day.  A 2010 study interviewing 499 
PLHIV from 26 public health centres, non-governmental organisation (NGOs) and faith-based 
health facilities reported that 79% did not pay for their treatment, while among those that were 
charged, 95% paid the subsidized amount of US$ 10 and 5% paid only a part of the subsidized 
amount ranging from US$1 To US$2.50 [264].  The State procures ARVs via the Global Fund and 
distributes them to public services centres or NGOs based on estimated needs [265]. In 2011, the 
then President, Blaise Compaoré, announced ARVs would be free of charge, and in 2012, 
committed to reducing the country’s dependence on external funding by expanding the share of 
domestic resources allocated to the HIV response from 15% to 25% (Table 2.6).    
2.11.1.2 Cervical cancer control and prevention  
Burkina Faso has a population of 5 million women aged 15 years and older who are at risk of 
developing cervical cancer [266] (Table 2.6). Cervical cancer ranks as the most frequent cancer 
among women in Burkina Faso. In Burkina Faso, cervical cancer incidence and mortality was 23.3 
and 18.6 per 100,000 per year- in 2012 (age standardised rate) [9].  
Visual inspection using VIA or VILI is the current method for cervical cancer screening. A WHS (WHO 
Household Survey) carried out between 2001 and 2002 found that 5.5% of all women aged 18-69 
years were screened within the previous 3 years  [266]. An updated WHS survey in 2008 reported 
cervical cancer screening coverage to be 7.8%; this was highest among women 25-34 years old 
(11.8%) and decreased to 6.5% among those 35-44 years old with further decreases among older 
women.    
The quadrivalent (Gardasil®, Merck) vaccine is licensed for use in Burkina Faso, but there is currently 
no organised vaccination programme. 
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2.11.2 South Africa 
South Africa has a total population of 55 million (Table 2.6), 29% of whom are <15 years old, with a 
life expectancy of 57 years.  South Africa is an upper middle-income country (GDP of US$5,724), 
and is the second largest economy in the African region (after Nigeria), yet just under a fifth of the 
population live below the poverty line of less than $1.90 a day.  
2.11.2.1 HIV control and prevention  
South Africa has the largest number of WLHIV in the world, with the highest prevalence (4 million 
women ≥15 years among a total of 19.8 million women in 2015, Figure 2.13), and the highest number 
of new infections per year (200,000 in 2015) [10]. The highest HIV prevalence is in the eastern 
province of KwaZulu-Natal; 27.6% among girls <18 years and 52.0% among women ≥18 years [267] 
(Figure 2.14).  
Figure 2.14. HIV Prevalence by district in South Africa 2012 [268] 
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HIV incidence among women ≥15 years peaked in 1997 and 1998 (440,000 new infections recorded 
in each year) and was in decline between 2000-2009, which may be due to the scaling up of 
combination prevention programs, such as medical male circumcision and treatment expansion at 
higher CD4+ cell counts [269]. However, from 2010 to 2016, it has been on the increase (from 
170,000 new infections among women ≥15 years in 2009 to 200,000 in 2016) (Figure 2.13). Although 
South Africa’s National Integrated Strategy on HIV, STIs and TB (2012-2016) [270] aimed to reduce 
HIV incidence by 50%, young people aged 15-24 years continue to have high incidence of HIV. In 
particular, young women aged 15-19 years have the highest incidence (4.7 per 100 woman years in 
KwaZulu-Natal [267]) and are 8-times more likely to become HIV-infected compared to males in 
the same age group [268], which may in part be attributed to having older male partners [271].  
ART became available to adults and children in April 2004 in several accredited service points across 
the country. By September 2005, only 5% of all public healthcare facilities were providing ART and 
85,000 people were enrolled on ART in the public sector. The availability of wide-scale ART was 
hampered during the Mbeki government between 1999 and 2008, characterised by denial of the 
causal link between HIV and AIDS.  As a direct result of delay in wide-scale roll-out of ART, it is 
estimated that more than 330,000 lives were lost [272], and those that survived may have suffered 
more severe HIV disease progression.  In 2009 with a change in government, a national counselling 
and testing (HCT) campaign was established, in addition to the abandonment of the accreditation 
of health centres for ART provision and an increase in HIV prevention measures such as medical 
male circumcision [269]. The national ART guidelines were revised in 2010, expanding treatment to 
children <1 year, all pregnant women regardless of CD4+ cell count and all TB-HIV co-infected 
patients with CD4+ count of <350 cells/µl, as well as changing ART for first and second-line therapy, 
followed by the inclusion of  sex workers, men who have sex with men, truckers and adolescents 
in 2011 [269]. In 2012, the initiation CD4+ count threshold was increased to 350 cells/µl for all adults, 
as well as expanded access thresholds for children. By mid-2016 3,710,130 people living with HIV 
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were receiving ART; and 2,133,020 of these were women aged 15 years and over (coverage of 53%) 
[10] (Figure 2.13).  
A study using demographic and HIV surveillance data in KwaZulu-Natal between 2001 and 2014 
investigated changes in life expectancy before, during, and after ART was rolled out. The authors 
report that 5.2 and 17.1 years of life were gained for men and women, respectively, after ART 
introduction [273], however these estimates were dependent on lower CD4+ cell count thresholds 
for ART initiation and decentralised healthcare availability. Beginning in September 2016, the 
Department of Health announced the introduction of immediate ART initiation for those testing 
positive for HIV in the public sector [274] following WHO recommendations. The wide-scale 
availability of this “test-and-treat” strategy is still uncertain. Studies have shown that women are 
at decreased risk of HPV persistence [209] and CIN2+ [193] if ART is initiated at higher CD4+ counts 
(>500 cells/mm3), and earlier ART initiation promises a potential reduction in cervical precursor 
lesions and ICC if ART is made available to all.  However, there remains a generation of women who 
started ART at lower CD4+ cell counts according to older guidelines and they remain at increased 
risk of ICC. Improved survival among these women may lead to increased ICC rates [208]. 
2.11.2.2 Cervical cancer control and prevention  
South Africa has a population of 19.8 million women aged 15 years and older who are at risk of 
developing cervical cancer [275] (Table 2.6). Cervical cancer ranks as the second most frequent 
cancer among women (breast cancer being the first) and the most frequent cancer among women 
between 15 and 44 years of age. Cervical cancer incidence and mortality was 31.7 and 18.0 per 
100,000 per year-in 2012 (age standardised rate) [9] (Table 2.6).   
The South Africa national policy on cervical screening, established in 2002, allows for three 
cytological smears in a woman’s lifetime taken at 10-year intervals from 30 years of age. [276]. 
Women with LSIL or ASCUS on cytology have repeat smears within 12 months and are referred to 
colposcopy if the outcome is the same or worse. Women with HSIL or atypical glandular (i.e. from 
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the endocervical epithelium) cells of underdetermined significance (AGUS) are immediately 
referred to colposcopy, and if they have abnormal findings, are managed for cervical lesions. This 
policy has been implemented in some areas but not throughout the country. Currently there is no 
population-wide screening programme in SA. In several areas partial screening does take place, 
and opportunistic screening is commonly practised in the private sector.  Using data from the WHS 
in 2008, cervical cancer coverage in South Africa was reported to be 23.2% in 2008; this was highest 
among younger women; 27.7%, 28.5%, 13.3% and 14.0% among women aged 25-34, 35-44,  45-54 and 
55-64 years, respectively [277]. And in 2014, the uptake of cervical screening was estimated to be 
21.4% among women aged 30-39 [275]. The goal set in 2002 was to achieve screening of 70% of 
women ≥30 years within 10 years of the introduction of screening [274]. 
The national cancer control programme is currently being revised, to be implemented in 2017, to 
1.) include HPV DNA testing where feasible; 2.) upgrade cytology-based programmes where they 
exist; and 3.) include a programme for WLHIV following international recommendations [274]. 
Current international guidelines recommend that cervical cancer screening should be started in 
sexually active girls and women, as soon as they have tested positive for HIV [278]. If the screening 
test is negative, a repeat test is done within three years. Women receiving treatment should 
receive follow-up at one year post-treatment [278]. WLHIV who have invasive cervical cancer 
should be managed in the same way as HIV-negative women [278, 279].  
Both the bivalent (Cervarix®, GSK) and quadrivalent (Gardasil®, Merck) vaccines are licensed for use 
in SA. Between March and April 2014, the SA government piloted an HPV vaccination programme 
using 2 doses of the Cervarix® vaccine among schoolgirls and achieved 91% school coverage, in total 
vaccinating over 340,000 girls [280]. The vaccine was introduced in the public sector in 2014 
through the Integrated School Health Program and is offered to schoolgirls ≥9 years, annually.  
Pilot studies have been completed in KwaZulu-Natal and Gauteng and have been positively 
evaluated in terms of vaccine uptake in 2015 [281, 282].  
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3 ANTIRETROVIRAL THERAPY, HIGH-RISK HUMAN PAPILLOMAVIRUS AND 
CERVICAL INTRAEPITHELIAL NEOPLASIA: A SYSTEMATIC REVIEW AND 
META-ANALYSIS  
 
As combined ART is scaled-up, longer survival times among WLHIV may increase the rates of cervical 
cancer.  The interactions of ART and the natural history of HR-HPV and cervical lesions in WLHIV are 
poorly understood. Observational studies differ with respect to study design, outcomes, timing of 
ART initiation and effectiveness of ART use, making it difficult to estimate the true effect of ART.  
Previous systematic reviews have explored the association of ART and HR-HPV and cervical lesions 
[173, 211, 212] but no meta-analysis has quantified the risk of HR-HPV and cervical lesions among ART 
users compared to ART-naive women. Given the large and increasing number of women on ART, 
improved understanding of the interplay of ART, immune recovery and virological control on the 
natural history of HR-HPV infection and CIN progression is needed to guide screening programs.  
In this chapter, I perform a systematic review of the literature on the association of ART with HR-HPV 
prevalence, and cytological and histological cervical lesions. This review was originally performed to 
inform the cross-sectional and prospective analyses as part of Study 1 (Chapter 7) which investigated 
the association of HIV-related factors, including ART, CD4+ cell count and HIV-1 PVL with HR-HPV and 
CIN2+ outcomes.  
Note: An updated version of this review was performed in November 2016 to update the literature 
before publication (currently under review with Lancet HIV) as there were additional studies 
published that were relevant to the review. As such, the data originating from this thesis on the 
association of ART with HR-HPV prevalence and CIN2+ prevalence and incidence (as part of the HARP 
study) are also included in the meta-analysis.  
78 
 
 
 
3.1 Objectives 
 To evaluate the association of ART with HR-HPV prevalence, and with 
cervical lesion prevalence, incidence, progression and regression 
 To investigate the role of HIV-related co-factors that might modify these 
associations, such as ART duration, timing of ART initiation and immune 
suppression and recovery 
(Objective 1.1) 
3.2 Methods 
3.2.1 Literature search 
Medline and Embase databases were searched for publications in the English language using 
search terms for HPV, CIN, SIL and ART (Appendix 1). Reference lists of review articles and all 
articles identified in the systematic search were checked. The search was carried out from January 
1996 (when highly active ART [HAART] became utilised) up to 05 November 2016. All abstracts 
were screened by one author (HK). Full text copies of relevant publications were obtained and 
assessed for eligibility by two authors (Helen Kelly [HK] and Philippe Mayaud [PM]). Consensus 
was reached on potential relevance.  
3.2.2 Inclusion and exclusion criteria 
Exposure and outcome measures 
Studies were eligible if they reported the association of combination ART (cART) or HAART use 
with the following outcomes: HR-HPV prevalence and cervical lesion prevalence, incidence, 
progression or regression among WLHIV. Studies were also considered eligible if they provided 
raw data to calculate an unadjusted effect estimate.  
For HR-HPV outcomes, studies reporting genital HR-HPV only were included. There were no 
exclusions on HPV test methods. For the prevalent lesion outcomes, studies reporting low-grade 
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lesions and greater (LSIL+) or a combined outcome measure of “any CIN grade” which could 
include CIN1, were excluded as they are not considered true measures of disease, as were studies 
reporting cervical lesions using visual inspection using acetic acid (VIA) or Lugol’s iodine (VILI) due 
to the poor sensitivity and specificity in detecting high-grade lesions. Studies on invasive cervical 
cancer (ICC) cases were excluded due to the difficulty in accounting for temporal associations in 
the longer duration of ICC development.  
Types of studies 
For prevalent outcomes, cross-sectional studies were included if they reported the association of 
ART use with HR-HPV and/or high-grade lesions (histological CIN grade 2 or higher [CIN2+] or 
cytological high-grade SIL or higher [HSIL+]). Cohort studies were included if participants initiated 
ART at enrolment, were followed-up and had measures of HR-HPV at baseline and in the follow-up 
visit.   
For the longitudinal outcomes, cohort studies reporting the association of ART with the incidence, 
progression and regression of “any SIL”, which could include atypical squamous cells of 
undetermined significance (ASCUS) as well as LSIL and HSIL+ lesions were included as SIL 
represents various incremental degrees of HR-HPV persistence and subsequent lesion 
development.  
For publications that reported results from the same cohort, but at different follow-up visits, the 
publication that gave the most relevant description of the cohort and study design and the most 
complete set of results was included. There was no restriction on age or geographical location.  
3.2.3 Data extraction 
From the consensus list, data were extracted by one author (HK) and a random sample of 25% was 
checked by a second author (Helen Weiss [HW]). For studies reporting prevalence of HR-HPV or 
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cervical lesions, Odds Ratios (OR) were extracted. For studies reporting cervical lesion incidence, 
progression or regression, Hazard Ratios (HR) or OR were extracted.  
3.2.4 Methodological quality assessment 
Studies were assessed primarily on adjustment for HIV-related factors (current and nadir CD4+ cell 
count and ART duration). Cross-sectional studies that adjusted for either current or nadir CD4+ 
count or ART duration were considered separately in sensitivity analysis, as were cohort studies 
that adjusted for time on ART during follow-up. Study quality was also assessed on participant 
selection, statistical method and HPV test used, and cervical lesion classification (cytological or 
histological) (Appendix 2 to Appendix 4).  
3.2.5 Statistical analysis  
Meta-analyses were performed for the discrete outcomes of HR-HPV prevalence, high-grade lesion 
(CIN2+ or HSIL+) prevalence and incidence, progression and regression of “any SIL”, respectively.   
Adjusted effect estimates were reported where available. For the cross-sectional studies in which 
adjusted effect estimates were not reported but raw data were provided, crude ORs were 
calculated (HK) and independently verified (HW and PM). Authors were contacted when the paper 
suggested that relevant data was collected but not reported.  
Random-effects meta-analysis were used to estimate pooled effects to account for between-study 
heterogeneity.[283]  Heterogeneity was examined using the I2 statistic and publication bias using 
funnel plots and Begg’s test for correlation between the effect estimate and their variances.[284, 
285]  An influence analysis was performed to assess the robustness of the pooled summary effects 
by excluding each of the studies from the pooled estimate. Sub-group analyses by geographic 
region were performed to compare pooled effects and heterogeneity. Sensitivity analyses 
excluding studies unadjusted for HIV related factors were performed. Data were analysed using 
Stata version 14 (Stata Statistical Software, College Station. TX: Stata Corporation).  
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This review was reported according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analayses (PRISMA)[286] and the Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines [287] and was registered on the PROSPERO database at the Centre of Reviews 
and Dissemination, University of York; registration number CRD42016039546.  
 
3.3 Results 
3.3.1 Antiretroviral therapy and HR-HPV Prevalence 
The review identified 521 publications through Medline and Embase searches, of which 176 
duplicates were removed and 312 excluded after abstract review, leaving 33 articles for full text 
review. Finally, 14 articles matched the inclusion criteria and four additional publications were 
identified through cross-referencing (Figure 3.1 (A)). Data were extracted from 18 publications (14 
cross-sectional; four cohort) representing 19 discrete populations and providing data from 6,441 
WLHIV, of whom 3,677 (57%) were taking ART (ranging from 19-85% in cross-sectional studies), 
2,032 (32%) were ART-naive and 732 (11%) were ART initiators. Three ART initiation studies compared 
HR-HPV before and after ART initiation (i.e. women acted as their own controls) [288-290](Table 
3.1). One publication provided data from two countries [291] and was considered as two individual 
studies in the analysis, resulting in a total of 19 included studies.  
The pooled OR among 19 studies [184-186, 188, 192, 288-300] indicates that WLHIV on ART had a 
lower risk of HR-HPV prevalence compared to ART-naïve (crude Odds Ratio [OR]=0.80, 95%CI: 0.66-
0.97), but there was a high degree of heterogeneity between studies (I2=72%, p-value for 
heterogeneity <0.001; Table 3.4, Figure 3.2).  Restricting the analysis to the 12 studies that adjusted 
for either current or nadir CD4+ cell count, or ART duration [185, 186, 188, 288-293, 295, 300] the 
OR was similar but with a moderate degree of heterogeneity (adjusted OR=0.83, 95%CI: 0.70-0.99, 
I2=51%, p=0.02). The reduction in heterogeneity on adjustment for confounding was most 
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noticeable among the studies from Africa; among six studies[186, 288, 291-293] the aOR was 0.70 
(95%CI: 0.56-0.88) with no evidence of heterogeneity (I2=0%, p=0.97). Similarly, among studies from 
Europe/North America, three studies [185, 289, 290] showed a similar reduction in HR-HPV 
(aOR=0.74, 95%CI: 0.59-0.93, I2=48%, p=0.14). This was in contrast with the two studies from 
Asia[188, 295] (aOR=1.72, 95%CI: 1.10-2.68, I2=0%, p=0.34) and three from Latin America [298-300] 
(crude OR=1.08, 95%CI: 0.84-1.39, I2=0%, p=0.99).  
The pooled OR from three cohort studies that followed women before and after ART initiation 
[288-290] provides strong evidence of a decreased risk of HR-HPV after compared to before ART 
initiation (aOR=0.79, 95%CI: 0.71-0.88, I2=48%; p=0.15, data not shown).  
Nine studies reported the association of ART duration with HR-HPV prevalence.[185, 186, 291-293, 
295, 296, 299] While HR-HPV prevalence was similar among the ART-naïve and short-duration users 
(≤2 years), the pooled OR suggests that HR-HPV was lower among prolonged ART users (>2 years) 
compared to short-duration users and ART-naïve combined (crude OR=0.65, 95%CI: 0.55-0.77, 
I2=0.0%, p=0.92 data not shown), and among the seven adjusted studies [185, 186, 291-293, 295] the 
association was similar (aOR=0.65, 95%CI: 0.55-0.78, I2=0%, p=0.91, adjusted for current and nadir 
CD4+ cell count, data not shown). 
 
Sensitivity analysis  
There was no evidence to suggest publication bias; i.e. smaller studies were not more likely to 
report a positive association (Beggs rank correlation test; p=0.12 for the crude analysis; p=0.34 for 
adjusted analysis; Appendix 5).  
 
3.3.2 Antiretroviral therapy and cervical cytological and histological lesions 
This review identified 661 publications for ART and cervical lesion prevalence, incidence, 
progression or regression, of which 165 duplicates were removed and 446 excluded after abstract 
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review, leaving 50 articles for full review. Finally, 20 articles matched the inclusion criteria and 12 
additional publications were identified through cross-referencing (Figure 3.1 (B)).  
Thirteen studies [186, 193, 194, 202, 222-225, 291, 301-303] reported the association of ART with 
CIN2+/HSIL+ prevalence among 8,262 WLHIV, of whom 4,463 (54%) were taking ART (range across 
studies: 16-76%) and 3,799 (46%) were ART-naïve (Table 3.2). One publication provided data from 
two countries,[291] and was considered as two individual studies in the analysis.  
Ten studies reported the association of ART with incident SIL or LSIL from a combined total of 
3,266 women, all of which used time-to-event analyses [195-197, 200, 201, 289, 304-307], and two 
studies reported the association of ART with incident CIN2+ using logistic regression[291, 
308](Table 3). Ten studies [189, 190, 192, 195, 197-199, 201, 218, 309] were included for SIL 
progression from a combined total of 6,212 women; six of these used time-to-event analysis[189, 
192, 198, 199, 201, 218], and nine studies [189, 192, 195, 197, 218, 289, 309-311] for SIL regression from 
a combined total of 5,059 women, five of these used time-to-event analysis [189, 192, 218, 289, 
310](Table 3.3). 
 
Cervical lesion prevalence  
The pooled OR among 13 studies [186, 193, 194, 202, 222-225, 291, 301-303] suggests no evidence of 
an association of ART with high-grade cervical lesion prevalence (crude OR=0.90, 95%CI: 0.68-1.20, 
I2=61.0%, p=0.002; Table 3.4, Figure 3.3). The nine African studies [186, 193, 194, 222-224, 291, 301] 
found weak evidence of an association of ART with high-grade lesion prevalence [crude OR=0.84, 
95%CI: 0.64-1.10, I2=45.5%, p=0.07). When analyses were restricted to four studies [186, 291, 302] 
that adjusted for both current CD4+ cell count and ART duration there was some evidence that 
ART users had decreased odds of high-grade lesion prevalence compared to ART-naive women  
(aOR=0.65, 95%CI: 0.40-1.06, I2 =29.5%, p=0.24).  
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Sensitivity analysis 
There was a large variation in the study size [range: 70-3185]; the largest study [193] enrolled 3,185 
WLHIV (40% of participants included in the meta-analysis). However, excluding this study did not 
change the overall results. The next largest study [201] enrolled 1,010 WLHIV in Johannesburg and 
reported an increased risk among ART users (crude OR=1.31, 95%CI: 0.92-1.86), but the estimate 
was not adjusted for CD4+ cell count or ART duration. When excluded, the pooled OR among eight 
studies in Africa showed a protective effect of borderline significance (crude OR=0.77, 95%CI: 0.59-
1.01) with less between-study heterogeneity (I2=30.4%; p=0.19).  There was no evidence to suggest 
publication bias (Beggs rank correlation test; crude analysis: p=0.46, adjusted analysis: p=0.50; 
Appendix 5). 
 
Cervical lesion incidence  
The pooled Hazard Ratio (HR) among 10 studies [195-197, 200, 201, 289, 304-307] provides weak 
evidence of an association of ART with incident SIL (crude HR=0.75, 95%CI: 0.56-1.00, I2=41%, p=0.09; 
Table 3.4, Figure 3.4). Among five studies that adjusted for the time-varying effects of ART [196, 
197, 289, 306, 307] there was evidence of a reduction in SIL incidence among ART users (aHR=0.64, 
95%CI: 0.47-0.86, I2=19.4%, p=0.29).  
When restricting analysis to five studies reporting incidence of any SIL grade [197, 201, 289, 306, 
307] there was a reduction among ART users (crude HR=0.66, 95%CI: 0.52-0.83, I2=0.0%; p=0.72), 
but not among five studies reporting the association of ART on incidence of ≥LSIL[195, 196, 200, 
304, 305](crude HR=0.91, 95%CI:0.44-1.87, I2=64.8%; p=0.02, data not shown). 
Whilst not included in the meta-analysis due to the use of logistic regression instead of time-to-
event analysis, two studies reported a reduction in incident CIN2+ among ART users. Clifford et 
al[308] report that those with prolonged ART use (>2 years) at baseline had a decreased odds of 
CIN2/3 incidence (aOR=0.64, 95%CI: 0.42-0.98, adjusted for nadir CD4+ cell count) compared to 
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ART-naïve in a case-control study in Switzerland (Table 3). Similarly, Kelly et al[291] reported a 
reduction in incident CIN2+ over 16 months among ART users compared to those who remained 
ART-naïve (aOR=0.39, 95%CI: 0.15-1.01, adjusted for baseline CD4+ cell count) in South Africa.  
There was no evidence to suggest publication bias for SIL incidence studies (Beggs rank correlation 
test; crude analysis: p=0.42, adjusted analysis: p=1.00; Appendix 5). 
 
Cervical lesion progression and regression  
The pooled HR among six studies[189, 192, 198, 199, 201, 218] suggests a decreased hazard of SIL 
progression among ART users (crude HR=0.64, 95%CI: 0.56-0.74, I2=0%, p=0.42; Table 3.4; Figure 
3.5). Restricting the analysis to four studies[189, 198, 199, 218] that adjusted for time-varying ART 
did not vary the estimate (aHR=0.64, 95%CI: 0.54-0.75, I2=17.8%, p=0.30). Similarly, there was no 
variation by region.  
The pooled HR among five regression studies[189, 192, 218, 289, 310] suggests an increased 
likelihood of SIL regression among ART users (crude HR=1.67, 95%CI: 1.32-2.12, I2=31.0%, p=0.22; 
Table 3.4, Figure 3.6). Restricting the analysis to four studies[189, 218, 289, 310] that adjusted for 
time-varying ART during follow-up did not vary the estimate (aHR=1.58, 95%CI: 1.28-1.94, I2=18.2%, 
p=0.30).  
Sensitivity analysis  
While most studies reported progression of any SIL grade, one study reported progression of LSIL 
to a higher grade.[218] No effect in the estimate was observed when excluding that study (crude 
HR=0.63, 95%CI:0.51-0.78, I2=18%, p=0.30). There was no evidence to suggest publication bias for 
the progression studies (Beggs rank correlation test; p=0.85, Appendix 5), but there was some 
evidence for the regression studies (p=0.01; Appendix 5), as more of the small studies reported 
positive association of ART with regression. However, even the largest study (enrolling 1048 
WLHIV followed up over a median 18 months[218]) reported a significant increased likelihood of 
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regression among ART users compared to ART-naïve (aHR=1.71, 95%CI: 1.29-2.27, adjusted for ART 
duration, age and excision treatment), suggesting a real beneficial effect of ART.    
 
3.4 Discussion 
This systematic review and meta-analysis confirms that women on ART have a lower prevalence of 
both HR-HPV and high-grade cervical lesions, a reduction in SIL incidence and progression, and an 
increase in regression, after adjusting for CD4+ cell count and duration on ART. It is also the first 
study to quantify the association of ART with prevalent HR-HPV and high-grade cervical lesions.  
Performing a meta-analysis of observational studies for HR-HPV and cervical lesion outcomes has 
difficulties due to inherent differences in study populations, definitions of exposure and outcomes 
used, and varying approaches to adjustment of effect estimates. In particular, a major limitation of 
cross-sectional studies is the difficulty in establishing the timing of HPV infection and development 
of cervical lesions with regard to ART initiation and nadir CD4+ cell count. While pooling studies 
with and without adjustment for nadir or current CD4+ cell count or ART duration may have shown 
a limited effect of ART on HR-HPV or cervical lesions, restricting analysis to those studies that did 
adjust for any of these factors suggests that ART is associated with a reduction in any of the 
outcomes, with less between-study heterogeneity. Among studies that report limited or no 
association, immune reconstitution by ART may not be established early enough after HPV 
infection to prevent or reverse the development of HR-HPV persistence or CIN2+.  
Several studies reported that a high nadir CD4+ cell count was associated with between a 36-70% 
decreased risk of HR-HPV [185, 300] and 36-80% decreased risk of CIN2+ [193, 202, 308] compared 
to those with low nadir CD4+ cell count.  Once on ART, others have shown that ‘effective’ ART (i.e. 
prolonged duration with sustained HIV-1 viral suppression and stable high CD4+ cell count) was 
associated with a reduction in HR-HPV persistence and CIN2+ [185, 291]. The protective effect of 
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ART may only be seen over prolonged duration, accompanied by HIV-1 viral suppression and 
immune reconstitution.  
There has been a steadily increasing representation of studies from African settings in recent years, 
while many of the earlier studies were performed in the USA or Europe, leading to a geographical 
and period heterogeneity. The African studies provide encouraging indication that earlier initiation 
and effective ART over prolonged duration can prevent cervical lesion incidence and progression 
and promote regression.  
There were fewer studies from Latin America and Asia and the majority were cross-sectional in 
design. These studies reported an opposite increased risk of HR-HPV and high-grade cervical 
lesions among ART users. It is still unclear if this is due to lower nadir CD4+ cell count before ART 
initiation. Thus, regular cervical cancer screening remains important especially among women on 
ART if they have started at a low nadir CD4+ cell count. This concerns a generation of women who 
may have started ART under older guidelines at specific lower CD4+ cell count thresholds and who 
may never have fully recovered their HPV-specific mucosal immune response.  
 
Limitations 
The majority of cross-sectional studies compared HR-HPV and CIN2+/HSIL+ using a binary category 
of ART users and ART-naïve. A more informative analysis would be to measure the effect of ART 
duration as there is a non-comparability among women initiated on ART due to decreasing CD4+ 
cell count compared to those with stable CD4+ cell count not yet needing treatment. Women who 
initiate ART are more likely to have advanced HIV disease, lower nadir CD4+ cell counts and higher 
HIV-1 viral loads compared to those who have not yet started ART.  
Significant between-study heterogeneity was found when pooling geographical regions, which 
suggests differing epidemiology and related risk factors by region. Subgroup analyses by regions 
however reduced this heterogeneity.  
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There was variation in the outcome definitions for cervical lesions, in particular the use of 
cytological versus histological measurement and definition of progression and regression between 
grades varied. The majority of the prospective studies used cytological outcomes instead of a more 
desirable histological endpoint and there was variation in the way SIL were grouped (i.e. any grade 
change vs. LSIL and HSIL). This may overestimate the effect of ART as the beneficial effect of ART 
is less pronounced in advanced SIL. Coupled with the variation in ART exposure (e.g. varying ART 
regimens and duration) between populations makes interpretation of pooled data less clear. There 
is also the possibility of unmeasured confounding. Additional data that would have been useful to 
understand predictors of progression or regression of cervical lesions include the nadir CD4+ 
count, ART adherence and virological control, which was not always reported across studies. 
Although, where available, we performed sensitivity analysis that adjusted for time-varying ART. 
3.5 Recommendations 
This review has practical implications for the management of HIV patients and cervical cancer 
control worldwide. Encouraging earlier ART initiation with rapid virological control, and ensuring 
sustained adherence is likely to improve and maintain higher CD4+ cell counts, leading to possibly 
more complete immune reconstitution. It is expected that the consequence will be a reduction of 
HR-HPV infection and SIL incidence or progression. ART users with low or unknown nadir CD4+ cell 
count should be screened frequently.   
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3.6 Summary of findings 
METHODS:  
 A systematic review and meta-analysis was performed by searching Medline and Embase 
databases for cross-sectional or cohort studies from 1 January 1996 to 5 November 2016 
that reported the association of ART with prevalence of HR-HPV or prevalence, 
incidence, progression or regression of histological/cytological cervical abnormalities.  
 Random-effects meta-analyses were used to estimate summary statistics. 
Heterogeneity was examined using the I2 statistic.   
RESULTS:  
 A total of 6,441 and 8,262 WLHIV were included from 29 studies evaluating the 
association of ART with prevalence of HR-HPV, and high-grade cervical intraepithelial 
neoplasia (CIN2+) or squamous intraepithelial lesions (HSIL+), respectively.  
 WLHIV on ART had lower HR-HPV prevalence than those not on ART (adjusted Odds 
Ratio [aOR]=0.83, 95%CI: 0.70-0.99, I2=51%, adjusted for CD4+ cell count and ART 
duration). 
 There was some evidence of association with CIN2+/HSIL+ (aOR=0.65, 95%CI: 0.40-1.06, 
I2=30%).  
 Sixteen studies reported the association of ART with longitudinal cervical lesion 
outcomes, from a combined 6,664 WLHIV.  
 ART was associated with a decreased risk of SIL incidence (adjusted Hazard Ratio 
[aHR]=0.64, 95%CI: 0.47-0.86, I2=19%), and progression (aHR=0.64, 95%CI: 0.54-0.75, 
I2=18%) and increased likelihood of regression (aHR=1.58, 95%CI: 1.28-1.94, I2=18%).  
CONCLUSION:  
 Prolonged ART use in WLHIV can decrease the risk of HR-HPV, SIL incidence and 
progression and induces regression of lesions. 
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3.7 Findings in context 
3.7.1 Evidence before this study 
This is the first meta-analysis investigating the association of ART with prevalent HR-HPV and high-
grade cervical lesion outcomes. Studies that adjusted for either nadir or current CD4+ cell count 
and time-varying effects of ART were more likely to show a protective effect of ART on these 
outcomes. 
Studies from Africa and Europe/North America provide indication that ART is associated with lower 
prevalence of HR-HPV and cervical lesions, and over prolonged duration, ART can prevent cervical 
lesion incidence and progression and promote regression. Fewer studies exist from Asia and Latin 
America with the majority being cross-sectional in design, and these studies were less likely to 
report any protective association of ART. As some studies from Latin America have reported an 
increased risk of HR-HPV and CIN2+ among women with a lower nadir CD4+ count, the lack of 
association may reflect the timing of ART in relation to HPV infection and cervical lesion 
development in these populations, although more longitudinal studies from these settings are 
warranted.   
3.7.2  Implications of the available evidence 
These findings highlight the importance of early ART initiation (before reaching a low nadir CD4+ 
cell count) and sustained effectiveness, as evidenced by duration, high adherence, virological 
control and CD4+ cell recovery, in controlling HPV infection and cervical disease progression. ART 
users with low or unknown nadir CD4+ cell count should be screened frequently.  
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Table 3.1. Summary of studies investigating the association of ART with HR-HPV prevalence   
First author, year Study design Location 
Enrolment 
period 
Sample 
size 
% ART users 
HR-HPV+ 
prevalence 
CD4+ count, cells/mm3 
Median [IQR] or mean 
(SD or range) 
Comparison group 
Crude  
Odds Ratio 
(95% CI) 
Adjusted  
Odds Ratio 
(95% CI) 
Africa           
Kelly, 2016 [291] Cohort Burkina Faso- Ouagadougou 2011-2012 570 67% 59.3% ART-naïve: 417 (315-606) 
ART: 446 (309-600) 
ART vs. ART-naive 0.95 (0.66-1.39) 0.76 (0.47-1.22)a 
Kelly, 2016 [291] Cohort South Africa-Johannesburg 2011-2012 613 65% 78.8% ART-naïve: 448 (353-614) 
ART: 420 (279-567) 
ART vs. ART-naive 0.69 (0.45-1.05) 0.61 (0.37-1.01)b 
Zeier, 2015 [288] Cohort: ART 
initiation  
South Africa –Western Cape 2009-2011 300 68% initiated 
during FU 
94.3% (Mean, SD): 
[188]194 [77-311] 
ART vs. ‘not on treatment’, i.e. not 
yet initiated or interruption for >1 
month 
0.33 (0.24-0.44) 0.72 (0.39-1.32)c 
Ezechi, 2014 [184] Cross-sectional Nigeria-Ogun & Lagos NR 220 72% 24.5% 500 [347-685] ART vs. ART-naive 0.36 (0.19-0.69) 0.40 (0.30-0.50)d 
Reddy, 2014 [292] Cross-sectional Malawi-Lilongwe 2011-2012 294 85% 38.8% 337 [215,491] ART vs. ART-naive 0.78 (0.40-1.52) 0.71 (0.30-1.67)e 
De Vuyst, 2012 [186] Cross-sectional Kenya-Nairobi 2009 497 75% 52.7% ART naïve: 407 
In ART users <2y: 333  
In ART users ≥2y: 483  
cART vs. cART-naive 0.75 (0.49-1.13) 0.64 (0.40-1.02)f 
Jaquet, 2012 [293] Cross-sectional Côte d'Ivoire-Abidjan Jun-Oct 2010 254 75% 52.8% 471 [318-629] ART vs. ART-naive 1.07 (0.60-1.88) 0.84 (0.46 - 1.54)g 
Veldhuijzen, 2011 [294] Cross-sectional Rwanda-Kigali 2006-2009 124 40% 50.8%  ART vs. ART-naive 0.77 (0.38-1.59) - 
Asia           
Menezes, 2015 [296] 
 
Cross-sectional India-Chennai July-Aug 2011 50 48% 48.0% 425 [range: 106-1229] ART vs. ART-naive 0.61 (0.20-1.88) - 
Zhang, 2014 [295] 
 
Cross-sectional China-Yunnan NR 301 64% 37.5% 571 ART vs. ART-naive 0.97 (0.60-1.58) 2.30 (1.09-4.85)h 
Mane, 2012 [188] 
 
Cross-sectional India-Pune NR 277 56% 35.3% 372 [241-556] ART vs. ART-naive - 1.46 (0.84-2.54)i 
Aggarwal, 2012 [297] 
 
Cross-sectional India-Chandigarh NR 130 75% 20.0% 398 HAART vs. HAART-naive 3.11 (0.87-11.13) - 
Latin America  
 
 
 
  
  
  
Rocha-Brischiliari, 2014 [298] Cross-sectional Brazil-Maringa city Apr-Oct 2011 178 79% 46.6% 64% with CD4+≥200 HAART vs. HAART-naive 1.04 (0.50-2.14) - 
Dames, 2014 [299] 
 
Cross-sectional Bahamas-Nassau Feb-Sep 2008 165 81% 78.2% 47% with CD4+ >200 HAART vs. HAART-naive 1.06 (0.41-2.70)  
Grinsztejn, 2009 [300] Cross-sectional Brazil-Rio de Janeiro 1996-2006 634 68% 45.0% 74% with CD4+≥200 HAART ≥2 months vs. HAART-naive - 1.09 (0.82-1.44)j 
Europe/North America  
 
 
 
  
  
  
Konopnicki, 2013 [185] Cohort Belgium-Brussels 2002-2011 652 79% 42.8% 426 [302-601] cART vs. cART-naive 0.73 (0.50-1.07) 0.72 (0.41-1.27)k 
Blitz, 2013 [192] Cohort Canada-11 cities 1993-2002 750 19% 46.3% 336 [180-515] HAART vs. ART-naïve or non-
HAART regimen 
0.70 (0.48-1.01) - 
Minkoff, 2010 [289]  Cohort: ART 
initiation  
USA-5 US cities 1994-2002 286 0% 22.4% 73% with CD4+ ≥200 Adherent ART users followed up 
to 30 months after vs. before ART 
initiation 
(within woman analysis) 
- 0.60 (0.44-0.81)l 
Fife, 2009 [290] Cohort: ART 
initiation  
USA/Puerto Rico 2001-2005 146 0% 62.0% 238 [121-339] 6 months after vs. before     ART-
initiation 
(within woman analysis) 
0.40 (0.24-0.69) 0.83 (0.74-0.94)m 
NR=not reported; cART=combination ART; HAART=highly active antiretroviral therapy; aadjusted Odds Ratio, adjusted for CD4+ count, ART duration, alcohol use, marital status, age at first pregnancy and cervicitis,; badjusted Odds Ratio, adjusted for CD4+ count, ART duration, 
age, smoking, injectable contraception, genital warts, condom use, vaginal cleansing, Chlamydia trachomatis, Bacterial vaginosis and Trichomonas vaginalis; cadjusted Odds Ratio, adjusted for CD4+ count, ART duration, age, sexual activity,  months since cervical lesion excision, 
HIV-1 plasma and cervical viral load; dadjusted Odds Ratio, adjusted for age, type of community, life time sexual partner and marital status; eadjusted for nadir CD4,; months since HIV diagnosis and age; fadjusted Odds Ratio, adjusted for CD4+ count, ART duration and age; 
gadjusted for CD4+ count, age, marital status and age at first sex; hadjusted Odds Ratio, adjusted for CD4+ count, ART duration and age; iAdjusted Odds Ratio, adjusted for CD4+ count,  age, marital status, education, income, parity, age at first sex, LTSP, past history of STI and 
tobacco; jAdjusted Prevalence Ratio, adjusted for nadir CD4+ count, age, marital status, drug use, age at first sex, LTSP, history of HPV and condom use; kAdjusted Odds Ratio, adjusted for current and nadir CD4+ count, ART duration, age, , CDC stage, HIV duration of follow-up, 
and HIV plasma VL; lAdjusted Odds Ratio, adjusted for CD4+ count pre- and post-HAART and treatment of CIN, madjusted Odds Ratio, adjusted for current CD4+ count, age, sexual activity at baseline LSIL+ at baseline and HIV-1 PVL.
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Table 3.2. Summary of studies investigating the association of ART with high-grade cervical lesion prevalence  
First author, year Study design Location 
Enrolment 
period 
Sample 
size 
% ART 
users 
CD4+ count, cells/mm3 
Median [IQR] or mean (SD or range) 
Lesion 
definition 
Lesion 
prevalence 
Comparison group 
Crude 
Odds Ratio 
(95% CI) 
Adjusted 
Odds Ratio 
(95% CI) 
Africa            
Kelly, 2016 [291] Cohort Burkina Faso-
Ouagadougou 
2011-2012 530 73% ART-naïve: 417 (315-606) 
ART: 446 (309-600) 
CIN2+ 5.8% ART vs. ART-naive 1.63 (0.66-4.04) 0.86 (0.26-2.83)a 
Kelly, 2016 [291] Cohort South Africa-
Johannesburg 
2011-2012 613 65% ART-naïve: 448 (353-614) 
ART: 420 (279-567) 
CIN2+ 22.4% ART vs. ART-naive 0.80 (0.53-1.20) 0.54 (0.32-0.91)b 
Memiah, 2015 [223] Cross-sectional Kenya-Kiambu 2009-2010 686 16% 45% had baseline CD4+ <200 cells/mm3 CIN2+ 6.1% ART vs. ART-pre-ART 0.55 (0.19-1.56) - 
Huchko, 2014 [193] Cross-sectional Kenya-Kisumu 2007-2010 3185 50% 356 [218-530] CIN2+ 9.0% HAART vs. HAART-naïve 0.96 (0.75-1.23) 1.01 (0.79-1.30)c 
De Vuyst, 2012 [186] Cross-sectional Kenya-Nairobi 2009 470 75% ART naïve: 407  
ART users  <2 yrs: 333  
ART users ≥2 yrs: 483  
CIN2+ 24.0% cART vs. cART-naïve 1.12 (0.69-1.84) 0.91 (0.51-1.62)d 
Mabeya, 2012 [222] Cross-sectional Kenya-Eldoret NR 149 67% Mean (range): 400 (10-1198) CIN2+ 30.9% HAART vs. HAART-naïve 1.18 (0.56-2.49) - 
Ezechi, 2014 [301] Cross-sectional Nigeria-Ogun & Lagos NR 490 76% mean: 532 [263-801] HSIL+ 5.1% ART vs. ART-naive 0.44 (0.19-1.01) - 
Firnhaber, 2010 [194] Cross-sectional South Africa-
Johannesburg 
NR 1010 65% 231 (range:1-1789) HSIL+ 18.0% HAART vs. HAART-naïve 1.31 (0.92-1.85) - 
Mogtomo, 2009 [224] Cross-sectional Cameroon-Douala NR 70 50% Mean : 253 among ART and 165 among 
ART-naive 
HSIL+ 31.4% HAART vs. HAART-naïve 0.44 (0.16-1.26) - 
Asia            
Feng, 2012 [302] 
 
Cross-sectional China-Yunnan 2009 301 64% 571 CIN2+ 9.3% HAART vs. HAART-naïve 0.45 (0.20-0.98) 0.14 (0.02-1.09)e 
Sahasrabuddhe, 2010 
[225] 
Cross-sectional India-Pune 2006-2007 271 26% 343 [244-495] CIN2+ 15.9% ART vs. ART-naïve 2.16 (1.09-4.28) 2.24 (1.17-4.26)f 
Latin America            
De Andrade, 2011 [202] Cohort Brazil-Rio de Janeiro 1996-2007 340 26% 347 [193-546] CIN2+ 6.5% ART (≥2 months) vs. ART-
naive 
2.31 (1.02-5.22) - 
Europe            
Patrelli, 2013 [303] Cohort Italy-Parma 1993-2010 194 66% ART-naïve: 487 [±238] 
ART users: 411 [±188] 
HSIL+ 35.1% Receiving ART vs. ART-
naïve or women refusing 
treatment (but in need of 
treatment) 
0.64 (0.35-1.18) - 
NR=not reported; cART=combination ART; HAART=highly active antiretroviral therapy; aadjusted for CD4+ count, ART duration, age, Bacterial vaginosis and cervical ectopy; badjusted for CD4+ count, ART 
duration, age at first pregnancy, injectable contraception and number of lifetime sex partners; cAdjusted for age and site; dAdjusted for CD4+ count, ART duration and age; eAdjusted for CD4+ count, ART 
duration and age; fAdjusted for CD4+ count, age, education, income, age at first sex, LTSP, parity, WHO stage and HR-HPV DNA. 
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Table 3.3. Summary of studies investigating the association of ART with cervical lesion incidence, progression and regression    
First author, year Location 
Enrolment 
period 
Sample 
size 
% ART users 
CD4+ count, cells/mm3  
Median [IQR] or mean 
(SD) 
Median 
interval 
between 
smears  
(months) 
Outcome definition Comparison group 
Effect 
size (ES) 
Adjusted ES 
(95%CI) 
Incidence studies           
Africa           
Adler, 2012 [197] South Africa-Soweto 2003-2010 767 2% at baseline;  17% 
initiation during FU 
CD4+ count <350;  
ART users: 56%  
ART naïve:  42%  
14  
[range: 6-77] 
Normal to ASCUS+ ART ≥6 mths vs. ART-naive at 
baseline 
HR 0.62 (0.42-0.91)a 
Firnhaber, 2012 [201] South Africa-
Johannesburg 
NR 326 71% at baseline ART users: 248 (152,382);  
ART-naive: 299 (174,448) 
6 Normal to ASCUS+ ART at baseline vs. ART-naive at 
baseline 
HR 0.55 (0.34-0.90)b 
Kelly, 2016 [291] South Africa-
Johannesburg 
2011-2012 379 71% at end of FU ART users: 439[322-604] 
ART-naïve: 437 [346-543] 
16 <CIN2 to CIN2/3 ART >16 months vs. ART-naive OR 0.39 (0.15-1.01)c 
Latin America           
Kreitchmann, 2013 
[304] 
 
Brazil-Porto Alegre 1997-2007 349 38% 436  
[range: 9-1571] 
14 <LSIL to LSIL+ HAART vs. HAART-naive HR 1.90 (0.90-4.01)d 
Europe/North America           
Minkoff, 2010 [289] USA- 5 cities 
 
1994-2002 286 All ART initiators 73% with CD4+ ≥200 6 Normal to ASCUS+ Adherent ART period vs. pre-
HAART period (within-woman 
analysis) 
HR 0.68 (0.25-1.85)e 
Sirera, 2008 [200] Spain- Barcelona 1997-2006 127 71% at baseline Mean:  
ART users: 646 
ART naive: 681 
12 Normal to LSIL+ HAART prior to baseline vs. ART-
naive throughout FU 
HR 1.66 (0.16-17.03)f 
Soncini, 2007 [196] Italy-Parma 1993-2003 101 43% through FU  50% with CD4+ count 
between 200-499  
6 Normal to LSIL+ HAART (time-dependent) vs. ART-
naïve 
HR 0.30 (0.13-0.68)g 
Lehtovirta, 2006 [305] Finland-Helsinki 1989-2003 55 48% at baseline; 64% at FU 45% with CD4+ >500 6 Normal to LSIL+ HAART during FU vs. ART-naive HR 0.80 (0.35-1.83)h 
Heard, 2006 [306] France- Paris 1993-2005 298 49% through FU 400 [250,574] 6 Normal to ASCUS+ HAART during FU vs. non-HAART 
and ART-naive 
HR 0.70 (0.40-1.20)i 
Schuman, 2003 [195] USA- 4 cities  1993-1995 629 33% at baseline 16% with CD4+ <200; not 
stratified by ART 
6 Normal to LSIL+ HAART (time-dependent) vs. ART-
naive 
HR 1.20 (0.49-2.94)j 
Ellerbrock, 2000 [307] USA –New York 1991-1996 328 54% on ≥1 ARV for at least 
6mths during study 
period; 41% on only 1 ARV; 
0.9% on 3 drugs. 
429; 24% with CD4+ <200 6 Normal to ASCUS+ ARV (time-dependent) vs. ARV-
naive 
HR 1.00 (0.50-2.00)k 
Clifford, 2016 [308] Switzerland-5 cities 1988-2013 1451 54% NR ~5 years <CIN2 to CIN2/3 >2years vs. ART naive OR 0.64 (0.42-0.98)l 
Progression studies           
Africa           
Zeier, 2012 [218] South Africa-  
Western Cape 
2004-2009 1,048 18% started before LSIL+; 
41% after LSIL+ 
312 Not reported LSIL to  HSIL+  HAART (time-varying) vs. naive 
before lesion detection 
HR 0.66 (0.54-0.81)m 
Firnhaber, 2012 [201] South Africa -
Johannesburg 
NR 326 As before As before As before ASCUS+ to HSIL+ ART at baseline vs. ART-naive at 
baseline 
HR 0.52 (0.27-1.01)n 
Omar, 2011 [198] South Africa- Soweto 2003-2010 1,074 6% on ART at baseline; 20% 
were initiated during FU 
356 [215,474] 5.5 Normal to LSIL+; 
LSIL to HSIL+/ASCH 
HAART (time-varying) vs. naive HR 0.72 (0.52-0.99)o 
Adler, 2012 [197] South Africa-Soweto 2003-2010 1,123 As before As before As before Subsequent smear with 
worsening dysplasia 
ART ≥6 mths vs. ART-naive at 
baseline 
OR 0.80 (0.57-1.13)p 
Europe/North America           
Kim, 2013 [199] USA- New York 1991 - 2011 245 NR Nadir: 206 12 normal->ASCUS+; ASCUS-
>LSIL+ 
HAART vs. other regimens or ART 
naïve  
HR 0.47 (0.33-0.67)q 
Blitz, 2013 [192] Canada- 11 cities 1993-2002 326 19% on HAART at baseline; 
64% by end of study 
336 [180, 515] 8 [6,13] ASCUS  to greater HAART during study vs. ART-naïve 
or non-HAART 
HR 1.02 (0.40-2.59)r 
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First author, year Location 
Enrolment 
period 
Sample 
size 
% ART users 
CD4+ count, cells/mm3  
Median [IQR] or mean 
(SD) 
Median 
interval 
between 
smears  
(months) 
Outcome definition Comparison group 
Effect 
size (ES) 
Adjusted ES 
(95%CI) 
Paramsothy, 2009 
[189] 
USA- 4 cities 1996-2000 537 46.9% during study ART-naïve: 48% CD4≥500 
vs. 24% of ART users 
6 Normal to ASCUS; ASCUS 
to LSIL; LSIL to HSIL 
HAART use during study period vs. 
pre-HAART or never on ART 
HR 0.70 (0.60-1.00)s 
Schuman, 2003 [195]  USA- 4 cities  1993-1995 629 As before As before As before Normal/ASCUS to LSIL+, 
LSIL to HSIL 
HAART (time-dependent) vs. ART-
naive 
OR 1.50 (0.90-2.49)t 
Minkoff, 2001 [309] USA- 6 cities 1994-1995 741 0.9% at baseline 36% with CD4<200 6 subsequent pap with any 
grade higher than 
baseline  
HAART vs. off-HAART (women 
never received HAART or among 
initiators, prior to HAART initiation 
OR 0.68 (0.52-0.88)u 
Lillo, 2001 [190] Italy- Milan 1995-1997 163 46% through FU HAART : 260 (±23); 
 ART-naïve: 627 (±38) 
6 Normal to LSIL+; LSIL to 
HSIL 
HAART during study vs. ART-naïve 
or non-HAART  
OR 3.50 (1.01-12.12)v 
Regression studies           
Africa           
Zeier, 2012 [218] South Africa-  
Western Cape 
2004-2009 1,048 18% started before LSIL+; 
41% after LSIL+ 
 
312 Not reported ≥LSIL to <LSIL 
(2 normal results at least 4 
weeks apart)  
HAART (time-varying) vs. naive 
before lesion detection 
HR 1.71 (1.29-2.27)m 
Adler, 2012 [197] South Africa-Soweto 2003-2010 1,123 As before As before As before Subsequent improvement 
in cytological results 
ART ≥6 mths vs. ART-naive at 
baseline 
OR 2.61 (1.75-3.89) p 
Europe/North America           
Blitz, 2013 [192] Canada- 11 cities 1993-2002 326 As before As before As before ≥ASCUS to <ASCUS HAART during study vs. ART-naïve 
or non-HAART 
HR 3.32 (1.22-9.04)r 
Minkoff, 2010 [289] USA-5 US cities 1994-2002 286 As before As before As before SIL to lower grade Adherent ART period vs. pre-
HAART period (within-woman 
analysis) 
HR 2.25 (1.03-4.92)w 
Paramsothy, 2009 
[189] 
USA- 4 cities 1996-2000 537 As before As before As before HSIL to LSIL, LSIL to 
ASCUS, ASCUS to normal 
HAART use during study period vs. 
pre-HAART or never on ART 
HR 1.30 (1.00-1.70)s 
Heard, 2002 [310] France- Paris 1993-1999 
 
168 56% through FU 250 [139-400] 6 Reversion to normal or 
from HG to LG 
HAART (time-dependent) vs. ART-
naive 
HR 1.93 (1.14-3.28)x 
Del Mistro, 2004 [311] Italy- Vicenza & Padova 1994-2002 
 
201 37% 292 (range: 2-1445) 6-12 ≥LSIL to <LSIL HAART at baseline and FU vs. ART-
naive at baseline and FU OR non-
HAART OR change in regimen 
during FU 
OR 1.87 (0.71-4.93)r 
Schuman, 2003  [195] USA- 4 cities  1993-1995 629 As before As before As before ≥LSIL+ to <LSIL HAART (time-dependent) vs. ART-
naive 
OR 0.86 (0.50-1.47) t 
Minkoff, 2001 [309] USA- 6 cities 1994-1995 741 As before As before As before Lower grade abnormality 
than baseline east one 
HR-HPV infection at all 
visits 
HAART vs. off-HAART (women 
never received HAART or among 
initiators, prior to HAART initiation 
OR 1.40 (1.06-1.85) u 
NR-not reported; FU=follow-up; aadjusted for time-varying ART, current CD4+, weight, sexual activity, STI symptom; badjusted for CD4+ at baseline;  cadjusted for  number of lifetime sex partners and baseline CD4+ count; dage,  education, 
log viral load  and CD4+ count; eadjusted for time-varying ART and adherence; fadjusted for baseline/nadir CD4+ count;  gadjusted for time-varying ART and baseline CD4+ count; hadjusted for age; iadjusted for time-varying ART, age, 
ethnicity, smoking, LTSP, jadjusted for baseline CD4+, time (visit), study site, age, race/ethnicity and education contraception use, condom, inclusion period;  kadjusted for time-varying ART, baseline CD4+, age, smoking, HPV persistence; 
lcase-control study matched on enrolment centre, HIV-transmission category, age at enrolment, year of enrolment and adjusted for  nadir CD4+;  madjusted for duration on ART, age and excision treatment; nadjusted for CD4+ at baseline;  
oadjusted for time-varying ART; CD4+ at baseline, age, baseline smear result, smoking;  padjusted for current CD4+, weight, sexual activity, STI symptom;   qadjusted for time-varying CD4+, duration of HIV infection, menopausal, smoking; 
runadjusted;  sadjusted for time-varying CD4+; HPV positive, baseline pap result;  tadjusted for baseline CD4+, time (visit), study site, age, race/ethnicity and education;  uadjusted for baseline CD4+ and baseline pap result; vadjusted for 
CD4+, HIV-1 RNA and gynecological treatment;  wadjusted for time-varying ART, treatment of CIN, baseline CD4+; xadjusted for time-varying ART, CIN grade, CD4+ at lesion detection.
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Table 3.4. Meta-analysis of the association of ART with HR-HPV and cervical lesions among 
WLHIV 
 Crude analysis
1 Adjusted analysis2 
  
N 
studies OR (95%CI) I2 
P for 
heterogeneity 
N 
studies OR (95%CI) I2 
P for 
heterogeneity 
HR-HPV Prevalence         
All 19 0.80 (0.66-0.97) 71.7% <0.001 12 0.83 (0.70-0.99) 51.0% 0.02 
Africa 8 0.62 (0.49-0.80) 49.4% 0.05 6 0.70 (0.56-0.88) 0.0% 0.97 
Asia 4 1.60 (0.93-2.75) 38.6% 0.18 2 1.72 (1.10-2.68) 0.0% 0.34 
Latin America 3 1.08 (0.84-1.39) 0.0% 0.99 - - - - 
Europe/North America 4 0.75 (0.63-0.88) 29.9% 0.23 3 0.74 (0.59-0.93) 48.4% 0.14 
CIN2+ Prevalence         
All 13 0.90 (0.68-1.20) 61.0% 0.002 4 0.65 (0.40-1.06) 29.5% 0.24 
Africa 9 0.84 (0.64-1.10) 45.5% 0.07 3 0.70 (0.48-1.01) 0% 0.40 
Asia 2 0.67 (0.05-9.90) 84.3% 0.01 - - - - 
Latin America 1 2.31 (1.02-5.23) - - - - - - 
Europe/North America 1 0.64 (0.35-1.18) - - - - - - 
         
 Crude analysis1 Adjusted analysis3 
  
N 
studies HR (95%CI)4 I2 
P for 
heterogeneity 
N 
studies HR (95%CI) 4 I2 
P for 
heterogeneity 
SIL Incidence         
All  10 0.75 (0.56-1.00) 41.0% 0.09 5 0.64 (0.47-0.86) 19.4% 0.29 
Africa  2 0.59 (0.44-0.80) 0.0% 0.71 1 0.62 (0.42-0.91) - - 
Latin America 1 1.90 (0.90-4.01) - - - - - - 
Europe/North America 7 0.73 (0.52-1.03) 14.0% 0.32 4 0.64 (0.40-1.02) 39.0% 0.18 
SIL Progression         
All 6 0.64 (0.56-0.74) 0.0% 0.42 4 0.64 (0.54-0.75) 17.8% 0.30 
Africa 3 0.67 (0.56-0.79) 0.0% 0.68 2 0.68 (0.57-0.80) 0.0% 0.65 
Europe/North America 3 0.62 (0.43-0.90) 46.4% 0.16 2 0.57 (0.39-0.85) 58.0% 0.12 
SIL regression          
All 5 1.67 (1.32-2.12) 31.0% 0.22 4 1.58 (1.28-1.94) 18.2% 0.30 
 Africa - - - - 1 1.71 (1.29-2.27) - - 
Europe/North America 4 1.76 (1.21-2.58) 44.5% 0.14 3 1.57 (1.13-2.19) 32.5% 0.23 
 
1includes studies with either 1.) no adjustment and 2.) studies that adjust for sociodemographic factors only and no adjustment for HIV 
related factors 
2adjusted for at least one of the following: current CD4+; nadir CD4+; ART duration 
3adjusted for at least one of the following: time-varying ART, time-varying CD4+ count  
4only studies that reported Hazard Ratio (HR) from time-to-event analysis included in the meta-analysis 
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Figure 3.1.Study selection for outcomes of HR-HPV (A) and cervical lesions (B). 
                
521 records identified through database searching 
345 records after duplicates removed 
345 of records screened 
19 full-text articles 
excluded, with reasons 
 
Longitudinal HR-HPV=4 
Not HR-HPV=2 
SIL outcome=1 
Combined cervical/anal HPV=1 
Genotype specific analysis=1 
No ART stratification; n=7 
No stratification by gender=1 
Results from same cohort at 
different timepoint=2 
312 records excluded 
 
33 full-text articles assessed 
for eligibility 
 
18 studies included in 
qualitative synthesis  
  
18 studies included in 
quantitative synthesis 
 (meta-analysis) 
  
(A) 
4 records identified through 
cross-referencing 
661 records identified through database 
searching 
496 records after duplicates removed 
496 records screened 
30 full-text articles excluded, 
with reasons 
 
Any CIN grade/CIN3+/visual 
inspection as outcome; n=12 
No ART stratification; n=8 
Same cohort at different timepoint; 
n=2 
No effect estimate given and no raw 
data=4 
Research letter=4 
446 records excluded 
 
50 full-text articles assessed 
for eligibility 
 
32 studies included in 
qualitative synthesis  
Prevalence=12 
Incidence=12 
Progression=10 
Regression=9 
 
18 studies included in 
quantitative synthesis (meta-
analysis) 
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Figure 3.2. Meta-analysis of HR-HPV prevalence among ART users compared to ART-naive in 19 
studies  
 
*Studies that adjusted for ART duration, current or nadir CD4+ cell count 
 
 
NOTE: Weights are from random effects analysis
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Figure 3.3. Meta-analysis of high grade cervical prevalence among ART users compared to ART-
naive in 13 studies  
  
*Studies that adjusted for ART duration, current or nadir CD4+ cell count 
NOTE: Weights are from random effects analysis
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Figure 3.4. Meta-analysis of high grade cervical incidence among ART users compared to ART-
naïve in 10 studies 1   
 
1only studies that reported Hazard Ratio (HR) from time-to-event analysis included in the meta-analysis in Table 3.4.  
*adjusted for the time-varying ART or CD4+ cell count 
** median interval (months) between pap smears, or between histological evaluations 
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Figure 3.5. Meta-analysis of high grade cervical progression among ART users compared to ART-
naïve in 6 studies 1  
 
1only studies that reported Hazard Ratio (HR) from time-to-event analysis included in the meta-analysis in Table 3.4. 
 *adjusted for the time-varying ART and CD4+ cell count 
 
 
 
 
 
 
NOTE: Weights are from random effects analysis
.
.
Hazard Ratio
Zeier, 2012*
Firnhaber, 2012
Omar, 2011*
Kim, 2013*
Blitz, 2013
Paramsothy, 2009*
Subtotal  (I-squared = 0.0%, p = 0.417)
Odds Ratio
Adler, 2012
Schuman, 2003
Minkoff, 2001
Lillo, 2001
Subtotal  (I-squared = 76.2%, p = 0.006)
Study
1048
326
1074
245
326
537
1123
629
741
163
Sample
18
15
30
12
24
24
32
48
6
15
Followup
HG progression
Any progression
Any progression
Any progression
Any progression
Any progression
Any progression
Any progression
Any progression
Any progression
Outcome
0.66 (0.54, 0.81)
0.52 (0.27, 1.01)
0.72 (0.52, 0.99)
0.47 (0.33, 0.67)
1.02 (0.40, 2.59)
0.70 (0.49, 1.00)
0.64 (0.56, 0.74)
0.80 (0.57, 1.13)
1.50 (0.90, 2.49)
0.68 (0.52, 0.88)
3.50 (1.01, 12.12)
1.04 (0.65, 1.65)
estimate (95% CI)
Effect
South Africa
South Africa
South Africa
USA
Canada
USA
South Africa
USA
USA
Italy
Country
  
1.1 5
Effect estimate
101 
 
 
 
Figure 3.6. Meta-analysis of high grade cervical regression among ART users compared to ART-
naïve in 5 studies 1  
 
1only studies that reported Hazard Ratio (HR) from time-to-event analysis included in the meta-analysis in Table 3.4. 
*adjusted for the time-varying ART and CD4+ cell count 
NOTE: Weights are from random effects analysis
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4 THE ASSOCIATION OF DNA METHYLATION OF HUMAN GENES AND 
HPV16 WITH CERVICAL INTRAEPITHELIAL NEOPLASIA AND INVASIVE 
CERVICAL CANCER: A SYSTEMATIC REVIEW 
 
The utility of HPV-DNA based assays for the detection of CIN2+ are limited among WLHIV because of 
the high prevalence of HR-HPV in these populations. Human gene and HPV viral DNA methylation are 
novel biomarkers that may help distinguish non-progressive HPV infections from those that progress 
to cancer. DNA methylation assays using human genes are now available for use in early detection of 
various cancers, including bladder, breast, colorectal, oesaphagal, gastric, head and neck, liver, lung 
and prostate cancers. Data on the validation of DNA methylation assays of various human genes and 
the HPV virus for CIN2+ detection are more recently available. However, a wide variety of human genes 
have been studied, and associations of various genes and HPV types with CIN2+ is still unclear.  
In this chapter, I perform a systematic review of the literature on DNA methylation of human genes 
and HPV types, and their association with CIN2+, in order to summarise the evidence on the most 
frequently studied human genes and HPV types.  
The majority of publications in the field reported this association using performance measures 
(receiver operating characteristic [ROC] curves, and sensitivity and specificity). I aim in this chapter to 
interpret this data in order to understand the role of DNA methylation with CIN2/3, CIN3 and ICC.  
This data will inform the case-control study in Study 3 (Chapter 10), which evaluated DNA methylation 
assays for human gene EPB41L3 and HPV16 for the detection of CIN2+ among WLHIV.  
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4.1 Introduction 
There is strong evidence that HPV DNA based screening allows for earlier diagnosis of high-grade 
CIN and is more effective in prevention of ICC [235]. However, HPV testing detects many transient 
infections, meaning that its specificity for high-grade CIN is low. Furthermore, a recent (2012) 
review of HPV DNA based tests for the detection of cervical lesions reported that for a 10% increase 
in HR HPV prevalence, HR-HPV DNA based test specificity decreased by 8.4% [95% confidence 
interval (CI): 8.02-8.81] [239]. This has important implications for screening WLHIV who have a high 
prevalence of HR-HPV. Cervical cytology and visual inspection using VIA/VILI are more frequently 
used in the Africa region, but also have poor accuracy and reproducibility [227].  Novel methods 
are thus required to identify which HPV positive women need colposcopy referral, avoiding repeat 
testing which can result in substantial loss to follow-up [240, 241].  
While infection with HR-HPV is necessary for the development of CIN [35, 37], other molecular 
changes occur with HR-HPV infection, leading to subsequent  development of alterations  in the 
functions of gene products regulating tumor suppression, DNA repair, apoptosis, metastasis and 
invasion [242, 243]. Such alterations can result from DNA nucleotide mutations, structural genomic 
variations or epigenetic alterations, such as DNA methylation [244, 312]. Aberrant DNA methylation 
is a potentially good early indicator of existing disease [245] and a predictor of future disease 
development [246].   
 
4.1.1 DNA methylation of human genes 
DNA methylation mainly occurs at CpG dinucleotide sites (cytosine and guanine separated by one 
phosphate), known as CpG islands. CpG islands are most commonly associated with promoter 
regions and are present in approximately 60% of human genes [313]. DNA methylation occurs 
following the addition of a methyl group to position 5 of the cytosine (C) ring immediately 
preceding a guanine (G) in the DNA sequence (Figure 4.1). The process is mediated by DNA 
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methyltransferases (DNMTs), which are histone modifying enzymes. This change forms 
methylated CpG dinucleotides which is associated with the loss of gene expression and function 
[314].  
 
Figure 4.1.DNA methylation of a CpG island resulting in gene silencing  
 
From http://missinglink.ucsf.edu/lm/genes_and_genomes/methylation.html 
 
Controlled methylation of these CpG islands are essential for normal biological process [315, 316]. 
It has an important role in regulating cellular processes such as embryonic development, 
chromosome instability and protection from invading foreign viral DNA [317, 318]. However, 
aberrant DNA methylation of certain genes is a widespread phenomenon in cancer and may be 
among the earliest changes to occur in oncogenesis [319]. It is therefore a potentially good early 
indicator of existing disease [245] and predictor for future development of disease [246]. 
 
4.1.2 DNA methylation of HPV virus 
DNA methylation of HPV can occur in two ways depending on the site of methylation; as a form of 
defence by the host, or to allow the virus to persist. As part of a host defence mechanism, the 
genomes of tumour viruses are subject to selective differential methylation and silencing. E6 and 
E7 have shown to be down-regulated through the DNA methylation of the HPV16 LCR [320]. DNA 
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methylation induced gene silencing on the integrated viral DNA is important for the host cell to 
subdue the foreign DNA and maintain genome stability [313].  
In contrast, methylation of the HPV late regions (L1 and L2) has been reported to be an indicator 
of viral persistence and cell immortalization [321]. A number of HR-HPV types have been 
investigated for methylation of the L1/L2 regions, including HPV16, 18, 31, 33, 45, 58 and 58 [322-
325]. These studies have shown that the methylation patterns are similar across the different HPV 
types. In a study using cervical specimens with a range of pathological diagnoses, HPV18 L1 
sequences were found to be more strongly methylated in all cervical carcinomas, while the LCR 
and E6 remained unmethylated [326]. In a separate study using samples from women with normal 
cytology, there was low or absent methylation levels in the LCR and E6 regions, but increased 
methylation levels were found in E1, E2 and E7, with the highest levels in the L1 and L2 regions. 
Methylation levels in the L1 and L2 regions have shown to become higher with increasing disease 
severity [321].  
Human gene and HPV viral DNA methylation are novel biomarkers that may help distinguish non-
progressive HPV infections from those that progress to cancer. There have been a wide range of 
studies on DNA methylation of human genes and the HPV virus in earlier detection of HPV related 
lesions. Many of these studies have looked at different human genes and HPV types, or different 
CpG sites within genes and the HPV virus. [257].  
 
4.1.3 DNA methylation methylation markers for CIN2+ detection  
Host gene methylation 
A previous systematic review conducted in 2009 [15] of host gene methylation markers and their 
association with high-grade cervical lesions (including HSIL+, CIN2/3 and ICC) reported 51 studies 
analysing 68 different human genes among 4,376 specimens representing all stages of cervical 
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disease. Many of the genes were selected for the review because they are known tumour genes 
(TSG) and aberrant methylation had been previously reported in other types of cancer [327]. Only 
3 host genes DAPK1, CADM1 and RARB showed elevated methylation in cervical cancers consistently 
across all studies. This review reported methylation frequencies of each gene and the authors 
concluded that a rigorous meta-analysis was not possible given the high degree of heterogeneity 
in methylation methods (methylation specific polymerase chain reaction [MSP], quantitative 
methylation specific polymerase chain reaction [qMSP], bisulfite sequencing, restriction enzyme- 
based methylation detection, pyrosequencing and next generation DNA sequencing [NGS] 
methods) and specimens used (fresh frozen material, exfoliated cells and paraffin-embedded 
tissue) combined with the low number of studies analysing the same gene.  
More recently in 2014, the methylation of 26 genes which showed promise in earlier studies CIN2+ 
detection, including DAPK1, CADM1 and RARB, were evaluated using 20 CIN3 cases and 20 ≤CIN1 
controls [328]. Eight of these genes showed elevated methylation in CIN3 cases and were further 
validated using 205 CIN2/3 cases and 366 ≤CIN1 controls from a colposopy referral following a 
cytology finding of ‘mild dyskaryosis or worse’. Of the 8 genes, the EPB41L3 gene demonstrated 
the best separation of CIN2+ cases from ≤CIN1 controls with an area under the Receiver Operating 
Characteristic (AUC) of 0.73.  
 
HPV DNA methylation 
Three recent reviews performed between 2012-2013 [247-249] have reported DNA methylation of 
different regions of the HPV16 genome given it is the most widely studied HPV type for DNA 
methylation studies;  while a positive association between increased methylation of L1 gene and 
high-grade cervical lesions has been shown consistently, there are inconclusive results about 
methylation of CpGs in the upstream regulatory region (URR), with some studies reporting 
decreasing methylation with increasing grades of CIN and others showing increasing methylation 
levels with increasing grades of CIN.  
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4.2 Rationale for an updated review 
There has not been a systematic review of the literature performed since 2013. Given that there 
has been a growing number of publications on DNA methylation of both human genes and the HPV 
virus, and their association with CIN2+ and ICC detection in the intervening time period, an update 
of the evidence on DNA methylation of human genes and HPV virus is warranted.  
 
4.3 Aim of review 
The aim of this review is to systematically summarise the data on the levels of DNA methylation 
markers (human genes and HPV virus) associated with histologically confirmed high-grade cervical 
lesions.  Given the relative sparsity of studies investigating DNA methylation of HPV types other 
than HPV16, this review will focus on the literature which investigated DNA methylation of HPV16.   
 
4.4 Objectives 
 To summarise the association of DNA methylation (human genes and 
HPV16) with cervical intraepithelial lesions and invasive cervical cancer; 
 To summarise the diagnostic performance of DNA methylation assays 
(human genes and HPV16) for the detection of CIN2+. 
 
(Objective 1.2) 
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4.5 Methods 
4.5.1 Outcome  
Studies were included if they reported the percentage of DNA methylation according to CIN grade, 
or sensitivity and specificity of the DNA methylation assays for the detection of the outcome. This 
review was restricted to all human genes which reported associations with histologically 
confirmed cervical lesions (CIN). Studies reporting DNA methylation of HPV16 were included, 
however, given the small number of studies which evaluated DNA methylation of HPV18, 31, 33 and 
45, they were not included in this review.  
4.5.2 Reference or comparison group 
Studies were included if methylation markers were assessed against a histological endpoint of CIN 
grade 2 or higher (CIN2/3, CIN2+ or CIN3+ which can include carcinoma in situ [CIS] and ICC). Studies 
with cytological endpoint assessment only were excluded because of the lower sensitivity for 
cytology measures in detection of high-grade disease [229]. Studies among ICC cases only were 
excluded when authors did not include a reference group (i.e. normal cervix) as the aim of this 
review is to investigate the association of DNA methylation with cervical lesions compared to 
normal cervix.  
4.5.3 Search   
Medline, Embase and Cochrane databases were searched using the following search terms:  DNA 
methylation [Title/Abstract] OR epigenetic [Title/Abstract] OR methylation [MeSH Terms] AND 
nucleic acids [MeSH Terms] OR CpG islands [MeSH Terms] AND HPV [Title/Abstract] OR human 
papillomavirus [Title/Abstract] OR carcinogenesis [MeSH Terms] OR Cervical Intraepithelial 
Neoplasia/ or intraepithelial neoplasia [Title/Abstract] OR Anus Neoplasms/ or anal intraepithelial 
lesion [Title/Abstract]. The search was carried out up to 5 November 2016. All abstracts were 
screened by one author (HK).  
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4.5.4 Inclusion and exclusion criteria 
Studies that reported only crude percentage methylation estimates without a validated cut-off for 
CIN2+ detection were excluded as they were not verified or validated. Studies not in the English 
language or conference abstracts were excluded due to difficulty in assessing the quality of the 
methodology, as were studies with fewer than 50 participants which could result in an imprecise 
effect measurement. Whereby publications provided DNA methylation measures using a 
combination set of gene markers, the DNA methylation of the individual markers as well as the 
combination panel are presented separately in the results.  
4.5.5 Data extraction 
From the consensus list, data were extracted by one author (HK) using a standardized form. The 
majority of studies which investigate the association of DNA methylation of human genes and HPV 
virus do so through validation of DNA methylation assays for the detection of CIN2+. HK extracted 
performance measures, including sensitivity and specificity, to interpret the association of DNA 
methylation with CIN2+. For all studies, the following variables were recorded: year of study, study 
location, origin (country) of study population, outcomes of interest (histological confirmed lesion 
CIN2+/CIN3+), DNA methylation marker evaluated, DNA methylation positive among CIN2+ (true 
positives), and ≤CIN1 (false positives), and DNA methylation negative among ≤CIN1 (true 
negatives) and CIN2+ (false negatives), where given.  
4.5.6 Statistical analysis  
 The numbers of true positives, false positives, true negatives and false negatives were extracted 
where available, obtained using study-specific thresholds (cut-offs) to define methylation 
positivity. Many of the included studies reported performance measures for the detection of CIN2+ 
(sensitivity or specificity, or receiver operating characteristics [ROC] curves). Where several 
thresholds for methylation positivity were reported or where only ROC curves were presented, 
data was extracted based on a threshold that obtained at minimum a 70% specificity, as 1.) this 
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would be considered to be the minimum requirement for an acceptable screening test for CIN2/3 
[229] and 2.) this was most commonly reported minimum specificity across the publications for the 
various methylation markers. Results are summarised in table format, separately by individual 
human gene and HPV16.  
This review is registered with on the PROSPERO database at the Centre of Reviews and 
Dissemination, University of York; registration number CRD42016052119.  
 
4.6 Results 
4.6.1 Search result 
The review identified 2,106 publications through Medline, Embase and Cochrane library searches 
which reported the association of the methylation of human genes or of any HPV type with any of 
the following outcome groups: CIN2/3, CIN3, CIN2+ and CIN3+ (Figure 4.2), of which 802 duplicates 
were removed and 1,142 excluded after abstract review, leaving 162 articles for full text review. 
Finally, 31 articles were selected which matched the inclusion criteria, among which there were at 
minimum three reports for any single gene. The characteristics of these studies are summarised in 
Appendix 6. Among these, 23 reported the association of single human gene DNA methylation with 
CIN2+, including seven for cell adhesion molecule 1 (CADM1) [17, 329-333]; seven for myelin and 
lymphocyte (MAL) [17, 329-333]; five for erythrocyte membrane protein band 4.1 like (EPB41L3) 
[254, 256, 328, 334, 335]; eight for paired box 1 (PAX1) [329, 336-342] and two for sex-determining 
region Y, box 1 (SOX1) [339, 342]. Ten studies reported the association of HPV16 methylation with 
CIN2+ [256, 334, 343-350].  
In addition, nine studies reported the association of combination panel markers with CIN2+ which 
included five for CADM1 and MAL [330, 332, 351, 352]; two for MAL and microRNA 124-2 (MIR) [331, 
353] and two for CADM1, MAL and MIR [17, 354].  
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Of the 23 human gene studies, the majority included women who were HR-HPV positive, with the 
exception of two studies which evaluated CADM1, MAL and MIR-124 DNA methylation [330, 354] 
and two studies which evaluated EPB41L3 DNA methylation irrespective of HPV status [334, 335]. 
Of the eight studies which evaluated PAX1 or SOX1 DNA methylation, six included women 
irrespective of HPV positive test result and two studies did not report HPV testing result [337, 340]. 
All studies which evaluated HPV16 DNA methylation included women who were HPV16 positive.  
4.6.2 DNA methylation of CADM1, MAL and MIR for the detection of CIN2/3, CIN3 and CIN3+ 
Because CADM1, MAL and MIR were tested in the same populations by the same authors, and used 
in multi-gene panels, result are presented here together. For CADM1, seven publications were 
identified; four of these provided data to estimate performance measures for detection of CIN2/3, 
three for CIN3 and two for CIN3+  (Appendix 7). The same seven publications also provided 
estimated for MAL (Appendix 8). For MIR, there were only 2 studies that provided performance 
measures as a single gene; 1 for CIN2/3 [17] and 2 for CIN3+ [17, 331]. Because there were few studies 
that reported performance of MIR independently, only the studies whereby MIR is part of a multi-
gene panel with CADM1 and MAL are presented. Combination panels of CADM1, MAL and MIR genes 
are summarised in Appendix 9.   
Sensitivity, specificity, PPV (positive predictive value) and NPV (negative predictive value) for 
individual studies are summarised in Appendix 7 (CADM1), Appendix 8 (MAL) and Appendix 9 
(combination panels of CADM1, MAL and MIR). From the data available in the literature, it was 
possible to obtain a range of sensitivity estimates based on a specificity of 70% for all single and 
combination markers among CADM1, MAL and MIR.  These summary ranges of estimates, by gene, 
are summarised in Table 4.1.   
Based on a minimum specificity of 70%, sensitivity estimates for CADM1 as a single marker ranged 
between 13-79% for CIN2/3, 33-87% for CIN3 and 47-79% for CIN3+ (Table 4.1). The sensitivity 
estimates for MAL as a single marker ranged between 2-64% for CIN2/3, 42-83% for CIN3 and 60-67% 
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for CIN3+ (Table 4.1). The best sensitivity estimates across all outcome group (CIN2/3, CIN3, CIN3+) 
appeared to be obtained when CADM1, MAL and MIR were combined in a single panel; with 
increasing sensitivity estimates achieved with increasing CIN grades; 48-65% for CIN2/3, 69-77% for 
CIN3 and 95% for CIN3+ (Table 4.1).  
DNA methylation of EPB41L3 for the detection of CIN2/3, CIN3 and CIN3+ 
Four studies were identified that reported performance of EPB41L3 for the detection of CIN2/3, two 
for CIN3, two for CIN2+ and one for CIN3+ (Appendix 10).  The available data allowed extraction of 
sensitivity estimates for a minimum specificity of between 57-60%. Based on this specificity, 
sensitivity estimates for EPB41L3 as a single marker ranged between 50-60% for CIN2/3 and 68-84% 
for CIN3 (Table 4.1). When combined with HPV16, 18, 31 and 33, sensitivity for CIN2+ ranged 
between 65-74%, and combined with other human genes (JAM3, TERT and C13ORF18), sensitivity for 
CIN2+ ranged between 82-84%.  
4.6.3 DNA methylation of PAX1 and SOX1 for the detection of CIN2/3, CIN3, CIN2+ and CIN3+ 
For PAX1, eight publications were identified; four of these provided data to estimate performance 
measures for detection of CIN2/3, two for CIN3, four for CIN2+ and five for CIN3+ (Appendix 11). 
For SOX1, two publications were identified; one of these provided data to estimate performance 
measures for detection of CIN2+ and both for CIN3+ (Appendix 12).  
The data for both PAX1 and SOX1 suggests that for both markers the sensitivity was low for 
CIN2/3 (Table 4.1). For a minimum specificity of 90%, sensitivity estimates for PAX1 as a single 
marker ranged between 15-79% for CIN2/3, 36-92% for CIN3 and 52-95% for CIN3+.  SOX1 was less 
frequently studied. For a minimum specificity of 80%, sensitivity estimates for SOX1 as a single 
marker were 44% for CIN2+ but ranged between 81-88% for CIN3+.  
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4.6.4 DNA methylation of HPV16 L1/L2 and LCR regions for the detection of CIN2/3, CIN3, CIN2+ 
and CIN3+ 
Ten studies were identified that reported methylation of HPV16 L1/L2 regions associated with 
CIN2+ (Appendix 13). The studies reported a wider range of specificity estimates, making it 
difficult to provide a summary range of sensitivity estimates. Based on a specificity of 70% that 
was reported in four studies, sensitivity for CIN2/3 ranged from 21-93%, and 61-80% for CIN3+ 
(Table 4.1). As previously described, a combination panel which included EPB41L3, and HPV types 
18, 31 and 33 had reasonable sensitivity and specificity for CIN2+ and CIN3+ detection.   
4.6.5 Meta-analysis of the performance of DNA methylation markers for the detection of 
CIN2/3 and CIN3+ 
When restricting the analysis to studies that used samples from population-based screening (Table 
4.2), there were too few studies to evaluate pooled sensitivity and specificity for individual gene 
markers. However, when combining the various DNA methylation markers (HPV16, EPB41L3, MAL 
and MIR combination, CADM1+MAL and CADM1, MAL and MIR combination), the pooled sensitivity 
and specificity for CIN2/3 detection were 65% (95%CI: 55-74) and 70% (95%CI: 68-72) respectively 
among 6 studies (Figure 4.3). The corresponding pooled estimates for sensitivity and specificity 
for CIN3+ detection were 62% (95%CI: 56-69) and 70% (95%CI: 68-73) respectively among 7 studies 
(Figure 4.4). Heterogeneity across studies was high for both CIN2/3 and CIN3+ outcomes (Figure 
4.3, Figure 4.4), and a more formal meta-anaysis (which is on-going) would be required to take into 
account the different study characteristics (study design, sample types and storage, and the assays 
used), as well as separate analysis for the HPV16 and human gene markers.  
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4.7 Summary 
DNA methylation assays using single genes for the detection of CIN2/3, CIN3 or CIN3+ appeared to 
vary in sensitivity, based on an established specificity of >60%. But there appeared to be less 
variation in sensitivity when gene markers were combined. Based on a set specificity of between 
60-90% (depending on the DNA methylation marker evaluated), the sensitivity estimates appeared 
to increase with increasing grades from CIN2/3 to CIN3+ (Table 4.1). Furthermore, the best 
performance, incorporating high specificity and sensitivity, was observed among women with 
CIN3+ relative to ≤CIN1. These data also suggest that the association between human gene and 
HPV DNA methylation increases with increasing CIN grade, and the variability in this association 
may suggest that different tumour suppressor genes (TSG) are implicated at different stages of 
cervical carcinogenesis, however there is no data to confirm this. Furthermore, the differences in 
thresholds used to define methylation positivity in this review prevent a full assessment of this.   
An increase in aberrant DNA methylation patterns of TSG with increasing CIN grade is plausible. 
Silencing of TSG activity through DNA methylation has been reported in cervical cancer cells for 
CADM1 [355, 356] and MAL [357].  Methylation of the CpG regulatory regions of micro RNAs 
(miRNA), including that of MIR-124-2, can lead to their deregulation. Deregulation of MIR-124-2 has 
been shown in cervical cancer, and has been linked to increased promoter methylation of its genes 
[358-361]. EPB41L3 encodes the DAL-1 protein, and methylation of its promoter is associated with a 
loss in tumour suppressor activity. It has been frequently studied in lung adenocarcinoma [250, 
362] and breast [251] and prostate cancer [252], but there are as yet no studies which have 
investigated its role in cervical carcinogenesis.  
PAX1 is a transcription factor involved in developmental processes. It is suggested to be a TSG and 
is silencing by methylation in ovarian cancer [363] and ICC [364]. Its precise function is yet to be 
determined. In animal studies, overexpression of SOX1 was associated with tumour suppression by 
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inhibiting cell proliferation and invasion in vitro, and interferes with the Wnt/β-catenin signalling 
pathway in cervical cancer [365]. Its silencing in DNA methylation restricts this regulation.   
While aberrant methylation of HPV during disease progression is common, and most pronounced 
in the L1 and L2 regions [366] , it remains uncertain whether HPV DNA methylation provides the 
infected cell with a growth advantage [366] or whether it is indirectly involved in DNA methylation 
of human genes. 
It was not the aim of this review to assess the accuracy of the various DNA methylation markers 
for the detection of CIN2/3, CIN3 and CIN3+ and a more formal pooling and meta-analysis of the 
data, as well as full assessment of sources of heterogeneity would be required to do this. The 
diversity of studies and performance is further compounded by the diversity of use in different 
screening/triaging settings. However, based on a crude assessment of the summary data in Table 
4.1, it appears that the majority of DNA methylation markers detect CIN3+ with greater accuracy 
(i.e. high sensitivity and specificity), suggesting the DNA methylation is a process which occurs 
late in the pathway to ICC, and it could be used in triage after a more sensitive test such as HPV 
DNA testing.  
Previous data has shown that if left untreated, lesions from approximately <5% of HIV-negative 
women with CIN1, 12-20% of women with CIN2 and 35-65% of women with CIN3 or carcinoma in situ 
(CIS) would progress to ICC during a normal life span [367], and there could be  a role for a marker 
that could detect women who were likely to have lesion progression, similar to what has been 
reported for p16INK4A (cyclin-dependent kinase inhibitor), a tumour suppressor gene implicated in 
CIN2+.  In a study among 1,137 HIV-negative women in Italy, among whom 40% were found to over-
express p16 INK4A at baseline, the cumulative incidence of CIN2+ over 3 years was 8.8% in p16 INK4A -
positive HR-HPV+ women and 3.7% in p16INK4A -negative HR-HPV+ women, giving a RR of 
progression to CIN2+ of 2.61 [368].  
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Given that WLHIV have faster progression to CIN2 and greater [171]– and the value of HPV DNA 
testing is limited because of the high prevalence of HPV in this population – such a marker would 
be valuable in distinguishing CIN2/3 lesions that persist or progress from those that spontaneously 
regress.   
DNA methylation of human genes have rarely been studied among WLHIV and HPV16 DNA 
methylation has never been studied among WLHIV. In this thesis, baseline and endline samples 
from the HARP study were used in a case-control design to evaluate the DNA methylation of the 
human gene EPB41L3 and HPV16 for the detection of CIN2+ at baseline, and incident CIN2/3 at 
endline. Furthermore, among the women who were not treated for prevalent CIN2+ during the 18-
months follow-up period, the baseline methylation levels of EPB41L3 among women with 
persistent or progressive CIN2/3 were compared with those from women that had spontaneous 
regression of CIN2/3 lesions at endline. The finding of these analyses are summarised in Chapter 
10.  
EPB41L3 gene was selected as it generated reasonable performance among HIV-negative women, 
and had more consistent sensitivity and specificity estimates across studies with less variation in 
these estimates. DNA methylation of the HPV16 L1 region was also explored so that a comparison 
of its association with CIN2+ is similar to that of EPB41L3 methylation.  
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Summary of findings 
 
 Databases were searched using search terms for human gene and HPV DNA methylation 
and cervical lesions.  
 Of 2,106 records initially identified, 23 studies were included that investigated the 
association of human gene DNA methylation with histologically confirmed CIN2+ relative 
to ≤CIN1, including CADM1, MAL, MIR-124, EPB41L3, PAX1 and SOX1, and 12 studies were 
included that investigated HPV16 DNA methylation with CIN2+.  
 There was significant variation in reporting of data across studies; studies reported 
various thresholds of DNA methylation to define methylation positivity and various 
outcome groups were used (CIN2/3, CIN3, CIN2+, CIN3+).  
 CADM1, MAL and MIR-124 genes were most frequently studied in combination panels 
together. For a specificity of 70%, a combination of the 3 genes gave a range of 
sensitivity between 48-65% for CIN2/3, 69-77% for CIN3 and 95% for CIN3+.  
 EPB41L3 as a single test had a range of sensitivity between 50-60% for CIN2/3 and 68-84% 
for CIN3, based on a specificity of 57%. In combination with HPV16, 18, 31, 33, or with 
other human genes, sensitivity was increased; 65-74% for CIN2+ and 82-84% for CIN3+.  
 PAX1 and SOX1 both had very high specificity when evaluated individually (≥80%). 
Sensitivity was low for CIN2/3 (15-79%) but higher for CIN3 (37-78%) and CIN3+ (52-95%).  
 HPV16 as a single gene had a wide range of sensitivity values (21-93%) for CIN2/3 
detection based on specificity of 70%, but increased to 61-80% for CIN3+.  
 Although there was much variation in reporting of DNA methylation of human genes 
and HPV16, the data appears to suggest that DNA methylation markers are able to detect 
CIN3+ lesions with high sensitivity and with a reasonable specificity (70%).  
 Restricting the analysis to studies using samples from population based screening, the 
pooled sensitivity and specificity of various DNA markers combined (HPV16, EPB41L3, 
CADM1, MAL and MIR) for CIN2/3 detection were were 65% (95%CI: 55-74) and 70% (95%CI: 
68-72) respectively among 6 studies, and for CIN3+ were 62% (95%CI: 56-69) and 70% 
(95%CI: 68-73) respectively among 7 studies. However, heterogeneity across studies was 
high, and a more formal meta-anaysis would be required to take into account the 
different study characteristics. 
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Figure 4.2. Flowchart for study selection 
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Table 4.1. Summary range of Sensitivity estimates for detection of CIN2/3, CIN3 and CIN3+ relative to ≤CIN1, based on different specificity values as 
reported in literature  
   
CIN2/3 
 
CIN3 
 
CIN2+ 
 
CIN3+ 
 
 Marker Panel Minimum specificity* N studies Range Sens. N studies Range Sens. N studies Range Sens. N studies Range Sens. 
CADM1 Single 70% 4 13-79% 3 33-87% - - 2 47-79% 
MAL Single 70% 4 2-64% 3 42-83% -  2 60-67% 
CADM1/MAL Combination 70% 3 36-62% 3 50-90% - - 2 68% 
MAL/MIR Combination 70% 1a 31% 1 41% - - - - 
CADM1/MAL/MIR Combination 70% 2 48-65% 2 69-77% - - 1 95% 
           
EPB41L3 Single 57% 3 50-60% 2 68-84% - - - - 
 Combination 60% - -   2
b 65-74% 2c 82-84% 
           
PAX1 Single 90% 4 15-79% 2 36-92% 4 37-78% 5 52-95% 
SOX1 Single 80% - - - - 1 44% 2 81-88% 
           
HPV16 L1/L2 Single 70% 4 21-93% 1 61% - - 1 80% 
  60% - - - - 4 60-92% - - 
  40% 2 90-92% - - - - - - 
 Combination 60% - - - - 1 74% 1 84% 
abased on 57% specificity; bbased on 65% specificity and combination panel (either HPV16,18,31,33 or JAM3, TERT, C13ORF18; cbased on 60% specificity and combination panel (either HPV16,18,31,33 or JAM3, 
TERT, C13ORF18);* obtained the highest possible specificity values for each marker as reported in the literature. From these estimates, a range of sensitivity values was generated  
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Table 4.2. Performance of DNA methylation markers for the detection of CIN2/3, CIN2+, CIN3 and CIN3+ among population based screening studies 
Author, year Methylation marker Country Sample size Endpoint N cases Sens. Spec. PPV NPV 
DeVuyst, 2015 CADM1+MIR+MAL Kenya-Nairobi 248 CIN2/3 93 72.0% 70.0% 58.8% 80.7% 
Verhoef, 2015 CADM1+MAL The Netherlands 358 CIN2/3 84 57.1% 72.3% 38.7% 84.6% 
Verhoef, 2014 MAL+MIR The Netherlands 1019 CIN2/3 212 46.7% 68.1% 28.1% 82.7% 
Vasiljevic, 2014 EPB41L3 UK-London 1456 CIN2/3 531 61.0% 70.0% 54.9% 75.0% 
Brentnall, 2014 HPV16 UK-London 556 CIN2/3 323 78.0% 70.0% 78.3% 69.7% 
Lorincz, 2013 HPV16 UK-Wales 73 CIN2/3 25 77.0% 70.0% 57.6% 85.0% 
          
DeStrooper, 2014 CADM1+MAL The Netherlands 234 CIN2+ 58 62.1% 78.4% 48.6% 86.3% 
Hesselink, 2014 MAL+MIR The Netherlands 355 CIN2+ 94 59.6% 70.0% 41.8% 82.8% 
Bryant, 2015 HPV16 UK-Cardiff 200 CIN2+ 145 61.9% 66.0% 82.6% 39.6% 
          
DeVuyst, 2015 CADM1+MIR+MAL Kenya-Nairobi 248 CIN3 43 79.0% 70.0% 42.0% 92.4% 
Verhoef, 2015 CADM1+MAL The Netherlands 330 CIN3 56 66.1% 72.3% 32.7% 91.2% 
Verhoef, 2014 MAL+MIR The Netherlands 1019 CIN3 134 51.5% 68.1% 21.4% 89.3% 
          
DeStrooper, 2014 CADM1+MAL The Netherlands 234 CIN3+ 38 68.4% 75.5% 35.1% 92.5% 
Hesselink, 2014 MAL+MIR The Netherlands 355 CIN3+ 74 64.9% 70.0% 36.4% 88.3% 
Verhoef, 2014 MAL+MIR The Netherlands 1019 CIN3+ 147 55.1% 68.1% 24.3% 89.1% 
Bryant, 2015 HPV16 UK-Cardiff 200 CIN3+ 145 60.5% 70.3% 84.6% 40.6% 
PPV=Positive predictive value; NPV=Negative predictive value
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Figure 4.3. Meta-analysis of the performance of DNA methylation markers for the detection of 
CIN2/3 in 6 studies.  
 
Figure 4.4. Meta-analysis of the performance of DNA methylation markers for the detection of 
CIN3 and CIN3+ in 7 studies.  
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5 OVERALL STUDY METHODOLOGY 
 
In this chapter, I firstly describe the overall design of this research thesis. I then describe the HARP 
specific study design, objectives and methods within which this PhD is nested, and laboratory 
methods for HPV serology and DNA methylation. The statistical approaches are briefly described but 
specific statistical analyses for each of the research objectives are more clearly described in the 
respective chapter (Chapters 6 to 10 inclusive).  
 
5.1 PhD overall study design 
As described in Chapter 1 (Table 1.1), this PhD is comprised of three interrelated studies, each with 
their specific design and methods, although some of the laboratory methods and analytical 
approaches are shared. Figure 5.1 illustrates how the thesis is organised into the individual studies. 
The thesis begins with a series of systematic reviews. In terms of research study designs, the PhD 
comprises a combination of cross-sectional, cohort and case-control studies.  
A systematic review and meta-analysis exploring the association of ART with HR-HPV and cervical 
lesions (Objective 1.1) was needed to inform the analyses for STUDY 1 and STUDY 2, in order to 
understand whether women on ART had a different risk profile for HPV infection and cervical lesion 
incidence and progression compared to women not on ART.  
A second systematic review of the literature on DNA methylation of human genes and HPV types, 
and their association with CIN2+ (Objective 1.2), was performed in order to summarise the 
evidence on the most frequently studied human genes and HPV types, to justify the choice of DNA 
methylation targets in this thesis and to inform the analysis of STUDY 3.  
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The different study designs used to address the objectives in STUDIES 1, 2 and 3 are illustrated in 
Figure 5.2. STUDY 1 used a combination of cross-sectional and prospective data from the HARP 
study to describe the epidemiology of HR-HPV (prevalence, incidence, persistence and clearance) 
and CIN2+ (prevalence, incidence, persistence and spontaneous regression) at baseline and over 
18-months follow-up, and to explore socio-demographic, behavioural and HIV-related factors 
associated with these outcomes. STUDY 1 used a broader definition for HR-HPV and was defined 
as positive for any HR-HPV types.  
STUDY 2 also used a combination of cross-sectional and prospective data from the HARP study, but 
focussed on HPV genotype specific analyses. STUDY 2 uses the cross-sectional data to describe the 
HPV genotype specific prevalence and their association with prevalent CIN2+, as well as describing 
HPV type seroprevalence.  The prospective data is used to explore the association of specific HPV 
genotype persistence with CIN2/3 incidence, as well as HPV type specific seroincidence and 
seroconversion and associations with same-type HPV re-infection.  
The prospective study data was used from the HARP study as: i.) it allows for a precise definition 
of HPV incidence and HPV persistence; and CIN2+ incidence over the follow-up period, and ii.) it 
addresses the temporality between the risk exposure and the outcome, thereby allowing for 
exploration of the association of baseline risk factors with early disease outcomes, such as HR-HPV 
persistence and CIN2+ incidence. The prospective study excluded prevalent CIN2+ in the risk factor 
analysis so as to extend the findings to a wider population of women without CIN2+.  
Finally, STUDY 3 used a case-control design to investigate associations between human gene 
EPB41L3 and HPV16 DNA methylation and CIN2+ prevalence and incidence, and this is detailed in 
section 5.5.  
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Figure 5.1. Organization of the thesis in 4 sections and 11 Chapters.  
 
 
Chp.1 Chp.2 Chp.3 Chp.4 Chp.5 Chp.6 Chp.7 Chp.8 Chp.9 Chp.10 Chp.11
Chapter 6: 
Obj. 2.1, 2.2 & 2.3 
Chapter 3: 
Obj 1.1 
Chapter 4: 
Obj 1.2 
Chapter 7: 
Obj. 2.4 
Chapter 8: 
Obj. 3.1, 3.2 & 3.3 
Chapter 9: 
Obj. 3.4, 3.5 & 3.6 
Chapter 10: 
Obj. 4.1, 4.2 & 4.3 
SYSTEMATIC REVIEWS STUDY 1 STUDY 2 STUDY 3 
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Figure 5.2. Elements of the pathway from HPV infection to invasive cervical cancer addressed in this thesis 
 
126 
 
 
5.2 The HARP study  
The EU-funded HARP (HPV in Africa Research Partnership) study was established to evaluate cervical 
cancer screening strategies against histological (CIN) and cytological (SIL) endpoints among 
WLHIV recruited according to ART status in Burkina Faso and South Africa. The overall aim of HARP 
was to improve cervical cancer prevention programmes for WLHIV in South Africa and Burkina 
Faso, by evaluating the effectiveness and cost-effectiveness of alternative screening strategies, 
and by developing algorithms leading to earlier detection and management of cervical cancer in 
these high-risk populations.  
 
5.2.1 Study design 
The HARP study was conducted in two countries, with one study site in each country, and consisted 
of three interlinked substudies: 
 A cross-sectional study of HPV and cervical neoplasia screening among HIV-1 seropositive 
women attending HIV care centres in Burkina Faso and South Africa.  
 A prospective cohort study of HIV-1 seropositive women recruited in Study 1 including women 
without advanced histological lesions (≤CIN1), and women with CIN2+ up to 18 months (which 
was reduced to 16 months because of project constraints). 
 A health economics and modelling study using data from the cross sectional and cohort studies 
to determine cost-effectiveness of the various screening strategies in preventing cervical 
cancer cases.  
 
5.2.2 Sample size 
Sample size calculations for the HARP study were based on the comparison of the rate of 
progression to CIN2+ between HIV-1 positive patients taking ART or having low CD4+ T-
lymphocytes cell count at study entry versus those not on ART at study entry. Prevalence and 
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progression rates were based on the only available estimates of CIN2+ prevalence and incidence in 
WLHIV in UK and South African populations at the time of study design [369]. The sample size 
calculations took into account the approximate presentation of patients at HIV clinics in Africa with 
a 2:1 ratio of women enrolled ART-users:naïve. With total of 1200 women (400 not on ART, 800 on 
ART) over both sites, the study had over 80% power to detect a difference of 10% vs. 5% CIN2+ 
prevalence at enrolment. With total of 1200 women (400 not on ART, 800 on ART) enrolled in both 
sites, the study had 95% power to detect a difference of 15% vs. 7.5% in cumulative CIN2+ incidence 
over 18 months (the initially intended duration of the study). Calculations also allowed for 15% loss 
to follow-up, including any change of ART/CD4 group status. 
 
5.2.3 Visit schedule 
At the screening visit (Visit 0), participants were invited to enrol for the HARP study following 
assessment of eligibility criteria and were given at least 7 days reflection period before enrolment 
(Visit 1) in the study. Four to six weeks following enrolment (Visit 2), allowing for results guiding 
biopsy indication to be returned, all participants were examined by digital colposcopy; and four-
quadrant biopsy was taken if indicated.  
Participants were followed up every 6 months for 18 months, reflecting routine schedules for HIV 
follow-up and care in both countries, to evaluate the performance of screening methods for the 
detection of incident CIN2+. For that purpose, a colposcopy and biopsy visit was organised at 
Month 18 (M18) follow-up visit. In addition, a venous blood sample was collected at month 6 (M6), 
month 12 (M12) and M16 for CD4+ T-lymphocyte counts. The HARP study flow of procedures is 
shown in Figure 5.6.  
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5.2.4 Study population 
Participants were recruited from the Hôpital de Jour, the HIV outpatient clinic of the University 
Teaching Hospital of Ouagadougou, Burkina Faso (BF), and HIV treatment centres (Esselen Street 
Clinic and Ward 21, Hillbrow Community Health Centre) in inner city Johannesburg, South Africa 
(SA) from December 2011 to October 2012. Inclusion criteria were being HIV-1 seropositive, aged 
25-50 years and resident in the city. Exclusion criteria were history of prior treatment for cervical 
cancer, previous hysterectomy, and being pregnant or less than 8 weeks postpartum. To enable 
analysis of the effects of ART on cervical disease progression, enrolment was stratified in a 2:1 ratio 
of ART-users:naïve, similar to proportion of WLHIV using ART in other SSA countries [10]. At 
enrolment, eligibility for ART initiation in both countries followed the 2010 WHO guidelines with a 
CD4+ count threshold of 350 cells/mm3 [370]. Written informed consent was obtained at the 
screening visit when eligibility for the study was assessed and at enrolment. Data on clinical, socio-
demographic and behavioural characteristics were collected by interviewer-administered 
questionnaire. Participants were followed-up every 6 months for CD4+ cell count up to Month 18 
visit (endline) when procedures similar to baseline (Visit 1) were repeated. 
 
5.2.5 Specimen collection 
At enrolment, a venous blood sample was collected to confirm HIV-1 serostatus if needed, to 
perform HSV-2 and syphilis serologies and to obtain baseline HIV-1 RNA PVL and CD4+ cell counts. 
Urine pregnancy testing was performed. Cervical samples were collected by a nurse-midwife using 
a Digene cervical sampler (Qiagen, Courtaboeuf, France) at enrolment and using the careHPV 
cervical sampler (Qiagen, Gaithesburg, MD) at month 12 and at month 18 follow-up visits for HPV-
DNA testing and genotyping. A cytobrush for Papanicolaou smear cytology and a swab from the 
ecto/endocervix to detect cervical STIs by molecular methods were also collected. A vaginal smear 
was collected to diagnose bacterial vaginosis and Candida albicans by Gram stain. Participants were 
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assessed clinically using visual inspection with acetic acid or Lugol’s iodine (VIA/VILI). All 
participants were referred for colposcopy performed by trained colposcopists. Systematic 4-
quadrant cervical biopsy, including directed biopsy of any suspicious lesions, was performed for 
participants who had abnormalities detected by cytology (≥LSIL or atypical glandular cell of 
undetermined significant or greater [>AGUS]), VIA/VILI or colposcopy, or who were HR-HPV DNA 
positive (by Digene HC-II). The same genital sampling and examination procedures were repeated 
at the endline visit at Month 18 (HR-HPV DNA testing was done then by careHPV).  
 
5.2.6 HIV and STI laboratory testing  
HIV-1 serostatus was diagnosed according to national guidelines for each country [371, 372]. HSV-2 
serology was performed using the Kalon® IgG2 ELISA (Kalon Diagnostics, UK) and syphilis serology 
by a combination of a Treponema pallidum haemagglutination assay (TPHA) and rapid plasma 
reagin (RPR; BioMérieux, Lyon, France in BF; Immutrep carbon antigen RPR, Omega Diagnostics in 
SA). Plasma HIV-1 RNA was assessed using real-time PCR (Abbott RT HIV-1) in BF and COBAS 
Taqman (Roche Diagnostics) in SA, with a lower limit of detection of 40 copies/ml. Testing for CD4+ 
T-lymphocytes was performed using FACScount (Becton-Dickinson, NJ). Laboratories subscribed 
to international external quality assessment schemes; the UK-National External Quality 
Assessment Service for CD4+ cell counts [373] and Quality Control for Molecular Diagnostics for 
HIV-1 PVL testing [374].  
Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis 
were detected using nucleic acid amplification tests [NAATs], the Sacace simplex assays (Sacace, 
Como, Italy) in BF and the APTIMA Combo (Gen-Probe, San Diego, CA) in SA. The Nugent’s score 
[375] was used for vaginal flora reading of Gram-stained vaginal smears, with diagnosis of bacterial 
vaginosis made for scores >7, and examined for the presence of Candida spp.  
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5.2.7 HPV DNA assays 
HPV-DNA genotyping of all samples was performed at the virology laboratory of the Gui de 
Chauliac Teaching Hospital, University of Montpellier, France, using the qualitative Digene HC-II 
(Qiagen, Gaithersburg, MD), and genotyping with the INNO-LiPA HPV genotyping Extra® assay 
(Innogenetics, Courtaboeuf, France)[376, 377]. The Digene HC-II assay is based on hybridization of 
HPV DNA with a RNA probe cocktail with chemiluminescence signal amplification to detect the 13 
HR types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68).  
The careHPV assay (Qiagen, Gaithersburg, MD) is a new signal-amplification assay adapted from 
HC-II assay and targets the same 13 HR types as Digene, in addition to HPV66. Modifications were 
made to deploy this assay in low-resource environments. In HARP the careHPV assays were 
performed at the local laboratories, the Centre de Recherche Biomoléculaire Pietro Annigoni 
(CERBA) in Ouagadougou and the Sexually Transmitted Infections Reference Centre (STIRC) of the 
National Health Laboratory Service (NHLS) in Johannesburg. 
The INNO-LiPA HPV genotyping Extra® assay is based on the amplification of a 65-bp fragment in 
the L1 gene using the SFP10 broad-spectrum primers that enables the identification of 32 HPV types 
[376]. HR-HPV types were defined using the current International Agency for Research on Cancer 
(IARC) classification [4] to include: ‘carcinogenic to humans’ (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, and 59) and ‘probable carcinogenic’ (HPV68). The ‘possible carcinogenic’ types (HPV26, 53, 66, 
69, 70, 73, and 82) and other known low-risk types (HPV6, 11, 40, 43, 44, 54, 71, and 74) were 
considered as low-risk (LR-HPV), as summarised in Table 5.1. HPV types are further classified into 
sub-groups according to the nucleotide sequence of the L1 protein; the HR types are part of the 
alpha-7 and alpha-9 sub-group of HPV types.   
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Table 5.1. Definition of HPV categories using INNO-LiPA genotyping assay 
Outcome Group  HPV types 
HPV positive1 6, 11, 16, 18, 25, 26, 30, 31, 33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 
59, 66, 68, 69, 70, 71, 73, 74, 81, 82, 84 
HR-HPV (‘carcinogenic’ & ‘probable 
carcinogenic’2 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 
HR-HPV ‘possible carcinogenic’2 26, 53, 66, 69/71 (without distinction between 69 and 71), 70, 73, 82 
LR-HPV2  6, 11, 40, 43, 44, 54, 62, 74 
Alpha-9 HR-HPV3 16, 31, 33, 35, 52, 58 
Alpha-7 HR-HPV3 18, 39, 45, 59, 68 
Alpha-5 HR-HPV3 51 
Alpha-6 HR-HPV3  56 
Vaccine groups  
Bivalent vaccine types (2vHPV) 16, 18 
Quadrivalent vaccine types (4vHPV) 6,11,16,18 
Nonavalent vaccine types (9vHPV) 6, 11, 16, 18, 31, 33, 45, 52, 58 
1types detected by INNO-LiPA; 2Classification by [4]; 3classification in [378] 
5.2.8 Histology 
Cervical biopsies were processed at the local pathology laboratories in Ouagaoudou and 
Johannesburg and read using the three-tier CIN classification system [42]. Histology was classified 
as ‘negative’ (≤CIN1) or ‘positive’ (CIN2+) based on the highest reading across all findings from the 
4-quadrant biopsies and endocervical curettage, if indicated. All histological slides from women 
with a local diagnosis of CIN2+, all slides with an undecided diagnosis of CIN1/2 and approximately 
10% of slides from women with ≤CIN1 histological findings were reviewed by the HARP Endpoint 
Committee of five pathologists (one from each site plus 3 international from France and Spain) 
after each major endpoint visits were completed (i.e. Visit 2 and Visit 6, see HARP Flowchart, Figure 
5.6), for consensus classification (and if necessary adjustment of management of the patients). 
 
5.2.9 Management of CIN2+  
Participants were recalled for CIN2+ management, if found to have CIN2+ lesions by histology at 
enrolment. This visit was scheduled at the earliest convenient date once the result was known. Due 
to demands on local health services, especially in SA, this often meant that CIN2+ management 
was scheduled up to 14 months later. CIN2+ status was therefore defined according to whether 
the participant had received CIN2+ management between enrolment and follow-up (Table 5.3).  
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Management of CIN 2+ was according to local guidelines at each site, and included the following 
options: 
 Immediate treatment with cold coagulation or laser ablation  
 Use of loop excision techniques (Large loop excision of the transformation zone 
[LLETZ]/Loop Electrosurgical Excision Procedure [LEEP]) techniques according to IARC 
guidelines (http://screening.iarc.fr/colpo.php). 
 Referral for surgery for cone excision, cervix amputation or hysterectomy for higher grade 
or invasive lesions and according to the child-bearing intention of the women. 
Women who underwent hysterectomy were withdrawn from the follow-up study.  
 
5.3 Study 1: Epidemiology of HPV infection and cervical lesions  
Study 1 used secondary quantitative cross-sectional and longitudinal data collected as part of the 
HARP study and stored in the HARP database at the LSHTM. Histological measurements, in 
addition to data on HPV genotyping data and HIV related factors, such as ART status, ART duration, 
CD4+ cell count and HIV-1 PVL, socio-demographic and behavioural factors were used during the 
analysis (Chapters 6, 7 and 8).   
 
5.3.1 Definitions of HPV infection states 
HR-HPV type-specific persistence was defined as being positive for the same type at baseline and 
endline by genotyping (Table 5.2). Type-specific clearance was defined as being positive for a 
specific HR type at baseline and negative for the same type at endline, while complete clearance 
was defined as being positive for at least one HR type at baseline and negative for all HR types at 
endline. Results are presented in Chapter 6 (Objective 2.1) for HR-HPV prevalence, incidence, 
persistence and clearance, and in Chapter 8 (Objectives 3.1 & 3.2) for individual HPV genotype 
prevalence, incidence and persistence. 
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Table 5.2 Definition of HPV infection status at baseline and endline 
Outcome 
Group  
 Definition  Baseline result 
(Denominator) 
Endline result 
(Numerator) 
Analysis approach 
Incidence 1 Type specific incidence  Type specific negative  Same type positive  Per infection analysis 
2 Type swap  Positive for X HPV  
Negative for Y HPV  
Negative for X HPV  
Positive for Y HPV  
Per woman analysis 
3 Any HR-HPV incidence1 Negative for any HR-HPV  Positive for HR-HPV type not 
detected at baseline  
Per woman analysis 
Persistence 4 Type specific persistence  Type specific positive  Same type positive  Per infection analysis 
 5 Any HR-HPV persistence Positive for any HR-HPV Any HR-HPV type-persistence Per woman analysis 
Clearance 6 Type specific clearance  Type specific positive  Same type negative  Per infection analysis 
7 HR-HPV complete clearance  Positive for any HR-HPV  Negative for all HR-HPV  Per woman analysis 
1For the definition of ANY HR-HPV incidence : given that  no woman was infected by all 13 HR types, all women were at risk of acquiring 
at least one HR-HPV infection and all women were included in the risk factor analysis for HR-HPV incidence; the numerator include 
women with incident infection of any HR type 
 
5.3.2 Definitions of CIN2+ status 
CIN2+ status at baseline and endline was defined, as described in Table 5.3. Prevalent CIN2+ was 
defined as the number of women with CIN2+ detection at baseline among all women enrolled in 
the HARP study. There were no ICC detected at endline, therefore CIN2/3 is used at in the endline 
definitions of CIN status. Incident CIN2/3 at endline was defined as newly detected CIN2/3 at the 
endline visit among those without CIN2/3 at baseline. Recurrent CIN2/3 was defined as CIN2/3 
detection at endline among women who received management for prevalent CIN2+ diagnosis 
before the second biopsy visit at endline.  
Persistent CIN2, persistent CIN3 and progression from CIN2 to CIN3 were calculated among those 
participants that did not receive management for prevalent CIN2/3 diagnosis before the second 
biopsy visit at endline. Participants with CIN3 regression to CIN2 and CIN2/3 spontaneous 
regression to ≤CIN1 were similarly described.  
These descriptive results are presented in Chapter 6 (Objective 2.2). 
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Table 5.3. Definition of CIN2+ status at baseline and endline 
Management 
status 
Outcome Group Denominator Baseline Endline 
Not required CIN2+ prevalence All women at baseline CIN2+  
Not required Twice ≤CIN1 Women ≤CIN1 at baseline ≤CIN1 ≤CIN1 
 Incident CIN2/3  ≤CIN1 CIN2/3  
Treated for CIN2+ Successfully treated Women with CIN2+ at 
enrolment and treated before 
M18 
 
CIN2+ ≤CIN1 
 Recurrence CIN2+ CIN2/3 
Not treated for 
CIN2+ 
Persistent CIN2 Women with CIN2+ at 
enrolment and not treated 
before M18 
CIN2 CIN2 
 Persistent CIN3 CIN3 CIN3 
 Progression CIN2 to CIN3 CIN2 CIN3 
 Regression CIN3 to CIN2 CIN3 CIN2 
 Regression CIN2/3 to≤CIN1 CIN2/3 ≤CIN1  
 
5.3.3 Statistical analysis 
Individual research chapters provided thorough details of statistical analyses used, specific to each 
chapter, although some statistical approaches commonly used in the research chapters are 
described here.   
As HR-HPV prevalence was common, associations with exposure variables were estimated with 
prevalence ratios (PRs) obtained from logistic regression using marginal standardization to 
estimate PRs, and the delta method to estimate 95% confidence intervals (CI) [379]. Associations 
between HR-HPV persistence and exposure variables were estimated with generalised estimating 
equation to account for multiple HR-HPV infection and multiple infection states (persistence and 
clearance) [380]. For associations with CIN2+ prevalence and incidence over follow-up (measured 
once at endline), logistic regression was used to estimate odds ratios (ORs) and 95% CI.  
Multivariable analyses were adjusted for site and socio-demographic and behavioural factors 
which were independently associated in univariate analyses (with p values <0.10) with HR-HPV or 
CIN2+ for each country (Model 1). Given the wide range of risk factors included in the initial model, 
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a p-value of <0.10 was used to identify factors to carry forward in multivariate analysis. Results are 
presented in Chapter 6 (Objective 2.3). 
To explore associations of HR-HPV and CIN2+ outcomes with HIV-related factors, pre-specified 
analyses included stratification by site, ART use and duration (≤ or >2 years), HIV-1 viral suppression 
(< or ≥1000 RNA copies/ml) and CD4+ cell counts. Stable high CD4+ cell count was defined as having 
CD4+ counts >500 cells/mm3 at baseline, Month 12 and endline (M18) visits. A second logistic 
regression model (Model 2) incorporated baseline CD4+ cell count to Model 1 to explore 
associations with ART. Results are presented in Chapter 7 (Objective 2.4). 
All data in this thesis were analysed using Stata version 14 (Stata Statistical Software, College 
Station. TX: Stata Corporation). 
 
5.4 Study 2: HPV type specific infection and serodynamics among WLHIV  
5.4.1 Definitions of HPV type-specific DNA  
HR-HPV type-specific persistence and clearance are defined, as described previously (Table 5.2). 
Vaccine-type HPV groups are defined in Table 5.1. Results are presented in Chapter 8 (Objectives 
3.1 & 3.2) for individual HPV genotype prevalence, incidence and persistence. 
5.4.2 HPV serology assay 
HPV serology was tested using a multiplexed binding assay, which uses pseudovirions as antigen 
and detects HPV type specific IgG antibodies [PsV-Luminex]). Serology was performed for 
‘carcinogenic/probable carcinogenic’ types HPV16/18/31/33/35/39/45/52/56/58/59/68 (but not HR-
HPV type 51) and the ‘possible carcinogenic’ or low-risk types HPV6/11/73 at Karolinska Institute, 
Stockholm, Sweden [381]. Serum samples were analysed in a 1:50 and 1:150 dilutions. Cut-off values 
to define seropositivity were calculated independently for each HPV type by analysing the mean 
fluorescence intensity unit (MFI) values obtained from 100 Swedish children’s sera (≤12 years old). 
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The cut-off algorithm was as recommended by the global HPV LabNet (mean MFI value of a 
negative control serum panel plus 3 standard deviations) [382]. If this cut-off value was 
unreasonably low (less than 400 MFI), 400 MFI was used as cut-off to have sensitivity and 
specificity similar to classical ELISA [383].  
5.4.3 HPV serology definitions 
HPV serology results are presented as binary results (positive and negative for a given type) based 
on the cut-off estimated using negative panel (minimum 400 MFI). HPV seroprevalence rates are 
presented in Chapter 9 (Objective 3.4).  
HPV type-specific seroincidence was defined as being HPV-type seronegative at baseline and 
becoming same type seropositive at endline, irrespective of the DNA status at either baseline or 
endline. 
A more conservative definition was applied considering the HPV DNA status at baseline as evidence 
of past infection. HPV type-specific seroconversion was defined as being HPV DNA positive and 
same type seronegative at baseline, and becoming same type seropositive at endline, irrespective 
of the DNA status at endline. Results are presented in Chapter 9 (Objective 3.5). 
5.4.4 Statistical analyses 
HPV genotype-specific DNA (Objectives 3.1-3.3) 
For associations of prevalent HPV genotypes with CIN2+ prevalence at enrolment, and persistent 
HPV genotypes with CIN2+ incidence over follow-up, logistic regression was used to estimate odds 
ratios (ORs) and 95% CI. Results are presented in Chapter 8 (Objective 3.2). 
To explore associations of HR-HPV vaccine types (HPV16/18, nonavalent types, and non-vaccine 
types) with HIV-related factors, associations were estimated with PRs obtained from logistic 
regression using marginal standardization to estimate PRs, and the delta method to estimate 95% 
CI. Results are presented in Chapter 8 (Objective 3.3). 
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HPV Serology (Objectives 3.4-3.6) 
Associations between HPV seroconversion and exposure variables were estimated with 
generalised estimating equation to account for seropositivity by multiple HPV types [380]. To 
explore associations of HPV seroconversion with HIV-related factors, pre-specified analyses 
included stratification by ART duration (≤ or >2 years), HIV-1 viral suppression (≤ or >40 copies/ml) 
and CD4+ cell counts (Model 1). A second logistic regression model (Model 2) incorporated endline 
CD4+ cell count to Model 1 to explore associations with ART. Results are presented in Chapter 9 
(Objective 3.5). For associations of baseline seropositivity with HPV DNA incidence over follow-up, 
logistic regression was used to estimate ORs and 95% CI. Results are presented in Chapter 9; 
Objective 3.6).  
 
5.5 Study 3: Association of DNA methylation with CIN2+ 
Study 3 used cervical samples collected using a Digene cervical sampler (Qiagen, Courtaboeuf, 
France) at enrolment and using the careHPV cervical sampler (Qiagen, Gaithesburg, MD) at month 
18 follow-up visits, as previously described (section 5.2.5 Specimen collection). 
5.5.1 Study design  
Study 3 is a set of two case-control studies nested within the HARP study using cervical samples 
with matched genotyping and histological endpoints. Case-control study 1 was retrospective 
(Figure 5.3) and used samples collected at baseline to compare DNA methylation between CIN2+ 
cases and ≤CIN1 controls at baseline.  Case-control study 2 was prospective (Figure 5.4 and Figure 
5.5) and compared i.) the DNA methylation between incident CIN2/3 and ≤CIN1 controls at endline, 
and ii.) the change in methylation levels between baseline and endline among women with incident 
CIN2/3 and women who remained ≤CIN1 .   
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Cases and control were primarily selected for testing by the EPB41L3 human gene methylation 
assay (i.e. irrespective of whether they were HR-HPV positive), and a subsample was tested by the 
HPV16 methylation assay among those that were HPV16 positive at baseline.  
Case-control Study 1 (Retrospective design)(Figure 5.3) 
Definition of cases 
All cases of histologically confirmed CIN2+ detected at baseline (prevalent) were included in the 
case-control study 1, matched 1:1 with ≤CIN1 controls, as detailed in Figure 5.3.  
Definition of controls 
Controls were defined as ≤CIN1 at baseline with a corresponding histological result at endline, 
irrespective of whether they developed CIN2/3 or remained ≤CIN1 at endline.  
Controls were to be matched 1:1 to cases, according to: 
1) Age group (<35 years and ≥35 years), as methylation changes can occur during healthy 
aging as well as during disease development, and aberrant methylation changes during 
aging could underlie the development of cancer [384];  
2) Country of recruitment due to potential genetic differences and different environmental 
exposures in the two populations. 
Controls were randomly selected from among HARP participants who matched age and site 
requirements and had histological diagnoses at both time points.  
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Figure 5.3. Retrospective Case-control Study 1 design 
 
*1:Comparison of ’High’ methylation (exposure) between prevalent CIN2+ cases and ≤CIN1 controls 
 
Case-control Study 2 (Prospective design) (Figure 5.4 and Figure 5.5) 
Definition of cases 
All participants with ≤CIN1 in Case-control Study 1 were followed up at endline visit. Cases for Case-
control Study 2 were defined as all histologically-confirmed incident CIN2/3 detected at endline.  
Definition of controls 
Controls were sampled from the population still at risk at the end of the study and were defined 
as ≤CIN1 at both baseline and endline, confirmed histologically at both time points.  
Controls were to be matched 1:1 to cases according to age and country of recruitment, as described 
for Case-control Study 1.   
 
 
 
 
 
 
 
*1 
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Figure 5.4. Case-control study 1 and 2 flowchart  
 
Case-control study 2 compared i.) the DNA methylation between incident CIN2/3 and ≤CIN1 controls 
at endline, and ii.) the change in methylation levels between baseline and endline among women 
with incident CIN2/3 and women who remained ≤CIN1 .    
 
Figure 5.5. Prospective Case-control Study 2 design† 
  
†Figure depicts cases of incident CIN2/3, but same applies for CIN2/3 persistence, progression and regression *2:Comparison of ’High’ 
methylation (exposure) between incident CIN2+ cases and ≤CIN1 controls at endline; *3: Comparison of baseline and endline 
methylation levels of incident CIN2+ cases to observe change over time 
 
EPB41L3 DNA methylation was also performed among women with CIN2+ included in Case-Control 
1 and with an histological outcome at endline, and included the following outcomes:  persistent 
Case control 1
Cases
Prevalent CIN2+
Controls 
≤CIN1 at baseline
Case control 2
Cases
Incident CIN2+
Controls 
≤CIN1 at baseline and 
endline
*3 
*2 
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CIN2/3 and spontaneous regression to ≤CIN1 among those not treated. However, given the small 
number of cases, these analyses were considered to be exploratory.  
HPV16 DNA methylation analysis was not performed on longitudinal outcomes given the small 
number of incident HPV16-positive CIN2/3 outcomes.  
 
5.5.2 Sample size  
Sample size estimates were established for Case-control Study 1 using prevalent cases, given the 
higher number of cases. Methylation levels for EPB41L3 were dichotomized into ‘high’ and ‘low’ 
methylation levels using the second tertile (66.7 percentile point) based on the distribution in the 
control as a cut-point to define ‘high’ methylation, as previously used in other studies [385, 386]. 
To answer objective 3.1 (To determine the association of DNA methylation of a human gene 
EPB41L3 with CIN2+ prevalence), the study would have 95% power to observe ‘high’ methylation in 
at least 67% of prevalent CIN2+ cases (n=159) compared to 33% in ≤CIN1 controls (n=159), using the 
second tertile as a cut-point and a 1:1 ratio of cases: controls, as summarised in Table 5.4.  
Table 5.4 Power calculation to detect difference in ‘high’ methylation levels (exposure) 
between ≤CIN1 controls (n=159) and prevalent CIN2+ cases (n=159) 
Cut-point (percentile point) % exposed ≤CIN1 % exposed prevalent CIN2+ Power 
66.7 33.3% 50% >90% 
60% >95% 
70% >95% 
 
 
5.5.3 DNA isolation, bisulfite conversion and methylation assay 
The methylation assays for EPB41L3 (CpG sites: 438, 427 and 425) and HPV16 L1 region (CpG sites: 
6389 and 6367) were performed using DNA isolation, bisulfite conversion and quantification of 
methylation using pyrosequencing (PSQ) assays in single separate reactions [387].  
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Sodium bisulfite deaminates cytosine residues on single stranded DNA molecules and converts 
them to uracils, whereas 5-methyl cytosines (C) remain protected from conversion. When bisulfite 
modified DNA is subjected to PCR, the uracil residues are converted to thymidines (T) by DNA 
polymerase in the amplified products. The ratio of C/C+T indicates the proportion of methylated 
cytosines at each C in the assayed sample. Pyrosequencing provides an average estimate of 
methylation levels at a specific site by providing % incorporation of C (methylated) vs. T 
(unmethylated) in bisulfite treated DNA [388]. 
Cervical samples collected at the baseline using the Digene sampling brush and collection medium, 
and endline visit using the careHPV sampling brush and collection medium were used for the DNA 
methylation assays. After collection, the brush was stirred into the collection medium, the cell 
collection was homogenised by vortexing and divided into four 0.25-ml aliquots. DNA was 
extracted from one of the aliquots with the QIAamp DNA Mini Kit (Qiagen Inc, Hilden, Germany). 
Two hundred and fifty nanograms of DNA was used in the bisulfite conversion reactions, where 
unmethylated cytosines were converted to uracil with the EZ DNA methylation kit (Zymo research, 
Irvine, USA). Converted DNA was amplified by methylation‐independent PCR primers and the 
amplicons were tested by pyrosequencing for DNA methylation of EPB41L3 and the late (L1) region 
of HPV16.  
Briefly, 12.5 μl PCR master mix, 2.5 μl Coral red, 1 μl primer-mix, 2 μl DNA and optimised amount of 
MgCl2 were adjusted with water to give a final 25 μl reaction. The final concentration of each 
primer for EPB41L3 and HPV16 assays was 0.2 mM. All the assays were run with thermal cycling 
conditions: 95°C for 15 min, optimised number of cycles: 30 s at 94°C; 30 s at the optimised 
annealing temperature; 30 s at 72°C and a final extension varied between 5 and 10 min at 72°C. In 
each run, a non-template negative control was run in addition to a standard curve consisting of 
1 pg/ml of 0, 50 and 100% methylated HPV plasmid in a background of 10 ng/ml human DNA. The 
amplified DNA was confirmed on QIAxel capillary electrophoresis instrument (Qiagen). 10 μl of 
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PCR product was pyrosequenced using a PyroMark™Q96 ID (Qiagen) instrument [387]. 
Percentage methylation was taken from the singlicate result.    
 
5.5.4 Statistical analyses 
A description of the statistical analyses used for Study 3 are provided in Chapter 10, section 10.2.3.  
 
5.6 Data Management  
Type of data: 
This study will involve the following types of data:   
1) The use of secondary quantitative longitudinal data collected and recorded during 
participant visits to the local clinics in Burkina Faso and South Africa as part of the HARP 
study and stored in the HARP database using Stata version 14 at the LSHTM. Endpoint data 
(histological measurements), in addition to data on HPV genotyping data, socio-
demographic, behavioural and HIV related factors, such as ART status, ART duration, CD4+ 
count and HIV-1 PVL were used during analysis. 
2) The generation of new quantitative data using results of HPV serology assays and DNA 
methylation assays on samples previously collected as part of the HARP study.  
Format of data: 
As part of the HARP study, socio-demographic and behavioural, HPV genotyping, HIV-related and 
histological endpoint data have been collected using Case Report Forms (CRFs) at the local sites in 
Burkina Faso and South Africa and double entered using Stata version 14 and validated locally 
before being sent to the central database at LSHTM. The Stata file was stored on a shared, 
password-protected folder on the LSHTM main server, which was backed up on a daily basis. The 
HPV serology and DNA methylation data were received in Excel format and added to the HARP 
database by HK. 
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Data quality and standards: 
Standard operating procedures (SOPs) for data management procedures were prepared in English 
and French for the HARP study for use at the local sites. All CRFs were checked for missing data 
and other errors and quality control of 10% of all source documents and records are performed on 
a weekly basis at local sites for HARP study documents. A senior data manager managed central 
coordination at LSHTM. Overall monitoring of the quality of the data collection processes across 
the sites was co-ordinated by the LSHTM statistician and myself (HK), as the HARP international 
study coordinator. Similar methods were used during the collection and validation of the serology 
and DNA methylation data.  
Metadata standards and data documentation: 
The HARP study had an associated predefined Data Management Plan, including a series of SOPs 
describing procedures for data entry, CRF completion and Quality Control (QC), and a statistical 
analysis plan. All HARP related data was coded and annotated CRFs and a data dictionary provides 
traceability to all codes and variables. The data dictionary was password protected. HPV serology 
and methylation data were added as continuous variables to the database.  
Formal information/data security standards: 
Data and specimens collected from participants were labelled with the corresponding unique pre-
printed bar-coded numbers and were linked to the research data but not to names or other 
individually-identifying information. All study data were kept in a secure location in accordance 
with the terms of the Data Protection Act 1998. The laboratory testing was conducted under GLP 
(Good Laboratory Practice), including security of data and specimens, in a masked fashion. All test 
results were treated as confidential medical records according to legal requirements. Access to the 
data was only available to the principal investigators and the study coordinators.  In both countries, 
signed consent forms, bearing identifiers of the participants, were kept separately from the other 
study data to preserve anonymity and confidentiality. HARP data was double-entered locally and 
saved daily on password protected computers.    
145 
 
 
 
Figure 5.6. HARP study visits and procedures 
Study procedures: Study 1                                                           Study procedures: Study 2 
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6 STUDY PARTICIPANTS DESCRIPTION AND RISK FACTORS FOR HR-HPV 
AND CIN2+ 
 
In this Chapter, I will firstly provide a summary of the study population characteristics at baseline 
including HR-HPV and CIN2+ prevalence, by country. I will summarise the socio-demographic, 
behavioural and HIV-related factors known to be associated with HR-HPV infection and CIN2+, as 
summarised in Chapter 2, section 2.7 (according to Conceptual framework in Figure 2.7). I will also 
provide a summary of HIV-related factors (ART status and CD4+ cell count) at endline to reflect 
changes in immune reconstitution or immunosuppression over time.  
Finally, I will investigate the association of socio-demographic and behavioural factors with the 
prevalence of HR-HPV and CIN2+ at baseline in multivariate risk factor analyses. I will then extend the 
multivariate risk factor analyses to explore the association of baseline risk factors for longitudinal HR-
HPV outcomes (HR-HPV incidence, persistence and clearance) and CIN2+ incidence.  
I will then discuss these findings in the context of what is already known of these risk factors, before 
evaluating the effect of HIV-related factors on HR-HPV and CIN2+ outcomes in Chapter 7.  
 
6.1 Objectives 
In a cohort of WLHIV in Burkina Faso and South Africa, at enrolment:  
 To describe the prevalence of HR-HPV infection and CIN2+; (Objectives 2.1 & 2.2) 
 To investigate the associations of HR-HPV and CIN2+ prevalence with 
socio-demographic and sexual behaviour factors, and other STIs. 
(Objective 2.3) 
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In a cohort of WLHIV with ≤CIN1 at enrolment and followed over 18 months:  
 To describe the incidence and persistence of HR-HPV, and incidence of 
CIN2+;  
(Objectives 2.1 & 2.2) 
 To investigate the associations of HR-HPV incidence and persistence, and 
CIN2+ incidence with socio- demographic and sexual behaviour factors, 
and other STIs. 
(Objective 2.3) 
In a cohort of WLHIV with CIN2+ at enrolment and followed over 18 months:  
 To describe the recurrence of CIN2+ among those who were treated for CIN2+ at baseline, 
and persistence and regression to ≤CIN1 among those not treated for CIN2+.  
 
6.2 Statistical Methods 
A full description of the HARP enrolment procedures is provided in Chapter 5, section 5.2. Specific 
statistical methods for univariate and multivariate risk factor analysis are detailed here.  
Univariate and multivariate risk factor analyses were performed for HR-HPV and CIN2+ prevalence, 
using all known risk factors for HR-HPV and CIN2+, as presented in (Figure 2.7, Chapter 2). The 
frequencies of these risk factors are summarised, by country, in Table 6.2 of this chapter.  
As prevalence measures do not allow assessment of the temporal associations between a risk 
factor and an outcome, I extended the risk factor analyses to explore the baseline risk factors (and 
the endline status of ART and CD4+ cell count as a measure of immune reconstitution or 
immunosuppression over time) associated with longitudinal HR-HPV and CIN2+ outcomes. The 
definitions used for each of the HR-HPV outcomes according to the baseline and endline status are 
summarised in Table 5.2, and include: 
148 
 
 
 Incidence of any HR-HPV type among all women at risk of acquiring a HR-HPV infection 
(outcome 3 of Table 5.2).  
 Type-specific HR-HPV persistence among women who were HR-HPV positive at baseline 
(outcome 5 of Table 5.2). 
 Clearance of all HR-HPV types among women who were HR-HPV positive at baseline 
(complete clearance; outcome 7 of Table 5.2). 
 Incidence of CIN2+ among women with ≤CIN1 at baseline (defined Chapter 5, Table 5.3) 
Risk factor analysis was not performed for type-specific clearance as this is the opposite of type-
specific persistence (Table 5.2). Instead, risk factor analysis was performance for complete 
clearance of all HR-HPV types. Because known risk factors are specific to each woman, risk factor 
analyses were performed using a ‘per woman analysis’, rather than a per infection analysis.   
 
6.2.1 Univariate risk factor analysis 
For the univariate analysis of risk factors, risk factors were chosen a priori as part of a conceptual 
framework (Figure 2.7) of known risk factors for HPV acquisition, persistence and cervical lesion 
development and progression. Risk factors were organised into the following categories: socio-
demographic, sexual behaviour-related, STI-related, clinical signs and symptoms, hormonal or 
carcinogenic determinants and HIV-related factors (Table 6.1). Socio-demographic and sexual 
behaviour-related factors were considered important for understanding determinants of HR-HPV 
incidence, as illustrated in Figure 6.1. The presence of other STIs and clinical signs and symptoms 
were considered to understand the effects of inflammation on HR-HPV persistence and clearance, 
and the development of precursor lesions, as reviewed in Chapter 2 (section 2.7). The biological 
determinants included factors linked to carcinogenesis, including smoking, pregnancy and 
hormonal contraceptive use. HIV-related factors (ART, CD4+ cell count and HIV-1 PVL) were 
included in the univariate and multivariate risk factor analyses in order to evaluate the independent 
149 
 
 
association of socio-demographic, behavioural and biological determinants of HR-HPV infection 
and CIN2+ among WLHIV. An in-depth investigation of the independent associations of HIV-related 
factors on HR-HPV infection and CIN2+ is provided in Chapter 7.  
Unadjusted Prevalence Ratios (PR) for each risk factor with each HR-HPV outcome (HR-HPV 
prevalence, incidence, persistence and clearance) and unadjusted Odds Ratios (OR) for CIN2+ 
outcomes (CIN2+ prevalence and incidence) were obtained using Stata version 14. PRs or ORs were 
considered significant if p<0.10 for HR-HPV prevalence and CIN2+ prevalence. Given the wide range 
of risk factors included in the univariate model and larger number of prevalent outcomes, a p-value 
of <0.10 was used to identify factors to carry forward in multivariate analysis (MVA) for prevalent 
outcomes. A higher p-value (p<0.20) was considered for the longitudinal outcomes (HR-HPV 
prevalence, incidence, persistence and clearance and CIN+ incidence) given the smaller number of 
cases for each outcome group.  
For the longitudinal outcomes, analyses were restricted to women with ≤CIN1 at baseline in order 
to understand the natural history of HPV infection among women without cervical disease and 
remove the potential bias among women with prevalent CIN2+ as the majority will be HR-HPV 
infected, and could have a higher persistence of infection.  
The total number of women was used as denominator (as opposed to number of infections).  
Denominators for each of the individual analyses are summarised in Appendix 14.  
6.2.2 Multivariate risk factor analysis 
Factors considered significant in univariate analysis were adjusted for each other in multivariate 
analysis, using PR for HR-HPV outcomes and OR for CIN2+ outcomes. Factors that persisted in MVA 
(with p<0.10) were selected for the final model. Final models were specific for each outcome 
group, and were done separately for each country.   
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Table 6.1. Known risk factors* for HR-HPV infection and CIN2+ 
Socio-
demographic 
Sexual behaviour-
related 
STI-related Clinical signs and 
symptoms 
Hormonal/ 
carcinogenic 
factors 
HIV-related 
Age AFSI Neisseria gonorrhoeae Genital warts Smoking Years since HIV 
diagnosis 
Education AFP (proxy for above) Chlamydia trachomatis Cervicitis AFP  
Marital status Condom use Trichomonas vaginalis Cervical ectopy1 Parity ART status 
Alcohol use Regular male sex 
partner 
 
Mycoplasma genitalium Vulvar lesions Hormonal 
contraception 
ART duration 
 Age of current male 
sex partner 
Bacterial vaginosis Genital blisters, 
ulcers or sores 
 
 ART adherence 
 Number of LTSP Candida albicans Past history of 
genital blisters, 
ulcers or sores 
 HIV-1 PVL 
detection 
 Number of recent 
male sex partners 
 
HSV-2 serology   HIV-1 PVL 
suppression 
 HIV status of current 
male sex partners 
 
Active syphilis serology   CD4+ count at 
baseline 
 Circumcision status of 
male partner 
 
   CD4+ count at 
endline 
 Vaginal cleansing    CD4+ count 
change during 
follow-up 
*Some of the risk factors included in this table have been shown to associated with HR-HPV and CIN/SIL lesions and ICC, as reviewed 
in Chapter 2, section 2.7; and 2.8; although not all risk factors included in the table were reviewed as they were less commonly studied 
(and Chapter 2 focussed on evidence from meta-analyses), these risk factors have been shown to increase acquisition of other STIs, 
and a priori decision was made to include them in univariate analysis. 
AFSI=age at first sexual intercourse; AFP=age at first pregnancy; LTSP=lifetime sex partners; defined as normal, 1<20% and ≥20% of 
columnar epithelium on the ectocervix  
 
Figure 6.1. The association of risk factors types with HR-HPV infection and cervical lesion 
development 
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6.3 Results 1: Study population description  
6.3.1 Study population at baseline 
Of 1,473 women screened, 1,238 were enrolled (BF: 615; SA: 623; Figure 6.2). In SA, 775 women 
were screened. Among those screened, 128 failed to present for enrolment within the specified 
window; and 24 women were ineligible for the study; of whom: 7 were HIV negative; 6 had previous 
cervical abnormality; 6 were pregnant or planning to become pregnant; 3 were outside the age 
criteria; 1 was planning to relocate and 1 was not well enough to be enrolled. In BF, 698 women 
were screened. Among those screened, 62 failed to present for enrolment within the specified 
window (phone contacts not working, not answering phone call, moved to another town or 
death); and 21 women were ineligible for the study; of whom: 3 were HIV-2 positive; 11 had previous 
cervical abnormality; 2 were pregnant or planning to become pregnant and 5 were outside the age 
criteria. 
The median age of participants was 36 (interquartile range [IQR], 31-41) years in BF and 34 (IQR, 
30-40) years in SA (Table 6.2). Participants in BF had lower levels of education and were less likely 
to be employed than those in SA. Classical risk factors for HR-HPV and CIN, including smoking, 
hormonal contraception use and higher number of sexual partners, were more prevalent in SA 
than BF, as were all STIs, except Candida infection. About half (49.6%) of SA participants had ever 
had a Pap smear, and a fifth (20.8%) of BF participants had ever had a VIA/VILI examination, the 
primary cervical cancer screening modality in each country, respectively.  
At enrolment, 422 (68.6%) participants were on ART in BF and 406 (65.2%) in SA, reflecting the 2:1 
stratification ratio. There were 126 women in BF and 22 in SA who initiated ART in the month prior 
to enrolment. The median duration on ART was 17 (IQR, 0-63) months in BF and 28 (IQR, 10-50) 
months in SA. The median CD4+ count among ART-naive and ART users was 417 (IQR, 315-606) 
cells/mm3 and 446 (IQR, 309-600) cells/mm3, respectively, in BF; and 448 (IQR, 353-614) cells/mm3 
and 420 (IQR, 279-567) cells/mm3, respectively, in SA. HIV-1 RNA was undetectable (<40 copies/ml) 
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in 69.9% and 33.7% of ART users in BF and SA, respectively, while HIV-1 viral suppression (<1000 
copies/ml) was noted for 79.9% and 80.3% among ART users in BF and SA, respectively. Overall, 32 
participants (BF: 24; SA: 8; overall 2.6%) denied being on ART at enrolment despite undetectable 
HIV-1 PVL. Of these, 23 (72%) had CD4+ count >500 cells/mm3. Given the uncertainty of their status, 
these women were excluded from the risk factors analyses.  
6.3.2 Prevalence of HR-HPV and CIN2+ at baseline  
Of the 1,238 participants enrolled, 1215 (98.1%) had valid HPV genotyping results (BF: 96.6%; SA: 
99.7%)  (Figure 6.2). The prevalence of any HPV type was 75.3% in BF and 88.7% in SA (p<0.001). HR-
HPV prevalence was lower in BF than SA (BF: 59.1% vs. SA: 79.1%; p<0.001) (Table 6.2).  
Overall, 1,128 (91.1%) participants (BF: 90.1%; SA: 92.1%) had valid histology. CIN2+ prevalence was 
5.8% (32/554) in BF and 22.5% (129/574) in SA (p<0.001) (Table 6.2).  
6.3.3 Study population at endline 
Of the 1,077 women without CIN2+ at baseline, 963 (89.4%) were seen at endline visit (median 
follow-up 16 months, IQR, 15.6-16.8; Figure 6.2). Fifty-three women (10.4%) in BF and 25 (5.5%) in SA 
initiated ART during follow-up (Table 6.3). The median CD4+ count changes among ART users at 
baseline, ART initiators and those who remained ART-naive were +105, +123 and +65 cells/mm3 per 
year respectively in BF, and +5, +83 and -53 cells/mm3 per year respectively in SA.  
Genotyping data at both baseline and endline was available for 922 (95.7%) women (BF: 476; SA: 
446) and histology results were available for 809 (84.0%) women (BF: 430; SA: 379).  
6.3.4 Cumulative HR-HPV incidence over 16 months  
Among 922 women without CIN2+ at baseline and with HPV-genotyping results for baseline and 
endline (BF: 476; SA: 446), 448 (48.6%) had incident HR-HPV of any type during follow-up: this was 
similar by site (BF: 47.9%; SA: 49.3%). When restricted to women who were negative for all HR-HPV 
types at baseline, 169/312 (54.2%) had an incident infection at endline, which was also similar by site 
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(BF: 55.3%; SA: 51.9%). The total number of incident HR-HPV infections was 350 in BF and 328 in SA 
(Table 6.3).  
6.3.5 HR-HPV persistence and complete clearance at endline 
Among 610 women without CIN2+ but HR-HPV positive at baseline, the total number of baseline 
infections was 1028 (BF: 416; SA: 612; Table 6.3). Persistent infection of an HR-HPV type at endline 
was slightly higher in BF (BF: 41.1% vs. SA: 30.2%; p<0.001). Complete clearance of all HR-HPV types 
was similar in both sites (BF: 24.4% of women; SA: 26.5% of women).  
6.3.6 CIN2/3 incidence over 16 months 
The incidence of CIN2+ over 16 months was higher in SA (BF: 1.2% [5/430] vs. SA: 5.8% [22/379]; 
p<0.001; Table 6.3). 
6.3.7 Outcomes among prevalent CIN2+ detected at baseline  
In BF, of 32 CIN2/3 detected at baseline, 28 returned for management of their CIN2/3 lesions before 
the colposcopy/biopsy visit at endline. In SA, among 97 prevalent CIN2+ cases who returned for 
endline visit, only 61 had obtained treatment before the endline colposcopy/biopsy visit. Of the 36 
participants who did not undergo treatment before the endline colposcopy/biopsy visit, 20 (55.6%) 
had CIN2/3 detected again at endline (persistent CIN2/3), and 16 (44.4%) had ≤CIN1 (spontaneous 
regression to ≤CIN1 ; Figure 6.3).  
 
6.4 Results 2: Risk factor analysis  
The socio-demographic, behavioural and biological determinants found to be associated with each 
of the HR-HPV and CIN2+ outcomes are summarised in Table 6.4 and Figure 6.4.  HIV-related factors 
found to be associated with HR-HPV and CIN2+ are discussed in Chapter 7.  
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6.4.1 Socio-demographic and behavioural factors associated with HR-HPV at baseline  
In BF, HR-HPV prevalence was higher among those with occurrence of anogenital warts (AGW) 
compared to those without (80.0% vs. 57.4%; adjusted Prevalence Ratio [aPR]=1.47, 95%CI: 1.18-1.83, 
adjusted for all factors that persisted in MVA; Table 6.5). Women in BF with a HIV-positive partner 
were less likely to have HR-HPV compared to women with a HIV-negative partner (53.2% vs. 71.2%; 
aPR=0.75, 95%CI: 0.58-0.97). 
In SA, HR-HPV prevalence was higher among younger age groups (25-29 years vs. 45-50 years: 88.1% 
vs. 65.3%; aPR=1.28, 95%CI: 1.04-1.58), and among smokers (ever smoked vs. never smoked: 92.1% 
vs. 76.9%; aPR=1.18, 95%CI: 1.09-1.29; Table 6.5).  
6.4.2 Socio-demographic and behavioural factors and STIs associated with HR-HPV incidence  
Women who ever used condoms were less likely to have a new HR-HPV infection detected at 
endline compared to women who never used condoms, in both countries (in BF: sometimes vs. 
never: 40.7% vs. 59.6%; aPR=0.66, 95%CI: 0.45-0.97, in SA: always vs. never: 46.8% vs. 72.0%; 
aPR=0.63, 95%CI: 0.46-0.86; Table 6.6).  
In SA, women were more likely to have HR-HPV incidence if any of the following were detected at 
baseline; bacterial vaginosis (presence vs. absence: 54.1% vs. 45.4%; aPR=1.26, 95%CI: 1.02-1.56) and 
Chlamydia trachomatis (positive vs. negative: 73.7% vs. 48.2%; aPR=1.63, 95%CI: 1.22-2.19) and was 
marginally associated with Trichomonas vaginalis (positive vs. negative: 57.8% vs. 47.7%; aPR=1.30, 
95%CI: 1.00-1.68). But women who ever performed vaginal cleansing were less likely to have HR-
HPV incidence (ever vs. never: 45.5% vs. 52.2%; aPR=0.76, 95%CI: 0.61-0.97).  
6.4.3 Socio-demographic and behavioural factors associated with HR-HPV persistence  
In BF, HR-HPV persistence was associated with frequent alcohol use compared to women who 
never drink alcohol (80.0% vs. 52.2%, aPR=1.45, 95%CI: 1.11-1.91), and marginally associated with 
cervicitis at baseline (62.4% vs. 48.0% without cervicitis; aPR=1.25, 95%CI: 1.00-1.57; Table 6.7). 
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In SA, HR-HPV persistence was associated with evidence of genital blisters, ulcers or sores at 
baseline (60.9% vs. 43.4%; aPR=1.43, 95%CI: 1.01-2.03) and with AGW occurrence at baseline (68.4% 
vs. 43.2%, aPR=1.61, 95%CI: 1.16-2.24). 
6.4.4 Socio-demographic and behavioural factors associated with HR-HPV complete clearance  
In BF, clearance of all HR-HPV infection was less likely among women with cervicitis at baseline 
(9.4% vs. 30.9% without cervicitis; aPR=0.06, 95%CI: 0.03-0.15; Table 6.8Error! Reference source not 
found.). Women with cervical ectopy at baseline were also less likely to have clearance of all HR-
HPV types (<20% ectopy vs. normal: 11.1% vs. 29.0%; aPR=0.30, 95%CI: 0.23-0.40; ≥20% ectopy vs. 
normal: 9.7% vs. 29.0%; aPR=0.31, 95%CI: 0.24-0.41). While women who sometimes used condoms 
were more likely to have complete HR-HPV clearance compared to women who never used 
condoms (36.7% vs. 15.2%; aPR=2.76, 95%CI: 1.11-6.86).  
In SA, complete clearance of HR-HPV was higher among women who were divorced, separated or 
widowed compared to women who were never married (42.1% vs. 23.4%; aPR=2.12, 95%CI: 1.23-3.66) 
but was lower among women with a higher number of lifetime sex partners (≥2 vs. 1 LTSP: 25.8% 
vs. 55.6%; aPR=0.41, 95%CI: 0.24-0.72). Complete clearance was also lower among women with 
older age at first pregnancy (≥25 years vs. <17 years: 13.2% vs. 40.5%; aPR=0.27, 95%CI: 0.12-0.63). 
6.4.5 Socio-demographic and behavioural factors associated with CIN2+ prevalence and 
incidence over 16 months 
In BF, CIN2+ prevalence was higher among older age groups (<35 years vs. ≥35 years: 2.8% vs. 8.3%; 
aOR=3.47, 95%CI: 1.34-9.01), among women with bacterial vaginosis (presence vs. absence: 9.6% vs. 
3.9%; aOR=2.78, 95%CI: 1.25-6.20; Table 6.9), AGW occurrence (12.5% vs. 5.5%; aOR=3.61, 95%CI: 1.17-
11.18) and cervical ectopy (≥20% ectopy vs. normal: 16.7% vs. 3.8%; aOR=7.42, 95%CI: 2.90-18.95). 
CIN2+ incidence was also higher among women with cervical ectopy at baseline (≥20% ectopy vs. 
normal: 4.9% vs. 0.7%; aOR=16.18, 95%CI: 1.59-164.12; Table 6.10). 
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In SA, CIN2+ prevalence was associated with current injectable contraceptive use compared to 
never users (38.2% vs. 18.6%; aOR=2.21, 95%CI: 1.19-4.10), and with cervicitis (35.6% vs. 19.7% without 
cervicitis; aOR=2.00, 95%CI: 1.19-3.35; Table 6.9). Women who reported having a partner who was 
circumcised had lower incidence of CIN2+ compared to women whose partner was uncircumcised 
(4.0% vs. 10.6%; aOR=0.36, 95%CI: 0.13-0.99; Table 6.10).  
 
6.5 Discussion 
This study found a high prevalence and persistence of HR-HPV among women living with HIV-1 in 
Burkina Faso and South Africa. However, the prevalence and incidence of CIN2+ were higher in 
South Africa. This was despite similar distribution of ART use, similar median duration on ART and 
median CD4+ cell counts at study enrolment in both countries, and similar HR-HPV persistence 
rates over 16 months. The higher CIN2+ prevalence and incidence in South Africa may be explained 
by the higher prevalence of HR-HPV in SA, and by other cofactors for HR-HPV infection and CIN2+, 
as well as HIV-related factors, which differed in both countries. Because women in the two 
countries differed with respect to socio-demographic and behavioural factors, this justified 
separate risk factor analyses for each country.  
Co-infection with other STI, and associated inflammation, appeared to be consistently associated 
with HR-HPV and CIN2+ outcomes in both countries. Women in SA had a higher prevalence of other 
STIs which were found to be associated with HR-HPV incidence. By contrast, women in BF were 
more likely to have cervicitis detected during the clinical exam, and this was found to associated 
with HR-HPV persistence and CIN2+ prevalence. Both countries had a high prevalence of bacterial 
vaginosis, which was found to increase acquisition of HR-HPV among women in SA, and with CIN2+ 
prevalence in BF. Other co-factors known to be associated with cervical lesion progression, such 
as smoking and injectable contraception, were more frequently reported among women in SA, and 
were found to be associated with HR-HPV and CIN2+ prevalence, respectively. The risk factors 
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found to be associated with each of the HR-HPV and CIN2+ outcomes are illustrated in Figure 6.4, 
and summarised in Table 6.4, and further discussed here.  
Co-infection with other sexually transmitted infections (STIs) 
In BF, the factors found to be associated with HR-HPV infection and CIN2+ were related to the 
occurrence of AGW, cervicitis and cervical ectopy, all of which are either a consequence of HPV 
infection, or a co-infection with other STIs.  
Women with AGW occurrence had a higher prevalence of both HR-HPV and CIN2+ in BF. A higher 
risk of anogenital cancers has been reported in studies among both women and men with a history 
of AGW. A prospective study among 10,971 patients diagnosed with AGW in Sweden and followed 
for a median of 13 years found that AGW occurrence was associated with an increased incidence 
of vulvar and vaginal cancers and cervical carcinoma among women, and penile cancer among men 
[389]. Furthermore, in a large prospective study which followed 50,000 Danish women and men 
who were diagnosed with AGW from 1978 to 2008 [390], an increased risk of ICC was reported 
among women with AGW diagnosis compared to the general population (SIR=1.5, 95%CI: 1.3-1.8). 
However, many of these studies have not directly measured LR-HPV types 6 and 11 in the biopsy 
tissue, and among those that did, the prevalence of single HPV6/11 infections was rare, or co-
existed with a HR-HPV type [391]. It has been suggested that, rather than LR-HPV types having a 
direct role on cervical lesion development, this association may be due to i.) a shared exposure of 
LR and HR-HPV types; and ii.) impaired immune response which facilitates AGW, HR-HPV 
persistence and cervical lesion development [391]. The findings in this chapter show that AGW 
occurrence was also associated with HR-HPV persistence in SA, and these associations were 
independent of ART, CD4+ cell count and HIV-1 PVL. However, the association of AGW with CIN2+ 
was not adjusted for HR-HPV infection, and could be a function of co-infection. In both countries, 
all prevalent CIN2+ cases with AGW occurrence were also infected with HR-HPV types, making it 
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unlikely that AGW occurrence, or HPV6/11 which cause AGW, have a direct role in CIN2+ 
development.   
Women with cervicitis were at increased risk of HR-HPV persistence, and a decreased likelihood of 
full clearance of HR-HPV in BF. The association of cervicitis with cytological high-grade cervical 
lesions has been previously reported among HR-HPV infected women [392]. Genital Chlamydia 
trachomatis (CT) can cause chronic cervicitis and pelvic inflammatory disease (PID). CT infection 
has been shown to facilitate the entry and persistence of multiple HR-HPV types [145, 146] and has 
been linked to the disruption of the immune response required to clear the virus [147]. Chlamydia 
trachomatis may be linked to the inflammatory cytokine responses during infection which may lead 
to reactive oxidative metabolite production, causing DNA damage or modification, resulting in 
genetic instability, particularly if infection persists [93, 147, 148]. Furthermore, in vitro data show 
that CT may inhibit cell apoptosis, linked to carcinogenesis [149].  
Cervical ectopy, or the presence of columnar epithelium on the ectovervix, was associated with a 
decreased likelihood of complete HR-HPV clearance, and with an increased risk of CIN2+ 
prevalence and incidence in BF. Associations between cervical ectopy and CT, HPV and HIV have 
been reported [393] but not with ICC [394], although ectopy represents a region of cell 
transformation associated with squamous metaplasia, which could lead to abnormal 
transformation in the presence of HR-HPV types [40]. While cervical ectopy was not observed in 
as many women in SA, this may be observer-dependent during clinical exam. 
The presence of STIs such as CT and Trichomonas vaginalis (TV), and vaginal flora changes, such as 
bacterial vaginosis (BV), was associated with increased risk of HR-HPV incidence among WLHIV in 
SA, while condom use (which is meant to be protective against STIs) was associated with a 
decreased risk. The presence of genital infections may disrupt the mucosal epithelial barrier 
through inflammation and micro-ulcerations, thereby facilitating entry of the HPV virus [139]. 
Researchers in Tanzania have shown an increased risk of HR-HPV acquisition among 324 women 
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positive for TV (OR=4.1, 95%CI: 1.7-9.8, adjusted for presence of BV and clinical PID) [87]. In a meta-
analysis which included 12 studies among 6,372 women [88], BV was associated with a 1.4-fold 
(OR=1.43, 95%CI: 1.11-1.84) increased prevalence of cervical HPV. Bacterial vaginosis is associated 
with changes in the physiochemical and immunological environment of the vagina; resulting in the 
loss of hydrogen peroxide-producing lactobacilli which have a role in defence mechanisms, and 
changes in the production of cytokines such as IL-1β and IL-10 [162], which could facilitate the 
acquisition and persistence of other STIs, including HPV [88].   
Bacterial vaginosis was also associated with an increase in CIN2+ prevalence among women in BF. 
This is similar to the findings of a meta-analysis which evaluated the association of bacterial 
vaginosis with cervical precursor lesions (cytological [LSIL, HSIL], or histological [CIN1, CIN2 or 
CIN3]) including over 10,000 women: the study found a 1.5-fold increase in SIL (LSIL/HSIL) or CIN 
(CIN1-3) prevalence (combined cytology/histology outcome: OR=1.51, 95%CI: 1.24-1.83) among 
women positive for bacterial vaginosis [161]. Biologically, this is plausible: as well as facilitating 
acquisition of other STIs, anaerobes found in the vaginal flora of women with BV can release 
volatile amines which may form carcinogenic compounds such as nitrosamines in combination with 
nitrates, produced by nitrate reducing bacteria [163]. The local accumulation of nitrosamines 
during BV episodes may induce cervical epithelial cell transformation in the presence of oncogenic 
HPV infection [152-155]. Furthermore, the disrupted vaginal environment induced by bacterial 
vaginosis is associated with alterations in the inflammatory cytokine profile which could promote 
cervical lesion development [162].  
Infection with herpesvirus (HSV-2) has been reported to be strongly associated with ICC [96]. HSV-
2 associated clinical and subclinical recurrences are likely to facilitate HR-HPV acquisition via the 
production of (mini)ulcerative lesions, and to enhance HR-HPV persistence because of increased 
inflammation [141, 142].  WLHIV in this study had a strikingly high prevalence of HSV-2 at baseline: 
nearly all women in SA (95.2%) and three-quarters of women in BF (74.9%) were HSV-2 seropositive, 
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and this may have precluded finding any associations, due to the small number of women who 
were HSV-2 negative.  Despite this limitation, the high co-infection rate of HR-HPV and HSV-2 
suggests there may be some common mechanisms that facilitate this co-existence. Furthermore, 
the increased risk of HR-HPV persistence among women with genital ulcer, blisters or sores in SA 
might suggest these women had frequent clinical HSV-2 recurrences, which could facilitate HR-HPV 
persistence. Genital HSV-2 measures (such as shedding) may have been more appropriate to 
evaluate associations with HR-HPV infection at the mucosal level. Further studies addressing these 
interactions are warranted.  
The differences in the prevalence of the various STIs among women in BF and SA may in part 
explain the differences in associations observed; the prevalence was higher for all STIs among 
women in SA, although the prevalence of BV was similar in both sites.  
Interestingly, vaginal cleansing was found to be associated with a decreased risk of HR-HPV 
incidence, and weakly associated with increased likelihood of complete HR-HPV clearance among 
WLHIV in SA. Just under half (43%) of women in SA reported vaginal cleansing, while >99% of 
women in BF reported doing so. Among those who report vaginal cleansing in SA, 93% do so daily, 
using water (68%) and soap (34%); 76% reported using their fingers. Others have shown that a high 
frequency of vaginal cleansing, and cleansing using water and soap were significantly associated 
with bacterial vaginosis. However no direct association between vaginal cleansing and acquisition 
of HIV or other STIs was found [395]. A prospective study among 503 girls aged 15-16 years seen 
every 3 months in Mwanza, Tanzania found weak evidence of a lower HPV incidence among girls 
who reported vaginal cleansing (adjusted Rate Ratio=0.69, 95%CI: 0.43-1.10), similar to this finding 
among WLHIV in SA [396]. On the one hand, it would be expected that vaginal cleansing may 
increase the risk of acquisition of other STIs, including HPV, depending on cleansing products used. 
Furthermore, its association with BV would suggest an inflammatory environment that would 
facilitate HR-HPV persistence. On the other hand, it could be possible that daily cleansing may have 
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removed the superficial layer of cells with HPV virus; leading to a reduction in detectable HPV on 
the day of cervical sampling, although this has never been previously reported in other studies.  
Age, HR-HPV and CIN2+ 
The relationship between age and HR-HPV prevalence among WLHIV in SA is similar to what has 
been shown worldwide [73]; younger women have higher prevalence of HR-HPV. The peak 
transmission of HPV infections is typically among young women following sexual debut [76] 
because HPV is highly prevalent in younger age groups, and is easily transmitted [77]. In BF, older 
women (≥35 years) had a higher risk of CIN2+ prevalence, and this relationship between age and 
CIN2+ is similar to what has been shown worldwide. Several studies which have examined the 
influence of age on the risk of incident CIN2+ have reported that among women with prevalent 
HPV infections detected at baseline, the risk of HPV persistence and CIN3 incidence during follow-
up increases with older age [49, 78-80]. However, the same association was not observed among 
women in SA and younger women (<35 years) in SA had higher CIN2+ prevalence compared to 
older women, although this association was not significant in MVA. This finding is similar to a study 
among 1,371 previously unscreened WLHIV in Cape Town, South Africa, which similarly reported 
high CIN2+ prevalence among this age group [397]. In South Africa, the incidence of HIV infection 
is highest among young women aged 15-19 years. It is possible that, depending on the number of 
years living with HIV, the CD4+ cell count decline in this period and access to ART, that young 
WLHIV could have a similarly high, or higher, risk of CIN2+ as WLHIV in older age groups. 
Furthermore, it is unclear whether the CIN2/3 lesions detected at baseline among young women 
would be more likely to spontaneously regress compared to those among older women, similar to 
the trend observed between HR-HPV persistence and age. The small number of non-treated CIN2/3 
in this study does not allow an accurate assessment of this association, however of the 16 cases of 
CIN2/3 that remained untreated during the follow-up period and who had spontaneous regression 
to ≤CIN1 at endline, less than half of them (41%) were <35 years.  
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Marital status and sexual behaviour  
Women who were divorced/separated or widowed in SA were more likely to clear infection 
compared to women who were never married, but those with a higher number of LTSP were least 
likely to clear all types, as well as having a higher risk of CIN2/3 incidence.  Previous studies have 
reported that women with fewer (≤5) LTSP had increased likelihood of clearing an HPV infection 
compared to women with higher (>5) LTSP (aOR=4.1, 95%CI: 1.4-11.5) [398]. The decrease in risk 
among women with fewer partners may also signify a decreased likelihood of past STI infections 
which could have facilitated HR-HPV persistence and cervical lesion development.   
As well as a lower number of LTSP, women with a male partner who was circumcised in SA had a 
reduced risk of CIN2/3 incidence, suggesting these women were possibly at lower risk of acquiring 
a HR-HPV type that could persist and allow cervical lesions to progress. Male circumcision has been 
shown to decrease the risk of ICC in female partners of circumcised men. Monogamous women 
whose male partners were circumcised, and who engaged in risky sexual behaviour (i.e. had 6 or 
more sexual partners, or sex with prostitutes) had a 58% reduction in ICC (aOR=0.42, 95%CI: 0.23-
0.79, adjusted for AFSI and number of LTSP) compared to monogamous female partners of 
uncircumcised men. This association between male partner circumcision and a reduction in CIN2+ 
incidence is likely to result from an overall reduction in HPV prevalence among men as they are less 
likely to acquire HPV, and therefore a reduction in transmission of HR-HPV types between partners. 
Male circumcision has shown to decrease transmission of HPV from HIV-negative men to their 
female partners [85]. In Rakai, Uganda, 1,245 HIV-negative female partners of HIV-negative men 
enrolled in two randomised controlled trials of male circumcision had 23% lower HR-HPV incidence 
over 24 months compared to women in the control group (Incidence Rate Ratio [IRR]=0.77, 95%CI: 
0.63-0.93), and increased HR-HPV clearance (Risk Ratio=1.12, 95%CI: 1.02-1.22).   
A curious finding in this study is that women in BF who had a HIV-positive male partner had a lower 
prevalence of HR-HPV at baseline compared to women who had a HIV-negative male partner (53.2% 
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vs. 71.2%; aPR=0.75, 95%CI: 0.58-0.97), and this persisted even after adjustment for condom use 
with that partner (aPR=0.74, 95% CI: 0.57-0.96).  This finding is contrary to the evidence that HIV 
seroconcordance is one of the strongest risk factors for HPV concordance between heterosexual 
couples [399]. Studies of heterosexual couple from Cape Town have shown that HPV concordance 
(penile-cervical) between couples was significantly higher among HIV-infected couples than 
among HIV-seronegative couples [400], and women with a high HPV viral load frequently shared 
HPV types with their male partners [117].  
In this study, condom use and HIV status of current partner are all based on self-report, and the 
possibility of recall bias (in particular for condom use), or social desirability bias (higher reported 
condom use may seem preferable) cannot be excluded. Another limitation is that we do not know 
the frequency of sex acts between couples, nor the behaviour of the male partners that might 
explain why women in HIV-concordant partnership have lower HR-HPV prevalence.  
 Another unexpected finding was that women with a younger age at first pregnancy in SA were 
more likely to have complete clearance of HR-HPV. Young age at first pregnancy is a known risk 
factor for ICC [91], related to cervical ectopy and hormonal changes that occur during pregnancy.  
Age at first pregnancy (AFP), and age at first sexual intercourse (AFSI) are highly interrelated 
measures [90] and AFP is often a proxy measure for AFSI. The finding in this study could be linked 
with age at first exposure to HPV infection. It is possible that some women who reported older 
AFP may have acquired a HR-HPV infection at an older age which then persisted, and HR-HPV 
persistent infections become more dominant with older age [78]. However, while a young AFP is 
suggestive of a young AFSI, an older AFP does not suggest an older AFSI, especially given the high 
proportion of women who used hormonal contraception in SA. A second explanation relates to 
the fact that complete clearance was defined as clearance of all HR-HPV types at endline, and did 
not consider the total number of infections that cleared. The likelihood of clearing a single infection 
between baseline and endline is different to the likelihood of clearing multiple types. Women who 
reported a young AFP were less likely to have multiple HR-HPV infections at baseline compared to 
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women with older AFP (<17 years vs. >25 years: 33.8% vs. 66.0%; p=0.05), and this could explain why 
women with young AFP had a higher clearance of all types compared to women with older AFP.   
It remains uncertain whether AFP is associated with complete clearance of HR-HPV, or whether 
the association is confounded by some other unmeasured factor. Furthermore, AFSI was included 
in the univariate analysis and did not persist in MVA. Both AFP and AFSI measures are crude as they 
are rely on both recall bias, and potentially social desirability bias. 
Smoking and Hormonal contraception 
Carcinogenic factors, such as smoking and hormonal factors, such as injectable contraception were 
associated with HR-HPV and CIN2+, respectively. Smoking is a well-established risk factor for HPV 
infection through modulating effects on local and systemic immunity [401]. It is known to suppress 
the immune response by reducing the number of Langerhans cells and other immune markers [89], 
thereby allowing HPV to persist and cervical lesion to develop [86, 104]. Compared to HPV-positive 
women who never smoked, HPV-positive women who have ever smoked tobacco have a 4.6 
(95%CI: 0.9-22.9), 2.2 (95%CI: 1.4-3.4) and 2.2 (95%CI: 1.5-3.2) increased odds of CIN2/3, CIN3 and 
CIS/ICC, respectively [86, 89, 98-103]. The amount of smoking (number of cigarettes per day) and 
duration of smoking history were also shown to increase the odds of CIS/ICC [89].  
Both oral and injectable contraception have been associated with increased risk of acquisition of 
HPV and other STI [123-129] by influencing the differentiation and maturation of the cervical 
epithelium, which can lead to thinning of the mucosal epithelium and microtearing [123, 126-130]. 
A systematic review and meta-analysis investigating the association of hormonal contraceptive use 
with ICC included 28 cohort and case-control studies, half of which were from developing countries 
and included 12,531 women with ICC [92]. Compared with never users of oral contraceptives (OC), 
women taking OC for durations of <5 years, 5-9 years and ≥10 years had Relative Risk of 0.9 (95%CI: 
0.7-1.2), 1.3 (95%CI: 1.0-1.9), and 2.5 (95%CI: 1.6-3.9) among HPV positive women. However a weaker 
association was observed for injectable contraception (which includes the progesterone-only NET-
EN and DMPA) use with ICC.  
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The results presented in this chapter confirm that known determinants for HR-HPV infection and 
CIN2+ are similar in WLHIV as in HIV-negative populations, and remain significant after adjustment 
for HIV-related factors, including ART status, CD4+ cell count and HIV-1 PVL.  
6.6 Study limitations 
This study was constrained by the limited number of intermediate visits and overall follow-up 
duration. The definition of cumulative HR-HPV incidence over 16 months is at the same time crude 
and of limited duration to assess the associations of risk factors with HR-HPV incidence. Other 
studies have used shorter time intervals for defining HR-HPV incidence [396] because of the 
transient nature of HR-HPV infection. Furthermore, the study could not rule out type-specific 
clearance and reinfection when estimating persistence during the 16-months interval between HPV 
testing.  The evaluation of HPV at two time points only did not allow precise estimation of the 
duration of infections. Longer duration of follow-up would have allowed to accrue a larger number 
of incident CIN2+ cases, and more robustly assess the association of risk factors on CIN2/3 
incidence.  
The inclusion of a wide array of risk factors in the univariate analysis, in addition to the separate 
risk factor analyses for each of the HR-HPV outcomes (prevalence, incidence, persistence and 
clearance) and CIN2+ outcomes (prevalence and incidence), by country, did not always result in 
consistent findings. It is possible that the multiple comparisons may have resulted in spurious 
findings that have arisen by chance, such as the finding that women with a HIV-positive partner in 
BF were less likely to have HR-HPV at baseline compared to women with a HIV-negative partner, 
or that younger age at first pregnancy was associated with increased likelihood of HR-HPV 
clearance in SA.  
The use of the baseline status of individual risk factors to predict endline outcomes was considered 
for all factors, except for CD4+ cell count for which baseline and endline values were used. This 
strategy was considered appropriate for the majority of factors, such as injectable contraception 
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use or smoking for which there is a residual risk, even in absence of its use (i.e. termination of use). 
However, contemporary measures for STIs and HIV-1 PVL may have been more informative to 
evaluate associations with HR-HPV incidence and persistence and CIN2/3 incidence. The presence 
of other STIs may present a short-term risk, at the time of infection, which is reduced if treatment 
is received. Unfortunately, the HARP study did not include repeat STI or HIV-PVL measure at 
endline. Therefore, it cannot be ruled out that HR-HPV itself may have been the causative agent of 
cervicitis, which was found to be associated with its persistence and with CIN2+ prevalence in BF.  
The differences in the prevalence of some risk factors, such as STIs, hormonal contraception and 
smoking between the two countries may have led to some inconsistencies in associations, but they 
reflect the different risk profiles for HR-HPV and CIN2+ in the two populations.  However, there 
was consistency in the strength and direction of associations for STIs and cervicitis with increased 
risk of HR-HPV and CIN2+ outcomes in both countries, even at different prevalence levels, which 
underscore the importance of these cofactors in the natural history of HR-HPV.  
The small number of CIN2+ cases in BF at baseline, and similarly small number of incident CIN2/3 in 
BF and SA at endline, did not allow for a meaningful analysis of risk factors associated with CIN2+ 
prevalence in BF or incidence in either country.     
Women who were not biopsied were considered as ≤CIN1. Biopsy decision was based on screen-
positive for any test, which included VIA/VILI, cytology, colposcopy or HPV DNA test. There is a 
potentially greater risk of ascertainment bias in BF as fewer women were biopsied and biopsy 
decision was largely based on HC-II test positivity. However, given the high sensitivity and NPV of 
HC-II [377, 402] it is unlikely that many cases would have been missed. In addition, the HARP study 
built a strong review of histological results by consensus of 5 pathologists, which included all CIN1/2 
and CIN2+ cases and 10% of <CIN1 cases (among women who had been biopsied for at least one 
positive screening tests).   
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6.7 Summary of findings 
 In the HARP study, the prevalence of HR-HPV at baseline, was 59.1% (351/594) in BF and 
79.1% in (491/621) in SA. CIN2+ prevalence was 5.8% in BF and 22.5% in SA.  
 At endline, HR-HPV incidence, persistence and complete complete clearance was 
47.9%, 51.5% and 24.4% respectively among women in BF and 49.3%, 44.7% and 26.5%, 
respectively in SA. CIN2+ incidence over 16 months was 1.2% in 405 women in BF and 
5.9% in 375 women in SA.  
 Condom use was associated with a decreased risk of HR-HPV incidence in both 
countries  
 Among women in SA, the presence of other STIs (Chlamydia trachomatis, Trichomonas 
vaginalis) and BV were associated with a 1.6, 1.3 and 1.3-fold increased risk, respectively 
of HR-HPV incidence.  
 HR-HPV persistence was marginally higher among women with cervicitis in BF (1.3-fold 
increased risk), and with genital ulcers (1.4 fold increased risk) in SA.  
 CIN2+ prevalence was higher among women with bacterial vaginosis in BF (3.5-fold 
increase), and cervicitis in SA (2-fold increase).   
 Older women (≥35 years) and women with large cervical ectopy (≥20%) had higher 
prevalence and incidence of CIN2+ in BF.  
 Injectable contraception was associated with 2.2-fold increased odds of CIN2+ 
prevalence among WLHIV in SA.  
Conclusion:  The presence of other STIs increases the risk of HR-HPV incidence and 
persistence, and may increase the risk of CIN2+ prevalence. Injectable contraception use is 
common among WLHIV in SA, and increases the risk of CIN2+.  
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6.8 Findings in context 
Studies among HIV-negative women have shown that the presence of Chlamydia trachomatis, 
Trichomonas vaginalis and bacterial vaginosis were associated with an increase in prevalence, 
incidence and persistence of HR-HPV [87, 88, 145-147], and with ICC [94, 95, 161]. The findings in 
this study show that these associations are similar among WLHIV. While there are no systematic 
reviews that shown a similar effect on CIN2/3 lesions, the inflammatory environment associated 
with STI is likely to facilitate HR-HPV persistence and cervical lesion development.   
A systematic review and meta-analysis investigating the association of hormonal contraceptive use 
with ICC [92] reported that women taking oral contraceptives (OC) had up to 2.2-fold increased 
risk of ICC, depending on duration of use, but a similar association was not observed for injectable 
contraception. This is the first study to report an increased risk of CIN2+ among women taking 
injectable contraception in South Africa. Others have shown no significant association of injectable 
or oral contraception use with cytology-determined LSIL and HSIL [403]. Given the high frequency 
of use among WLHIV in SA, the convenience of its use in this population, and the benefits 
associated with its use (unwanted pregnancy avoidance), further studies are warranted to confirm 
these findings.  
 
 
169 
 
 
Figure 6.2. HARP study flowchart  
*Type swap is defined as clearance of one genotype and acquisition of a different genotype; §Figure 2 for prevalent CIN2+ 
outcomes at endline
Screened
N=1473
BF=698; SA=775
Enrolled
n=1238 (BF=615; SA=623)
Genotyping: n=1215 (98.1%) (BF=594; SA=621)
Histology: n=1128 (91.1%)  (BF=554; SA=574)
Eligible for follow-up: n=1077 
(BF=583; SA=494)
Returned for Endline Visit: n=963 (89.4%) 
(BF=512; SA=451)
Genotyping: n=922 (95.7%) 
(BF=476; SA=446)
HR-HPV positive at 
baseline: n=610
BF=270; SA=340
Type Persistence: n=291 
(47.7%)
BF=139; SA=152
Clearance of all HR-HPV: 
n=156 (25.6%)
BF=66; SA=90
Type swap*: n=163 
(26.7%)
BF=65; SA=98
HR-HPV negative at 
baseline: n=312
BF=206; SA=106
HR-HPV incidence: n=169 
(54.2%)
BF=114; SA=55
Histology: n=809 (84.0%)
(BF=430; SA=379)
Incident CIN2+: n=27
(BF=5; SA=22)
Loss to Follow-Up=114 
(10.6%)
(BF=71; SA=43)
Exclude 
Prevalent CIN2+§=161
(BF=32; SA=129)
Refusals/
Lost to follow-up=190
(BF=62; SA=128)
Ineligible=45
(BF=21; SA=24)
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Figure 6.3. Study flowchart among prevalent CIN2+ 
 
Prevalent CIN2+, n=161
(BF=32; SA=129)
Histology available at endline 
n=124 
(BF=27 ; SA=97)
Not treated before endline 
n=36
(BF=0 ; SA=36)
Persistent CIN2/3
(n=20, 56%)
Persistent CIN2=7
Persistent CIN3=5
Regression CIN3 to CIN2=5
Progression CIN2 to CIN3=3
Regression to ≤CIN1
(n=16, 44%)
Regression CIN3 to ≤CIN1=3
Regression CIN2 to ≤CIN1=13
Treated before endline n=88
(BF=27 ; SA=61)
Recurrent CIN2/3
n=6
(BF=1; SA=5)
≤CIN1
n=82
(BF=26; SA=56)
Loss to Follow-Up, n=114 
(10.6%)
(BF=71; SA=43)
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Table 6.2. Study population characteristics at baseline visit 
  Burkina Faso South Africa p-value 
  N=615 N=623   
  n or median (%) or [IQR] n or median  (%) or [IQR]   
Socio-demographic factors      
Age-years  36 (31, 41) 34 (30, 40) <0.001 
Place of birth      
Burkina Faso 517 (84.1) -   
Ghana 4 (0.7) -   
Ivory Coast 81 (13.2) -   
Mali 4 (0.7) -   
Niger 0 (0.0) -   
South Africa -  450 (72.2)  
Lesotho -  2 (0.3)  
Mozambique -  2 (0.3)  
Swaziland -  3 (0.5)  
Zimbabwe -  158 (25.4)  
Other 9 (1.5) 8 (1.3)  
Ethnicity     0.32 
        Black 615 (100.0) 622 (99.8)  
        Coloured (Mixed-race) 0 (0.0) 1 (0.2)  
Education         <0.001 
No schooling 268 (43.6) 7 (1.1)  
Primary/Incomplete secondary 324 (52.7) 349 (56.0)  
Completed secondary 15 (2.4) 249 (40.0)  
Graduate/postgraduate 7 (1.1) 18 (2.9)   
Not known 1 (0.2) 0 (0.0)  
Currently employed     <0.001 
No 538 (87.5) 281 (45.1)  
Yes 77 (12.5) 342 (54.9)  
 Marital status         <0.001 
Never married 74 (12.0) 318 (51.0)  
Divorced/separated 95 (15.4) 23 (3.7)   
Widowed 143 (23.3) 18 (2.9)  
Married/cohabiting 302 (49.1) 264 (42.4)   
Not known 1 (0.2) 0 (0.0)  
Ever Smoke     <0.001 
Never 610 (99.2) 545 (87.5)  
Ever 5 (0.8) 78 (12.5)  
Alcohol use         0.12 
Never 409 (66.5) 432 (69.3)  
Sometimes but <Monthly 141 (22.9) 146 (23.4)  
At least monthly 65 (10.6) 45 (7.2)   
Age at first pregnancy-years  20 (18-22) 20 (18-22) 0.12 
Number of pregnancies 3 (2-5) 2 (2-3) <0.001 
Number of live births 2 (1-4) 2 (1-3) <0.001 
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  Burkina Faso South Africa p-value 
  N=615 N=623   
  n or median (%) or [IQR] n or median  (%) or [IQR]   
Ever use contraception  508 (82.9) 600 (96.3) <0.001 
Ever used hormonal contraception     <0.001 
No 105 (17.1) 23 (3.7)  
Yes 313 (50.9) 535 (85.9)  
Not known 197 (32.0) 65 (10.4)  
Injectable contraception         <0.001 
No 487 (79.2) 173 (27.8)  
Past or current 123 (20.0) 450 (72.2)  
Not known 5 (0.8) 0 (0.0)  
Oral contraception         0.23 
No 446 (72.5) 428 (68.7)  
Past or current 165 (26.8) 195 (31.3)  
Not known 4 (0.7) 0 (0.0)  
Condom use     <0.001 
Never 62 (10.1) 53 (8.5)  
Ever 448  (72.9) 547 (87.8)  
Not known 105  (17.1) 23 (3.7)  
      
Sexual behaviour factors      
Age at first sex-years 18 (17, 19) 18 (16, 19) 0.01 
Lifetime sex partners         <0.001 
1 143 (23.3) 17 (2.7)  
2-4 406 (66.0) 284 (45.6)  
5+ 66 (10.7) 228 (36.6)   
Not known 0 (0.0) 94 (15.1)  
Number of male partners in last 3 months         <0.001 
0 224 (36.4) 111 (17.8)  
1 374 (60.8) 475 (76.2)  
≥2 17 (2.8) 35 (5.6)   
Not known 0 (0.0) 2 (0.3)  
Current male sex partner     <0.001 
       No 76 (12.4) 11 (1.8)  
       Yes 315 (51.2) 501 (80.4)  
       Did not respond 224 (36.4) 111 (17.8)  
Current male sex partner circumcised       
No 0 (0.0) 222 (44.3) 0.01 
Yes 10 (3.2) 243 (48.5)  
Not known/No response 305 (96.8) 36 (7.2)  
Current male sex partner HIV seropositive      
No 64 (20.3) 113 (22.6) 0.04 
Yes 100 (31.7) 196 (39.1)  
          Not known  
 
 
151 (47.9) 192 (38.3) 
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  Burkina Faso South Africa p-value 
  N=615 N=623   
  n or median (%) or [IQR] n or median  (%) or [IQR]   
Condom use with current partner         <0.001 
Never 72 (22.9) 29 (4.7)  
Less than half the time 66 (21.0) 60 (9.6)  
More than half the time 7 (2.2) 112 (18.0)   
Always 168 (53.3) 299 (48.0)  
Not known 2 (0.6) 1 (0.2)  
 
Ever cleanse vagina 
    
 
<0.001 
No 3  (0.5) 353  (56.7)  
Yes 242 (39.4) 253 (40.6)  
Sometimes 370 (60.2) 17 (2.7)  
Cervical cancer screening      
Ever had Pap smear     <0.001 
No 541 (88.0) 313 (50.2)  
Yes 72 (11.7) 309 (49.6)  
Not known 2 (0.3) 1 (0.2)  
Number of pap smears (IQR) 1 (1-1) 1 (1-2) 0.14 
Ever had visual inspection (VIA/VILI)     <0.001 
No 487 (79.2) 588 (94.4)  
Yes 128 (20.8) 16 (2.6)  
Don’t know 0  (0.0) 19 (3.1)  
Number of visual inspection exams (IQR) 2 (1-3) 1 (1-2) 0.02 
 
HIV-related factors 
     
Median duration since HIV diagnosis (years) 5  (2-8) 4 (2-7) 0.03 
Median age at HIV diagnosis  31 (27-36) 30 (26-35)  
ART status at enrolment*      0.01 
ART >2 years 196 (31.9) 227 (36.4)  
ART ≤2 years 226  (36.8) 179  (28.7)  
ART-naïve 193 (31.4) 217 (34.8)  
Median duration on ART (months) 16.6 (0.0-63.4) 28.1 (10.3-49.9) 0.002 
Self-reported ART adherence (among ART users)        <0.001 
         >90% 0 (0.0) 0 (0.0)  
60-90% 387 (91.7) 339 (83.5)  
<60% 10 (2.4) 63 (15.5)   
Not known 25 (5.9) 4 (1.0)  
HIV-1 PVL suppression (<1000 copies/ml) among ART users     <0.001 
No 56  (13.3) 76 (18.7)  
Yes 337 (79.9) 326  (80.3)  
Failed result 29 (6.9) 4  (1.0)  
HIV-1 PVL undetectable (≤40 copies/ml) among ART users     <0.001 
No 98 (23.2) 265 (65.3)  
Yes 295 (69.9) 137 (33.7)  
Failed result 29 (6.9) 4 (1.0)  
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  Burkina Faso South Africa p-value 
  N=615 N=623   
  n or median (%) or [IQR] n or median  (%) or [IQR]   
HIV-1 PVL among ART-naïve, RNA copies/ml 48,800 (10870-206557) 19,300 (4680-55400) <0.001 
Baseline CD4+ count among ART users, cells/mm3         0.18 
>500 170 (40.3) 139 (34.2)  
351-500 121 (28.7) 114 (28.1)   
200-350 82 (19.4) 102 (25.1)   
<200 48 (11.4) 51 (12.6)   
Missing 1 (0.2) 0 (0.0)  
Baseline CD4+ count among ART-naïve, cells/mm3     0.01 
>500 74 (38.3) 92 (42.4)  
351-500 51 (26.4) 72 (33.2)  
200-350 49 (25.4) 47 (21.7)  
<200 19 (9.8) 6 (2.8)  
 
Clinical signs and symptoms 
     
 Cervical ectopy     <0.001 
Normal 419 (68.1) 597 (95.8)  
<20% cervical surface 114 (18.5) 19 (3.1)  
≥20% cervical surface 79  (12.9) 7 (1.1)  
Not known 3 (0.5) 0 (0.0)  
Cervicitis     <0.001 
No 409 (66.5) 508 (81.5)  
Yes 200  (32.5) 112 (18.0)  
Not known 6 (1.0) 3 (0.5)  
 Anogenital warts     0.19 
No 566 (92.3) 587 (94.2)  
Yes 47 (7.7) 36 (5.8)  
Laboratory STIs      
Neisseria gonorrhoeae 4 (0.7) 14 (2.3) 0.02 
Chlamydia trachomatis 13 (2.1) 31 (5.0) 0.01 
Trichomonas vaginalis - - 101 (16.2)  
Mycoplasma genitalium 4 (0.7) 46 (7.4) <0.001 
Bacterial vaginosis 205 (34.6) 254 (41.6) 0.01 
Candida albicans 87 (14.7) 52 (8.4) <0.001 
HSV-2 serology 459 (74.9) 590 (95.2) <0.001 
Active syphilis serology 1 (0.2) 7 (1.1) 0.02 
HR-HPV       
HR-HPV positive 351 (59.1) 491 (79.1) <0.001 
CIN status       
Normal 373 (67.3) 261  (45.5) <0.001 
CIN1 149 (26.9) 184 (32.1)  
CIN2 19 (3.4) 76 (13.2)  
CIN3+ 13 (2.4) 53 (9.2)  
*The study was designed to include two-thirds of participants on ART in each site 
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Table 6.3. Study population characteristics at endline visit, among ≤CIN1 at baseline 
  Burkina Faso South Africa p-value 
  N=512 N=451  
  n or median (%) or [IQR] n or median (%) or [IQR]  
      
Duration of follow-up (FU) 16.4  [16.1-17.0] 15.9 [14.4-16.8]  
      
ART status at FU     0.002 
ART users before enrolment 350 (68.4) 296 (65.6)  
ART initiators during FU 53 (10.4) 25 (5.5)  
ART naive at FU 109 (21.3) 130 (28.8)  
      
Median CD4+ count (cells/mm3) at M18      
ART users before enrolment 614 [434-819] 439 [322-604] <0.001 
ART initiators during FU 461 [312-613] 442 [366-601] 0.92 
ART naive at FU 582 [439-868] 437 [346-543] <0.001 
      
Median CD4+ count (cells/mm3) change per year      
ART users before enrolment 105 [18-207] 5 [-56 to 88] <0.001 
ART initiators during FU 123 [35, 258] 83 [-50 to 211] 0.17 
ART naive at FU 65 [-24 to 185] -53 [-117 to 21] <0.001 
      
Patients with stable high CD4+ count (>500 cells/mm3)      
ART users before enrolment 129 (36.9) 62 (21.0) <0.001 
ART initiators during FU 3 (5.7) 1 (4.0) 0.76 
ART naive at FU 47 (43.1) 27 (20.8) <0.001 
      
HR-HPV status (number of women) N n (%) N n (%)  
HR-HPV persistence 270 139 (51.5) 340 152 (44.7) 0.10 
HR-HPV complete clearance  270 66 (24.4) 340 90 (26.5) 0.57 
HR-HPV clearance of any type 270 180 (66.7) 340 268 (78.8) 0.001 
HR-HPV incidence of any type 476 228 (47.9) 446 220 (49.3) 0.67 
HR-HPV incidence among HR-HPV negative at baseline 206 114 (55.3) 106 55 (51.9) 0.56 
      
HR-HPV status (number of infections) N n (%) N n (%)  
HR-HPV persistence 416 171 (41.1) 612 185 (30.2) <0.001 
HR-HPV clearance  416 245 (58.9) 612 427 (69.8) <0.001 
HR-HPV clearance, in absence of persistence 416 189 (45.4) 612 295 (48.2)  
HR-HPV incidence   350  328  
      
CIN 2+ status       
Incidence 430 5 (1.2) 379 22 (5.8) <0.001 
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Table 6.4. Summary of risk factors observed among WLHIV in Burkina Faso (BF) and South Africa (SA) 
Risk factor Outcome Effect Effect estimate (95% CI) Country 
observed 
     
Socio-demographic      
Age HR-HPV Prevalence Compared to women aged 45-50 years, women aged 25-29 years had 
higher prevalence of HR-HPV 
aPR 1.28 (1.04-1.58) SA 
 CIN2+ Prevalence Compared to younger women (25-29 years), older women had higher 
prevalence of CIN2+ 
aOR 35-39yrs: 5.58 (1.12-27.67) 
40-44 yrs: 6.79 (1.30-35.51) 
BF 
Marital status HR-HPV complete 
Clearance 
Compared to never married women, divorced/separated or widowed had 
increased likelihood of clearance of all HR-HPV 
 
aPR 2.12 (1.23-3.66) SA 
Alcohol use HR-HPV Persistence Compared to women who never drink alcohol, women who drink alcohol at 
least once per month had increased risk of HR-HPV persistence 
aPR 1.45 (1.11-1.91) BF 
      
Sex behaviour      
HIV+ partner HR-HPV Prevalence Compared to women with a HIV-negative partner, women with a HIV-
positive partner had a decreased risk of HR-HPV prevalence 
aPR 0.75 (0.58-0.97) BF 
Condom use HR-HPV Incidence 
 
Compared to women who never used condoms, women who sometimes 
used condoms had a decreased risk of HR-HPV incidence 
aPR 0.66 (0.45-0.97) BF 
 Compared to women who never used condoms, women who always used 
condoms had a decreased risk of HR-HPV incidence 
aPR 0.63 (0.46-0.86) SA 
 HR-HPV complete 
Clearance 
Compared to women who never used condoms, women who sometimes 
used condoms had an increased likelihood of HR-HPV clearance of all HR-
HPV 
aPR 2.76 (1.11-6.86) BF 
Number of lifetime sex 
partners (LTSP) 
HR-HPV complete 
Clearance  
Compared to women with <2 LTSP, women with ≥2 LTSP had a decreased 
likelihood of HR-HPV clearance of all HR-HPV 
aPR 0.41 (0.24-0.72) SA 
Circumcision status of 
male partner 
CIN2+ Incidence Compared to women whose male partner was uncircumcised, women with 
a partner who was circumcised had lower incidence of CIN2/3 
aOR 0.36 (0.13-0.99) SA 
Vaginal cleansing HR-HPV Incidence Compared to women who said they never cleanse the vagina, women who 
said they did had a lower risk of HR-HPV incidence 
aPR 0.76 (0.61-0.97) SA 
 
 
 
     
Presence of other STIs      
Bacterial vaginosis (BV) HR-HPV Incidence Compared to women without BV women, women with BV had an increased 
risk of HR-HPV incidence 
aPR 1.26 (1.02-1.56) SA 
 CIN2+ Prevalence Compared to women without BV women, women with BV had an increased 
risk of CIN2+ Prevalence 
aOR 2.78 (1.25-6.20) BF 
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Risk factor Outcome Effect Effect estimate (95% CI) Country 
observed 
 
Chlamydia trachomatis (CT) HR-HPV Incidence Compared to CT negative women, CT positive women had an increased risk 
of HR-HPV incidence 
aPR 1.63 (1.22-2.19) SA 
Trichomonas vaginalis (TV) HR-HPV Incidence Compared to TV negative women, TV positive women had an increased risk 
of HR-HPV incidence 
aPR 1.30 (1.00-1.68) SA 
Anogenital warts (AGW) HR-HPV Prevalence Compared to women without AGW, women with AGW occurrence had an 
increased risk of HR-HPV prevalence 
aPR 1.47 (1.18-1.83) BF 
 CIN2+ Prevalence Compared to women without AGW, women with AGW occurrence had an 
increased risk of CIN2+ Prevalence 
aOR 3.61 (1.17-11.18) BF 
 HR-HPV Persistence Compared to women without AGW, women with AGW occurrence had an 
increased risk of HR-HPV persistence 
aPR 1.61 (1.16-2.24) SA 
      
Clinical signs      
Cervicitis HR-HPV persistence Compared to women without cervicitis, women with cervicitis had an 
increased risk of HR-HPV persistence 
aPR 1.25 (1.00-1.57) BF 
 HR-HPV complete 
Clearance 
 
Compared to women without cervicitis, women with cervicitis had a 
decreased likelihood of HR-HPV clearance 
aPR 0.06 (0.03-0.15) BF 
 CIN2+ Prevalence Compared to women without cervicitis, women with cervicitis had an 
increased risk of CIN2+ prevalence 
aOR 2.00 (1.19-3.35) SA 
Blisters, sores or ulcers on 
genitals 
HR-HPV Persistence Compared to women without, women with blisters, sores or ulcers on 
genitals had an increased risk of HR-HPV persistence 
aPR 1.43 (1.01-2.03) SA 
Cervical ectopy  HR-HPV complete 
Clearance 
 
Compared to women with normal cervical ectopy, women with <20% and 
≥20% ectopy had a decreased risk of HR-HPV clearance 
aPR <20%: 0.30 (0.23-0.40) 
≥20%: 0.31 (0.24-0.41) 
BF 
 CIN2+ Prevalence Compared to women with normal cervical ectopy, women with ≥20% 
ectopy had an increased risk of CIN2+ prevalence 
aOR 7.42 (2.90-18.95) BF 
 CIN2/3 Incidence Compared to women with normal cervical ectopy, women with ≥20% 
ectopy had an increased risk of CIN2+ incidence 
aOR 16.18 (1.59-164.12) BF 
      
Carcinogenic/Hormonal factors     
Smoking  HR-HPV Prevalence Compared to never smokers, women who ever smoked had an increased 
risk of HR-HPV prevalence 
aPR 1.18 (1.09-1.29) SA 
Age at first pregnancy HR-HPV complete 
Clearance 
Compared to young age at first pregnancy (<17 years), women with older 
age at first pregnancy (≥25 years) had a decreased likelihood of HR-HPV 
clearance 
aPR 0.27 (0.12-0.63) SA 
Injectable contraceptive 
use 
CIN2+ Prevalence Compared to never users, current injectable contraception users had an 
increased risk of CIN2+ prevalence 
aOR 2.21 (1.19-4.10) SA 
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 Figure 6.4. Risk factors associated with HR-HPV infection and CIN2+ among WLHIV in Burkina Faso and South Africa 
 
 
LTSP=lifetime sex partners; AFP=age at first pregnancy
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Table 6.5. Multivariate analysis of HR-HPV prevalence: associations with baseline sociodemographic factors, behavioural factors, HIV-related factors, 
clinical symptoms/signs and STIs  
  
Burkina Faso 
N=570 
 
  
South Africa 
N=613 
 
  n (%) aPR* 95% CI P-value  n (%) aPR* 95% CI P-value 
HIV status of current male partner     Age group (years)  
   
Negative 37 (71.2) 1.00    25-29 118 (88.1) 1.28 1.04-1.58 0.02 
Positive 50 (53.2) 0.75 0.58-0.97 0.03 30-34 145 (81.9) 1.20 0.97-1.47 0.09 
     35-39 111 (76.0) 1.13 0.92-1.40 0.24 
Anogenital warts     40-44 77 (72.0) 1.07 0.86-1.33 0.56 
No 300 (57.4) 1.00   45-50 32 (65.3) 1.00   
Yes 36 (80.0) 1.47 1.18-1.83 0.001   
   
     Marital status     
     Never married 251 (80.5) 1.00   
     Divorced/separated/widowed 25 (62.5) 0.83   0.67-1.04 0.10 
     Married/cohabiting 207 (79.3) 0.98 0.90-1.06 0.56 
          
     Smoker     
     Never 413 (76.9) 1.00   
     Ever 70 (92.1) 1.18 1.09-1.29 <0.001 
       
   
     CD4+ count (cells/mm3)     
     >350 313 (76.7) 1.00   
     ≤350 167 (82.7) 1.07 0.99-1.17 0.10 
          
ART status       ART status      
ART >2 years 101 (52.1) 1.00   ART >2 years 163 (72.4) 1.00   
ART ≤2 years 142 (65.1) 1.41 1.10-1.80 0.01 ART ≤2 years 147 (82.1) 1.09 0.98-1.21 0.12 
ART-naive 95 (60.1) 1.21 0.94-1.56 0.14 ART-naive 173 (82.8) 1.09 0.98-1.20 0.10 
*All factors in table adjusted for each other 
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Table 6.6. Multivariate analysis of HR-HPV incidence: associations with sociodemographic and HIV-related factors, clinical symptoms/signs and STIs1 
Burkina Faso (N=460) South Africa (N=440) 
  n (%) aPR* 95% CI P-value   n (%) aPR* 95% CI P-value 
Education      Condom     
Primary or less 154 (51.0) 1.00   Never 18 (72.0) 1.00   
More than primary 65 (42.8) 0.96 0.73-1.26 0.76 Sometimes 60 (51.7) 0.77 0.56-1.06 0.11 
      Always 101 (46.8) 0.63 0.46-0.86 0.003 
Age at first pregnancy          
<20 years 103 (52.0) 1.00   Current male sex partner     
≥20 years 112 (45.9) 0.93 0.71-1.22 0.62 Yes, cohabiting 86 (45.5) 1.00   
     Yes, non cohabiting 91 (55.2) 1.22 0.98-1.52 0.07 
Condom      No 4 (50.0) - - - 
Never 31 (59.6) 1.00        
Sometimes 22 (40.7) 0.66 0.45-0.97 0.03 Years since HIV diagnosis     
Always 65 (50.4) 0.82 0.62-1.08 0.16 <5yrs 130 (54.2) 1.00   
     5-9 years 67 (45.0) 0.80 0.63-1.03 0.09 
Vulvar lesions      ≥10 years 20 (39.2) 0.71 0.44-1.15 0.17 
No 204 (47.4) 1.00         
Yes 18 (62.1) 1.17 0.73-1.86 0.52 Bacterial vaginosis     
     Absence 114 (45.4) 1   
ART status      Presence 99 (54.1) 1.26 1.02-1.56 0.03 
ART >2 years 95 (45.5) 1        
ART ≤2 years 69 (53.9) 1.21 0.88-1.67 0.24 Chlamydia trachomatis     
ART-naive 58 (47.2) 1.01 0.74-1.39 0.94 Negative 203 (48.2) 1   
     Positive 14 (73.7) 1.63 1.22-2.19 0.001 
          
     Trichomonas vaginalis     
     Negative 176 (47.7) 1   
     Positive 41 (57.8) 1.30 1.00-1.68 0.05 
          
     Ever cleanse vagina     
     Never 131 (52.2) 1.00   
     Ever  86 (45.5) 0.76 0.61-0.97 0.02 
          
     CD4+ count at baseline (cells/mm3)     
     >350 149 (48.1) 1.00   
      201-350 46 (46.5) 0.88 0.64-1.19 0.40 
     ≤200 21 (72.4) 1.48 1.06-2.05 0.02 
*All factors in table adjusted for each other;  
1all factors measured at baseline unless otherwise indicated  
     
CD4+ count at endline (cells/mm3)     
>350 124 (45.1) 1   
201-350 51 (55.4) 1.24 0.98-1.58 0.08 
     ≤200 13 (65.0) - - - 
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Table 6.7. Multivariate analysis of HR-HPV persistence:  associations with sociodemographic and HIV-related factors, clinical symptoms/signs and 
STIs1 
Burkina Faso 
N=263 
South Africa 
 N=334 
  n (%) aPR* 95% CI P-value   n (%) aPR* 95% CI P-value 
Alcohol use      Age at first sexual intercourse     
Never 85 (52.2) 1.00 -   <18 years 65 (38.5) 1.00   
Less than monthly 33 (44.0) 0.89 0.67-1.18 0.402 ≥18 years 84 (50.9) 1.26 0.97-1.63 0.08 
At least once per month 20 (80.0) 1.45 1.11-1.91 0.01      
     Number of lifetime sex partners     
Cervicitis      1 2 (22.2) 1.00   
No 84 (48.0) 1.00 -   2-4 70 (51.9) 2.42 0.74-7.86 0.14 
Yes 53 (62.4) 1.25 1.00-1.57 0.05 ≥5 53 (39.9) 2.05 0.63-6.71 0.24 
           
ART status  
 
    
Number of male sexual partners in last 3 months 
(at baseline)  
 
   
ART >2 years 51 (46.4) 1.00   0 26 (46.4) 1.00   
ART ≤2 years 35 (44.3) 0.93 0.68-1.27 0.64 1 118 (46.6) 1.05  0.75-1.45 0.78 
ART-naive 52 (70.3) 1.36 1.05-1.76 0.02 ≥2 5 (21.7) 0.28 0.08-1.02 0.05 
          
CD4+ count change during follow-up     Anogenital warts     
Stable >350 cells/mm3 70 (46.1) 1.00   No 136 (43.2) 1.00 -  
Increasing ≤350 to >350 cells/mm3 24 (54.6) 1.08 0.78-1.49 0.64 Yes 13 (68.4) 1.61 1.16-2.24 0.005 
Decreasing >350 to ≤350 cells/mm3 10 (83.3) 1.56 1.04-2.33 0.03      
Stable ≤350 cells/mm3 28 (65.1) 1.30 0.99-1.72 0.06 Genital blisters, ulcers or sores     
     No 135 (43.4) 1.00 -  
     Yes 14 (60.9) 1.43 1.01-2.03 0.05 
          
     HIV viral suppression (<1000 copies/ml)     
     No 77 (55.0) 1.45 1.13-1.85 0.003 
     Yes 72 (37.1) 1.00   
*All factors in table adjusted for each other; 1all factors measured at baseline unless otherwise indicated
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Table 6.8. Multivariate analysis of HR-HPV complete clearance: associations with sociodemographic factors, HIV-related factors, clinical 
symptoms/signs and STIs1 
 
Burkina Faso  
N=263  
South Africa  
N=334 
  n (%) aPR* 95% CI P-value   n (%) aPR* 95% CI P-value 
Alcohol use      Marital status     
Never 38 (23.3) 1.00   Never married 40 (23.4) 1.00   
Less than monthly 22 (29.3) 0.95 0.56-1.63 0.86 Divorced/separated/widowed 8 (42.1) 2.12 1.23-3.66 0.01 
At least once per month 2 (8.0) 0.22 0.04-1.18 0.11 Married/Cohabiting 41 (28.5) 1.11 0.73-1.71 0.62 
          
Ever used injectable contraceptive     Age at first pregnancy (years)     
No 43 (20.3) 1.00   <17 15 (40.5) 1.00   
Past 16 (44.4) 1.67 0.97-2.87 0.07 17-19 29 (25.0) 0.57 0.34-0.93 0.03 
Current 3 (23.1) 1.06 0.34-3.34 0.92 20-24 34 (31.2) 0.70 0.43-1.13 0.14 
     ≥25 7 (13.2) 0.27 0.12-0.63 0.002 
Condom          
Never 5 (15.2) 1.00   Number of lifetime sex partners     
Sometimes 11 (36.7) 2.76 1.11-6.86 0.03 1 5 (55.6) 1.00   
Always 18 (26.1) 1.76 0.72-4.30 0.22  2-4 135 (20.0) 0.32 0.17-0.61 <0.001 
     ≥5 42 (31.6) 0.51 0.28-0.91 0.02 
HSV-2          
Negative 18 (32.7) 1.00   Bacterial vaginosis     
Positive 44 (21.2) 0.66 0.39-1.12 0.13 Negative 56 (30.6) 1.00   
     Positive 33 (22.6) 0.70 0.46-1.06 0.09 
Cervicitis          
No 54 (30.9) 1.00   Ever cleanse vagina     
Yes 8 (9.4) 0.06 0.03-0.15 <0.001 Never 45 (23.7) 1.00   
     Ever 44 (30.6) 1.29 0.87-1.92 0.20 
Cervical ectopy          
Normal 54 (29.0) 1.00        
<20% 5 (11.1) 0.30  0.23-0.40 <0.001      
≥20 3 (9.7) 0.31 0.24-0.41 <0.001      
          
CD4+ count at baseline (cells/mm3)          
>350 48 (27.6) 1.00        
201-350 8 (14.3) 0.36 0.13-0.97 0.04      
≤200 6 (18.2) 0.67 0.22-2.09 0.49      
          
*All factors in table adjusted for each other; 1all factors measured at baseline unless otherwise indicated
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Table 6.9. Multivariate analysis of CIN2+ prevalence: associations with sociodemographic factors and HIV-related factors, clinical symptoms/signs 
and STIs1 
Burkina Faso 
N=530 
South Africa 
N=566 
  n (%) aOR* 95% CI P-value   n (%) aOR* 95% CI P-value 
Age group (years)      Age group (years)     
25-29 2 (2.2) 1.00   25-29 35 (28.2) 1   
30-34 4 (3.2) 2.37 0.40-14.08 0.34 30-34 41 (24.0) 0.91 0.51-1.63 0.75 
35-39 13 (9.9) 5.58 1.12-27.67 0.04 35-39 32 (23.9) 0.88 0.48-1.62 0.69 
40-44 9 (8.2) 6.79 1.30-35.51 0.02 40-44 14 (14.1) 0.54 0.26-1.15 0.11 
45-50 4 (5.6) 4.59 0.75-28.26 0.10 45-50 6 (15.8) 0.68 0.24-1.90 0.46 
      
     
Bacterial vaginosis      Age at first pregnancy (years)     
Absence 13 (3.9) 1    <17 9 (15.3) 1   
Presence 17 (9.6) 2.78 1.25-6.20 0.01 17-19 56 (27.2) 1.87 0.82-4.27 0.14 
     20-24 46 (24.2) 1.73 0.76-3.94 0.19 
Anogenital warts     ≥25 13 (15.9) 1.00 0.38-2.64 1.00 
No 27 (5.5) 1.00        
Yes 5 (12.5) 3.61 1.17-11.18 0.03 Ever used injectable contraceptive     
     No 29 (18.6) 1   
Cervical ectopy    
 Past 57 (19.0) 0.94 0.54-1.61 0.81 
Normal 14 (3.8) 1    Current 42 (38.2) 2.21 1.19-4.10 0.01 
<20% 6 (6.7) 2.19 0.77-6.23 0.14      
≥20 12 (16.7) 7.42 2.90-18.95 <0.001 Cervicitis      
     No 91 (19.7) 1   
CD4+ count (cells/mm3)      Yes 36 (35.6) 2.00 1.19-3.35 0.01 
>350 19 (5.3) 1         
201-350 5 (4.4) 0.84 0.29-2.44 0.75 ART status      
≤200 8 (13.8) 3.59 1.33-9.68 0.01 ART >2 years 31 (15.0) 1   
     ART ≤2 years 47 (29.2) 1.93 1.09-3.42 0.02 
     ART-naive 50 (25.3) 1.61 0.94-2.77 0.08 
          
     CD4+ count (cells/mm3)     
      >350 69 (18.3) 1.00   
      201-350 38 (27.5) 1.62 0.98-2.67 0.06 
     ≤200 20 (41.7) 2.80 1.33-5.87 0.01 
           
*All factors in table adjusted for each other; 1all factors measured at baseline unless otherwise indicated
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Table 6.10. Multivariate analysis of CIN2/3 incidence: associations with sociodemographic and HIV-related factors, clinical symptoms/signs and STIs1 
 
Burkina Faso  
N=412  
South Africa  
N=373 
  n (%) aOR* 95% CI P-value   n (%) aOR** 95% CI P-value 
          
Hormonal contraception     Lifetime sex partners     
Never 1 (0.5) 1.00   1 0 (0.0) 1.00   
Ever 4 (1.8) 10.69  0.79-144.79 0.08  2-4 12 (7.4) - - - 
     ≥5 2 (1.4) - - - 
          
Cervical ectopy     Current male partner circumcised     
Normal 2 (0.7) 1.00   No 13 (10.6) 1.00   
<20% 1 (1.3) 1.66  0.14-19.49 0.69 Yes 6 (4.0) 0.36 0.13-0.99 0.05 
≥20 2 (4.9) 16.18 1.59-164.12 0.02      
          
     Mycoplasma genitalium     
CD4+ count at endline (cells/mm3)     No 18 (5.3) 1.00   
>350 2 (0.6) 1.00   Yes 4 (12.9) 2.69 0.80-9.37 0.12 
201-350 2 (3.8) 7.41 0.89-61.86 0.06      
≤200 1 (4.8) 14.85 1.05-209.02 0.05 Anogenital warts     
     No 19 (5.4) 1.00   
     Yes 3 (14.3) 3.48 0.84-14.35 0.08 
          
*All factors in table adjusted for each other; **In SA, there was no adjustment for LTSP because reference group has zero values; 1all factors measured at baseline unless otherwise indicated 
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7 HIV-RELATED RISK FACTORS FOR HR-HPV AND CIN2+  
 
The meta-analysis in Chapter 3 has shown that ART is associated with a decrease in HR-HPV prevalence, 
CIN2//HSIL+ prevalence and SIL incidence and progression, and is associated with an increased 
likelihood of SIL regression. These associations were strongest when ART was considered “effective” 
(i.e. with high adherence, HIV viral suppression and immune reconstitution) and taken over longer 
durations. However, few longitudinal studies have reported the effect of ART, CD4+ cell count and 
HIV-1 PVL on the simultaneous natural history of HR-HPV infection and histological cervical lesions. The 
aims of this Chapter, therefore, are to evaluate the associations of ART, CD4+ cell count and HIV-1 PVL 
prospectively on HR-HPV and CIN2+ outcomes in the HARP cohort.  
 
7.1 Objectives 
In a cohort of WLHIV in Burkina Faso and South Africa at enrolment:  
 To evaluate the association of HR-HPV and CIN2+ prevalence with ART 
status, CD4+ cell count and HIV-1 PVL. 
(Objective 2.4) 
In a cohort of WLHIV with ≤CIN1 at enrolment and followed over 18 months: 
 To evaluate the association of HR-HPV incidence, persistence and 
complete clearance, and CIN2+ incidence with ART status, CD4+ cell count 
and HIV-1 PVL at baseline and (where available) at endline.  
(Objective 2.4) 
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7.2 Methods 
A full description of the HARP enrolment procedures is provided in Chapter 5, section 5.2. Specific 
statistical methods for univariate and multivariate risk factor analysis are detailed here.  
7.2.1 Statistical methods 
The HR-HPV and CIN2+ outcomes in this Chapter, are as defined previously: HR-HPV prevalence, 
incidence, persistence and complete clearance (Table 5.2); and CIN2+ prevalence and incidence at 
endline (Table 5.3).  
As HR-HPV prevalence, incidence and clearance were common, associations with HIV-related 
variables were estimated with prevalence ratios (PRs) obtained from logistic regression using 
marginal standardization to estimate PRs, and the delta method to estimate 95% CI [379]. 
Associations between HR-HPV persistence and HIV-related variables were estimated with 
generalised estimating equation (GEE) to account for multiple HR-HPV infection and 
coexisting/concomitant infection states (e.g. persistence and clearance of different types in the 
same woman) [380].  
For associations with CIN2+ prevalence and incidence over follow-up (much rarer outcomes), 
logistic regression was used to estimate odds ratios (ORs) and their 95% CI.  
7.2.2 Adjustment factors 
Multivariable analyses (MVA) were adjusted for site and socio-demographic and behavioural 
factors which were independently associated in multivariate analyses with HR-HPV or CIN2+ for 
each country, as described in Chapter 6 (Model 1). Adjustments were made separately for each 
country, given the differences observed in the study population characteristics and risk factor 
associations with HR-HPV and CIN2+ outcomes, and are summarised in Table 7.1.  
Adjustment factors were considered at two levels; a.) factors found to be associated with 
acquisition of HR-HPV infection  in Chapter 6 (condom use, age, vaginal cleansing, presence of 
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other STIs including bacterial vaginosis (BV), Chlamydia trachomatis and Trichomonas vaginalis and  
high-risk behaviours associated with HR-HPV acquisition in Chapter 6 (such as alcohol use and 
number of lifetime sex partners); and b.) factors linked to inflammation and carcinogenesis and 
found to be associated with HR-HPV persistence (cervicitis, cervical ectopy and smoking) and 
CIN2+ prevalence and incidence in Chapter 6 (age, cervical ectopy, BV, cervicitis and injectable 
contraception).  
Table 7.1. Summary of adjustment factors found to be associated with HR-HPV and CIN2+ in 
multivariate analysis (Chapter 6) and used as adjustment factors in this Chapter (Model 1) 
 Burkina Faso 
(Model 1) 
South Africa 
(Model 1) 
HR-HPV outcomes Condom use 
Alcohol use 
Cervicitis 
Cervical ectopy 
Condom use 
Age 
Vaginal cleansing 
Bacterial vaginosis 
Chlamydia trachomatis 
Trichomonas vaginalis 
Number LTSP 
Smoking 
CIN2+ Prevalence Age 
Cervical ectopy 
Bacterial vaginosis 
Cervicitis 
Injectable contraception 
 
CIN2+ Incidence Cervical ectopy Cervicitis 
Injectable contraception 
 
Given that WLHIV in the HARP study were infected with multiple HR-HPV types, and had multiple 
coexisting infection states (i.e. an individual woman could have incidence, persistence or clearance 
of different types at the same time point), the same adjustment factors were used for all HR-HPV 
outcomes (prevalence incidence, persistence, clearance), as summarised in Table 7.1.  
Similarly, due to possible imprecision in MVA because of the small number of incident CIN2/3 cases, 
I limited the range of risk factors used for adjustment and only used those found to be associated 
with CIN2+ prevalence at baseline for the CIN2+ incidence analyses. For BF, because there were 
only 5 incident CIN2+ cases, I restricted adjustment to cervical ectopy, as it was found to be 
associated with both CIN2+ prevalence and incidence in MVA in Chapter 6.    
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Other factors found to persist in MVA in Chapter 6 (such as marital status, AGW occurrence, 
presence of genital blisters or sores, male partner’s circumcision status, HIV-positive male partner 
and age at first pregnancy) were not considered as additional adjustment factors in this chapter, 
for the following reasons:  
Marital status 
In Chapter 6, the MVA showed that women who were divorced/separated/widowed were more 
likely to clear HR-HPV infection compared to never married women in SA. It could be speculated 
that unmarried women were younger and engaged in more risky sexual behaviours compared to 
other women leading to a higher risk of persistent infection, but the HARP data does not support 
this. Unmarried women, divorced/separated/widowed women and married/cohabiting women all 
had a similar number of LTSP and a similar number of recent sex partners (in last 3 months). It may 
because formerly married women were less likely to be current users of injectable contraception 
(9.8% vs. 19.1% of married or cohabiting women). Injectable contraception is a known 
immunomodulatory factor and was found to be associated with CIN2/3 prevalence in SA. It is 
possible that these associations are linked given that HR-HPV persistence is a precursor for CIN2/3.   
Number of lifetime sex partners 
Although incident CIN2+ appeared higher among those with a higher number of LTSP (in women 
with more than 1 LTSP) in SA, there were no cases of incident CIN2+ in the reference group (1 LTSP), 
and it is not clear if there an association of LTSP with incident CIN2+, as an OR could not be 
calculated. For this reason, LTSP was not included in the Model 1 for incident CIN2/3.  
 
Male circumcision 
Circumcision of current male sex partner was associated with a decreased risk of incident CIN2/3 
in SA, but not with HR-HPV outcomes. HR-HPV incidence was similar among women with 
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circumcised partners and among women with uncircumcised partners (49.2% vs. 53.4%, p=0.45). 
Although HR-HPV prevalence was marginally higher among women with uncircumcised partner 
compared to those with a circumcised partner (81.9% vs. 76.0%; unadjusted PR=1.08, 95%CI: 0.98-
1.18) this association was weakly statistically significant in univariate analysis at the established 
high cut-off (p=0.12), and it did not persist in MVA. Given the longer time period for CIN2+ 
development, it is possible that circumcision status is linked to a HR-HPV type acquired in the past 
prior to enrolment in the study, which may have been detected as a prevalent (and which may have 
been truly persistent) infection at baseline which developed into incident CIN2+ during the follow-
up period. However, just under three-quarters of women in SA reported the circumcision status of 
their male partner, and given the small number of incident CIN2+ cases in SA, adjusting for this 
variable resulted in a less precise measure, with some missing values.   
HIV-positive male partner 
As discussed in Chapter 6, it was unclear why women with a HIV-positive male partner had lower 
prevalence of HR-HPV compared to those with a HIV-negative male partner, but it could be linked 
to the reliability of condom use reporting, as well as unmeasured confounding for sexual behaviour 
(male partner sexual behaviour patterns or frequency of sex).  
 
Age at first pregnancy (AFP) 
Women with a young AFP were more likely to have complete clearance of HR-HPV compared to 
those with older AFP. As discussed in Chapter 6, AFP can be used as a proxy measure for AFSI, but 
this association was not similarly observed for AFSI. Given the lack of correlation in these findings, 
it remains unclear if there is unmeasured confounding. Furthermore, the definition of complete 
clearance may be limited as it does not account for the number of infections that were cleared.  
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Anogenital warts (AGW) 
The occurrence of AGW was shown to be associated with HR-HPV and CIN2+ prevalence in BF, and 
HR-HPV persistence in SA in MVA in Chapter 6. However, there is limited evidence in the literature 
that AGW occurrence results in HR-HPV persistence and CIN2+ development. AGW occurrence is 
not known to be a causative agent of CIN2+ and is considered to be a reflection of infection with 
LR-HPV types, which in turn frequently co-exist with HR-HPV types.   
Presence of genital blisters, ulcers or sores 
The presence of genital blisters, ulcers or sores which were associated with increased risk of HR-
HPV persistence in SA, were detected during clinical exam by nurse/midwife. Their presence could 
be correlated with other STI, particularly HSV-2 given the high prevalence among women in SA 
(95%). However, HSV-2 was not found to be associated with HR-HPV or CIN2+ outcomes, probably 
because of its high prevalence (and there were no measures of HSV-2 shedding in this study). Given 
that adjustments are made for bacterial vaginosis, Chlamydia trachomatis, Trichomonas vaginalis 
and cervicitis in SA, and to avoid possible over adjustment of factors that are correlated with each 
other, there will be no further adjustment for genital blisters/ulcers/sores.  
7.2.3 HIV-related factor definitions 
To explore associations of HR-HPV and CIN2+ outcomes with HIV-related factors, pre-specified 
analyses included stratification by site, ART, HIV-1 viral suppression, HIV-1 viral detection and CD4+ 
cell counts. ART was stratified by user status (ART use:naïve) and duration of use at baseline 
(prolonged ART >2 years; short duration ART ≤2 years and ART-naïve), as other studies have done 
[209, 213], allowing for comparison with these other studies. Associations of ART initiation with 
HR-HPV and CIN2+ outcomes were not explored because of the small number of women that 
initiated ART during follow-up (BF: n=53; SA:, n=25). However, cumulative duration of ART use was 
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assessed from both baseline and endline (duration at baseline+follow-up duration) timepoints  was 
assessed for the longitudinal outcomes.  
Among ART users, HIV-1 viral suppression was stratified as having < or ≥1000 HIV-1 RNA copies/ml 
of plasma, according to WHO definitions [404], and HIV-1 viral detection (≤40 and >40 HIV-1 RNA 
copies/ml) was defined by the lowest limit of detection of the HIV-1 RNA assays used in each 
country (Abbott RT HIV-1 in BF and COBAS Taqman in SA). 
A variable of “stable high CD4+ cell count” was created as a measure of immune stability and 
defined as having CD4+ counts >500 cells/mm3 at all follow-up visits, i.e. baseline, Month 12 and 
endline visits. Stable high CD4+ cell count was assessed separately among ART users and ART-
naïve.  
CD4+ cell count has been shown to be an independent determinant of HR-HPV and CIN2+ [183]. 
Because ART users can have wide ranging CD4+ cell counts depending on how recently they 
initiated ART, or whether they have good treatment adherence, a second logistic regression model 
(Model 2) incorporated baseline CD4+ cell count to Model 1 to explore associations with ART and 
HIV-1 PVL.  Table 7.1 summarises adjustment factors used in Model 1.  
 
7.3 Results 
7.3.1 Association of HR-HPV prevalence with ART and HIV-related factors 
Table 7.2 reports on these findings, by country. HR-HPV prevalence was higher among those with 
low CD4+ count in both countries (CD4+ count <200 vs. >500 cells/mm3: adjusted Prevalence Ratio 
[aPR]=1.38, 95%CI: 1.15-1.66 in BF and aPR=1.14, 95%CI: 1.01-1.30 in SA). This association was strongest 
among ART users (<200 vs. >500 cells/mm3: aPR=1.43, 95%CI: 1.15-1.77 in BF and aPR=1.16, 95%CI: 
1.00-1.35 in SA) but weaker evidence was observed among the ART-naive (<200 vs. >500 cells/mm3, 
aPR=1.19, 95%CI: 10.84-1.69 in BF and aPR=0.98, 95%CI: 0.64-1.50 in SA).  
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Compared to long-duration ART users (>2 years), HR-HPV prevalence was higher among those on 
short-duration ART in both countries (≤2 years), however when adjusted for CD4+ cell count, this 
association was observed in BF only (65.1% vs. 52.1% for ≤2 years compared to >2 years; aPR=1.21, 
95%CI: 1.03-1.44).  There was some evidence of an increase in HR-HPV prevalence among ART-naïve 
compared to long-term ART users in both countries, but this was not significant.  
7.3.2 Association of HR-HPV incidence with ART and HIV-related factors 
Table 7.3 reports on these findings. HR-HPV incidence was higher among those with low CD4+ cell 
count in SA only (CD4+ count <200 vs. >500 cells/mm3: 71.0% vs. 46.5%; aPR=1.61, 95%CI: 1.24-2.09), 
and this association was strongest among ART users (<200 vs. >500 cells/mm3: 71.4% vs. 43.4%; 
aPR=1.77, 95%CI: 1.31-2.39). Among ART users in SA, HR-HPV incidence was marginally associated 
with lack of HIV-1 viral suppression at baseline (women with PVL ≥1000 vs. <1000 copies/ml: 60.0% 
vs. 48.3%; aPR=1.27, 95%CI: 0.98-1.64).  
In BF, there was some evidence that HR-HPV incidence was higher among short-duration ART users 
compared to long-duration ART users, after adjustment for CD4+ cell count (53.9% vs. 45.5%; 
aPR=1.20, 95%CI: 0.96-1.50, Model 2).  
7.3.3 Association of HR-HPV persistence with ART and HIV-related factors 
Table 7.4 reports on these findings, by country. HR-HPV persistence was associated with low 
baseline CD4+ cell count in BF only (<200 vs. >500 cells/mm3: 54.6% vs. 36.8%; aOR=1.81, 95%CI: 1.10-
2.99, Model 1). HR-HPV persistence was higher among ART-naive compared to long-duration ART 
users in BF only (Model 1) and this association persisted when adjusted for baseline CD4+ cell count 
(Model 2; ART-naïve vs. ART >2 years: 58.6% vs. 37.7%; aOR=1.80, 95%CI: 1.21-2.66). HR-HPV 
persistence was similar among long-duration and short-duration users in BF (37.7% vs. 33.3%).  
By contrast, in SA, HR-HPV persistence was higher among short-duration compared to long-
duration ART users even after adjustment for CD4+ cell count (ART <2 years vs. ART >2 years: 35.2% 
193 
 
 
vs. 24.5%; aOR=1.75, 95%CI: 1.17-2.64; Model 2). HR-HPV persistence was also higher among ART-
naïve compared to long-duration users, but there was weak evidence of an association (ART >2 
years vs. ART naive: 31.8% vs. 24.5%; aOR=1.50, 95%CI: 0.94-2.40). Among ART users in SA, HR-HPV 
persistence was associated with lack of HIV-1 viral suppression at baseline (women with PVL ≥1000 
vs. <1000 copies/ml: 49.3% vs. 24.8%; aOR=3.35, 95%CI: 1.85-6.04).  
 Among participants who remained ART-naive throughout the follow-up period, women with 
unstable CD4+ count or stable low CD4+ count (≤500 cells/mm3) had increased persistence 
compared to those with stable high CD4+ count but the association was not statistically significant 
in BF, and borderline significant in SA (>500 cells/mm3; in BF: 64.2% vs. 45.0%; aOR=1.50, 95%CI: 0.33-
6.76 and in SA: 33.1% vs, 16.7%; aOR=2.20, 95%CI: 0.99-4.91). 
7.3.4 Association of HR-HPV complete clearance with ART and HIV-related factors 
Table 7.5 reports on these findings, by country. Among those with HR-HPV infection at baseline, 
complete clearance was lower among those with low CD4+ cell count in both countries, but the 
association was significant in SA only (CD4+ cell count <200 vs. >500 cells/mm3: 12.0% vs. 33.6%; 
aPR=0.33, 95%CI: 0.11-0.96), and this association was strongest among ART users (<200 vs. >500 
cells/mm3: 13.6% vs.38.5%; aPR=0.31, 95%CI: 0.10-0.94).    
Complete HR-HPV clearance was lower among ART-naïve women compared to long-duration ART 
users in both countries, but the association was significant in SA only (ART naive vs. ART >2 years: 
21.1% vs. 33.3%; aPR=0.65, 95%CI: 0.42-0.99, adjusted for CD4+ cell cell count; Model 2).  
7.3.5 Association of CIN2+ prevalence and incidence with ART and HIV-related factors 
Table 7.6 and Table 7.7 report on these findings, by country. CIN2+ prevalence was higher among 
participants with low baseline CD4+ cell count in both countries (CD4+ count <200 vs. >500 
cells/mm3: in BF: 14.0% vs. 6.3%; aOR=2.99, 95% CI: 1.05-8.58, and in SA: 42.0% vs. 19.1%; aOR=3.39, 
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95%CI: 1.70-6.75; Table 7.6) and this association was strongest among ART users (BF: aOR=4.34, 
95%CI: 1.25-15.10. SA: aOR=3.78, 95%CI: 1.73-8.24).   
Among ART-naive, CD4+ cell count below the threshold for ART initiation according to the 2010 
WHO guidelines was associated with higher risk of CIN2+ in SA only (<350 vs. >350 cells/mm3: 38.0% 
vs. 20.4%; aOR=2.57, 95%CI: 1.21-5.45, data not shown).  
CIN2+ prevalence was higher among participants on short-duration ART (≤2 years) and among ART-
naïve compared to long-duration ART users in SA and these associations persisted after adjustment 
for baseline CD4+ cell count (ART ≤2 years vs. >2 years: 29.2% vs. 15.0%; aOR=1.81, 95%CI: 1.03-3.17; 
ART-naïve vs. ART >2 years: 25.% vs. 15.0%; aOR=1.78, 95%CI: 1.06-2.99, Table 7.6).  
In SA, CIN2+ incidence was similar among short-duration and long-duration ART users at endline 
(4.5% each, Table 7.7), but there was some evidence that CIN2+ incidence was higher among those 
who remained ART-naïve at endline compared to all ART users, irrespective of duration (9.6% vs. 
4.5%; aOR=2.00, 95%CI: 0.80-5.04, adjusted for injectable contraception, cervicitis and baseline 
CD4+ count, data not shown). No association was observed in BF due to the small number of 
incident CIN2+ cases. No associations were observed with CD4+ cell count at either baseline or 
endline in either country.  
 
7.4 Discussion 
It was reported in Chapter 6 that WLHIV in Burkina Faso and South Africa had high prevalence and 
persistence of HR-HPV, but CIN2+ prevalence and incidence were higher in South Africa despite 
balanced distribution of ART use, similar median duration on ART and median CD4+ cell counts at 
study enrolment in both countries, and similar HR-HPV persistence rates over 16 months.  
In this Chapter we report that low baseline CD4+ cell count (<200 cells/mm3) was associated with 
a higher prevalence of HR-HPV and CIN2+ in both countries, with HR-HPV incidence in SA, and with 
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HR-HPV persistence in BF, similar to other studies that have shown CD4+ count to be one of the 
strongest predictors of HR-HPV infection [183] and cervical lesion development [173]. The lack of 
association of CD4+ count with CIN2/3 incidence is surprising, but may be a consequence of the 
short duration of follow-up resulting in a small number of cases for meaningful analysis.  
Prolonged duration of ART was also associated with lower CIN2+ prevalence and HR-HPV 
persistence, similar to other reports [209, 213, 288], and this association was independent of 
baseline CD4+ count. Although HR-HPV persistence was similar in both countries, cervical lesion 
progression was higher in South Africa and this may have been influenced to some extent by the 
role of HIV-related factors and other contributing cofactors such as injectable contraception and 
co-infection with other STIs, the frequency of which differed between the two countries.   
In Burkina Faso, prolonged and short-duration ART users had a similar risk of HR-HPV persistence 
when CD4+ counts were >500 cells/mm3. However the risk was higher among short-duration 
compared to long-duration ART users when CD4+ count was low (<200 cells/mm3). This suggests 
that once the recent ART initiators begin to recover CD4+ T-lymphocytes, they can control HR-HPV 
persistence, leading to the lower prevalence of CIN2+. The short duration of follow-up coupled 
with the small number of incident CIN2/3 and ART initiators over follow-up in BF may have 
influenced the lack of association between CD4+ count reconstitution and CIN2/3 incidence.  
By contrast, in South Africa, short-duration ART users had higher persistence of HR-HPV and higher 
prevalence of CIN2+, irrespective of baseline CD4+ cell count. This may be a consequence of several 
factors. Firstly, ART users in South Africa were not as well HIV-controlled as their counterparts in 
Burkina Faso. Effective ART use, as measured by HIV-1 RNA suppression (PVL <1000 copies/ml), was 
associated with a decrease in HR-HPV persistence over 16 months in South Africa, independent of 
baseline CD4+ cell count. Others have shown that HR-HPV persistence was increased 2-3 fold 
among women (6% ART users) with detectable genital tract HIV RNA levels, after adjusting for 
CD4+ cell count but not when adjusted for plasma HIV [405], thereby suggesting a possible direct 
role of HIV on HR-HPV through both local and systemic mechanisms. The greater proportion of 
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ART users in South Africa with detectable HIV-1 PVL (65% in South Africa vs. 23% in Burkina Faso) 
may be a consequence of their poor self-reported adherence, which was observed among both 
short and long-duration ART users. Women with suboptimal adherence may have developed, or 
initially acquired, some antiretroviral-resistant HIV strain, although we cannot verify this in the 
absence of HIV genotyping. Secondly, ART use in the short-term may be ineffective in clearing HR-
HPV if the infection is already well established. Women on short-duration ART in SA were less likely 
to clear all HR-HPV infections at endline compared to women on long-duration ART. Others have 
shown that ART users are at a higher risk of cervical disease if they have initiated ART at a lower 
nadir CD4+ count [193, 406, 407]. In such cases, the CD4+ T-lymphocyte reconstitution 
accompanying ART may be partial or functionally impaired and the beneficial effects of ART may 
only become apparent after long treatment periods [176].  
It is possible in our study that immune reconstitution achieved through recent ART initiation at the 
previous WHO cut-off of 350 cells/mm3 may have been insufficient to prevent HR-HPV persistence 
and/or CIN2+ development, in particular when coupled with detectable HIV, lower ART adherence 
and lower CD4+ T-lymphocyte recovery over time, as was the case among women in South Africa. 
Early ART initiation, coupled with rapid virological control, is likely to rapidly improve and maintain 
CD4+ count at a higher level [408], leading to possibly more complete and sustained immune 
reconstitution, thereby reducing the risk of persistent HR-HPV and cervical lesion development. 
Finally, the higher CIN2+ prevalence and incidence in South Africa could additionally be explained 
by other cofactors for such as greater frequency of contraceptive use and smoking and higher 
prevalence of mucosal STIs [89, 409, 410], as also described in Chapter 6. The presence of STIs can 
trigger genital HIV replication, a cascade of mucosal immunological synergies and vaginal biome 
changes [142, 411], which may interact with HR-HPV [412]. Addressing such cofactors should also 
be a priority of cervical cancer prevention programmes. 
Importantly, this study has found that ART use was associated with increased likelihood of clearing 
HR-HPV infections, and with a reduction in incident CIN2+ over 16 months in South Africa. 
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Furthermore, by endline, ART duration had increased to a median 44 months which may have 
played a role in promoting HR-HPV clearance and averting CIN development.  
ART-naïve women in South Africa had similar HR-HPV persistence, complete HR-HPV clearance and 
CIN2+ prevalence as prolonged ART users at high baseline CD4+ (>500 cells/mm3), but these 
outcomes worsened among the ART-naïve at low baseline CD4+ cell counts. This finding highlights 
the role of early ART initiation to favourably influence the natural history of HR-HPV and CIN.  
 
7.5 Study limitations 
As stated in previous chapters, this study is limited by the duration of follow-up and HR-HPV testing 
intervals. The definition of cumulative HR-HPV incidence over 16 months is of limited duration to 
assess the actual roles of HR-HPV incidence and persistence on CIN2+ incidence. The study could 
not rule out type-specific clearance and reinfection when estimating persistence during the 16-
months interval between HPV testing.  A longer duration of follow-up would have allowed to 
accrue a larger number of incident CIN2+ cases and more robustly assess the role of HIV-related 
factors on CIN development over sufficient follow-up time.  
This analysis was constrained by the absence of consistent data on nadir CD4+ cell count which 
would have allowed a better understanding of the higher CIN2+ rates among women in SA 
compared to women in BF, and may have helped to explain the higher CIN2+ prevalence among 
the short-duration ART users in comparison with the long-duration ART users. A low nadir CD4+ 
cell count has previously been shown to a strong predictor for HR-HPV infection among WLHIV in 
Belgium and Brazil [209, 220] and CIN2+ prevalence among WLHIV in Kenya and Brazil [193, 406].  
The absence of a HIV-1 PVL measure at the endline visit prohibited classification of ART users into 
and; i.e. according to whether they had sustained HIV-1 viral suppression (“effective” ART) or not  
(“ineffective” ART). Others have previously shown that sustained HIV-1 PVL suppression over 40 
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months was associated with a 20% reduction in HR-HPV detection during follow-up [209]. In this 
study, duration of ART was a proxy measure for “effective” ART use. This assumes that women 
were adherent, yet no woman reported >90% adherence in either country. ART adherence was 
crudely measured using self-reported use rather than pill count, pharmacy records or ARV drug 
compound testing which may be more robust methods. However, the HARP findings are similar to 
what has been reported elsewhere in SSA based on self-reporting [413]. In South Africa, Gauteng 
province where HARP was conducted, adherence was previously reported as 77% [414].  
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7.6 Summary of findings (Table 7.8 and Figure 7.1) 
 WLHIV with CD4+ <200 cells/mm3 had up to a 1.4-fold increased risk of HR-HPV 
prevalence, 1.6-fold increased risk of HR-HPV-incidence, 1.8-fold increase in HR-HPV 
persistence and over a 3-fold increase in CIN2+ prevalence.  
 In BF, compared to long-duration ART users (>2 years), short-duration ART users (≤2 
years) had higher HR-HPV prevalence (aPR=1.24, 95%CI: 1.04-1.47), while ART-naïve 
women had higher persistence of HR-HPV (aOR=1.80, 95%CI: 1.21-2.66).  
 In SA, compared to long-duration ART users (>2 years), short-duration ART users had 
higher persistence of HR-HPV (aPR=1.75, 95%CI: 1.17-2.64) and prevalence of CIN2+ 
(aOR=1.81, 95%CI: 1.03-3.17).  
 HR-HPV persistence was associated with lack of viral suppression in SA (HIV-1 PVL ≥1000 
vs, <1000 copies/ml; aPR=2.87, 95%CI: 1.63-5.05)  
 ART-naïve women in SA had a similarly high risk of CIN2+ prevalence compared to long-
duration ART users (aOR=1.78, 95%CI: 1.06-2.99) at baseline. 
 By endline, CIN2/3 incidence was similar among short and long-duration ART users in SA, 
but was higher among women who remained ART-naive compared to all ART users (9.6% 
vs. 4.5%; aOR=2.00, 95%CI: 0.80-5.04) 
 
Conclusion: Prolonged and effective ART, with high CD4+ cell count, is important in controlling 
HR-HPV and the development of CIN2+. 
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7.7 Findings in context 
The meta-analysis in Chapter 3 which evaluated the association of ART use with HR-HPV and 
cervical lesion outcomes found that ART use over prolonged duration, and with sustained HIV-1 
viral suppression, was associated with a reduction in the prevalence of HR-HPV and HSIL+/CIN2+, a 
reduction in SIL incidence and progression and an increase in SIL regression.   
The results of this study confirm the findings in the meta-analysis that prolonged ART use is 
associated with a reduction in HR-HPV prevalence and persistence and CIN2+ prevalence and 
incidence over 16 months.  ART users with suppressed HIV-1 PVL at baseline in SA were less likely 
to have HR-HPV persistence at endline, similar to findings among other WLHIV [209]. 
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Table 7.2.  Effect of HIV related factors on HR-HPV prevalence among 570 WLHIV in Burkina Faso and 613 in South Africa 
  HR-HPV Prevalence 
  Burkina Faso (N=570) South Africa (N=613) 
  N n (%) 
Model 11 Model 22 
N n (%) 
Model 11 Model 22 
aPR (95% CI)  aPR (95% CI)  aPR (95% CI)  aPR (95% CI)  
Baseline CD4+ count (cells/mm3)§                 
 <200  66 50 (75.8) 1.38  (1.15-1.66) - 57 50 (87.7) 1.14  (1.01-1.30) - 
200-350 125 76 (60.8) 1.10  (0.91-1.33) - 148 120 (81.1) 1.07  (0.96-1.19) - 
351-500 161 92 (57.1) 1.04  (0.87-1.25) - 183 141 (77.1) 1.02  (0.92-1.14) - 
>500 217 119 (54.8) 1.00 - 225 172 (76.4) 1.00 - 
 ART status at baseline              
ART >2 years 194 101 (52.1) 1.00 1.00 225 163 (72.4) 1.00 1.00 
ART ≤2 years 218 142 (65.1) 1.26  (1.07-1.50) 1.21  (1.03-1.44) 179 147 (82.1) 1.12  (1.01-1.24) 1.09  (0.98-1.22) 
ART-naive 158 95 (60.1) 1.16  (0.96-1.41) 1.12  (0.93-1.36) 209 173 (82.8) 1.11  (1.00-1.23) 1.10  (1.00-1.22)   
Among ART users:             
HIV-1 viral suppression†             
<1000 copies/ml 328 196 (59.8) 1.00 1.00 324 246 (75.9) 1.00 1.00 
≥1000 copies/ml 55 32 (58.2) 0.97  (0.76-1.24) 0.80  (0.59-1.10) 76 62 (81.6) 1.00  (0.87-1.16) 0.98  (0.84-1.14) 
HIV-1 viral detection†         
        ≤40 copies/ml 286 169 (59.1) 1.00 1.00 135 110 (81.5) 1.00 1.00 
        >40 copies/ml 97 59 (60.8) 1.02  (0.84-1.23) 0.92  (0.74-1.15) 265 198 (74.7) 0.90  (0.81-1.00) 0.90  (0.81-1.00) 
ART adherence‡             
Moderate adherence 
 (60-90%) 
378 223 (59.0) 1.00 1.00 337 253 (75.1) 1.00 1.00 
Low Adherence (<60%) 10 7 (70.0) 1.17  (0.77-1.80) 1.11  (0.68-1.79) 63 54 (85.7) 1.11  (0.97-1.26) 1.09  (0.96-1.25) 
Baseline CD4+ count (cells/mm3)§              
 <200  47 36 (76.6) 1.43  (1.15-1.77)   - 51 45 (88.2) 1.16  (1.00-1.35) - 
200-350 80 50 (62.5) 1.16  (0.93-1.45)     - 102 83 (81.4) 1.09  (0.95-1.25) - 
351-500 119 68 (57.1) 1.06  (0.86-1.31) - 113 81 (71.7) 0.99  (0.86-1.15) - 
>500 165 88 (58.3) 1.00 - 138 101 (73.2) 1.00 - 
Among ART-naïve:              
Baseline CD4+ count (cells/mm3)              
 <200  19 14 (73.7) 1.19  (0.84-1.69)    - 6 5 (83.3) 0.98  (0.64-1.50) - 
200-350 45 26 (57.8) 0.95  (0.68-1.32) - 46 37 (80.4) 0.98  (0.81-1.18)   - 
351-500 42 24 (57.1) 0.89  (0.62-1.27) - 70 60 (85.7) 1.06  (0.93-1.21) - 
>500 52 31 (59.6) 1.00 - 87 71 (81.6) 1.00 - 
Adjusted Prevalence Ratio (aPR): 1Model1: In BF, associations with HR-HPV were adjusted for condom use, alcohol use, cervicitis, and cervical ectopy; and in SA, associations with HR-HPV were adjusted for 
age, smoking, condom use, vaginal cleansing, bacterial vaginosis (BV), infection with Chlamydia trachomatis and Trichomonas vaginalis, and number of lifetime sex partners ; 2Model 2: same as Model 1 with 
additional adjustment for baseline CD4+ count; §CD4+ count was unavailable for 1 participant on ART in BF; †HIV-1 PVL data was unavailable for 29 ART users in BF and 4 in SA; ‡Data on self-reported adherence 
was unavailable for 24 participants in BF and 4 in SA; there was no participants in either country in the high adherence category. 
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 Table 7.3.  Effect of HIV related factors on HR-HPV incidence among 460 WLHIV in Burkina Faso and 440 in South Africa 
 
  Burkina Faso 
(N=460) 
South Africa 
(N=440) 
    Model 11 Model 22   Model 11 Model 22 
   N n (%) aPR (95% CI) aPR (95% CI) N n (%) aPR (95% CI) aPR (95% CI) 
Baseline CD4+ count (cells/mm3)         
   <200  46 24 (52.2) 1.14  (0.83-1.57) - 31 22 (71.0) 1.61  (1.24-2.09) - 
  200-350 98 51 (52.0) 1.15  (0.90-1.48) - 99 46 (46.5) 1.03  (0.79-1.34) - 
  351-500 136 64 (47.1) 1.01  (0.80-1.29) - 140 70 (50.0) 1.10  (0.87-1.38)    - 
  >500 180 83 (46.1) 1.00 - 170 79 (46.5) 1.00 - 
ART status at baseline         
  ART >2 years 209 95 (45.5) 1.00 1.00 175 85 (48.6) 1.00 1.00 
  ART ≤2 years 128 69 (53.9) 1.22  (0.98-1.52) 1.20  (0.96-1.50)    122 64 (52.5) 1.08  (0.87-1.36) 1.01  (0.79-1.28)    
  ART-naive 123 58 (47.2) 1.05  (0.82-1.35)   1.03  (0.80-1.32) 143 68 (47.6) 0.95  (0.75-1.20) 0.95  (0.76-1.20) 
Among ART users§ :         
HIV-1 viral suppression*         
   <1000 copies/ml 274 130 (47.5) 1.00 1.00 240 116 (48.3) 1.00 1.00 
   ≥1000 copies/ml 39 19 (48.7) 1.02  (0.72-1.44)   1.00  (0.67-1.48) 55 33 (60.0) 1.27  (0.98-1.64)   1.24  (0.96-1.61)   
HIV-1 viral detection*         
   ≤40 copies/ml 240 113 (47.1) 1.00 1.00 96 51 (53.1) 1.00 1.00 
   >40 copies/ml 73 36 (49.3) 1.01  (0.77-1.33) 0.98  (0.72-1.32) 199 98 (49.3) 0.95  (0.75-1.20) 0.94  (0.74-1.19) 
Baseline CD4+ count (cells/mm3)         
   <200 31 16 (51.6) 1.09  (0.74-1.61) - 28 20 (71.4) 1.77  (1.31-2.39) - 
   200-350 63 37 (58.7) 1.30  (0.99-1.70)     - 75 36 (48.0) 1.16  (0.85-1.60) - 
   351-500 99 45 (45.5) 0.97  (0.73-1.29) - 88 47 (53.4) 1.24  (0.92-1.66)    - 
   >500 144 66 (45.8) 1.00 - 106 46 (43.4) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)          
   No 213 106 (49.8) 1.06  (0.84-1.33)   - 235 120 (51.1) 1.08  (0.81-1.44)   - 
   Yes 124 58 (46.8) 1.00 - 62 29 (46.8) 1.00 - 
Among ART-naïve:          
Baseline CD4+ count (cells/mm3) †          
   <200 1 1 (100.0) - - 1 1 (100.0) - - 
   200-350 21 7 (33.3) 0.64  (0.30-1.34)    - 14 7 (50.0) 1.24  (0.76-2.03) - 
   351-500 26 15 (57.7) 1.13  (0.70-1.84) - 46 18 (39.1) 0.84  (0.54-1.31) - 
   >500 33 15 (45.5) 1.00 - 62 31 (50.0) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)‡         
   No 54 27 (50.0) 1.10  (0.63-1.93) - 99 44 (44.4) 0.78  (0.52-1.18)   - 
   Yes 27 11 (40.7) 1.00 - 24 13 (54.2) 1.00 - 
Adjusted Prevalence Ratio (aPR): 1Model1: In BF, associations with HR-HPV were adjusted for condom use, alcohol use, cervicitis, and cervical ectopy; and in SA, associations with HR-HPV were adjusted for 
age, smoking, condom use, vaginal cleansing, bacterial vaginosis (BV), infection with Chlamydia trachomatis and Trichomonas vaginalis, and number of lifetime sex partners ; 2Model 2: same as Model 1 with 
additional adjustment for baseline CD4+ count; §ART use was defined as being on ART at both baseline and endline; *HIV-1 PVL data was unavailable for 24 ART users in BF and 2 in SA; †Baseline CD4+ among 
participants who were ART-naïve at baseline ‡ ART-naïve participants were defined as being ART-naive at both baseline and endline.  
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Table 7.4.  Effect of HIV-related factors on HR-HPV persistence, using infections as unit of measure, among 404 WLHIV in Burkina Faso and 598 in 
South Africa  
 
  Burkina Faso 
(N=404) 
South Africa 
(N=598) 
    Model 11 Model 22   Model 11 Model 22 
   N n (%) aOR (95% CI) aOR (95% CI) N n (%) aOR (95% CI) aOR (95% CI) 
Baseline CD4+ count (cells/mm3)         
   <200  55 30 (54.6) 1.81 (1.10-2.99) - 39 11 (28.2) 1.10 (0.39-3.12) - 
  200-350 86 39 (45.4) 1.12 (0.64-1.95) - 148 47 (31.8) 1.27 (0.97-1.66) - 
  351-500 127 51 (40.2) 1.05 (0.72-1.52) - 189 63 (33.3) 1.36 (0.89-2.08) - 
  >500 136 50 (36.8) 1.00 - 222 60 (27.0) 1.00 - 
ART status at baseline 
   
 
   
 
  ART >2 years 170 64 (37.7) 1.00 1.00 200 49 (24.5) 1.00 1.00 
  ART ≤2 years 123 41 (33.3) 0.79 (0.51-1.22) 0.73 (0.45-1.21) 162 57 (35.2) 1.78 (1.24-2.57) 1.75 (1.17-2.64) 
  ART-naive 111 65 (58.6) 1.93 (1.28-2.91) 1.80 (1.21-2.66) 236 75 (31.8) 1.55 (0.97-2.46) 1.50 (0.94-2.40) 
Among ART users§ :         
HIV-1 viral suppression*         
   <1000 copies/ml 244 82 (33.6) 1.00 1.00 294 73 (24.8) 1.00 1.00 
   ≥1000 copies/ml 32 13 (40.6) 1.21 (0.67-2.18) 0.99 (0.49-1.99) 67 33 (49.3) 3.25 (1.76-6.02) 3.35 (1.85-6.04) 
HIV-1 viral detection*         
   ≤40 copies/ml 205 63 (30.7) 1.00 1.00 124 32 (25.8) 1.00 1.00 
   >40 copies/ml 71 32 (45.1) 1.64 (1.06-2.54) 1.56 (1.01-2.42) 237 74 (31.2) 1.24 (0.57-2.70) 1.22 (0.57-2.60) 
Baseline CD4+ count (cells/mm3)         
   <200 34 16 (47.1) 1.57 (0.93-2.65) - 34 9 (26.5) 1.04 (0.34-3.21) - 
   200-350 56 23 (41.1) 1.24 (0.72-2.14) - 103 28 (27.2) 1.11 (0.75-1.64) - 
   351-500 93 30 (32.3) 0.92 (0.64-1.32) - 103 35 (34.0) 1.47 (0.79-2.74) - 
   >500 110 36 (32.7) 1.00 - 122 34 (27.9) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)          
   No 196 75 (38.3) 1.28 (0.83-1.98) - 298 88 (29.5) 1.10 (0.54-2.23) - 
   Yes 97 30 (30.9) 1.00 - 64 18 (28.1) 1.00 - 
Among ART-naïve:          
Baseline CD4+ count (cells/mm3) †          
   <200 21 14 (66.7) 1.37 (0.48-3.89) - 5 2 (40.0) 2.54 (0.45-14.32) - 
   200-350 30 16 (53.3) 0.62 (0.21-1.87) - 45 19 (42.2) 1.41 (0.73-2.74) - 
   351-500 34 21 (61.8) 1.23 (0.49-3.09) - 86 28 (32.6) 1.30 (0.59-2.89) - 
   >500 26 14 (53.9) 1.00 - 100 26 (26.0) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)‡         
   No 53 34 (64.2) 1.50 (0.33-6.76) - 160 53 (33.1) 2.20 (0.99-4.91) - 
   Yes 20 9 (45.0) 1.00 - 42 7 (16.7) 1.00 - 
Adjusted Odds Ratio (aOR) using generalised estimating equation: 1Model 1: In BF, associations with HR-HPV were adjusted for alcohol use , condom, cervicitis, and cervical ectopy; In SA, associations with HR-
HPV  were adjusted for age, smoking, condom, vaginal cleansing, bacterial vaginosis, Chlamydia trachomatis, Trichomonas vaginalis and LTSP; 2Model 2: same as Model 1 with additional adjustment for baseline 
CD4+ count; §ART use was defined as being on ART at both baseline and endline; *Baseline HIV-1 PVL data was unavailable for 12 participants in BF (representing 17 infections) and 1 in SA (representing 1 
infection);  †Baseline CD4+ among participants who were ART-naïve at baseline ‡ ART-naïve participants were defined as being ART-naive at both baseline and endline.  
204 
 
 
Table 7.5.  Effect of HIV-related factors on HR-HPV complete clearance among 263 WLHIV in Burkina Faso and 334 in South Africa 
  
  Burkina Faso 
(N=263) 
South Africa 
(N=334) 
    Model 11 Model 22   Model 11 Model 22 
   N n (%) aPR (95% CI) aPR (95% CI) N n (%) aPR (95% CI) aPR (95% CI) 
Baseline CD4+ count (cells/mm3)         
   <200  32 6 (18.8) 0.83  (0.40-1.76)   - 25 3 (12.0) 0.33  (0.11-0.96) - 
  200-350 57 8 (14.0) 0.57  (0.28-1.15) - 78 20 (25.6) 0.77  (0.50-1.19) - 
  351-500 80 23 (28.8) 1.16  (0.73-1.83)    - 103 23 (22.3) 0.77  (0.51-1.15) - 
  >500 94 25 (26.6) 1.00 - 128 43 (33.6) 1.00 - 
ART status at baseline         
  ART >2 years 110 31 (28.2) 1.00 1.00 126 42 (33.3) 1.00 1.00 
  ART ≤2 years 79 18 (22.8) 0.79  (0.48-1.29) 0.81  (0.50-1.33) 94 23 (24.5) 0.70  (0.46-1.06) 0.82  (0.53-1.26) 
  ART-naive 74 13 (17.6) 0.69  (0.40-1.20) 0.70  (0.41-1.22) 114 24 (21.1) 0.65  (0.42-0.99) 0.65  (0.42-0.99) 
Among ART users§ :         
HIV-1 viral suppression*         
   <1000 copies/ml 157 41 (26.1) 1.00 1.00 177 57 (32.2) 1.00 1.00 
   ≥1000 copies/ml 20 7 (35.0) 1.42  (0.80-2.52)   1.49  (0.82-2.70)    42 7 (16.7) 0.49  (0.23-1.02) 0.52  (0.25-1.06) 
HIV-1 viral detection*         
   ≤40 copies/ml 136 38 (27.9) 1.00 1.00 78 24 (30.8) 1.00 1.00 
   >40 copies/ml 41 10 (24.4) 1.06  (0.62-1.80)    1.14  (0.64-2.04) 141 40 (28.4) 1.00  (0.65-1.54) 1.00  (0.65-1.52) 
Baseline CD4+ count (cells/mm3)         
   <200 21 6 (28.6) 1.17  (0.58-2.38) - 22 3 (13.6) 0.31  (0.10-0.94)    - 
   200-350 38 5 (13.2) 0.55  (0.23-1.30)   - 59 18 (30.5) 0.74  (0.45-1.21) - 
   351-500 56 18 (32.1) 1.35  (0.82-2.22) - 61 14 (23.0) 0.72  (0.43-1.22) - 
   >500 74 20 (27.0) 1.00 - 78 30 (38.5) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)          
   No 125 33 (26.4) 1.11  (0.68-1.80) - 177 50 (28.3) 0.92  (0.56-1.51) - 
   Yes 64 16 (25.0) 1.00 - 43 15 (34.9) 1.00 - 
Among ART-naïve:          
Baseline CD4+ count (cells/mm3) †          
   <200 1 0 (0.0) - - 1 0 (0.0) - - 
   200-350 12 1 (8.3) 0.33  (0.07-1.50) - 12 2 (16.7) 0.46  (0.11-2.02) - 
   351-500 18 2 (11.1) 0.61  (0.19-1.98)   - 37 8 (21.6) 0.76  (0.37-1.57) - 
   >500 19 5 (26.3) 1.00 - 48 13 (27.1) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)‡         
   No 35 3 (8.6) 0.33  (0.10-1.06) - 78 17 (21.8) 0.83  (0.38-1.82)   - 
   Yes 15 5 (33.3) 1.00 - 20 6 (30.0) 1.00 - 
Adjusted Prevalence Ratio (aPR): 1Model1: In BF, associations with HR-HPV were adjusted for condom use, alcohol use, cervicitis, and cervical ectopy; and in SA, associations with HR-HPV were adjusted for 
age, smoking, condom use, vaginal cleansing, bacterial vaginosis (BV), infection with Chlamydia trachomatis and Trichomonas vaginalis, and number of lifetime sex partners ; 2Model 2: same as Model 1 with 
additional adjustment for baseline CD4+ count; §ART use was defined as being on ART at both baseline and endline; *HIV-1 PVL data was unavailable for 12 ART users in BF and 1 in SA; associations of HIV-PVL  in 
SA not adjusted for Chlamydia trachomatis due to small numbers; †Baseline CD4+ among participants who were ART-naïve at baseline ‡ ART-naïve participants were defined as being ART-naive at both baseline 
and endline.  
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Table 7.6.  Effect of HIV-related factors on CIN2+ prevalence among 530 WLHIV in Burkina Faso and 566 in South Africa 
  CIN2+ Prevalence 
  
Burkina Faso South Africa 
(N=530) (N=566) 
  N n (%) 
Model 11 Model 22 
N n (%) 
Model 11 Model 22 
aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) 
Baseline CD4+ count (cells/mm3)§                 
    <200  57 8 (14.0) 2.99 (1.05-8.58) - 50 21 (42.0) 3.39 (1.70-6.75) - 
   200-350 116 5 (4.3) 0.72 (0.23-2.21) - 138 38 (27.5) 1.61 (0.95-2.74) - 
   351-500 151 6 (4.0) 0.69 (0.24-2.01) - 174 30 (17.2) 0.90 (0.52-1.54) - 
   >500 205 13 (6.3) 1.00 - 204 39 (19.1) 1.00 - 
ART status at baseline             
  
   ART >2 years 182 10 (5.5) 1.00 1.00 207 31 (15.0) 1.00 1.00 
   ART ≤2 years 206 16 (7.8) 1.44 (0.59-3.54) 1.22 (0.48-3.08) 161 47 (29.2) 2.35 (1.39-3.97) 1.81 (1.03-3.17) 
   ART-naive 142 6 (4.2) 1.33 (0.42-4.25) 1.20 (0.37-3.94) 198 50 (25.3) 1.76 (1.05-2.94) 1.78 (1.06-2.99) 
Among ART users:                 
HIV-1 viral suppression†                 
   <1000 copies/ml 309 22 (7.1) 1.00 1.00 294 62 (21.1) 1.00 1.00 
   ≥1000 copies/ml 52 4 (7.7) 1.45 (0.43-4.89) 0.55 (0.12-2.45) 71 15 (21.1) 0.94 (0.49-1.80) 0.72 (0.36-1.44) 
ART adherence‡                 
   Moderate adherence 
 (60-90%) 
358 26 (7.3) 
1.00 1.00 
311 64 (20.6) 
1.00 1.00 
   Low Adherence (<60%) 7 0 (0.0) - - 53 13 (24.5) 1.31 (0.65-2.65) 1.27 (0.62-2.63) 
Baseline CD4+ count (cells/mm3)§                 
   <200  42 7 (16.7) 4.34 (1.25-15.10) - 45 19 (42.2) 3.78 (1.73-8.24) - 
   200-350 76 4 (5.3) 1.10 (0.29-4.13) - 92 20 (21.7) 1.22 (0.61-2.44) - 
   351-500 113 6 (5.3) 1.03 (0.31-3.39) - 107 16 (15.0) 0.78 (0.38-1.61) - 
   >500 156 9 (5.8) 1  - 124 23 (18.6) 1.00 - 
Among ART-naïve:                 
Baseline CD4+ count (cells/mm3)                
 <200  15 1 (6.7) 0.60 (0.05-7.56) - 5 2 (40.0) 2.27 (0.27-19.47) - 
200-350 40 1 (2.5) 0.30 (0.03-3.16) - 46 18 (39.1) 2.97 (1.25-7.07) - 
351-500 38 0 (0.0) - - 67 14 (20.9) 1.21 (0.52-2.81) - 
>500 49 4 (8.2) 1.00 - 80 16 (20.0) 1.00 - 
 
Adjusted Odds Ratio (aOR):  1Model 1 : In BF, associations with CIN2+ were adjusted for age, BV and cervical ectopy; and in SA, associations with CIN2+ were adjusted for injectable contraception and 
cervicitis; 2Model 2: same as Model 1 with additional adjustment for baseline CD4+ ; §CD4+ count was unavailable for 1 participant on ART in BF; †HIV-1 PVL data was unavailable for 29 ART users in BF and 4 in 
SA; ‡Data on self-reported adherence was unavailable for 24 participants in BF and 4 in SA 
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Table 7.7.  Effect of HIV-related factors on CIN2/3 incidence among 412 WLHIV in Burkina Faso and 373 in South Africa 
    Combined sites (N=785) South Africa (N=373) 
    Model 11 Model 22   Model 11 Model 22 
   N n (%) aOR (95% CI) aOR (95% CI) N n (%) aOR (95% CI) aOR (95% CI) 
Baseline CD4+ count (cells/mm3)3         
   <200 62 2 (3.2) 0.93 (0.20-4.41) - 24 1 (4.2) 0.58 (0.07-4.87) - 
   200-350 177 5 (2.8) 0.72 (0.24-2.14)  88 4 (4.6) 0.68 (0.20-2.29)  
   351-500 239 9 (3.8) 0.85 (0.33-2.21)  120 8 (6.7) 0.99 (0.36-2.69)  
   >500 307 11 (3.6) 1.00 - 141 9 (6.4) 1.00 - 
Endline CD4+ count (cells/mm3)         
   <200 44 1 (2.3) 0.75 (0.46-3.16)  23 0 (0.0) -  
   200-350 132 6 (4.6) 1.19 (0.42-3.36)  79 4 (5.1) 0.73 (0.22-2.43)  
   351-500 180 8 (4.4) 1.21 (0.46-3.16)  107 8 (7.5) 1.09 (0.41-2.92) - 
   >500 429 12 (2.8)   164 10 (6.1) 1.00 - 
ART status at baseline         
  ART >2 years 337 7 (2.1) 1.00 1.00 153 6 (3.9) 1.00 1.00 
  ART ≤2 years 214 9 (4.2) 1.80 (0.63-5.10) 1.95 (0.66-5.74) 99 5 (5.1) 1.33 (0.39-4.52) 1.53 (0.43-5.46) 
  ART-naive 234 11 (4.7) 2.01 (0.75-5.41) 2.04 (0.76-5.49) 121 11 (9.1) 2.26 (0.80-6.39) 2.26 (0.80-6.41) 
ART status at endline         
  ART >2 years 422 13 (3.1) 1.00 1.00 202 9 (4.5) 1.00 1.00 
  ART ≤2 years 171 4 (2.3) 0.90 (0.28-2.88) 0.91 (0.30-3.04) 67 3 (4.5) 0.95 (0.25-3.64) 1.03 (0.25-4.22) 
  ART-naive 192 10 (5.2) 1.63 (0.67-3.96) 1.65 (0.67-4.04) 104 10 (9.6) 2.08 (0.80-5.39) 2.02 (0.77-5.29) 
Among ART users§ :         
HIV-1 viral suppression*         
   <1000 copies/ml 84 3 (3.6) 1.00  46 2 (4.4) 1.00 1.00 
   ≥1000 copies/ml 448 13 (2.9) 1.29 (0.35-4.76) 1.30 (0.34-4.97) 204 9 (4.4) 0.98 (0.19-4.90) 1.01 (0.20-5.14) 
HIV viral detection*         
   ≤40 copies/ml 301 6 (2.0) 1.00 1.00 83 3 (3.6) 1.00 1.00 
   >40 copies/ml 231 10 (4.3) 2.05 (0.62-6.79) 2.17 (0.65-7.27) 167 8 (4.8) 2.03 (0.58-7.08) 1.96 (0.56-6.87) 
Baseline CD4+ count (cells/mm3)         
   <200 47 2 (4.3) 1.16 (0.23-5.92) - 22 1 (4.6) 0.84 (0.09-7.81) - 
   200-350 122 3 (2.5) 0.64 (0.16-2.57) - 65 2 (3.1) 0.52 (0.09-2.84) - 
   351-500 163 4 (2.5) 0.52 (0.13-2.09) - 77 3 (3.9) 0.66 (0.15-2.97) - 
   >500 219 7 (3.2) 1.00 - 88 5 (5.7) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)          
   No 388 13 (3.4) 1.19 (0.32-4.45) - 202 9 (4.5) 0.92 (0.19-4.53) - 
   Yes 163 3 (1.8) 1.00 - 50 2 (4.0) 1.00 - 
Among ART-naïve:          
Baseline CD4+ count (cells/mm3) †          
   <200 15 0 (0.0) - - 2 0 (0.0) - - 
   200-350 55 2 (3.6) 1.18 (0.19-7.30) - 23 2 (8.7) 1.12 (0.18-7.00) - 
   351-500 76 5 (6.6) 1.54 (0.37-6.40) - 43 5 (11.6) 1.55 (0.37-6.43) - 
   >500 88 4 (4.6) 1.00 - 53 4 (7.6) 1.00 - 
Stable high CD4+ (≥500 cells/mm3)‡*         
   No 124 8 (6.5) 1.23 (0.24-6.37) - 78 8 (10.3) 1.23 (0.24-6.37) - 
   Yes 54 2 (3.7) 1.00 - 23 2 (8.7) 1.00 - 
Adjusted Odds Ratio (aOR):  1Model 1 : In BF, associations with CIN2+ incidence were adjusted for cervical ectopy; and in SA, associations were adjusted for injectable contraception and cervicitis; 2Model 2: 
same as Model 1 with additional adjustment for baseline CD4+ ; 3too few cases to allow for greater number of CD4+ groups as per previous tables; §CD4+ count was unavailable for 1 participant on ART in BF; 
†HIV-1 PVL data was unavailable for 29 ART users in BF and 4 in SA;* There were no incidence CIN2/3 among ART-naive in BF, hence the association when combining sites is the same as that in SA.  
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Table 7.8.  Summary of HIV-related risk factors observed among WLHIV in Burkina Faso (BF) and South Africa (SA) 
Risk factor Outcome Effect Effect estimate (95% CI) Country 
observed 
     
HIV-related factors      
CD4+ count HR-HPV Prevalence Compared to women with CD4+ >500 cells/mm3, women with CD4+ <200 cells/mm3 had higher 
prevalence of HR-HPV  
aPR 1.38 (1.15-1.66) BF 
 aPR 1.14 (1.01-1.30) SA 
HR-HPV Incidence Compared to women with CD4+ >500 cells/mm3, women with CD4+ <200 cells/mm3 had higher 
incidence of HR-HPV 
aPR 1.61 (1.24-2.09) SA 
HR-HPV Persistence Compared to women with CD4+ >500 cells/mm3, women with CD4+ <200 cells/mm3 had higher 
persistence of HR-HPV  
aOR 1.81 (1.10-2.99) BF 
HR-HPV complete clearance Compared to women with CD4+ >500 cells/mm3, women with CD4+ <200 cells/mm3 had 
decreased likelihood of complete clearance of HR-HPV  
aPR 0.33 (0.11-1.96) SA 
CIN2+ Prevalence Compared to women with CD4+ >500 cells/mm3, women with CD4+ <200 cells/mm3 had higher 
prevalence of CIN2+  
aOR 2.99 (1.05-8.58) BF 
 Compared to women with CD4+ >500 cells/mm3, women with CD4+ <200 cells/mm3 had higher 
prevalence of CIN2+  
aOR 3.39 (1.70-6.75) SA 
CIN2+ Incidence* Compared to women with CD4+ >350 cells/mm3, women with CD4+ ≤350 cells/mm3 had higher 
incidence of CIN2+  
aOR 5.80 (0.93-36.19) BF 
ART  HR-HPV Prevalence Compared to long-duration ART users (>2 years), women with short-duration ART use (≤2 years) 
had higher prevalence of HR-HPV 
aPR 1.21 (1.03-1.44) BF 
HR-HPV Persistence Compared to long-duration ART users (>2 years), women with short-duration ART use (≤2 years) 
had higher persistence of HR-HPV 
aOR 1.75 (1.17-2.64) SA 
 Compared to long-duration ART users (>2 years), women not taking ART had higher persistence 
of HR-HPV 
aOR 1.80 (1.21-2.66) BF 
HR-HPV complete clearance Compared to long-duration ART users (>2 years), women not taking ART had decreased 
likelihood of complete clearance of HR-HPV 
aPR 0.65 (0.42-0.99) SA 
CIN2+ Prevalence Compared to long-duration ART users (>2 years), women with short-duration ART use (≤2 years) 
had higher persistence of HR-HPV 
aOR 1.81 (1.03-3.17) SA 
 Compared to long-duration ART users (>2 years), women not taking ART had higher persistence 
of HR-HPV 
aOR 1.78 (1.06-2.99) SA 
CIN2+ Incidence* Compared to women taking ART, women not taking ART at endline had higher CIN2+ incidence aOR 2.00 (0.80-5.04) SA 
HIV-1 suppression HR-HPV Persistence Compared to women with HIV-1 viral suppression (<1000 copies/ml), women with lack of HIV-1 
viral suppression had higher persistence of HR-HPV 
aOR 3.35 (1.85-6.04) SA 
HIV-1 viral detection HR-HPV Persistence Compared to women with undetectable HIV-1 viral load (≤40 copies/ml), women with 
detectable HIV-1 had higher persistence of HR-HPV 
aOR 1.56 (1.01-2.42) BF 
* signifies associations that were not significant 
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Figure 7.1. HIV-related risk factors associated with HR-HPV and CIN2+ outcomes in Burkina Faso and South Africa 
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8 ASSOCIATIONS OF HPV GENOTYPES WITH CIN2+ 
 
WLHIV have been shown to be more commonly infected with types other than HPV16 or 18 [415] and 
their high-grade cytological lesions are frequently attributed to types other than HPV16/18 [13].  
Primary prevention of HPV infection through vaccination could reduce the burden of infection and 
disease and on screening and treatment services. Current bivalent and quadrivalent HPV vaccines 
target two HR types (HPV16 and 18) responsible for about 70% of cervical cancers [37], whereas the 
nonavalent vaccine which protects against a wider range of HR-HPV types (HPV16/18/31/33/45/52/58), is 
estimated to prevent up to 90% of cervical cancers in women from the general population [37, 416]. 
These potential benefits have seldom been estimated among WLHIV, particularly in sub-Saharan 
Africa. An improved understanding of HPV type distribution associated with histological lesions in this 
population is needed to guide HPV vaccine programme decisions.   In this chapter, I describe (i) the 
prevalence, persistence, incidence and genotype distribution of HPV, and (ii) their association with 
prevalent and incident CIN2+. 
8.1 Objectives 
In a cohort of WLHIV in Burkina Faso and South Africa at enrolment:  
 To describe the prevalence of individual genotypes;  (Objective 3.1) 
 To assess the associations of prevalent HPV genotypes with prevalent 
CIN2+. 
(Objective 3.2) 
 
In a cohort of WLHIV with ≤CIN1 at enrolment and followed over 18 months;  
 To describe the incidence and persistence of individual genotypes;  (Objective 3.1) 
 To assess the associations of persistent HPV genotypes with incident 
CIN2+. 
(Objective 3.2) 
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 To evaluate the association of individual HPV genotype prevalence with 
HIV-related risk factors. 
(Objective 3.3) 
 
8.2 Methods 
8.2.1 Statistical analysis 
A full description of the HARP procedures is provided in Chapter 5, section 5.2. Specific statistical 
methods for univariate and multivariate risk factor analysis are detailed here.  
Definition of HPV infection status at baseline and endline 
Definitions for HR-HPV prevalence, incidence, persistence and clearance are provided in Chapter 5, 
section 5.3. HPV groupings (alpha-9 and alpha-7 types, and HPV vaccine types) are defined in Table 
5.1 and definition of HPV infection status are defined in Table 5.2, but in brief:  
 Cumulative incidence of any HR-HPV was defined as the proportion of women who were 
negative for a specific type at baseline and positive for that type at endline visit (outcome 
group 1 of Table 5.2). 
 HR-HPV genotype-specific persistence was defined as being positive for the same HR-HPV 
type at baseline and endline visits (outcome group 4).  
 Any type clearance was defined as being positive for a specific HR type at baseline and 
negative for that type at endline visit (outcome group 6).  
Association of prevalent CIN2+ with prevalent HPV gentypes, and incident CIN2+ with persistent HPV 
genotypes.  
Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) for 
associations of prevalent and incident CIN2+ with individual HR-HPV types. These associations were 
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adjused for other co-factors found to be associated with CIN2+ in this study, as described in 
Chapter 7, Table 7.1.  
Association of ART and CD4+ count with prevalent HPV genotypes at baseline  
As HR-HPV prevalence was common, associations with HIV-related variables were estimated with 
PRs obtained from logistic regression using marginal standardization to estimate PRs, and the 
delta method to estimate 95% CI [379]. 
 
8.3 Results 
8.3.1 Prevalence of HPV genotypes and association with CIN2+ at baseline 
Of the 1238 participants enrolled, 1215 (98.1%) had valid HPV genotyping results (BF: 96.6%; SA: 
99.7%) and 998 (82.1%) were positive for any HPV (BF: 75.3%; SA: 88.7%). As described in Chapter 6, 
HR-HPV prevalence was lower in BF (BF: 59.1%, 95%CI: 55.0-63.1 vs. SA: 79.1%, 95%CI: 75.7-82.2; 
p<0.001; result provided again here in Table 8.1), as was the proportion of women with multiple 
HR-HPV genotypes (BF: 41.9% vs. SA: 55.2%; p<0.001). HPV52 was the most prevalent type in both 
countries (BF: 20.4%; SA: 24.2%). HPV16/18 were detected in 15.0% of participants in BF vs. 29.0% in 
SA (p<0.001). Among those without infection with either HPV16 or HPV18,  the proportion infected 
by any of the additional HR types included in the nonavalent vaccine (HPV31/33/45/52/58) was 30.1% 
in BF and 36.7% in SA (p<0.001). The prevalence of any of the non-vaccine HR types 
(HPV35/39/51/56/59/68) was 35.5% in BF and 49.1% in SA (p<0.001) irrespective of co-infection with 
any of the vaccine types, and was 14.0% in BF and 13.4% in SA among those not co-infected by any 
vaccine types.  
Overall, 1128 (91.1%) participants had valid histology results at enrolment. CIN2+ prevalence was 
5.8% (32/554) in BF (95%CI: 4.0-8.1%) and 22.5% (129/574) in SA (95%CI: 19.1-26.1%). Among women 
with both histology and HPV results (BF: 546; SA: 573), the prevalence of HR-HPV was higher 
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among those with higher CIN grades in both settings (BF: 48.4% in CIN normal, 71.8% in CIN1, 100% 
in CIN2 and 100% in CIN3+, p<0.001; SA: 72.4% in CIN normal, 81.4% in CIN1, 89.5% in CIN2 and 92.5% 
in CIN3+, p<0.001;) (Figure 8.1 and Figure 8.2). The prevalence of any HR-HPV genotypes included 
in the bi/quadrivalent and nonavalent HPV vaccines was 45.2% and 90.3% among women with CIN2+ 
in BF, respectively, and 37.2% and 79.8% in SA, respectively. In the absence of any vaccine types, the 
prevalence of any non-vaccine types was 9.7% (3/31) in BF and 10.9% (14/129) in SA.  
In both countries, HPV58 was the genotype most strongly associated with CIN2 compared to ≤CIN1 
cases (adjusted Odds Ratio [aOR]=5.40, 95%CI: 2.77-10.53), while types most strongly associated 
with CIN3+ were HPV16 in BF (aOR=34.56, 95%CI: 5.70-209.49) and HPV58 in SA (aOR=3.65, 95%CI: 
1.42-9.37) (Figure 8.3; Figure 8.4 and Table 8.2). The prevalence of HPV58 was 22.1% and 21.1% 
among women with CIN2 in BF and SA respectively, and 23.1% and 15.1% among women with CIN3+.  
The prevalence of CIN2+ was significantly higher among those positive for HPV16/18 compared to 
those who were negative for both types in BF (17.7% vs. 3.6%; aOR=7.90, 95%CI: 3.23-19.33) and in 
SA (29.1% vs. 19.9%, aOR=1.49, 95%CI: 0.95-2.34), although the latter was not statistically significant 
(Table 8.2).  Among 875 women without co-infection of either HPV16 or 18, the prevalence of CIN2+ 
was higher among women positive for any of the additional HR-HPV types targeted by the 
nonavalent vaccine (31/33/45/52/58) compared to women negative for all of these types in both 
countries (BF: 8.8% vs. 1.0%; SA: 25.2% vs. 13.7%; aOR=2.78, 95%CI: 1.67-4.64 for both countries 
combined). The prevalence of CIN2+ was similar among women who were positive or negative for 
any of the non-vaccine HR-HPV types. However, among 498 women without infection with vaccine 
types (BF: 308, SA: 190), the prevalence of CIN2+ was higher among women positive for any of the 
non-vaccine types compared to women who were HR-HPV negative (11.1% vs. 3.4%; aOR=3.35, 
95%CI: 1.36-8.26).  
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8.3.2 Incidence and persistence of HR-HPV genotypes at endline 
Of the 963 women without CIN2+ at enrolment who returned at follow-up M18 visit (median of 
actual follow-up 16 months [IQR, 15.6-16.8]), genotyping data at both visits was available for 922 
(95.7%) women. The proportion of women with an incident HR-HPV infection was similar in both 
sites (BF: 47.9% [228/476] vs. SA: 49.3% [220/446]; p=0.67). Type-specific incident infection was 
highest for HPV52 in both countries (BF: 12.7%; SA: 16.6%). Incident infection of HPV16/18 was 
observed in 14.6% of women in BF and 14.7% in SA. In the absence of HPV16/18 co-infection, incident 
infection of any of the additional HR-HPV types of the nonavalent vaccine was observed in 19.7% of 
women in BF and 23.9% in SA; incident infection of non-vaccine HR-HPV types in the absence of 
vaccine type co-infection was observed in 14.0% in BF and 13.5% in SA (Table 8.1).  
Persistence of any HR-HPV was more frequent in BF than SA (BF: 51.5% [139/270] vs. SA: 44.7% 
[152/340]; p=0.10) (Table 8.1). Persistence was highest for HPV58 (72.2%) in BF and HPV35 (42.6%) 
in SA. Forty-nine women (18.2%) in BF and 80 (23.5%) in SA had at least one persistent and one 
cleared infection during the 16 months follow-up period. 
8.3.3 Association of incident CIN2/3 with HR-HPV persistence at endline 
Among 922 women with genotyping data at both visits, concomitant histology results were 
available for 780 (84.6%) women (BF: 405; SA: 375). The cumulative incidence of CIN2+ over 16 
months was 1.2% (5/405) in BF and 5.9% (22/375) in SA (p=0.001). Cumulative incidence of CIN2+ was 
higher among those with HR-HPV persistence compared to those who cleared or who were HR-
HPV negative at baseline in both settings (BF: 3.5% vs. 0.3%; SA: 13.4% vs. 2.0%; both countries 
combined aOR=7.90, 95%CI: 3.11-20.07, Table 8.3).   
CIN2+ incidence was found to be significantly associated with the persistence of any members of 
the alpha-9 HPV (HPV16-related) and any alpha-7 HPV (HPV-18 related) genotypes in both countries 
(Table 8.3). In particular, CIN2+ incidence was higher among women with persistent HPV16/18 
214 
 
 
compared to those who cleared either of those types, or who were negative for both at baseline 
(BF: 7.7% vs. 0.8%; SA: 18.2% vs. 4.7%; both sites combined: aOR=5.25, 95%CI: 2.14-12.91).  
Among 721 women without persistent HPV16 or 18, CIN2+ incidence was higher among those with 
persistence of any of the additional 5 HR-HPV included in the nonavalent (both sites combined: 
6.1% vs. 2.0% aOR=3.23, 95%CI: 1.23-8.54). In the absence of co-persistence by any of the vaccine 
types (606 women), CIN2+ incidence was higher among women with persistent non-vaccine types 
compared to those who cleared or who were HR-HPV negative at baseline in both settings (8.8% 
vs. 1.1%; aOR=7.87, 95%CI: 2.40-25.81). 
8.3.4 HR-HPV persistence and CIN2/3 persistence at endline  
Among the 36 women in SA with prevalent CIN2/3 at baseline and who remained untreated before 
endline visit, any type HR-HPV persistence was highest among those with persistent CIN2/3 at 
endline (79.0%; 15/19) but lower among those that had spontaneous regression to ≤CIN1 (42.9%; 
6/14). The small number of cases percluded genotype-specific analysis.  
8.3.5 Association of HIV-related factors with HR-HPV prevalence at baseline  
The prevalence of HR-HPV types was similar among ART users and ART-naive participants at 
baseline in BF, whilst in SA, the prevalence of HPV16/18 was higher among ART-naïve participants 
(Table 8.4, Table 8.5).  Among ART users in BF, the prevalence of any nonavalent HR-HPV in the 
absence of HPV16/18 was higher among women with low CD4+ count (<200 cells/mm3) compared 
to those with high CD4+ count (>500 cells/mm3) and this association was significant among ART 
users only, however no association was observed for HPV16/18 or the non-vaccine types. In SA, only 
the prevalence of non-vaccine HR-HPV was higher among ART-taking women with low CD4+ cell 
count (Table 8.5).   
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8.4 Discussion 
Women living with HIV (WLHIV) in Burkina Faso and South Africa have a high prevalence, incidence 
and persistence of HR-HPV, and a high prevalence and persistence of multiple genotypes. While 
HR-HPV prevalence was higher in South Africa at baseline, HR-HPV persistence was higher among 
women in Burkina Faso. This may be due to the fact that estimates of HR-HPV persistence were 
restricted to women without evidence of CIN2+ at baseline, who underwent treatment. As there 
was a higher prevalence of CIN2+ at baseline in South Africa, their exclusion from the follow-up 
analysis potentially reduced the overall proportion of women with persistent infection at endline. 
By contrast, because of the lower prevalence of CIN2+ in Burkina Faso at baseline, fewer women 
were excluded in the follow-up analysis, which potentially allowed a greater number of persistent 
HR-HPV cases to accrue during the follow-up period. In addition, we cannot exclude the possibility 
that the 4-quadrant biopsy may have helped clear HR-HPV from the cervical epithelium, as a greater 
proportion of women in South Africa underwent a 4-quadrant biopsy (97% in South Africa vs. 60% 
in Burkina Faso).  
HPV52 was the type most frequently detected overall in both countries, but HPV58 was the type 
most strongly associated with cervical lesions, and one of the most likely to persist in both 
countries. The difference in the distribution profiles between BF and SA were further explored by 
assessing the prevalence of HPV types among HR-HPV positive women, thereby comparing the 
two HPV profiles adjusting for the overall higher prevalence in SA.  There were four HPV types 
which appeared more prevalent in SA: HPV16, 18, 33 and 56. The higher prevalence of CIN2 in 
SA may be partially explained by the higher prevalence of HPV33 in SA given the strength of 
association of this type with CIN2 (Table 8.2); and the higher prevalence of CIN3 in SA may be 
partially explained by the higher prevalence of HPV16 in SA. However, there are other cofactors 
that explain the higher CIN2 and CIN3 in SA, including the higher frequency of other STI, injectable 
contraception, and HIV-related factors, which have been further discussed in Chapters 6 and 7.  
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In a meta-analysis describing HPV type distribution among 5578 WLHIV from 20 studies including 5 
from African countries, HPV16, 18 and 58 were the most prevalent among those with cytological 
HSIL+ [417]. Additionally, WLHIV with HSIL+ were less likely to harbour HPV16 compared to those 
with HSIL in the general population, and more likely to be infected with HPV18/33/51/52/58 [418]. 
The high prevalence of types other than HPV16 and HPV18 among WLHIV in this study is similar to 
what has been reported in a study among WLHIV in Belgium, 80% of whom were of African origin  
[415].   
This study found that up to 45% of CIN2/3 in BF and 37% of CIN2/3 in SA could be prevented by 
the HPV16/18-targeting vaccines, and that a further 45% of CIN2/3 in BF and 43% of CIN2/3 in SA could 
be prevented by the additional 5 types (HPV31/33/45/51/52) contained in the nonavalent vaccine, 
similar to studies in the general population [416, 419]. However, not all CIN2/3 develop into ICC, 
and not all HPV types found in CIN2 have the same propensity to evolve towards ICC. Clifford et al, 
in their systematic review comparing the HPV type distribution in ICC biopsy and 
cervical specimens of 770 HIV-positive women from 21 studies in 12 African countries [14], report a 
higher pooled prevalence of HPV16/18 (61.7%) than found in this study, whilst the prevalence of the 
other nonavalent vaccine types was 11.2%, lower than what we report in our study. These findings 
indicate that the relative contribution of HPV16/18 increases with increasing lesion grade, 
whilst the contribution of the additional nonavalent vaccine types still represents a 
significant preventable fraction of ICC.  
This study also shows that the persistence of any of the bi/quadrivalent and nonavalent HR-HPV 
types is strongly associated with the incidence of cervical lesions among WLHIV, as is the case for 
HIV uninfected women [5]. Moreover, this study found a significant proportion of women had an 
incident infection with any of the nonavalent vaccine types (35%) as well as incident infection of 
multiple HR-HPV types over the 16-month follow-up period. This emphasises the potential impact 
of vaccination in this population using an HPV vaccine with a broader-range protection potential, 
given that these types are also likely to persist in this population [167].  
217 
 
 
A smaller but non-negligible proportion (11%) of women with CIN2+ were exclusively infected by 
non-vaccine types at enrolment. In addition, the persistence of non-vaccine types in the absence 
of current vaccine types, was also strongly associated with incident CIN2+, and this was largely 
driven by persistence of HPV35 and 56. It cannot be ruled out that the CIN2+ lesions in this study 
could be attributed to other HPV genotypes which were undetected in the cervical samples, but 
which could be localised in the biopsy tissue. However, a large retrospective cross-sectional study 
using histologically conformed ICC collected from 38 countries worldwide reported that 7% of 
WLHIV with ICC were infected with non-vaccine types in the absence of any of the vaccine types, 
and this was highest for HPV35 [37]. Until further generation vaccines incorporate a wider range 
of HPV types, cervical screening will remain important among WLHIV where non-vaccine types are 
prevalent.  
ART-naïve women were at increased risk of HPV16 or 18 infection in South Africa at baseline. 
Among ART users, a decrease in CD4+ cell count was also associated with an increased risk of any 
of the nonavalent other than HPV16/18 and the non-vaccine type prevalence in Burkina Faso, and 
of the non-vaccine types in South Africa. Given that women on ART in South Africa were less likely 
to control HIV (measured by level of detectable HIV-1 PVL and ART adherence), this may have 
accounted for the persistence of non-vaccine types, such as HPV35, and their association with 
CIN2/3 among women in South Africa. 
However, there was no reduction in HPV16 or 18 prevalence with increasing CD4+ cell counts in 
either country. This is consistent with previous reports suggesting that HPV16 might be more 
weakly associated with immune suppression than other HR types due to its potential to evade the 
host immune response, thus explaining its greater contribution to high-grade lesions and cancer in 
immunocompetent women [420]. However, these associations may also be  reflective of the 
overall increased risk of any HR-HPV prevalence among those with low CD4+ cell count, as reported 
in Chapter 7 [291]. 
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Given that the bi/quadrivalent and nonavalent types are the most important contributors to 
cervical lesions in this population, maintaining a stable high CD4+ cell count is necessary to reduce 
the risks of HR-HPV persistence and cervical lesion development. This should be achieved by early 
initiation of ART before CD4+ cell counts decline and maintaining good HIV-1 virological control 
thereafter. In addition, HPV vaccination could be offered to these women before CD4+ cell counts 
decline.  
In conclusion, this study confirms that HR-HPV infection and cervical lesions are very common 
among WLHIV in Africa, and that a broader range of genotypes are potentially associated with 
CIN2+ development. While currently available bi/quadrivalent vaccines could prevent up to 45% 
(95%CI: 27.3-64.0) of treatable precursor lesions in BF and 37% (95%CI: 28.8-46.2) in SA, the 
nonavalent vaccine has the potential to prevent up to 90% (95%CI: 74.2-98.0) and 80% (95%CI: 71.9-
86.4) of cases in WLHIV in BF and SA, respectively. HPV vaccination could reduce the incidence of 
HR-HPV related disease among WLHIV in addition to contributing cost saving to current screening 
and treatment programmes, but this would require a formal health economic evaluation. 
 
8.5 Study limitations 
As stated in previous chapters, the definition of cumulative HR-HPV incidence over 16 months is of 
limited duration to assess the actual roles of HR-HPV incidence and persistence on CIN2+ incidence.  
The study could not rule out type-specific clearance and reinfection when estimating persistence 
during the 16-months interval between HPV testing.  Longer duration of follow-up would have 
allowed to accrue a larger number of incident CIN2+ cases and more robustly assess the role of 
incident HR-HPV on CIN development over sufficient follow-up time.  
HPV genotyping was measured in cervical swabs and not from the biopsies. This can preclude 
accurate attribution of CIN to individual genotypes, particularly when the co-existence of multiple 
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HR-HPV types was common. Other studies have accurately attributed individual HPV genotypes to 
specific CIN lesions using laser capture microdissection technique from biopsy tissue [421]. 
While HPV18 was found to be marginally associated with CIN2+ in BF (aOR=2.81, 95%CI: 0.83-9.44), 
the opposite was observed in SA (aOR=0.53, 95%CI: 0.27-1.05), however for both sites, those 
associations were not found to be significant, in part because of the small number of cases 
involved. HPV18 is a well-known contributor to CIN2 or CIN3 in many other studies [35]and it can 
only be speculated this was a spurious finding. In the longitudinal analyses, persistent HPV18 was 
found to be associated with incident CIN2/3, which supports its role in CIN2/3 development among 
WLHIV. 
Approximately 10% of prevalent CIN2+ cases in SA were HR-HPV negative by INNO-LiPA at baseline. 
It is not uncommon to find patients with CIN2+ being HR-HPV negative, and in most studies among 
CIN2+ and ICC cases, the prevalence of HR-HPV does not reach 100%. In their systematic review 
comparing the HPV type distribution in ICC biopsy and cervical cell specimens of 770 HIV-positive 
women from 21 studies in 12 African countries [14], Clifford et al report that prevalence of any HPV 
was 89% in biopsy samples and 95% in cervical samples. Moreover, in their review of 10,575 biopsies 
of invasive cervical cancer from around the world, De SanJose et al [37] found that only 85% were 
positive for ANY HPV. Similarly, in a subanalysis of a large cervical cancer screening study 
(ATHENA), among 497 cases of CIN2+, 55 (11%) tested negative by Cobas HPV test and 12 (2.4%) 
were negative by all HPV tests (Cobas, Amplicor and Linear Array) [422]. In this analysis, 4.7% (6/129) 
participants with CIN2+ in SA were negative for any HPV and 10.2% (12/129) were negative for any 
HR-HPV. Thus this finding of 5% of cervical samples being negative for any HPV is not dissimilar to 
these large international studies. It is not expected that this finding has obliterated the ability to 
find associations with CIN2/3 in SA compared to BF, given in part to the large number of CIN2/3 
cases in SA. Furthermore, the Study Endpoint Committee undertook an extensive review of all 
220 
 
 
cases of CIN2 and final classification was based on consensus of a minimum of 5 experts in order 
to minimize (but never can eliminate) the risk of misclassification. 
This study could not explore the association of HPV genotypes with ICC, as the majority of cases 
were CIN2/3. The contribution of individual HPV types to precursor lesions (CIN2 in particular) may 
not translate into a role in cervical cancer. However, it is still important to know the contribution 
of certain types to treatable lesions (CIN2 and CIN3), as vaccination against such types could have 
an impact on colposcopy referrals and management services.   
There was a higher number of multiple biopsies taken among women in SA because they were 
more frequently positive for screening tests, particularly HPV DNA, and it is possible that this may 
have led to clearance of undetected lesions between baseline and endline, which may harbour HR-
HPV. While there are no known studies which have reported clearance of HR-HPV following cervical 
biopsy, other have reported HPV clearance following excision of cervical lesions [423]. However, 
the biopsies taken in the HARP study were small (2mm) and a direct comparison of biopsy tissue 
with excisional treatment which involves a larger and deeper tissue section may not be 
appropriate– although this hypothesis cannot be ruled out.  
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8.6 Summary of findings 
 At baseline, the prevalence of HR-HPV was 59.1% in BF and 79.1% in in SA; and the 
prevalence of multiple genotypes was 41.9% in BF and 55.2% in SA.  
 HPV52 was the most prevalent genotype in both countries, but HPV58 was most strongly 
associated with CIN2+ (aOR=5.40, 95%CI: 2.77-10.53).  
 Among women with CIN2+, the prevalence of any HR-HPV genotypes included in the 
bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines ranged 
from 37% to 90%, while approximately 10% of CIN2+ cases were infected with non-vaccine 
types only. 
 At endline, HR-HPV persistence was 51.5% in BF and 44.7% in SA; CIN2+ incidence was 1.2% 
in 405 women in BF and 5.9% in 375 women in SA.  
 Persistence was highest for HPV58 (72.2%) in BF and HPV35 (42.6%) in SA.  
 Persistence of any HR-HPV was strongly associated with incident CIN2+ (aOR=7.90, 
95%CI: 3.11-20.07), as was persistence of HPV16/18 (aOR=5.25, 95%CI: 2.14-12.91) and the 
additional HR types in the nonavalent vaccine (aOR=3.23, 95%CI: 1.23-8.54).   
 
Conclusion:  HR-HPV persistence is very common among African WLHIV and is linked to incident 
CIN2+. HPV vaccines could prevent between 37-90% of CIN2+ among African WLHIV. Cervical 
cancer screening will continue to remain important as there remains a proportion of CIN2/3 cases 
that may not be preventable by currently available vaccines. 
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8.7 Findings in context 
A recent systematic review (Clifford et al, [14]) compared the HPV type distribution and the HPV 
vaccine type distribution in ICC biopsy and cervical cell specimens of 770 HIV-positive and 3846 HIV-
negative women from 21 studies in 12 African countries. The authors report that the fraction of ICC 
attributable to the HPV types included in the current bivalent (HPV16/18) and nonavalent 
(HPV16/18/31/33/45/52/58) vaccines was similar among HIV-positive and HIV-negative women 
(bivalent: 61.7% and 67.3%; nonavalent: 88.9% and 89.5%, respectively). However, a non-negligible 
proportion of ICC from both HIV-positive and HIV-negative women were infected with non-vaccine 
types in the absence of any of the vaccine types (7.0% and 7.9% of ICC from HIV-positive and HIV-
negative women, respectively), and this was highest for HPV35.  
The findings in this study also show that HPV16/18 are highly prevalent in CIN2/3 and there is 
proportion of CIN2/3 infected with nonvalent types, in the absence of HPV16/18, and a proportion 
of CIN2/3 infected exclusively with non-vaccine types, especially with HPV35.   
Primary prevention of HPV infection through vaccination could reduce HPV infection and HPV-
related disease in Africa among WLHIV. However, cervical cancer screening will continue to remain 
important as there remains a proportion of ICC cases that may not be preventable by currently 
available vaccines.  
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Figure 8.1. HR-HPV prevalence by CIN grade among 546 women living with HIV in Burkina Faso 
 
 
Figure 8.2. HR-HPV prevalence by CIN grade among 573 women living with HIV in South Africa 
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Figure 8.3. Association of HR-HPV prevalence with prevalent CIN2 and CIN3+ among 546 women 
living with HIV in Burkina Faso 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adjusted for age, cervical ectopy, bacterial vaginosis, CD4+ count and ART duration. 
 
Figure 8.4. Association of HR-HPV prevalence with prevalent CIN2 and CIN3+ among 573 women 
living with HIV in South Africa 
 
 
 
 
 
 
 
 
 
 
  
*Adjusted for injectable contraception, cervicitis, CD4+ count and ART duration
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Table 8.1. HR-HPV infection at baseline and endline follow-up among women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA)   
 HPV Prevalence HPV Incidence HPV Persistence 
 BF SA BF SA BF SA 
 N=594 N=621 At riska Incidence At riska Incidence Positive at M0 Persistence Positive at M0 Persistence 
 n (%) n (%) N n (%) N n (%) N n (%) N n (%) 
Any HR typesb 351 (59.1) 491 (79.1) 476 228 (47.9) 446 220 (49.3) 270 139 (51.5) 340 152 (44.7) 
           
Any alpha-9  264 (44.4) 392 (63.1) 476 152 (31.9) 446 154 (34.5) 198 98 (49.5) 260 99 (38.1) 
HPV16 51 (8.6) 119 (19.2) 445 43 (9.7) 377 49 (13.0) 31 17 (54.8) 69 23 (33.3) 
HPV31 47 (7.9) 65 (10.5) 445 44 (9.9) 404 22 (5.5) 31 19 (61.3) 42 6 (14.3) 
HPV33 19 (3.2) 51 (8.2) 464 8 (1.7) 419 17 (4.1) 12 3 (25.0) 27 4 (14.8) 
HPV35 62 (10.4) 103 (16.6) 429 24 (5.6) 385 34 (8.8) 47 18 (38.3) 61 26 (42.6) 
HPV52 121 (20.4) 150 (24.2) 378 48 (12.7) 337 56 (16.6) 98 37 (37.8) 109 39 (35.8) 
HPV58 27 (4.6) 55 (8.9) 458 15 (3.3) 417 14 (3.4) 18 13 (72.2) 29 11 (37.9) 
           
Any alpha-7  117 (19.7) 198 (31.9) 476 117 (24.6) 446 122 (27.4) 89 37 (41.6) 145 46 (31.7) 
HPV18 42 (7.1) 90 (14.5) 445 29 (6.5) 378 18 (4.8) 31 17 (54.8) 68 24 (35.3) 
HPV39 43 (7.2) 50 (8.1) 442 24 (5.4) 408 25 (6.1) 34 7 (20.6) 38 8 (21.1) 
HPV45 26 (4.4) 48 (7.7) 457 12 (2.6) 415 22 (5.3) 19 11 (57.9) 31 11 (35.5) 
HPV59 6 (1.0) 12 (1.9) 473 4 (0.9) 436 5 (1.2) 3 0 (0.0) 10 2 (20.0) 
HPV68 23 (3.9) 35 (5.6) 457 24 (5.3) 424 28 (6.6) 19 3 (15.8) 22 4 (18.2) 
           
Alpha-5 and -6          
HPV51 70 (11.8) 97 (15.6) 423 30 (7.1) 378 22 (5.8) 53 15 (28.3) 68 18 (26.5) 
HPV56 25 (4.2) 60 (9.7) 456 45 (9.9) 408 16 (3.9) 20 11 (55.0) 38 9 (23.7) 
           
Combinations           
HPV16/18 89 (15.0) 180 (29.0) 473 69 (14.6) 422 62 (14.7) 59 33 (55.9) 113 45 (39.8) 
Other 9vHPVc  179 (30.1)  228 (36.7) 473 93 (19.7) 422 101 (23.9) 155 70 (42.5) 198 61 (30.8) 
Any 9vHPV HRd 268 (45.1) 408 (65.7) 476 162 (34.0) 446 163 (36.6) 200 103 (51.5) 275 106 (38.6) 
Non-Vaccinee 83 (14.0) 83 (13.4) 473 66 (14.0) 422 57 (13.5) 112 36 (32.1) 141 46 (32.6) 
Multiple HRf 147/351 (41.9) 271/491 (55.2) 228 81 (35.5) 220  79 (35.9) 270 27/139 (19.4) 340 27/152 (17.8) 
           
Low risk types          
HPV6 34 (5.7) 33 (5.3) 450 22 (4.9) 422 13 (3.1) 26 6 (23.1) 24 2 (8.3) 
HPV11 9 (1.5) 33 (5.3) 470 3 (0.6) 420 15 (3.6) 6 1 (16.7) 26 4 (15.4) 
anegative for that HPV type at enrolment (3 participants in BF with positive 16 AND 18 at enrolment, and 24 in SA; no participant was infected by ALL nonavalent HR types or ALL non vaccine types; bAny HR-HPV type prevalence defined as 
positive for at least one HR type at baseline; any HR incidence defined as incident infection from at least  one HR type among those at risk for any HR infection (no participant was infected by all HR types at baseline); persistence defined as 
persistence of at least one HR type among those positive for any HR type at baseline; cOther 9vHPV=Positive for any of HPV31/33/45/52/ 58 in absence of HPV16/18; d9vHPV HR=Positive for any of HPV16/18/31/33/45/52/58; eNon Vaccine=Positive 
for any of HPV35/39/51/56/59/68 in absence of any vaccine type.; fCalculated among those positive for any HR type.  
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Table 8.2. Association of HPV type prevalence with prevalent CIN2 and CIN3+ among 546 women living with HIV in Burkina Faso and 573 in South Africa 
 
Burkina Faso South Africa 
 
CIN2 
(n=18) 
CIN3+ 
(n=13) 
CIN2+ 
(n-31) 
CIN2 
(n=76) 
CIN3+ 
(n=53) 
CIN2+ 
(n=129) 
 
HPV 
negative 
HPV 
positive aOR (95% CI )a 
HPV 
negative 
HPV 
positive aOR (95% CI )a aOR (95% CI )a 
HPV 
negative 
HPV 
positive aOR (95% CI )b 
HPV 
negative 
HPV 
positive aOR (95% CI )b aOR (95% CI )b 
 n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%) 
Any HR-HPV 0 (0.0) 18 (6.0) (-) 0 (0.0) 13 (4.4) (-) (-) 8 (7.0) 68 (16.8) 2.25 (1.02-4.95) 4 (3.6) 49 (12.7) 3.32 (1.15-9.63) 2.64 (1.37-5.07) 
 
              
Any alpha-9  1 (0.3) 17 (7.6) 24.72 (3.18-192.26) 1 (0.3) 12 (5.5) 15.84 (1.81-138.49) 19.89 (4.51-87.84) 16 (8.0) 60 (18.8) 2.81 (1.50-5.24)) 8 (4.2) 45 (14.8) 4.61 (1.97-10.76) 3.36 (1.99-5.66) 
HPV16 13 (2.6) 5 (13.2) 7.48 (2.22-25.27) 7 (1.4) 6 (15.4) 34.56 (5.70-209.49) 10.82 (4.03-29.06) 59 (13.6) 17 (19.5) 1.49 (0.78-2.85) 33 (8.1) 20 (22.2) 3.48 (1.78-6.80) 2.06 (1.25-3.39) 
HPV31 15 (3.0) 3 (7.5) 2.47 (0.63-9.72) 11 (2.3) 2 (5.1) 2.03 (0.28-14.55) 2.27 (0.71-7.26) 68 (14.4) 8 (16.3) 0.90 (0.35-2.32) 41 (9.2) 12 (22.6) 2.81 (1.28-6.14) 1.63 (0.85-3.11) 
HPV33 15 (2.9) 3 (20.0) 4.96 (0.87-28.47) 11 (2.1) 2 (14.3) 1.73 (0.20-15.23) 3.15 (0.76-13.06) 60 (12.6) 16 (35.6) 3.85 (1.86-7.94) 49 (10.6) 4 (12.1) 0.77 (0.24-2.39) 2.46 (1.29-4.70) 
HPV35 15 (3.1) 3 (5.6) 1.78 (0.45-6.98) 10 (2.1) 3 (5.6) 1.48 (0.25-8.64) 1.55 (0.51-4.70) 58 (13.0) 18 (24.0) 1.98 (1.04-3.77) 35 (8.3) 18 (24.0) 3.39 (1.71-6.71) 2.60 (1.56-4.34) 
HPV52 12 (2.8) 6 (5.6) 2.29 (0.78-6.70) 11 (2.6) 2 (1.9) 1.54 (0.28-8.43) 1.91 (0.76-4.83) 62 (15.7) 14 (11.2) 0.77 (0.40-1.48) 38 (10.2) 15 (11.9) 1.35 (0.68-2.67) 0.97 (0.59-1.59) 
HPV58 14 (2.7) 4 (20.0) 11.83 (2.76-50.75) 10 (2.0) 3 (15.8) 10.49 (1.34-82.44) 10.74 (3.18-36.33) 60 (12.6) 16 (35.6) 4.40 (2.11-9.19) 45 (9.8) 8 (21.6) 3.65 (1.42-9.37) 4.13 (2.16-7.88) 
 
              
Any alpha-7 13 (3.0) 5 (5.1) 1.77 (0.56-5.62) 12 (2.8) 1 (1.1) 0.42 (0.05-3.76) 1.19 (0.43-3.27) 53 (15.3) 23 (13.2) 0.66 (0.37-1.18) 42 (12.5) 11 (6.8) 0.38 (0.18-0.82) 0.55 (0.34-0.89) 
HPV18 15 (3.0) 3 (8.1) 3.64 (0.91-14.63) 12 (2.4) 1 (2.9) 1.63 (0.15-17.26) 2.81 (0.83-9.44) 64 (14.7) 12 (14.5) 0.85 (0.41-1.77) 51 (12.0) 2 (2.7) 0.10 (0.01-0.73) 0.53 (0.27-1.05) 
HPV39 17 (3.4) 1 (2.9) 0.68 (0.08-6.02) 12 (2.4) 1 (2.9) 1.55 (0.16-15.35) 0.90 (0.18-4.45) 71 (14.9) 5 (11.4) 0.76 (0.27-2.08) 50 (11.0) 3 (7.1) 0.65 (0.18-2.28) 0.74 (0.33-1.70) 
HPV45 17 (3.3) 1 (4.6) 2.06 (0.24-17.72) 13 (2.6) 0 (0.0) (-) 1.22 (0.15-10.04) 70 (14.6) 6 (14.6) 0.62 (0.22-1.78) 49 (10.7) 4 (10.3) 0.68 (0.21-2.21) 0.65 (0.28-1.49) 
HPV59 18 (3.4) 0 (0.0) (-) 13 (2.5) 0 (0.0) (-) (-) 76 (14.9) 0 (0.0) (-) 52 (10.7) 1 (8.3) 1.85 (0.20-16.80) 0.50 (0.06-4.16) 
HPV68 18 (3.5) 0 (0.0) (-) 13 (2.6) 0 (0.0) (-) (-) 71 (14.4) 5 (18.5) 1.00 (0.34-2.96) 50 (10.6) 3 (12.0) 0.88 (0.23-3.37) 1.00 (0.40-2.50) 
 
              
HPV51 16 (3.4) 2 (3.5) 1.39 (0.29-6.63) 9 (1.9) 4 (6.7) 8.15 (1.56-42.64) 2.54 (0.87-7.37) 67 (15.2) 9 (11.5) 0.71 (0.32-1.55) 44 (10.5) 9 (11.5) 0.96 (0.42-2.21) 0.78 (0.43-1.44) 
HPV56 17 (3.3) 1 (4.6) 1.63 (0.19-14.07) 13 (2.6) 0 (0.0) (-) 0.90 (0.10-7.85) 69 (14.7) 7 (14.3) 1.10 (0.45-2.68) 45 (10.1) 8 (16.0) 1.37 (0.54-3.50) 1.20 (0.60-2.42) 
 
              
Combinations               
HPV16/18 11 (2.4) 7 (9.7) 5.96 (2.04-17.43) 6 (1.3) 7 (9.7) 20.03 (3.67-109.35) 7.90 (3.23-19.33) 49 (13.0) 27 (18.8) 1.45 (0.83-2.53) 32 (8.9) 21 (15.2) 1.63 (0.86-3.10) 1.49 (0.95-2.34) 
9vHPV 5 HR 1 (0.3) 10(6.5) 22.27 (2.67-185.66) 2 (0.7) 4 (2.7) 2.88 (0.48-17.30) 12.30 (2.88-52.46) 15 (8.4) 34 (17.3) 2.10 (1.05-4.17) 11 (6.3) 21 (11.4) 1.95 (0.88-4.34) 1.98 (1.15-3.42) 
Any 9vHPV 7 
HR 
1 (0.3) 17 (7.5) 27.83 (3.49-221.68) 2 (0.7) 11 (5.0) 10.21 (1.73-60.10) 16.38 (4.43-60.58) 15 (8.4) 61 (17.9) 2.17 (1.16-4.05) 11 (6.3) 42 (13.0) 2.03 (0.98-4.18) 2.07 (1.26-3.41) 
Non Vaccine 0 (0.0) 1 (1.3) (-) 0 (0.0) 2 (2.6) (-) (-) 8 (7.0) 7 (10.8) 1.23 (0.38-4.06) 4 (3.6) 7 (10.8) 3.14 (0.80-12.37) 1.93 (0.80-4.67) 
Multiple HRc 10 (2.4) 8 (6.7) 3.71 (1.28-10.73) 6 (1.5) 7 (5.9) 7.07 (1.58-31.59) 4.26 (1.79-10.13) 34 (11.3) 42 (19.1) 1.89 (1.11-3.21) 22 (7.6) 31 (14.8) 1.81 (0.97-3.39) 1.85 (1.20-2.85) 
 
              
Low risk 
types 
              
HPV6 17 (3.4) 1 (3.3) 1.07 (0.13-9.07) 12 (2.4) 1 (3.3) 2.13 (0.19-23.91) 1.52 (0.30-7.59) 71 (14.5) 5 (17.2) 1.08 (0.35-3.34) 52 (11.0) 1 (4.0) 0.36 (0.05-2.84) 0.78 (0.28-2.18) 
HPV11 18 (3.4) 0 (0.0) (-) 13 (2.5) 0 (0.0) (-) (-) 73 (14.8) 3 (10.7) 0.62 (0.17-2.21) 50 (10.7) 3 (10.7) 0.59 (0.12-2.80) 0.62 (0.22-1.76) 
Adjusted Odds Ratio; aadjusted for age, cervical ectopy, bacterial vaginosis, CD4+ count and ART duration in BF; badjusted for injectable contraception, cervicitis, CD4+ count and ART duration in SA;  cReference 
group for any multiple HR-HPV is negative for any HR-HPV OR single HR-HPV infection   
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Table 8.3. Risk of incident CIN2+ according to HR-HPV infection status over 16 months among 405 women living with HIV (WLHIV) without CIN2+ at enrolment in 
Burkina Faso and 375 WLHIV in South Africa   
 
Burkina Faso South Africa Sites combined 
 
Always negative 
or incident 
infection 
Cleared 
infection or 
type swap* 
Persistent 
infection 
Always negative 
or incident 
infection 
Cleared infection 
or type swap* 
Persistent 
infection 
Always negative 
or incident 
infection 
Cleared infection 
or type swap* 
Persistent 
infection aOR (95%CI )d,e 
  Na n (%) Nb n (%) Nc n (%) Na n (%) Nb n (%) Nc n (%) Na n (%) Nb n (%) Nc n (%) 
Any HR typef 177 0 (0.0) 113 1 (0.9) 115 4 (3.5) 91 1 (1.1) 157 4 (2.6) 127 17 (13.4) 268 1 (0.4) 270 5 (1.9) 242 21 (8.7) 7.90 (3.11-20.07) 
                       
Any alpha-9  236 1 (0.4) 85 1 (1.2) 84 3 (3.6) 158 3 (1.9) 135 5 (3.7) 82 14 (17.1) 394 4 (1.0) 220 6 (2.7) 166 17 (10.2) 6.91 (3.05-15.63) 
HPV16 380 4 (1.1) 10 0 (0.0) 15 1 (6.7) 321 16 (5.0) 39 3 (7.7) 15 3 (20.0) 701 20 (2.9) 49 3 (6.1) 30 4 (13.3) 4.75 (1.47-15.36) 
HPV31 379 5 (1.3) 11 0 (0.0) 15 0 (0.0) 343 21 (6.1) 28 1 (3.6) 4 0 (0.0) 722 26 (3.6) 39 1 (2.6) 19 0 (0.0) - 
HPV33 395 4 (1.0) 7 1 (14.3) 3 0 (0.0) 354 21 (5.9) 19 1 (5.3) 2 0 (0.0) 749 25 (3.3) 26 2 (7.7) 5 0 (0.0) - 
HPV35 360 4 (1.1) 28 0 (0.0) 17 1 (5.9) 327 18 (5.5) 28 0 (0.0) 20 4 (20.0) 687 22 (3.2) 56 0 (0.0) 37 5 (13.5) 4.72 (1.62-13.71) 
HPV52 320 3 (0.9) 52 1 (1.9) 33 1 (3.0) 278 17 (6.1) 60 2 (3.3) 37 3 (8.1) 598 20 (3.3) 112 3 (2.7) 70 4 (5.7) 1.67 (0.55-5.05) 
HPV58 392 5 (1.3) 3 0 (0.0) 10 0 (0.0) 349 18 (5.2) 17 0 (0.0) 9 4 (44.4) 741 23 (3.1) 20 0 (0.0) 19 4 (21.1) 9.56 (2.77-32.98) 
                       
Any alpha-7 333 4 (1.2) 42 0 (0.0) 30 1 (3.3) 249 11 (4.4) 86 5 (5.8) 40 6 (15.0) 582 15 (2.6) 128 5 (3.9) 70 7 (10.0) 3.34 (1.33-8.37) 
HPV18 381 4 (1.1) 12 0 (0.0) 12 1 (8.3) 318 15 (4.7) 38 3 (7.9) 19 4 (21.1) 699 19 (2.7) 50 3 (6.0) 31 5 (16.1) 5.39 (1.83-15.82) 
HPV39 378 5 (1.3) 21 0 (0.0) 6 0 (0.0) 340 20 (5.9) 28 2 (7.1) 7 0 (0.0) 718 25 (3.5) 49 2 (4.1) 13 0 (0.0) - 
HPV45 388 5 (1.3) 7 0 (0.0) 10 0 (0.0) 348 20 (5.8) 16 1 (6.3) 11 1 (9.1) 736 25 (3.4) 23 1 (4.4) 21 1 (4.8) 1.28 (0.16-10.13) 
HPV59 404 5 (1.2) 1 0 (0.0) 0 0 (0.0) 365 21 (5.8) 8 0 (0.0) 2 1 (50.0) 769 26 (3.4) 9 0 (0.0) 2 1 (50.0) 16.03 (0.96-268.33) 
HPV68 388 5 (1.3) 14 0 (0.0) 3 0 (0.0) 357 21 (5.9) 14 0 (0.0) 4 1 (25.0) 745 26 (3.5) 28 0 (0.0) 7 1 (14.3) 4.15 (0.45-38.02) 
                       
HPV51 364 5 (1.4) 33 0 (0.0) 8 0 (0.0) 319 19 (6.0) 43 2 (4.7) 13 1 (7.7) 683 24 (3.5) 76 2 (2.6) 21 1 (4.8) 1.21 (0.15-9.53) 
HPV56 387 4 (1.0) 9 0 (0.0) 9 1 (11.1) 340 20 (5.9) 27 0 (0.0) 8 2 (25.0) 727 24 (3.3) 36 0 (0.0) 17 3 (17.7) 6.77 (1.69-27.04) 
                    
Combination 
     
                 
HPV16/18 358 3 (0.8) 21 0 (0.0) 26 2 (7.7) 284 12 (4.2) 58 4 (6.9) 33 6 (18.2) 642 15 (2.3) 79 4 (5.1) 59 8 (13.6) 5.25 (2.14-12.91) 
9vHPV 5 HRg 250 0 (0.0) 70 2 (2.9) 59 1 (1.7) 173 8 (4.6) 113 2 (1.8) 56 6 (10.7) 423 8 (1.9) 183 4 (2.2) 115 7 (6.1) 3.23 (1.23-8.54) 
Any 9vHPV 240 0 (0.0) 80 2 (2.5) 85 3 (3.5) 145 5 (3.5) 141 5 (3.6) 89 12 (13.5) 385 5 (1.3) 221 7 (3.2) 174 15 (8.6) 4.46 (2.02-9.86) 
Non-Vaccineh 224 1 (0.5) 66 0 (0.0) 30 1 (3.3) 164 3 (1.8) 84 2 (2.4) 38 5 (13.2) 388 4 (1.0) 150 2 (1.3) 68 6 (8.8) 7.87 2.40-25.81) 
                       
Selected low risk types 
   
                 
HPV6 382 5 (1.3) 19 0 (0.0) 4 0 (0.0) 354 22 (6.2) 19 0 (0.0) 2 0 (0.0) 736 27 (3.7) 38 0 (0.0) 6 0 (0.0) - 
HPV11 401 5 (1.3) 3 0 (0.0) 1 0 (0.0) 354 21 (5.9) 18 1 (5.6) 3 0 (0.0) 755 26 (3.4) 21 1 (4.8) 4 0 (0.0) - 
 
aTotal number of women who were negative throughout follow-up or who had incident type specific HPV infection; btotal number of women who had a cleared type specific infection or acquired a new type (type swap); ctotal number of 
women who had type specific persistent infection; dOR for incident CIN2+ among those with HR-HPV persistence compared to all other participants at endline (includes those that were negative for that type or those that developed incident 
infection with that type during follow-up; eadjusted for site and ART status at enrolment   fAny HR type persistence is defined as those that had at least one HR type persistence; clearance or incidence among those who did not persist; and 
negative at baseline includes those who were negative for all HR types at baseline; gPersistence of any of HPV31/33/45/52/58 among those without persistent HPV16/18; hPersistence of any of HPV35/39/51/56/59/68 among those without 
persistent HPV16/18/31/33/45/52/58; *Type swap is defined as clearance of one genotype and acquisition of a different genotype  
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Table 8.4. Association of HR-HPV type prevalence with ART and CD4+ count at enrolment among 
570 women living with HIV in Burkina Faso  
 
Burkina Fasoa 
  
HPV16/18 9vHPV HRb Non vaccine typesc 
  N n (%) aPR (95% CI) n (%) aPR (95% CI) n (%) aPR (95% CI) 
On ART 412 63 (15.3) 1.00 123 (32.2) 1.00 69 (30.5) 1.00 
ART-naive 158 22 (13.9) 0.94 (0.59-1.51) 51 (37.5) 1.03 (0.78-1.36) 25 (29.4) 0.91 (0.59-1.41) 
        
CD4+ count among ALL, 
cells/mm3 
      
<200 66 14 (21.2) 1.44 (0.80-2.60) 24 (46.2) 1.52 (1.06-2.18) 12 (42.9) 1.75 (1.00-3.07) 
201-350 125 17 (13.6) 0.92 (0.53-1.58) 42 (38.9) 1.16 (0.84-1.61) 21 (31.8) 1.23 (0.76-2.01) 
351-500 161 23 (14.3) 0.95 (0.57-1.59) 44 (31.9) 1.00 (0.72-1.38) 31 (33.0) 1.27 (0.82-1.96) 
>500 217 31 (14.3) 1.00 63 (33.9) 1.00 30 (24.4) 1.00 
        
CD4+ count among  
ART users, cells/mm3 
      
<200 47 9 (19.2) 0.98 (0.47-2.06) 16 (42.1) 1.66 (1.07-2.58) 11 (50.0) 2.05 (1.14-3.65) 
201-350 80 11 (13.8) 0.75 (0.39-1.43) 30 (43.5) 1.42 (0.96-2.10) 12 (30.8) 1.32 (0.74-2.35) 
351-500 119 17 (14.3) 0.75 (0.42-1.35) 33 (32.4) 1.16 (0.79-1.72) 23 (33.3) 1.23 (0.74-2.05) 
>500 165 26 (15.8) 1.00 43 (30.9) 1.00 23 (24.0) 1.00 
    
    
CD4+count among  
ART-naïve, cells/mm3 
  
    
<200 19 5 (26.3) 2.02 (0.63-6.45) 8 (57.1) 1.15 (0.59-2.24) 1 (16.7) 0.88 (0.13-5.76) 
201-350 45 6 (13.3) 1.25 (0.43-3.60) 12 (30.8) 0.66 (0.37-1.20) 9 (33.3) 1.25 (0.48-3.22) 
351-500 42 6 (14.3) 1.22 (0.41-3.63) 11 (30.6) 0.71 (0.39-1.27) 8 (32.0) 1.44 (0.58-3.57) 
>500 52 5 (9.6) 1.00 20 (42.6) 1.00 7 (25.9) 1.00 
 
aPR=adjusted Prevalence Ratio; aadjusted for condom use, alcohol, cervicitis and cervical ectopy in BF; b9vHPV HR includes 
HPV31/33/45/52/58 in absence of HPV16/18 compared to being negative for all of HPV31/33/45/52/58; cNon vaccine types includes 
HPV35/39/51/56/59/68 in absence of any nonavalent vaccine type compared to being HR-HPV negative.  
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Table 8.5. Association of HR-HPV type prevalence with ART and CD4+ count at enrolment among 
613 women living with HIV in South Africa 
 South Africaa 
  
HPV16/18 9vHPV HRb Non vaccine typesc 
  N n (%) aPR (95%CI) n (%) aPR (95%CI) n (%) aPR (95%CI) 
On ART 404 
100 
(24.8) 1.00 148 (48.7) 1.00 69 (44.2) 1.00 
ART-naive 209 79 (37.8) 1.42 (1.11-1.83) 76 (58.5) 1.16 (0.96-1.40) 20 (37.0) 0.92 (0.62-1.37) 
        
CD4+ count among ALL, 
cells/mm3 
      
<200 57 17 (29.8) 1.22 (0.77-1.93) 23 (57.5) 1.13 (0.85-1.50) 10 (58.8) 1.71 (1.06-2.75) 
201-350 148 53 (35.8) 1.47 (1.07-2.01) 48 (50.5) 0.90 (0.70-1.17) 21 (44.7) 1.27 (0.82-1.95) 
351-500 183 54 (29.5) 1.18 (0.86-1.63) 64 (49.6) 0.97 (0.78-1.20) 26 (40.0) 1.12 (0.73-1.70) 
>500 225 55 (24.4) 1.00 89 (52.4) 1.00 32 (39.5) 1.00 
     
 
  
CD4+ count among  
ART users, cells/mm3 
      
<200 51 15 (29.4) 1.57 (0.91-2.73) 20 (55.6) 1.05 (0.76-1.46)   10 (62.5) 1.82 (1.08-3.05) 
201-350 102 34 (33.3) 1.72 (1.09-2.71) 34 (50.0) 0.89 (0.65-1.20) 16 (47.1) 1.33 (0.79-2.24) 
351-500 113 26 (23.0) 1.20 (0.73-1.96) 35 (40.2) 0.79 (0.59-1.07) 23 (44.2) 1.21 (0.74-1.97) 
>500 138 25 (18.1) 1.00 59 (52.2) 1.00 20 (37.0) 1.00 
        
CD4+count among  
ART-naïve, cells/mm3       
<200 6 2 (33.3) 1.06 (0.34-3.29) 3 (75.0) 1.53 (0.83-2.83) 0 (0.0) - 
201-350 46 19 (41.3) 1.26 (0.80-1.98) 14 (51.9) 1.03 (0.62-1.70) 5 (38.5) 0.86 (0.37-2.00) 
351-500 70 28 (40.0) 1.26 (0.80-1.98) 29 (69.1) 1.45 (1.04-2.01) 3 (23.1) 0.57 (0.19-1.69) 
>500 87 30 (34.5) 1.00 30 (52.6) 1.00 12 (44.4) 1.00 
 
aPR=adjusted Prevalence Ratio; aadjusted for age, condom use, smoking, LTSP, vaginal cleansing, Chlamydia trachomatis, Trichomonas 
vaginalis and bacterial vaginosis in SA; b9vHPV HR includes HPV31/33/45/52/58 in absence of HPV16/18 compared to being negative for all 
of HPV31/33/45/52/58; cNon vaccine types includes HPV35/39/51/56/59/68 in absence of any nonavalent vaccine type compared to being 
HR-HPV negative.  
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9 TYPE-SPECIFIC SEROLOGIC RESPONSES TO HPV AMONG WLHIV IN 
SOUTH AFRICA: SEROPREVALENCE, SEROCONVERSION AND RISK OF 
RE-INFECTION 
 
The seropositivity for a range of HPV types and possible sero-protection following natural infection 
have never been evaluated prospectively among WLHIV and the evidence regarding protection 
against re-infection for the same HPV type induced after natural infection remains uncertain in both 
HIV-negative women and WLHIV.  An improved understanding of HPV type-specific serological 
responses in such high-risk populations and their risk of both reinfection of the same type or a newly 
acquired type is needed to guide HPV control efforts, including possible use of HPV vaccination.  
This Chapter incorporates data that was collected as part of a nested study which aimed to estimate 
the impact of HPV vaccination among WLHIV in South Africa.  This Chapter will describe the HPV 
serodynamics among WLHIV in South Africa; including the type-specific seroprevalence of 15 HPV 
genotypes, the seroconversion rates at endline following natural infection at baseline and the re-
infection rate among those with type-specific antibodies endline. Given the uncertainty regarding 
immune responses following natural HPV infection, this chapter will also explore the association of 
CD4+ cell count and ART at baseline and endline in mediating HPV serological response.    
 
9.1 Objectives 
In a cohort of WLHIV in South Africa at baseline, to describe:  
 To determine the seroprevalence of HPV genotypes and its 
determinants; 
(Objective 3.4) 
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 To describe the correlations of type-specific HPV serology and DNA.  
 
In a cohort of WLHIV with ≤CIN1 at baseline and followed over 18 months: 
 To determine type-specific HPV seroconversion rates and their 
determinants; 
(Objective 3.5) 
 To evaluate the risk of type-specific re-infection and DNA persistence 
following same-type seropositivity at baseline 
(Objective 3.6) 
 
9.2 Methods 
A full description of the HARP procedures including HPV serology testing is provided in Chapter 5, 
sections 5.2 and 5.4. Epidemiological definitions and specific statistical methods for univariate and 
multivariate risk factor analysis related to the use of HPV serology data are detailed below.  
9.2.1 HPV DNA and serology definitions  
The HPV serology assay detects only 15 HPV types while the HPV genotyping assay detects 28 HPV 
types. To ensure comparability between the two tests, I have modified the definition of HPV DNA 
positive in this chapter, as follows:  
HPV DNA positive 
 Women was considered “HPV DNA positive” if positive, by INNO-LiPA, for any of the HPV 
types included in the serology assay (HR types 16/18/31/33/35/39/45/52/56/58/59/68 and LR 
types 6/11/73), and “HPV DNA negative” if negative for any of these types.  
 Women who were positive for any of the other HPV DNA types detected by INNO-LiPA 
were considered “HPV DNA negative”.   
 All HR-HPV types briefly described in Chapters 6, 7 and 8 are included in this definition, 
except for HPV51.   
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HPV serology positive 
HPV serology results are presented as binary (positive or negative for a given type) based on the 
cut-off estimated using the negative panel (minimum 400 MFI), as described in Chapter 5, section 
5.4.2. Serology outcomes groups are defined as positive for any of the 15 types (12 HR types 
16/18/31/33/35/39/45/52/56/58/59/68 and 3 LR types 6/11/73) included in the serology assay.  
Each of the HPV serology outcome groups were defined as follows:  
 HPV seroprevalence was defined as being seropositive for any type at baseline among 
women with serology data at baseline.  
 HPV type-specific seroincidence was defined as being type seronegative at baseline and 
becoming same-type seropositive at endline, irrespective of the DNA status at either 
baseline or endline (Figure 9.1). The denominator was all women with serology data at both 
time points, and who were not seropositive for all HPV types at baseline.  
 A more conservative definition was applied considering the HPV DNA status at baseline as 
evidence of detectable infection. HPV type-specific seroconversion was defined as being 
HPV DNA positive and same type seronegative at baseline, and becoming same type 
seropositive at endline, irrespective of the DNA status at endline (Figure 9.1).  
 Type-specific seropersistence was defined as having same-type detectable antibody at 
baseline and endline, among all women who were seropositive for any HPV type at 
baseline.  
 Type-specific seroreversion was defined as being seropositive for a specific HPV type at 
baseline and seronegative for the same type at endline, among all women who were 
seropositive for any HPV type at baseline.  
The longitudinal analyses were restricted to women without prevalent CIN2+ at baseline, as the 
natural history of HPV infection and serology dynamics in these women, many of whom would 
have received ablative therapy, may be less easy to interpret.  
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Figure 9.1. Flowchart describing the seroincidence and seroconversion groups, according to 
serology and DNA status at baseline and endline 
 
 
 
*Seroincidence is defined as being type seronegative at baseline and becoming same-type seropositive at endline, irrespective of the 
DNA status; represented as boxes shaded in orange
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9.2.2 Statistical methods 
Univariate and multivariate risk factor analyses were performed for HPV seroprevalence and 
seroincidence, as described for HPV DNA in Chapter 6, section 6.2, but in brief: unadjusted PR for 
each risk factor (as described in Chapter 6, Table 6.1) with HPV seroprevalence and HPV 
seroincidence were obtained using Stata version 14. PRs were considered significant if p<0.10.  
 A separate risk factor analysis was performed for women with seroconversion, even though they 
were a subset of women within those with seroincidence, to confirm whether the same 
associations still applied. While MVA for seroconversion was performed using women as 
denominator, MVA were re-performed using infections as denominator, to confirm if the same risk 
factors persisted in both analyses.  
For analyses investigating the association of type-specific DNA prevalence (exposure) with same-
type seroprevalence (outcome), associations were adjusted for factors found to be independently 
significantly associated with HPV seroprevalence in MVA (Objective 3.4).  As HR-HPV 
seroprevalence and seroincidence were common, associations with risk factors were estimated 
with PRs obtained from logistic regression using marginal standardization to estimate PRs, and the 
delta method to estimate 95% CI, as previously described for HR-HPV DNA outcomes in Chapter 7, 
section 7.2.1 [379].  
Associations between HPV seroconversion and HIV-related factors were estimated with 
generalised estimating equation to account for multiple baseline HPV infections per woman and 
seropositivity by multiple HPV types [380].  
To explore associations of HPV seroconversion with HIV-related factors, pre-specified analyses 
included stratification by ART duration (≤ or >2 years), HIV-1 viral suppression (≤ or >40 copies/ml) 
and CD4+ cell counts. Multivariable analyses were adjusted for socio-demographic and behavioural 
factors which were independently associated in multivariate analyses with HPV seroconversion 
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(Model 1). A second logistic regression model (Model 2) incorporated endline CD4+ cell count to 
Model 1 to explore associations with ART.  
For associations of baseline seropositivity with HPV DNA incidence and persistence over follow-up, 
logistic regression was used to estimate ORs and 95% CI, adjusted for socio-demographic and 
behavioural factors found to be associated with HR-HPV infection in South Africa, as described in 
Chapter 7, Table 7.1. Although the serology panel includes 12 of the HR types used in previous 
definitions for HR-HPV infection (HPV51 is not part of the serology assay), it is assumed that its 
absence should not contribute to a difference in findings.  
For associations of baseline seropositivity with CIN2/3 incidence over follow-up, logistic regression 
was used to estimate ORs and 95% CI, adjusted for socio-demographic and behavioural factors 
found to be associated with HR-HPV infection, as described in Chapter 7, Table 7.1.    
 
9.3 Results 
9.3.1 Study population  
Of the 623 WLHIV enrolled in South Africa, 604 (97.0%) had valid results for both HPV serology and 
genotyping at baseline. Participant characteristics were as described in Chapter 6, section 6.3.1; 
median age was 34 years (IQR: 30-40), 396 (65.6%) participants were taking ART and their median 
duration on ART was 28 (IQR, 10-50) months. Prevalence by INNO-LiPA of HPV DNA for the 15 HPV 
types, and 12 HR-HPV types, tested by serology was 78.2% and 75.5%, respectively (compared to 
88.7% for all 28 HPV types and 79.1% for 13 HR-HPV types, as reported in Chapter 6, section 6.3.2).  
CIN2+ prevalence in this substudy was 22.3% (124/557) compared to 22.5% (129/574) in the full HARP 
population.  
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9.3.2 HPV seroprevalence at baseline  
Prevalence of any HPV type by serology was 93.2% (95%CI: 90.9-95.1%), of whom 89.9% (506/563) 
were seropositive for multiple types. The prevalence of any HR-HPV type by serology was 90.7% 
(95%CI: 88.1-92.9%). Overall, 591 (97.8%) women were positive by either serology or DNA for any 
HPV and 583 (96.5%) for any HR-HPV types.  
Seroprevalence was highest for HPV31 (59.6%), followed by HPV58 (54.8%) and HPV16 (43.1%) 
(Figure 9.2). The seroprevalence of any HPV genotypes included in the bivalent (HPV16/18), 
quadrivalent (HPV6/11/16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines were 59.3%, 
73.5% and 87.6%, respectively (Figure 9.2). Simultaneous seropositivity for all HPV types included in 
the nonavalent vaccine was 2.8%, while 21.4% and 10.9% were seropositive for all of the bivalent and 
quadrivalent HPV types, respectively.   
There was no difference in HPV or HR-HPV seroprevalence across age groups (Figure 9.3).  
9.3.3 Risk factors associated with HPV seroprevalence at baseline  
HPV seroprevalence was higher among past or current users of injectable contraception compared 
to never users (ever vs. never use: 95.2% vs. 88.5%; aPR=1.07, 95%CI: 1.01-1.14; Appendix 15), but was 
lower among women with lack of HIV-1 viral suppression (88.8% vs. 96.8% for women with PVL 
≥1000 copies/mL vs. <1000 copies/ml; aPR=0.93, 95%CI: 0.87-0.99). However, this association was 
marginally significant when the analysis was restricted to ART users (aPR=0.94, 95%CI: 0.88-1.01, 
data not shown). 
9.3.4 Correlation of HPV DNA and HPV antibody-specific prevalence  
Of 472 women DNA positive for any of the 15 HPV types by INNO-LiPA, 59.1% were seropositive for 
the same HPV type (range by type: 25.5% for HPV45 to 68.9% for HPV31), while among 456 women 
positive for any HR-HPV DNA, 58.6% were seropositive for the same type (Table 9.1). Of 132 women 
who were HPV DNA negative for all 15 types, 90.2% (119/132) had detectable antibody for at least 
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one HPV type, while among 148 HR-HPV negative women, 85.8% (127/148) had detectable antibody 
for at least one HR type.  
HPV seroprevalence was significantly higher among those with same-type DNA positive compared 
to same-type DNA negative for HPV35, HPV39, HPV52, HPV58  and low-risk type HPV11 (Table 9.1). 
9.3.5 HPV seroincidence and associated risk factors  
 Of the 451 women without CIN2+ at enrolment who returned at follow-up visit (median follow-up 
16 months [IQR, 15.6-16.8]), genotyping and serology data at baseline and endline were available 
for 433 (96.0%) women. Seroincidence of any HPV type was 52.2% (224/429) and any HR-HPV type 
was 46.0% (196/426). Four women were seropositive for all 15 HPV types at baseline, and 7 for all 
12 HR-HPV types.  
9.3.6 HPV type-seroconversion and associations with same-type DNA persistence  
There were 219 women who were type-specific HPV DNA positive and same type seronegative at 
baseline and same-type seroconversion was 23.3% (51/219) for any HPV and 23.1% (48/208) for any 
HR-HPV.  Among the 219 women, there was a total of 326 infections detected that were same-type 
seronegative at baseline. When considering the total number of baseline infections as 
denominator, there were 56 (17.2%) HPV seroconversion events (Table 9.2). There were differences 
in seroconversion rates according to HPV type. The type-specific seroconversion rate was highest 
for HPV31 (53.9%), HPV33 (33.3%) and jointly for HPV58 and HPV59 (25.0%), and lowest for HPV16 
and HPV18 (2.4% and 17.1%, respectively).  
Overall, the seroconversion rate was higher among women with same-type persistent infection 
compared to those who cleared infection (any HPV type seroconversion: 23.0% vs. 15.1%; crude 
OR=1.68. 95%CI: 0.91-3.11). A similar association was observed for seroconversion of any HR-HPV 
(23.2% vs. 14.8%; crude OR=1.73, 95%CI: 0.92-3.27). The numbers for individual HPV types were too 
small to calculate associations with DNA persistence. 
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9.3.7 Factors associated with HPV type-seroconversion  
HPV seroconversion rates were similar among WLHIV with baseline CD4+ count ≤350 and >350 
cells/mm3 (19.8% vs. 16.7%, p=0.51) but seroconversion was lower among those with endline CD4+ 
≤350 cells/mm3 compared CD4+ >350 cells/mm3 (10.8% vs. 19.4%; aOR=0.61, 95%CI:0.29-1.30, 
adjusted for injectable contraceptive use), and this association was significant among the ART 
users only  (≤350 vs. >350  cells/mm3: 8.0% vs. 26.3%; aOR=0.25, 95%CI: 0.08-0.75, adjusted for 
injectable contraceptive use; Table 9.3 ).   
Seroconversion rates were similar among women who remained ART-naïve throughout the follow-
up period and long-term (>2 years) ART users (ART naïve vs. long-term ART at endline: 14.2% vs. 
17.7%, p=0.43).  However, the highest seroconversion was observed among short-duration ART 
users (≤2 years ART vs. ART-naïve at endline: 24.6% vs. 14.2%; aOR=2.39, 95%CI: 1.02-5.62, adjusted 
for injectable contraceptive use and endline CD4+ cell count). HPV seroconversion was also more 
likely among women who reported high adherence to ART at baseline (60-90% vs. <60% adherence: 
22.4% vs. 7.1%; aOR=8.93, 95%CI: 1.13-70.36, adjusted for endline CD4+ cell count).  
9.3.8 Newly detected HPV DNA over 16 months according to type-specific seropositivity at 
baseline   
Among the 433 women with genotyping and serology data at both visits, 221 (51.0%) had newly 
detected HPV DNA during follow-up, including a total of 327 incident infections.  The risk of incident 
infection was lower among women who were same-type seropositive compared to seronegative 
at baseline for HPV18 (1.5% vs. 6.4%; aOR=0.14, 95%CI: 0.02-0.80, adjusted for baseline CD4+ cell 
count, ART status and seropositivity for any type from same HPV phylogenetic family, Table 9.4); 
HPV35 (4.1% vs 11.9%; aOR=0.26, 95%CI: 0.10-0.68) and HPV58 (1.8% vs. 5.4%; aOR=0.19, 95%CI: 0.04-
0.89;). Conversely, the risk was higher among those with same-type seropositivity at baseline for 
HPV45 (10.5% vs. 4.0%; association did not persist following adjustment for seropositivity from same 
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HPV family; aOR=2.81, 95%CI: 0.87-9.04) and HPV68 (11.5% vs. 4.4%; aOR=4.07, 95%CI: 1.52-10.90) 
(Table 9.4).    
9.3.9 HPV DNA persistence over 16 months according to type-specific seropositivity at 
baseline   
Persistent DNA infections were marginally higher among women who were seropositive for the 
same type at baseline (seropositive vs. seronegative: 32.3% vs. 26.1%, Appendix 16). Persistent HPV 
DNA was highest for HPV16, 33, 39, 45 and 56 although the association was significant only for 
HPV56 (seropositive vs. negative: 45.6% vs. 15.4%; aOR=12.79, 95%CI: 1.14-143.23).   
9.3.10 Persistence of type-specific antibody at endline  
The persistence of any HPV antibody was high over 16 months; among 403 women with detectable 
antibody at baseline, 384 (95.3%) had the same type detected again at endline (seropersistence). 
Despite this, DNA incidence remained high, particularly for HPV16, HPV56 and HPV68 compared to 
women who had seroreversion for the same type (Table 9.4).  
DNA persistence was similar among women with seropersistence and seroreverson (Appendix 16). 
Among 577 infections detected at baseline, 166 (28.8%) persisted at endline; 31.6% (67/212) among 
women with seropersistence, and 35.9% (14/39) among women with seroreversion.   
Seropersistence was high, irrespective of CD4+ cell count (96.1% and 96.6% among CD4+ <500 and 
<200 cells/mm3, respectively, data not shown). Compared to ART users, ART-naïve women had 
marginally higher seropersistence (97.6%, 95.5% and 92.1% among ART-naïve, short-duration ART 
and long-duration ART users, respectively).  
9.3.11 Incident CIN2/3 and seropositivity at baseline 
Among 365 women with histology data at endline, 22 (6.0%) had incident CIN2/3 at 16 months. All 
22 incident CIN2/3 cases were seropositive at baseline for any HPV, and all had type-specific 
seropersistence at endline.   
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Seropositivity at baseline was associated with incident CIN2/3 (Appendix 17), even after adjustment 
for same-type HPV DNA positivity at baseline. The associations were strongest for HPV types -31, -
56, -58, -59 and 68. This independent association of seropositivity at baseline with incident CIN2/3 
may be due to serum antibodies generated from a prior infection which may have persisted but 
either cleared, or was undetectable at the time of enrolment, but which nonetheless may be have 
initiated the pathway to cervical lesion incidence during follow-up in this study.  
CIN2/3 incidence was also significantly higher among women with seropersistence for HPV31, 58 
and 56 compared to women who had same-type seroreversion, after adjustment for same-type 
HPV DNA positivity at baseline (Appendix 17).  
 
9.4 Discussion 
This prospective study of serological dynamics for 15 HPV types among South African WLHIV found 
a very high seroprevalence (93%) at baseline and evidence of seroconversion (26%) and high 
seropersistence (95%) at endline. However, this population had high incidence (49%) and 
persistence of HPV DNA (45%) and high incidence of CIN2/3 (6%) over 16 months. Despite the high 
prevalence and persistence of detectable antibodies, there is therefore limited evidence to 
suggest that HPV antibodies can prevent same-type HPV DNA incidence and persistence.  
Seroprevalence is very high among WLHIV 
Although we found high prevalence of HPV vaccine types (59-88% depending on vaccine types), 
the simultaneous seropositivity for all HPV types included in the current HPV vaccines was low (21% 
for bivalent vaccine and 3% for nonavalent vaccine).  We report a similar seroprevalence for types 
HPV6, 11 and 16 (42.2%, 35.8% and 43.1%, respectively) as that reported elsewhere among WLHIV in 
South Africa (38.2%, 33.8% and 29.3% for HPV-6, -11 and -16, respectively) [424] but higher 
seroprevalence for HPV18 (37.6% in this study vs. 15.9%). These findings are also similar to that 
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reported by Viscidi et al [425] in a study enrolling 2815 WLHIV and 963 HIV-negative women in the 
US that found 54% of WLHIV were seropositive for HPV16, compared to 47% of HIV-negative 
women.  
A lower seroprevalence was reported among 54 HIV-positive pregnant women and 1103 HIV-
negative pregnant women in Uganda [426] for HR-HPV (HPV16/18/31/33/35/45/52/58); 43% among 
WLHIV compared to 36% HIV-negative women. The lower seroprevalence of all HR types could be 
due to differences in serology assay methods across studies, but also to the immunosuppression 
associated with pregnancy [427].   
Seroprevalence correlates with DNA detection at baseline among WLHIV  
We found that HPV seropositivity correlated with DNA detection at baseline; 59.1% of those with 
HPV infection, and 58.6% of those with HR-HPV infection had seropositivity for the same type at 
baseline. These findings are also similar to what was reported by Viscidi et al for HPV16 [425] 
whereby 56% of WLHIV with HPV DNA were seropositive for HPV16, compared to 63% of HIV-
negative women. Furthermore, among those who were DNA negative for all types in this study, 
10% had detectable antibody for any HPV type and 14% for HR-HPV at baseline. This does not 
necessarily suggest false positives, but may reflect the high past exposure in this population.   
As reported in HIV-negative women [428-430], a proportion of women were DNA positive but 
concurrently seronegative for the same type. This may reflect the timing of sampling in relation to 
HPV acquisition, as sampling early in course of infection may not yield detectable antibody; low 
titer or waning antibody, or failure to seroconvert [68, 69].  
These data suggests that WLHIV mount an antibody response, given the high seroprevalence, and 
they can maintain detectable antibody over 16 months, given the high rates of seropersistence. 
But these high rates of seroprevalence and seropersistence may simply be markers of past 
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infection, and it is necessary to ascertain the rate of seroconversion following infection, and 
whether HPV antibodies prevent establishment and persistence of infection.   
Seroconversion is associated with type-specific persistent infection among WLHIV 
At 16 months follow-up, we found that among those that were DNA positive and same type 
seronegative at baseline, 26% of women seroconverted for the same type, and this was higher 
among those with persistent compared to cleared infection at endline. To our knowledge, this is 
the first report to confirm seroconversion following natural infection among WLHIV.  
Seroconversion rates reported here are lower to what has been reported among HIV-negative 
unvaccinated women. Carter et al [68] in a study among 588 college women aged 18-20 years 
reported that 59.5%, 54.1% and 68.8% seroconverted for HPV-16, -18 and -6, respectively within 18 
months of detection of same-type incident infection, and seroconversion was more likely among 
those with same-type persistent infection. Lower seroconversion estimates for HPV16 were 
reported in a population of 6528 women from the general population in Guancaste, Costa Rica 
followed for a longer time period. Wang et al [431] reported that 21.7% of women with detectable 
DNA at baseline had seroconversion for HPV16 over a median of 6.4 years, and, similar to Carter et 
al, seroconversion was higher among those with persistent compared to cleared infection (37.9% 
vs. 16.3%, respectively). Castro et al [432] reported much lower seroconversion rates over a long 
follow-up period, and among women with a wider age range. Among 600 women from the general 
population in Chile aged 15-85 years with a HR-HPV seroprevalence of 43.2% at baseline and 
followed over 5 years, 21.6% of women who were initially seronegative seroconverted for any HR-
HPV type, and 7.4% for HPV16, although HPV DNA detection at baseline was not considered in these 
estimates.  Antibodies titres are known to peak and then wane over time, even in the presence of 
HPV DNA [68] and this may explain the lower seroconversion for HPV16 reported by the studies in 
Costa Rica and Chile.   
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While there are no studies among WLHIV to make any comparison, seroconversion among HIV-
infected MSM is similar to what is reported in this study. Among 245 HIV-infected MSM recruited 
from infectious disease and STI clinics in Amsterdam [433], seroconversion against any of 7 HR-
HPV types (HPV16/18/31/33/45/52/58) was 23% over 12 months following anal or penile HPV infection. 
Among 281 HIV-infected MSM initiating ART in the Swiss HIV Cohort Study (SHCS), seroconversion 
for any of 8 HR-HPV types (HPV16/18/31/33/35/45/52/58) was 42.1% over 24 months.  
It is however difficult to compare seroconversion estimates between women and men as HIV-
negative men are known to have lower seroprevalence compared to HIV-negative women, and this 
has been suggested to be linked to the site of infection; as infection at the mucosal cervical 
epithelium of the cervix and anal canal may induce stronger immune responses compared to 
infection at keratinised epithelia such as the genital skin [434, 435]. 
Seroconversion in this study varied by HPV type, and was highest for HPV31 (53.9%) but the lowest 
seroconversion was observed for HPV16 (2.4%). The type seroconversion rates reflected the type-
specific infection states at follow-up. The overall incident and persistent DNA was higher for HPV16 
than for other types (13.1% and 33.3% for HPV16 incidence and persistence respectively, compared 
to 5.1% and 14.3% for HPV31). The lower seroconversion and subsequent increased risk of HPV16 
incidence and persistence could be a result of its immune evasion mechansims. HPV16 prevalence 
amomg WLHIV has been reported to be less affected by CD4+ count decreases compared to other 
HR-HPV types [420].  
Seroconversion is associated with CD4+ count and ART  
While seroprevalence was not associated with CD4+ count at baseline, consistent with what has 
been reported elsewhere [424, 436], seroconversion was higher among women with higher 
contemporary (endline) CD4+ cell count (>350 cells/mm3) and this association was only observed 
in the ART users. Seroconversion was also higher among short-duration (≤2 years) ART users at 
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endline compared to women who remained ART-naïve throughout follow-up (24.6% vs. 14.2%, 
respectively). While no other studies among WLHIV are available for comparison, the SHCS study 
among 281 MSM initiating ART and followed for a median of 2 years [437] reported that those with 
lower nadir CD4+ cell count (<200 cells/mm3) at the time of ART initiation had the highest 
seroconversion rates for HR-HPV at endline, compared to MSM who initiated ART at ≥350 
cells/mm3. The authors suggest that ART-related immune reconstitution during the 2 year follow-
up may have promoted seroconversion, and this was highest among those with the lowest nadir 
CD4+ cell count. Although the authors did not report HPV DNA detection, it is possible that MSM 
with low nadir CD4+ cell count at ART initiation also had higher persistent infection compared to 
those with higher nadir CD4+ cell count, which may have resulted in higher seroconversion rates.  
While nadir CD4+ cell count is not available in this study, women on short-duration ART at endline 
(≤2 years) had a lower baseline CD4+ cell count (median baseline CD4+: 324 cells/mm3, IQR: 236-
403) compared to both the long-duration ART users (461, IQR: 335-593), or ART-naïve (497, IQR: 
386-622).  Although baseline CD4+ cell count was not associated with seroconversion, the 
subsequent increase in CD4+ cell count at endline through ART-initiated immune reconstitution 
may have promoted seroconversion among the recent ART users in response to the high rate of 
HPV DNA persistence.  
A second explanation for higher seroconversion among short-duration ART users is that these 
women had high DNA prevalence at baseline and higher persistence of infection at endline 
compared to prolonged ART users. This study, and others, have shown that seroconversion rates 
were higher among women with persistent compared to cleared infection. But while 
seroconversion may have increased, immune reconstitution achieved through recent ART initiation 
at the previous WHO-recommended cut-off of CD4+ 350 cells/mm3 may have been ineffective to 
prevent persistence in the short-term, as reported in Chapter 7 . Seroconversion has been 
previously shown to be dependent on time following incident infection; among HIV-negative 
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women aged 18-20 years, HPV6 seroconversion coincided with DNA detection but HPV16 
seroconversion occurred between 6 to 12 months after DNA detection [68]. The association of 
seroconversion with endline CD4+ count in this study, and not baseline CD4+ cell count, may also 
reflect the longer duration required for seroconversion to occur after infection. The frequency of 
HPV testing in this study however does not allow an estimation of duration of the infection 
detected at baseline.   
Thirdly, short-duration ART users and ART-naïve women had the highest CIN2+ prevalence at 
baseline. However, at endline, ART-naïve women had the highest CIN2/3 incidence (9.2%) while 
short-duration ART users had similar CIN2/3 incidence as the prolonged ART users (4.5%). While the 
numbers were too small to investigate associations of seroconversion with CIN2/3 incidence, the 
short-term ART users appeared to have gained sufficient immune responses to reduce the risk of 
cervical lesion incidence over 16 months.  
Of note, women taking ART for a prolonged duration (>2 years) had similarly low seroconversion 
(17.7%) as ART-naïve women (14.2%). The low seroconversion among prolonged ART users may be 
reflective of the lower rates of prevalent (72%) and persistent infection (25%; Chapter 7). However, 
women who were ART-naïve had equally high rates of persistent HR-HPV infection as short-
duration ART users (31.8% and 35.2%, respectively; Chapter 7), and in  contrast to ART users, CD4+ 
cell count at either time point was not associated with seroconversion among the ART-naïve 
women. These data suggest there may be some beneficial impact of ART in promoting 
seroconversion.  
 ART-related increases in HPV seropositivity have shown to be independent of CD4+ count in other 
studies among among MSM [437] and among WLHIV [425]. There are no studies that have 
compared seroconversion among ART users and ART-naïve women, but vaccination studies among 
WLHIV have shown that, while seroconversion rates are similar among ART users and ART-naive 
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women in the US and Puerto Rico [261], HPV16 and HPV18 antibody titres were lower among ART-
naïve but comparable between HIV-negative and ART users [261].  
HPV seropositivity at baseline provides limited protection against HPV re-infection and 
persistence among WLHIV 
HPV-16 and -18 antibodies have been shown to confer partial protection against reinfection by the 
same type in HIV-negative women [69]. This study found limited evidence that antibodies detected 
at baseline provided protection against reinfection against same-type infection. However, those 
with baseline seropositivity for HPV18, 35 and 58 were between 74-86% less likely to have newly 
detected DNA for the same type 16 months later, after adjustment for covariates of HPV infection 
and HPV antibody from the same HPV phylogenetic family at baseline. A recent meta-analysis 
which assessed whether naturally acquired immunity conferred protection against reinfection by 
the same type [69] reported that HIV-negative women with antibodies against HPV16 and HPV18 
had 35% and 30% lower risk of re-infection, respectively against the corresponding type. While this 
study saw no protection conferred by HPV16 antibodies against HPV16 re-infection, others have 
reported that HPV16 is better able to evade the host immune surveillance relative to other HPV 
types [438], which may explain its predominance in high-grade cervical lesions in HIV-positive and 
HIV-negative women [14] .  
In a prospective study among 829 WLHIV and risk matched with 413 HIV-negative women in the 
US, Viscidi et al [436] reported no statistically significant difference among WLHIV in the risk of 
reinfection of any HR-HPV (HPV16/18/31/35/45) among women with same-type seropositivity 
compared to same-type seronegative at baseline over a median 4.5 years, with the exception of a 
reduced risk of infection with HPV45 (Hazard Ratio=0.21, 95%CI: 0.05-0.89). Similarly, among HIV-
negative women in that study, HPV seropositivity at baseline was not associated with a reduced 
risk of any HPV infection. For both WLHIV and HIV-negative women, there was no evidence of 
protection for either transient or persistent same-type infection.  
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Other studies have evaluated whether HPV antibodies detected at two or more time points were 
associated with same-type re-infection among HIV-negative women. A prospective study with 
longitudinal serology measurements among 608 HIV-negative women (mean age of 20 years) seen 
at 6-month intervals for 3 years in the US [439] reported a 50% reduction in risk of HPV16 re-
infection among women with a sustained high level of HPV16 antibody (seropositivity at two or 
more time points) and its genetically related types (HPV31/33/58). No study has investigated 
whether persistent seropositivity is a marker of protection against re-infection among WLHIV.  
HPV seropersistence is high among WLHIV but is not associated with HPV DNA incidence or 
persistence  
HPV seropersistence among WLHIV in SA over 16 months was very high (95% for any HPV type), 
and was high for all individual HPV types (>80%), with the exception of HPV18, 39 and 45 (65.0%, 
57.1% and 46.9%, respectively). Seropersistence has been reported to be similarly high in HIV-
negative women; 82% of women in Chile had seropersistence for any HR-HPV type over 5 years 
[432] and 58% of women from the general population in Costa Rica had seropersistence for HPV16 
over 7 years [431]. 
In this study, WLHIV who had type-specific seropersistence had lower HPV DNA incidence 
compared to women with seroreversion at endline for all HPV types, with the exception of the HR 
types HPV16, 18, 45, 56 and 68. By contrast, women with seropersistence had higher, or similar 
rates of persistent infections as women with seroreversion. Although there are no other data 
among WLHIV for comparison purposes, persistent infection has been shown to be higher among 
HIV-negative women with seropersistence. Among 79 HIV-negative women in Guanacaste, Costa 
Rica, persistent HPV16 infection over a median of 6.4 years was 37.9% among those with 
seropersistence compared to 28.6% among women with seroreversion [431].  
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While there is no strong evidence to suggest that baseline serum antibodies protect against re-
infection and persistence, the higher rates of persistent infection among those with 
seropersistence may simply reflect the higher exposure to past infections in these populations. 
Women with baseline seropositivity and seroperistence of any HPV type were also more likely to 
have CIN2/3 incidence over 16 months compared to women with seroreversion or women without 
detectable antibody at baseline. This finding suggests that, rather than being markers of 
protection among WLHIV, seroprevalence and seropersistence may be markers of past exposure 
to HPV infection and persistence. In Chapter 7, it was reported that women with DNA persistence 
over 16 months had an increased risk of CIN2/3 compared to women with HPV clearance, and this 
was highest for types (in order of decreasing magnitude) HPV-58, -56 and -18. Similarly, women 
with seropersistence for HPV-58 and -56 had increased risk of CIN2/3 incidence, possibly reflecting 
the level of HPV DNA persistence.  
Implications for vaccination of WLHIV in South Africa 
This study shows that WLHIV have high seroprevalence and high rate of seropersistence of type-
specific antibodies, and there is evidence of seroconversion over 16 months. Despite this, WLHIV 
have high prevalence, incidence and persistence of HPV DNA, including multiple type infection. 
Given the limited evidence that natural immunity can protect against reinfection and persistence 
of infection, WLHA could benefit from HPV vaccination.  
Seroconversion following vacination with the bi- and quadri-valent vaccines has been reported to 
be high; between 92-100% [261] for the quadrivalent vaccine among 99 WLHIV aged 16-23 years in 
the US, and 100% for the bivalent vaccine among and 125 WLHIV aged 18-25 years in South Africa 
[440]. Antibody titres following vaccination were similar among WLHIV and HIV-negative women 
at 12-months post-vaccination, although ART-naïve women had lower antibody titres for HPV-16 
and -18 [261, 440]. However, there is no data yet available on HPV vaccine efficacy against HPV 
persistence and CIN outcomes.  A prophylactic HPV vaccination could be beneficial for WLHIV at 
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risk for exposure to new infections, given that current antibodies provide limited protection 
against re-infection, and clearance of infection. Furthermore, a multivalent vaccine, such as the 
nonavalent vaccine targeting 7 HR types (HPV16/18/31/33/45/52/58) and 2 LR types (HPV6/11) would 
be beneficial among WLHIV given that 55% of WLHIV have multiple HR-HPV infection at baseline 
and 18% had multiple persistent types at endline, and relatively few women had simultaneous 
seropositivity or DNA positivity for all vaccine types.  
 
9.5 Study limitations 
As stated in previous chapter, this study was constrained by the limited number of intermediate 
visits and overall follow-up duration. We cannot establish whether the seroconversion event 
occurred in response to either: i.) an infection which persisted during follow-up, or ii.) a baseline 
infection which cleared, but the woman was re-infected again with the same type during the 16-
months follow-up. 
Similarly, when evaluating the risk of re-infection according to same-type seropositivity at baseline, 
we cannot exclude the possibility that the newly detected infection at 16-months may truly be a 
reinfection or whether it is a recurrence of an existing infection that was latent or had persisted at 
an undetectable level. If it is the latter case, then we would not expect to see a decrease in risk of 
new DNA detection among women who were seropositive for that type at baseline, as antibodies 
are not known to clear existing infections.  
The reference panel used for generation of cut-off values for the serology assay was based on sera 
from children <12 years from Sweden. We cannot rule out the possibility that the assay was less 
specific for an African population, as others have reported higher prevalence of HPV among  
children <15 years SSA [441].  It cannot be ruled out that the serology assay had different 
specificities for individual HPV types and there may have been cross-reaction with types from the 
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same phylogenetic family, particularly given the very high rate of multiple HPV infections in this 
population (55%).  
There is a possibility that HPV infection could have occurred at another anatomical site (anal or 
oral) rather than cervix, which could have affected the estimates for seroconversion in response 
to cervical DNA infection.    
The type specific analyses were limited by the small numbers, in particular when investigating type-
specific seroconversion among those with DNA at baseline.  
The risk factor analysis for HPV seroprevalence at baseline should be treated with caution, given 
the very high seroprevalence (93%). A separate risk factor analysis was carried out for both 
seroincidence and seroconversion outcomes. Given that seroconversion is a sub-set of women 
from the seroincidence group, this may have been unnecessary. However, the MVA analyses 
further confirmed that injectable contraception use was associated with a decreased risk of 
seroconversion, as observed for seroincidence.    
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9.6 Summary of findings 
 Seroprevalence for any of 15 HPV types was very high among WLHIV (93%), reflecting high 
exposure through past and current infection  
 Among women positive for any of the 15 HPV DNA types, 60% were also seropositive for the same 
type at baseline, while among the those who were DNA negative for all 15 types tested, 10% had 
detectable antibodies for any of those types 
 Seroconversion for any of the 15 HPV types over median 16 months was 23%, and was 1.7 times 
higher among those with the same-type persistent HPV infection compared to those who cleared 
the same infection 
 Seroconversion was highest among women who recently (<2 years) initiated ART, and among 
those with higher CD4+ count at endline 
 There was some evidence that women with detectable HPV antibodies at baseline had a 
decreased risk of reinfection by the same type, but only for HPV18, 35 and 58  
 Although over 95% of women had type-specific antibodies detected at both baseline and endline, 
DNA incidence and persistence of infection was high 
 Incident CIN2/3 was higher among women who were seropositive at baseline, reflecting past 
infection, but little evidence of protection 
 
Conclusion:  
WLHIV have high levels of HPV antibodies at baseline and endline, they can mount an antibody 
response in response to detectable DNA infection at baseline, which is dependent on CD4+ cell 
count. However the presence of antibodies does not appear to be effective at clearing existing 
infection or preventing DNA re-infection  
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9.7 Findings in context 
There are few studies which have reported seroprevalence for a wide range of HPV types among 
WLHIV. Others have shown that WLHIV in Johannesburg have similarly high seroprevalence of HPV 
types as shown in this study (38.2%, 33.8% and 29.3% for HPV-6, -11 and -16, respectively).  
One other study in the US reported limited evidence that WLHIV with type-specific HPV antibodies 
had a decreased risk of re-infection, similar to this study. That study also reported similar findings 
among HIV-negative women in the same cohort.  
No studies have reported seroconversion among unvaccinated WLHIV. However, WLHIV have 
been shown to have similar seroconversion rates following vaccination with bi- or quadrivalent 
vaccine as HIV-negative and antibody titres were sustained up to 12 months post vaccination.   
Seropositivity appears to be marker of past infection, rather than conferring protection against re-
infection over 16 months. Given the limited evidence that natural immunity can protect against 
reinfection and persistence of infection, WLHA would benefit from HPV vaccination. 
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Figure 9.2. HPV type seropositivity among 604 WLHIV in South Africa at baseline 
 
* Any HPV type prevalence defined as positive for at least one HPV type (6/11/16/18/31/33/35/39/45/52/56/58/59/68/73) at baseline; Any 
HR-HPV type prevalence defined as positive for at least one HR type (16/18/31/33/35/39/45/52/56/58/59/68) at baseline; Any 9V=Positive 
for any of HPV6/11/16/18/31/33/45/52/58; Any 9V-HR=Positive for any of HPV16/18/31/33/45/52/58;  Any 4V= Positive for any of 
HPV6/11/16/18; Any 4V-LR= Positive for any of HPV6/11; Any 2V= Positive for any of HPV16/18; All 9V=Positive for ALL of 
HPV6,11,16,18,31,33,45,52 and 58; All 9V-HR=Positive for ALL of HPV16,18,31,33,45,52 and 58; All 4V=Positive for ALL of HPV6,11,16 and 18; 
All 2V=Positive for BOTH HPV16 and 18; All 4V-LR=Positive for BOTH HPV6 and 11.  
 
Figure 9.3. HPV seroprevalence by age among 604 WLHIV in South Africa at baseline 
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Table 9.1. Comparison of HPV seropositivity among type-specific HPV DNA positive and DNA negative WLHIV (N=604) at baseline 
 DNA positive Antibody positive Sero+/DNA+  DNA negative 
Antibody 
positive 
Sero+/DNA-  aPR (95%CI)1 
(N) (n) (%) (N) (n) (%)  
Bi-/Quadri-valent types        
HPV6 33 14 42.4 571 241 42.2 0.98  (0.65-1.49)  
HPV11 33 19 57.6 571 197 34.5 1.68  (1.23-2.29) 
HPV16 115 50 43.5 489 210 42.9 1.02  (0.81-1.29) 
HPV18 89 34 38.2 515 193 37.5 1.03  (0.78-1.37)    
        
Additional nonavalent types        
HPV31 61 42 68.9 543 318 58.6 1.19  (0.99-1.42)   
HPV33 48 25 52.1 556 219 39.4  1.29  (0.96-1.74)  
HPV45 47 12 25.5 557 107 19.2 1.47  (0.88-2.43)   
HPV52 146 60 41.1 458 129 28.2 1.47  (1.15-1.88) 
HPV58 54 36 66.7 550 295 53.6 1.26  (1.03-1.53)  
        
Non-vaccine types        
HPV35 99 59 59.6 505 197 39.0 1.53  (1.26-1.86) 
HPV39 48 25 52.1 556 199 35.8 1.48  (1.11-1.98)     
HPV56 58 20 34.5 546 183 33.5 1.06  (0.73-1.53) 
HPV59 11 6 54.5 593 201 33.9 1.59  (0.91-2.78) 
HPV68 33 12 36.4 571 166 29.1 1.26  (0.79-2.01)   
HPV73 10 4 40.0 594 130 21.9 1.97  (0.94-4.10) 
        
Any HPV 472 279 59.1 132 13 9.8  
Any HR-HPV 456 267 58.6 148 21 14.2  
aHPV type seropositive among DNA positive for the same type; b All HPV type seronegative among DNA negative for all types; 1adjusted Prevalence Ratio [PR] for type-specific seroprevalence if same-type DNA 
positive compared to DNA negative, adjusted for injectable contraception and HIV-1 viral suppression 
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Table 9.2. Type-specific seroconversion at 16 months among 219 WLHIV with ≤CIN1 at baseline  
 
All participantsa Participants with HPV DNA persistenceb Participants with HPV DNA clearancec 
 
DNA+ & sero-  
at baseline 
Seroconversion events 
DNA+ & sero- at 
baseline 
Seroconversion events 
DNA+ & sero- at 
baseline 
Seroconversion events 
 N infections n (%)
a N infections n (%)b N infections n (%)c 
 
      
HPV16 41 1 (2.4) 11 1 (9.1) 30 0 (0.0) 
HPV18 41 7 (17.1) 14 3 (21.4) 27 4 (14.8) 
HPV6 13 3 (23.1) 0 0 (0.0) 13 3 (23.1) 
HPV11 13 2 (15.4) 3 1 (33.3) 10 1 (10.0) 
 
 
 
    
HPV31 13 7 (53.9) 2 2 (100.0) 11 5 (45.5) 
HPV33 15 5 (33.3) 1 1 (100.0) 14 4 (28.6) 
HPV45 25 4 (16.0) 8 1 (12.5) 17 3 (17.6) 
HPV52 63 12 (19.1) 21 6 (28.6) 42 6 (14.3) 
HPV58 12 3 (25.0) 4 1 (25.0) 8 2 (25.0) 
 
 
 
    
HPV35 26 6 (23.1) 11 3 (27.3) 15 3 (20.0) 
HPV39 19 0 (0.0) 2 0 (0.0) 17 0 (0.0) 
HPV56 26 4 (15.4) 4 1 (25.0) 22 3 (13.6) 
HPV59 4 1 (25.0) 1 0 (0.0) 3 1 (33.3) 
HPV68 13 1 (7.7) 3 0 (0.0) 10 1 (10.0) 
 
 
 
    
HPV73 2 0 (0.0) 2 0 (0.0) 0 0 (0.0) 
       
Any HPV 326 56 (17.2) 87 20 (23.0) 239 36 (15.1) 
Any HR-HPV 298 51 (17.1) 82 19 (23.2) 216 32 (14.8) 
aSeroconversion calculated among 219 women with DNA+/sero- status at baseline representing 326 infections; bSeroconversion calculated among DNA+/sero- at baseline and with type-specific persistence at 
endline; cSeroconversion calculated among DNA+/sero- at baseline and type-specific clearance at endline
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Table 9.3. HIV-related factors associated with HPV seroconversion at 16 months using 
generalised estimating equation (GEE) using 319 events of DNA positive/same type seronegative 
at baseline (among 219 WLHIV)   
 
HPV Seroconversion  
N n (%) aOR (95% CI) 1 aOR (95% CI) 2 
All participants     
Baseline CD4+ count (cells/mm3)* 
   
 
                           <200 14 2 (14.3) 0.88 (0.19-4.14) - 
                           201-350 82 17 (20.7) 1.24 (0.65-2.37) - 
                          >350 221 37 (16.7) 1.00 - 
Endline CD4+ count (cells/mm3)* 
   
 
                           <200 15 0 (0.0) - - 
                           201-350 78 10 (12.8) 0.61 (0.29-1.30) - 
                          >350 191 37 (19.4) 1.00 - 
ART status at baseline 
   
 
ART >2 years 91 15 (16.5) 1.00 1.00 
ART ≤2 years 81 19 (23.5) 1.53 (0.72-3.26) 1.56 (0.72-3.40) 
ART-naive 147 22 (15.0) 0.85 (0.41-1.75) 0.85 (0.41-1.75) 
     
ART status at endline     
ART >2 years 124 22 (17.7) 1.00 1.00 
ART ≤2 years 61 15 (24.6) 1.48 (0.70-3.12) 1.35 (0.59-3.07) 
ART-naive 134 19 (14.2) 0.74 (0.38-1.45) 0.56 (0.27-1.18) 
     
Baseline ART users 
   
 
HIV-1 viral suppression at baseline     
          <1000 copies/ml 146 27 (18.5) 1.00 1.00 
           ≥1000 copies/ml 26 7 (26.9) 1.58 (0.60-4.17) 1.91 (0.67-5.38) 
ART adherence at baseline ** 
   
 
Low Adherence (<60%) 28 2 (7.1) 1.00 1.00 
Moderate adherence (60-90%) 143 32 (22.4) 3.54 (0.79-15.83) 8.93 (1.13-70.36) 
Baseline CD4+ count (cells/mm3) 
   
 
                           <200 12 2 (16.7) 1.00 (0.20-5.02)  
                           201-350 52 13 (25.0) 1.46 (0.65-3.28) - 
                          >350 106 19 (17.9) 1.00 - 
Endline CD4+ count (cells/mm3) § 
   
 
                           <200 11 0 (0.0) - - 
                           201-350 39  4 (10.3) 0.32 (0.10-0.99) - 
                          >350 99 26 (26.3) 1.00 
 
- 
    
 
ART-naïve †‡ 
   
 
Baseline CD4+ count (cells/mm3) † 
   
 
                           <200 2 0 (0.0) - - 
                           201-350 30 4 (13.3) 0.77 (0.23-2.50) - 
                          >350 115 18 (15.7) 1.00 - 
Endline CD4+ count (cells/mm3) ‡ 
   
 
                           <200 2 0 (0.0) -  
                           201-350 38 6 (15.8) 1.47 (0.48-4.51) - 
                          >350 81 9 (11.1) 1.00 - 
Adjusted Odds Ratio (aOR) using generalised estimating equation ; 1In Model 1, associations with HPV seroconversion were adjusted 
for injectable contraception use found to be associated with seroprevalence in Appendix 15; 2In Model 2, additional adjustment for 
CD4+ count at endline (except for associations with ART at baseline when baseline CD4+ was used for adjustment; *CD4+ count at 
baseline available for 317; CD4+ count at endline available for 284;  **ART adherence + measure available  for 171 of 172 ART at baseline;   
†Baseline CD4+ among participants who were ART-naïve at baseline ‡ ART-naïve participants were defined as being ART-naive at both 
baseline and endline. 
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Table 9.4. Newly detected HPV DNA among 433 WLHIV, measured over 16 months follow-up, stratified by same type seropositivity at baseline 
      Among seropositive at baseline 
  All participants 
Seronegative at 
baseline 
Seropositive  
at baseline 
aOR (95%CI)3 aOR (95%CI)4 
Seropersistence  
at endline 
Seroreversion 
 at endline 
aOR (95%CI)5 
  N1 n (%)2 N1 n (%)2 N1 n (%)2 Model 1 Model 2 N1 n (%)2 N1 n (%)2   
Any Alpha-9 HR-HPV types                  
HPV16 366 48 (13.1) 203 25 (12.3) 163 23 (14.1) 1.27 (0.66-2.44) 1.48 (0.69-3.15) 135 20 (14.8) 28 3 (10.7) 1.50 (0.39-5.72) 
HPV31 394 20 (5.1) 169 8 (4.7) 225 12 (5.3) 1.12 (0.45-3.11) 1.12 (0.36-3.45) 204 10 (4.9) 21 2 (9.5) 0.57 (0.11-2.92) 
HPV33 408 17 (4.2) 248 11 (4.4) 160 6 (3.8) 0.81 (0.28-2.35) 0.70 (0.21-2.33) 143 5 (3.5) 17 1 (5.9) 0.59 (0.06-5.60) 
HPV35 374 33 (8.8) 227 27 (11.9) 147 6 (4.1) 0.26 (0.10-0.68) 0.26 (0.10-0.68) 110 4 (3.6) 37 2 (5.4) 0.67 (0.11-4.13) 
HPV52 327 55 (16.8) 233 41 (17.6) 94 14 (14.9) 0.76 (0.37-1.55) 0.77 (0.36-1.65) 82 12 (14.6) 12 2 (16.7) 0.78 (0.14-4.37) 
HPV58 404 14 (3.5) 187 10 (5.4) 217 4 (1.8) 0.22 (0.05-0.88) 0.19 (0.04-0.89) 191 3 (1.5) 26 1 (3.9) 0.29 (0.02-3.48) 
             
 
Any Alpha-7 HR-HPV types             
HPV18 367 17 (4.6) 235 15 (6.4)  132 2 (1.5) 0.20 (0.04-0.91) 0.14 (0.02-0.80) 84 2 (2.4) 48 0 (0.0)  
HPV39 397 24 (6.1) 251 14 (5.6) 146 10 (6.9) 1.48 (0.60-3.62) 1.69 (0.65-4.42) 83 5 (6.0) 63 5 (7.9) 0.78 (0.21-2.85) 
HPV45 403 21 (5.2) 327 13 (4.0) 76 8 (10.5) 3.30 (1.17-9.31) 2.81 (0.87-9.04)  37 4 (10.8) 39 4 (10.3) 1.42 (0.27-7.66) 
HPV59 424 5 (1.2) 280 4 (1.4) 144 1 (0.7) 0.48 (0.04-5.77) 0.41 (0.02-8.74) 107 1 (0.9) 37 0 (0.0)  
HPV68 412 26 (6.3) 299 13 (4.4) 113 13 (11.5) 2.85 (1.20-6.78) 4.07 (1.52-10.90) 89 11 (12.4) 24 2 (8.3) 1.30 (0.26-6.60) 
             
 
Other HPV types             
HPV56  396 16 (4.0) 264 10 (3.8) 132 6 (4.6) 1.56 (0.51-4.76) - 98 5 (5.1) 34 1 (2.9) 1.51 (0.17-13.76) 
              
LR-HPV types              
HPV6 410 13 (3.2) 241 7 (2.9) 169 6 (3.6) 1.28 (0.41-4.03) - 142 5 (3.5) 27 1 (3.7) 1.09 (0.12-10.26) 
HPV11 408 15 (3.7) 269 10 (3.7) 139 5 (3.6) 1.16 (0.37-3.67) - 119 4 (3.4) 20 1 (5.0) 0.73 (0.08-7.07) 
HPV73 428 3 (0.7) 331 1 (0.3) 97 2 (2.1) 28.03 (0.98-798.1) - 72 1 (1.4) 25 1 (4.0) 0.40 (0.02-6.73) 
 
             
Any HPV 433a 327 427
b 209 (48.9) 400c 118 (29.5)        
1Number of women negative for that type at baseline; 2number of incident infections among women negative or that type at baseline; 3Model 1, adjusted Odds Ratio (OR) for DNA incidence among same-type 
seropositive vs. seronegative at baseline, adjusted for age, smoking, condom, vaginal washing, chlamydia, BV, CT, TV, CD4 count and ART status at baseline; 4Model 2, additional adjustment for seropositivity 
for HPV type from same family group, i.e. HPV16 DNA incidence adjusted seropositivity for types HPV31/33/35/52/58; 5adjusted OR for DNA incidence among seropersistent vs. seroreverted at endline, adjusted 
for CD4+ at baseline only due to small numbers;  aAll women at risk of acquiring a HPV infection (no woman infected by all types at baseline); ball women with any HPV type seronegative and same type DNA 
negative at baseline; cAll women with any HPV type seropositive and same type DNA negative at baseline. 
 
258 
 
 
10 ASSOCIATIONS OF DNA METHYLATION OF HUMAN GENE EPB41L3 AND 
HPV16 WITH CIN2+  
 
It was shown in Chapter 4 that the DNA methylation of the human gene EPB41L3 and HPV16 was 
associated with CIN2+, and had reasonable sensitivity and specificity for the detection of CIN2+ relative 
to low or absent disease (≤CIN1) in the general population.  However, there are as yet, no reports of 
the DNA methylation of EPB41L3 or HPV16 in the detection of CIN2+ among WLHIV. 
This Chapter describes the associations of DNA methylation of a human gene EPB41L3 and HPV16 with 
prevalent CIN2+ at baseline, and incident CIN2/3 at endline. The change in EPB41L3 methylation levels 
over time among CIN2/3 that persisted or regressed will also be described. Given that aberrant DNA 
methylation is a possible marker for high-grade disease, this chapter will also explore whether DNA 
methylation is associated with HIV-related factors, such as CD4+ cell count, HIV-1 PVL and ART.  
While the aim of this Chapter is to understand the associations of DNA methylation with CIN2+, its 
performance as a tool for detection of CIN2/3 among WLHIV will also be discussed.  
 
10.1 Objectives 
In a cohort of WLHIV in Burkina Faso and South Africa at baseline:  
 To determine the association of DNA methylation of a human gene 
EPB41L3 and HPV16 with CIN2+ prevalence;  
(Objective 4.1) 
 To evaluate the role of socio-demographic, behavioural and HIV-related 
factors on the EPB41L3 DNA methylation at enrolment. 
(Objective 4.2) 
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Among WLHIV with ≤CIN1 at baseline and followed over 18 months:  
 To determine the association of baseline and endline DNA methylation 
of EPB41L3 with CIN2+ incidence. 
(Objective 4.1) 
 
Among WLHIV with CIN2+ at baseline and followed over 18 months without receiving management 
for CIN2+ lesions:  
 To monitor the change in EPB41L3 methylation levels over time among 
CIN2/3 that persisted or spontaneously regressed to ≤CIN1. 
(Objective 4.3) 
 
10.2 Methods 
A full description of the HARP enrolment procedures is provided in Chapter 5, section 5.2. A full 
description of Study 3 design and sample selection is provided in Chapter 5, section 5.5. Specific 
statistical methods for Study 3 are detailed here.  
10.2.1 Participant samples for EPB41L3 DNA methylation assay 
The case-control study design was described in Chapter 5, section 5.5.1. The participant samples 
included in the study are described here.  
All cases of histologically confirmed CIN2+ detected at baseline (prevalent) with sufficient cervical 
material (BF: 28; SA: 124) were included in the study and matched with at least one control without 
CIN (≤CIN1) by (i) age group (<35 years and ≥35 years) and (ii) country of recruitment (BF: 66; SA: 
144; Table 10.1).  
Table 10.1. Sample selection for Case Control Study 1 matched for age and country  
 BF* SA 
Total BF Total SA 
Total 
samples  < 35 yrs ≥ 35 yrs < 35 yrs ≥ 35 yrs 
Cases 5 23 72 52 28 124 152 
Controls 21 45 84 60 66 144 210 
* additional controls in BF to compensate for low number of cases 
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Among the 210 women with ≤CIN1 at baseline (both countries combined), 185 (88.1%) had histology 
results at endline. Methylation assays were performed for 26 of the 27 incident CIN2/3 detected in 
the HARP study (BF: 4; SA: 22) at endline. All women with ≤CIN1 in the baseline study and who 
remained ≤CIN1 at endline (n=159; BF: 53; SA: 106) were included as controls.  
Among 36 women with prevalent CIN2+ included in Case Control Study 1 in SA and who did not 
receive ablative treatment before the endline visit, EPB41L3 DNA methylation was measured at 
baseline and endline to monitor methylation levels over time. The number of cases included in Case 
Control Study 2 are summarised in Table 10.2.  
Table 10.2. Control Selection decisions for Case Control Study 2* 
 BF 
Total BF 
SA 
Total SA 
Total 
samples  < 35 yrs ≥ 35 yrs < 35 yrs* ≥ 35 yrs 
Total Cases: 2 3 5 40 23 63 68 
Incident 2 2 4 15 7 22 26 
Recurrent 0 1 1 2 3 5 6 
Persistent - - - 13 7 20 20 
Regressed  - - - 10 6 16 16 
Controls 14 39 53 59 47 106 159 
*Cases and controls will come from same pool as for Case-control Study 1, detailed in Table 10.1 Error! Reference source not found. 
 
10.2.2 Participant samples for HPV16 DNA methylation assay 
HPV16 L1 DNA methylation was performed for all HPV16 positive sample at baseline only. In BF, 
33.3% (9/27) of CIN2+ cases and 27.3% (18/66) of ≤CIN1 controls were HPV16 positive at baseline. In 
SA, 28.2% (35/124) of CIN2+ cases and 33.3% (48/144) of ≤CIN1 controls were HPV16 positive at 
baseline. 
 The HPV16-positive CIN2+ cases available for testing (BF: 8; SA: 30) were tested using HPV16 DNA 
methylation assays, and matched 1:1 with all HPV16-positive ≤CIN1 controls (BF: 15; SA: 28) selected 
from the controls in Table 10.1.  
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HR-HPV status of selected cases and controls 
Whilst HR-HPV DNA positivity was not part of the selection criteria, it is a potential confounder for 
EPB41L3 methylation. For the CIN2+ cases at enrolment, HR-HPV positivity was 100% in BF and 90.7% 
in SA. Among the controls at baseline, HR-HPV positivity was 75.8% in BF and 84.0% in SA (Table 
10.3). At endline, HR-HPV was 100% among the cases in both countries, and among the controls at 
endline was 83.0% in BF and 82.1% in SA which was slightly higher than that observed in the overall 
cohort (59% in BF and 79% in SA, refer Chapter 6, Table 6.2).  
Table 10.3. HR-HPV DNA positivity among selected cases and controls  
  
 
Outcome BF SA 
Case-control Study 1 Case Prevalent CIN2+ 100.0 (31/31) 90.7 (117/129) 
 
Control ≤CIN1 at baseline 75.8 (50/66) 84.0 (121/144) 
Case-Control Study 2 Case Incident CIN2/3 100.0 (5/5) 100.0 (22/22) 
  
Recurrent CIN2/3 0.0 (0/1) 100.0 (5/5) 
  
Persistent CIN2/3 - 95.0 (19/20) 
  
Regression CIN2/3 - 87.5 (14/16) 
 
Control ≤CIN1 at baseline and endline 83.0 (44/53) 82.1 (87/106) 
 
 
10.2.3 Statistical analysis 
Comparison of methylation levels between cases and controls 
Given the EPB41L3 and HPV16 methylation values were not normally distributed (Figure 10.1), the 
median methylation of the average of the CpG sites for each gene in CIN2/3 cases and ≤CIN1 
controls were compared using the non-parametric Mann-Whitney U test [442]. All women who 
were ≤CIN1 at baseline were included as controls in the baseline study, irrespective of whether 
they went on to develop incident CIN2/3 or not (i.e. inclusive sampling) because there was no 
difference in the percentage baseline EPB413 median and IQR between women that remained 
≤CIN1 at endline and those who developed incident CIN2/3 at endline. 
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The Cuzick test for trend was used to evaluate trend in methylation levels by CIN grade [443]. The 
one-sided Wilcoxon matched pairs test was used to evaluate changes in median methylation levels 
between baseline and endline among the CIN2/3 outcome groups, and a p-value of 0.05 was 
considered significant [444].  
 
Figure 10.1. Histogram of EPB41L3 methylation percentage distribution, by country  
 
 
Measures of performance of EPB41L3 methylation assay for CIN2/3 detection 
Receiver operating characteristic (ROC) curves were plotted for EPB41L3 and HPV16 for the 
outcomes of CIN2/3 and CIN3, separately, as EPB41L3 methylation has shown to be higher among 
CIN3 and greater compared to CIN2 in previous studies reviewed in Chapter 4. The area under the 
ROC curve (AUC) was used to evaluate the performance of the methylation assay for the detection 
of CIN2/3 and CIN3, separately.  
Definition of ‘high’ methylation and associated risk factors  
Baseline methylation levels for EPB41L3 were further dichotomized into ‘high’ and ‘low’ 
methylation levels; whereby values were considered ‘high’ if above the second tertile (66.7 
percentile point) of the distribution in the control (≤CIN1) samples at baseline, and the cut-off was 
country-specific given the variation in percentage methylation values in each country. All women 
who were ≤CIN1 at baseline were included in estimation of the cut-off, irrespective of whether they 
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went on to develop incident CIN2/3 or not (i.e. inclusive sampling). This also maximised the number 
of samples on which the cut-off was based.  
Given that case-control studies do not directly estimate prevalence among the exposed and non-
exposed, prevalence ratios are not appropriate and logistic regression was used to obtain ORs and 
95% CI for ‘high’ methylation associated with socio-demographic, behavioural and HIV-related 
factors [445]. Multivariable analyses, as described for HPV DNA outcomes in Chapter 6, section 6.2, 
were adjusted for factors which were independently associated with ‘high’ methylation in 
univariate analyses for each country and a p-value of <0.10 was considered significant, given the 
smaller sample size for this study.  A priori adjustments for HR-HPV and CIN status at baseline were 
included, as both HR-HPV and CIN2+ are confounders of EPB41L3 methylation, but it is not yet clear 
if they are necessary for increased EPB41L3 methylation levels.  
 
10.3 Results 
10.3.1 Study population 
A full description of the participants is provided in Chapter 6. Among the 161 CIN2/3 cases detected 
in the HARP study at baseline, EPB41L3 methylation was performed for 152 CIN2/3 (CIN2: BF=17; 
SA=73; CIN3+: BF=11; SA=51) and 210 ≤CIN1- age and site matched controls (BF: 66; SA: 144) (Figure 
10.2). A single invasive cancer case was identified in BF. Among the 362 women selected for Case 
Control Study 1, HR-HPV positivity was slightly higher in cases (BF: 100.0%, SA: 90.7%) compared to 
controls (BF: 75.8%; SA: 84.0%), and HPV16 was detected in 29% (27/93) of all selected participants 
in BF and 31.0% (83/268) in SA.   
A description of the HARP study population characteristics is provided in Chapter 6, Section 6.3.1. 
In brief, for this study, the median age of 94 participants in BF was 39 (IQR, 35-43) years and among 
268 participants in SA was 33 (IQR: 30-38), similar to the overall HARP cohort. The median CD4+ T 
cell count at enrolment was 453 cell/mm3 (IQR: 303-594) in BF and 403 cell/mm3 (IQR: 283-551) in 
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SA. At enrolment, 80 (85.1%) participants were taking ART in BF and 162 (60.5%) in SA. While the 
proportion of ART users in BF was higher in that sub-sample than that reported in the main HARP 
cohort (68.6%), the median duration of ART use was similar: 16.9 (IQR: 0.0-79.1) months in BF and 
23.8 (IQR: 8.1-42.9) in SA.  
Among the 210 women with ≤CIN1 at baseline, 185 (88.1%) had histology results at endline, a median 
16 months later (IQR: 14.5-16.7). In the HARP study, there were 27 incident CIN2/3 detected over 16 
months and EPB41L3 methylation testing was performed for 26 incident CIN2/3 cases (BF: 4; SA: 22, 
Figure 10.2); 22 CIN2 (BF: 3; SA: 19) and 4 CIN3 (BF: 1; SA: 3) included in Case Control Study 2. All 
participants with ≤CIN1 in the baseline study who remained ≤CIN1 at endline (n=159; BF: 53; SA: 106) 
were included as controls for Case Control Study 2.    
Among the 124 SA women with prevalent CIN2/3 at baseline, 36 could not receive management for 
their lesions before the endline repeat colposcopy/biopsy visit, and thus the study was able to 
ascertain that 20 (55.6%) had persistent CIN2/3 and 16 (44.4%) had spontaneously regressed to 
≤CIN1 at endline (Table 10.4). When presenting results by CIN grade, among 23 women with 
baseline CIN2, 30.4% (7/23) had persistent CIN2, 13.0% (3/23) progressed to CIN3 and 56.5% (13/23) 
had spontaneous regression to ≤CIN1 at endline. Among 13 women with CIN3 at baseline, 38.5% 
(5/13) had persistent CIN3, 38.5% (5/13) regressed to CIN2 and 23.1% (3/13) had spontaneous 
regression to ≤CIN1 at endline.  
Table 10.4. CIN2+ status at endline among women with prevalent CIN2+ and untreated at 
endline 
 Baseline status 
Total 
Endline status CIN2 CIN3 
Persistent  7 5 12 
Progression CIN2 to CIN3 3 0 3 
Regression CIN3 to CIN2 0 5 5 
Regression CIN3 to≤CIN1 0 3 3 
Regression CIN2 to≤CIN1 13 0 13 
Total 23 13 36 
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10.3.2 Methylation of EPB41L3 at baseline for detection of prevalent CIN2/3 
The median methylation percentage of the average of three CpG sites for EBP41L3 increased with 
increasing CIN grade (Figure 10.3, Table 10.5). The Mann-Whitney U test indicated that methylation 
levels were elevated in CIN2/3 cases compared to controls in both countries (in BF: CIN2/3 
median=7.05, IQR: 1.72-17.68 vs. ≤CIN1 median=1.15, IQR: 0.0-2.93, p<0.001; in SA: CIN2/3 
median=1.77, IQR: 0.0-10.62 vs. ≤CIN1 median=0.0, IQR: 0.0-1.53, p<0.001, data not shown). The 
Cuzick test for trend indicated increasing methylation levels by CIN grade (BF and SA combined: 
p<0.001, Table 10.5). 
The ROC curve analysis for CIN2/3 detection relative to ≤CIN1 (Table 10.6) generates an area under 
the curve (AUC) of 0.77 (95%CI: 0.65-0.89) in BF and 0.68 (95%CI: 0.62-0.74) in SA. For a specificity 
set at 70%, this would give a sensitivity of 60.7% in BF and 58.9% in SA for CIN2/3 detection (Table 
10.6). The AUC did not vary when considering CIN3 alone as an outcome measure relative to ≤CIN1 
(Table 10.6). A set specificity of 70% would give a sensitivity of 63.6% in BF and 60.8% in SA for CIN3 
detection. 
 
10.3.3 Methylation of EPB41L3 at baseline and endline for the detection of incident CIN2/3 
The median methylation level for EBP41L3 at baseline was not significantly higher among women 
who developed incident CIN2/3 over 16 months compared to those who remained ≤CIN1 in either 
country (incident CIN2/3 vs. ≤CIN1: Mann-Whitney p=0.42 for BF, p=0.68 in SA; Table 10.7). 
However, the endline methylation was significantly higher in both countries among those with 
CIN2/3 compared to ≤CIN1 (BF: Mann-Whitney p=0.05; SA: p=0.07), and in SA for CIN3 compared to 
≤CIN1 (p=0.001; Table 10.7). Furthermore, EPB41L3 methylation increased at endline among those 
who developed incident CIN2/3 in BF (Wilcoxon matched pairs p=0.06), and among those that 
developed incident CIN3 in SA, although not significant due to small numbers of incident CIN3.  
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The ROC curve analysis of endline methylation for incident CIN2/3 detection relative to ≤CIN1 
generated an AUC of 0.80 (95%CI: 0.63-0.97) in BF and 0.60 (95%CI: 0.47-0.73) in SA, and an AUC of 
0.95 (95%CI :0.86-1.00) for CIN3 detection in SA (Table 10.6).   
10.3.4 Methylation EPB41L3 among women with CIN2/3 at baseline and followed up over 16 
months in SA  
An analysis of the baseline methylation values of women with prevalent CIN2/3 and followed up 
over 16 months, show that women with persistent CIN3, or CIN2 which progressed to CIN3 (CIN2/3 
persistence) had higher baseline methylation compared to women who regressed (CIN2/3 
persistence, median methylation=15.67, IQR: 3.13-24.70; CIN2/3 regression to ≤CIN1, median 
methylation=0.0, IQR: 0.0-3.83; Mann-Whitney p=0.016; Table 10.8). Women with persistent CIN2 
had low methylation values at both baseline and endline (Wilcoxon p=1.00).  
10.3.5 Socio-demographic and behavioural factors associated with high EPB41L3 methylation  
The proportion of women with ‘high’ methylation at baseline (defined as greater than the 66.7 
percentile point of the distribution in the ≤CIN1 samples) was 41.5% (39/94) in BF and 45.9% 
(123/268) in SA. 
In BF, a higher education level was associated with ‘high’ methylation in univariate analysis, which 
persisted in MVA (≤primary school attendance vs. >primary: 26.7% vs. 66.7%; aOR=3.89, 95%CI: 1.20-
12.62; Appendix 18). However, in SA, a lower education level was associated with ‘high’ methylation 
in univariate analysis, but this did not persist in MVA (Appendix 19).   
In BF, women with Candida albicans detected at baseline were less likely to have ‘high’ methylation 
compared (positive vs. negative: 15.4% vs. 42.5%; aOR=0.08, 95%CI: 0.01-0.99).  
 Due to uncertainty of the role of education in levels of EPB41L3 methylation, further analyses will 
not be adjusted for education. A priori adjustment factors include HR-HPV and CIN status at 
baseline in both countries, in addition to Candida albicans in BF.  
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10.3.6 HIV-related factors associated with EPB41L3 methylation  
Low CD4+ cell count was significantly associated with ‘high’ methylation in both countries (BF: 
66.7% among women with CD4+ count ≤200 cells/mm3 vs. 34.9% among women with CD4+ count 
≥350 cells/mm3: aOR=7.45, 95%CI: 1.53-36.22, adjusted for HR-HPV, CIN status and Candida albicans; 
Table 10.9 ; in SA: 68.8% vs. 39.4%; aOR=2.74, 95%CI: 1.16-6.47, adjusted for HR-HPV and CIN status). 
This was highest among ART users in both countries, although the associations were not significant 
(Table 10.9). 
In both countries, ‘high’ methylation was less frequent among ART-naïve women compared to 
long-term (>2 years) ART users, but this association was significant in SA only (35.6% vs. 54.4%; 
aOR=0.38, 95%CI: 0.20-0.74, adjusted for CD4+ cell count; Table 10.9). There was also some 
evidence in SA that short-duration (≤2 years) ART users were less likely to have ‘high’ methylation 
compared to long-duration ART users (aOR=0.48, 95%CI: 0.23-0.99, adjusted for CD4+ cell count). 
This finding was not observed in BF.  
10.3.7 HPV16 DNA methylation associated with prevalent CIN2/3 at baseline, and persistent 
infection and incident CIN2/3 at endline  
Among the 362 cases and controls selected for this study, there were 81 samples that were positive 
for HPV16 positive at baseline and available for testing for HPV16 L1 methylation (BF: 23; SA: 58). In 
the HARP cohort, the overall HPV16 prevalence was 14.0% (170/1215) and was higher in SA (BF: 8.6%; 
SA: 19.2%, p<0.001, Chapter 8, Table 8.1).  
HPV16 L1 methylation was higher among the prevalent CIN2/3 cases compared to ≤CIN1 in BF 
(CIN2/3 median methylation: 11.23, IQR: 4.18-43.38 vs. ≤CIN1 median methylation: 7.20, IQR: 2.80-
15.20) but the difference was not significant (Mann-Whitney p=0.61). There was no difference in 
HPV16 L1 methylation levels between participants in CIN2/3 and ≤CIN1 in SA (p=0.49; Appendix 20).    
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10.4 Discussion 
EPB41L3 is associated with CIN2+ among WLHIV 
This study reports that methylation of the host gene biomarker EPB41L3 increased with increasing 
grades of prevalent CIN among women living with HIV in Sub-Saharan Africa. Furthermore, EPB41L3 
methylation increased with increasing progression of CIN lesions over 16 months. These data 
suggest that EPB41L3 methylation may be useful in identifying women at risk of persistent or 
progressive high-grade CIN.  
While this is the first report of EPB41L3 methylation among WLHIV, the performance of EPB41L3 to 
detect CIN2/3 compared to ≤CIN1 is similar to reports among HIV-negative women in Canada [334], 
the Netherlands [254, 335] and the UK [256, 328].   
 
EPB41L3 as a single marker has reasonable performance for detection of CIN2+  
In Burkina Faso, EPB41L3 methylation values increased across all grades of CIN, and EPB41L3 
methylation assay had similar sensitivity estimates (61% for CIN2+ and 64% for CIN3+) for a set 
specificity of 70%, comparable to the studies conducted among HIV-negative women (also 
reported in Chapter 4). Such performance would not be superior to the current cervical cancer 
screening method of VIA/VILI in BF, which had a sensitivity of 56% and specificity of 78% for 
detection of CIN2/3 in the HARP study [446].  
In South Africa, the greatest increase in methylation values was among those with CIN3+, and with 
an AUC of 0.68 (95% CI 0.62-0.74) and for a set specificity of 70%, EPB41L3 methylation had a 
sensitivity of 59% for CIN2/3 detection. The current cervical cancer screening method in South 
Africa is cytology high-grade SIL and greater (HSIL+), which  had a sensitivity of 69% and specificity 
of 82% in this study, whilst cytology of low-grade SIL and greater (LSIL+) had a sensitivity of 98% 
and specificity of 13% for LSIL+ [446], findings which also have been reported among WLHIV in 
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Johannesburg [238]. There were small increases in sensitivity for CIN3+ detection in both countries 
(64% in Burkina Faso and 61% in South Africa, at set 70% specificity). These findings suggest that 
EPB41L3 on its own would not be any better than the current screening method, but in combination 
with other existing human gene markers and possibly HR-HPV methylation may increase 
performance as shown by others [256, 335], and reviewed in Chapter 4.  
An increase in performance was observed in the AUC of endline EPB41L3 methylation for the 
detection of incident CIN2/3 in Burkina Faso, and incident CIN3 in South Africa. A set specificity of 
70% gave a sensitivity of 75% for CIN2/3 detection in Burkina Faso, and 100% sensitivity for CIN3 
detection in South Africa. This suggests that EPB41L3-based methylation assay may be useful in a 
regularly screened population for the detection of incident CIN.  
 
EPB41L3 DNA methylation distinguishes persistent CIN2/3 from CIN2/3 that spontaneously 
regresses 
This study found that EPB41L3 methylation levels increased with increasing duration and severity 
of CIN lesion over 16 months, similar to what has been reported for other host gene markers 
CADM1, MAL [447] and FAM19A4 [448] in the general population in the Netherlands.  CIN2 and CIN3 
are transforming stages, and a marker which could predict progression or regression would be 
useful. This study found that an AUC of 0.84 (95%CI: 0.66-1.00) gave a sensitivity of 86% and a 
specificity of 81% for the detection of persistent CIN3 or CIN2 progressing to CIN3 relative to those 
who remained ≤CIN1 or who regressed to ≤CIN1 over 16 months. Although the number of outcomes 
were small in this study, it suggests that EPB41L3 methylation assay may be useful in predicting 
CIN2+ that progress from those that regress. CIN2 reflects heterogeneous disease, of which a 
substantial portion represents productive HR-HPV infections [449] that will regress spontaneously 
[450]. Given that 56% of the women in this study with CIN2/3 at baseline had spontaneous 
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regression to ≤CIN1 over 16 months, such a diagnostic tool would be useful to reduce over-referral 
with unnecessary colposcopies and overtreatment of women with clinical disease, particularly in 
settings with limited resources. 
While this is the first report on EPB41L3 methylation among WLHIV, others have recently reported 
on the performance of a CADM1/MAL/MIR human genes combined methylation assay among 248 
WLHIV in Kenya [17] and found that the tri-marker panel had an AUC of 0.80 for detection of 
prevalent CIN2/3 with comparable sensitivity and specificity as cytology (using cut-off of ASCUS); 
89% and 50%, respectively. The Kenya study also included women who were treated for CIN2+ 
lesions and followed-up 6-months later, but reported that the methylation levels for MAL and MIR 
remained unchanged 6-months later despite treatment and suggest a possible role of HR-HPV 
persistence in maintaining these methylation levels.   
 
HPV16 L1 DNA methylation does not distinguish CIN2+ from ≤CIN1  
DNA methylation of HPV16 L1 did not appear to discriminate between CIN2+ and ≤CIN1 in this study. 
While aberrant methylation of HPV during disease progression is common, and most pronounced 
in the L1 and L2 regions [366] , data are still largely inconsistent, as reviewed in Chapter 4, and by 
others [247, 248], and it remains uncertain whether HPV DNA methylation provides the infected 
cell with a growth advantage [366], or whether HPV methylation coincides or facilitates other host 
gene changes. HPV16 is known to evade the host immune response, and is likely to persist in 
WLHIV, and does not change according to CD4+ cell count, as has been reported for other HPV 
types [420]. A larger study with a HIV-negative comparator group may shed light on HPV16 
methylation profiles and the influence of HIV-related factors.   
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CD4+ cell count and ART status is associated with higher EPB41L3 methylation  
We found higher levels of EPB41L3 methylation among women with low CD4+ cell count (≤200 
cells/mm3). There have been no previous reports of cervical cancer-specific methylation markers 
and associations with immune status.  
It is unclear from the literature whether CD4+ T-lymphocytes are directly involved in regulating 
tumour suppressor genes such as EPB41L3, but CD4+ T-lymphocytes can regulate tumour cells 
indirectly through the action of cytokines. CD4+ T-cell mediated immune responses against 
tumours involve the secretion of cytokines IFN-γ and TNF-α (refer Figure 2.6, Chapter 2). Recent 
studies have shown that interferon (IFN)-γ and tumour necrosis factor (TNF)-α induce senescence 
of tumour cells in various cancers in mice and humans [451] and growth arrest and vulvar 
intraepithelial lesions (VIN) 3 are associated with IFN-γ producing CD4+ T-helper 1 cells [452, 453].  
The inverse correlation of methylation levels with CD4+ cell count may also reflect the association 
of HR-HPV infection with CD4+ cell count. HPV oncogenes E6 and E7 can activate DNA 
methyltransferases (DNMT1, DNMT3A and DNMT3B), which are responsible for initiating and 
maintaining tumour suppressor gene methylation and are overexpressed in several cancers [44]. 
HPV16 E7 has also been shown to bind DNMT1 and to stimulate its enzymatic activity [454]. While 
the association of CD4+ cell count with EPB41L3 methylation was independent of HR-HPV status, 
unmeasured HR-HPV, particularly in integrated form (E6/E7 integrated in host DNA) cannot be 
ruled out. Finally, chronic inflammation caused by past infection with other STIs, also linked with 
lower CD4+ cell count, can promote the initiation or progression of cancer (as reviewed in section 
2.7.4, Chapter 2).  
Higher methylation of EPB41L3 was found among ART users at baseline, in particular among 
women with long-duration ART use in SA and this was independent of CD4+ cell count and HR-HPV 
and CIN status but this association was not observed in BF.  This is a curious finding because long-
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duration ART users in SA had higher median CD4+ cell count and lower CIN2+ prevalence at 
baseline compared to ART-naïve women. Further examination of the data among the ≤CIN1 
controls showed that both long-duration and short-duration ART users with ≤CIN1 had slightly 
higher median methylation levels at baseline compared to ART-naïve women with ≤CIN1 (median 
of 0.0 (IQR: 0-2.9) for all ART users combined vs. 0.0 (IQR: 0.0-0.0) among ART naïve. It is possible 
that women who initiated ART at lower nadir CD4+ cell count may have experienced associated 
deregulation of normal TSG activity, resulting in their methylation and silencing. Over time, with 
increasing duration on ART, the corresponding CD4+ cell count recovery may be unable to 
completely reverse the DNA methylation and they could remain at low levels even among ≤CIN1. It 
is also possible that these women may have developed CIN2/3 lesions which were undetected but 
which resolved through CD4+ count recovery. Because the ART-naïve women had a median CD4+ 
count >350 cells/mm3, they never experienced severe immunosuppression which may have been a 
catalyst for past DNA methylation among the ART users.  This may also explain why the EPB41L3 
methylation assay generated poor performance data among women in SA, as the women without 
CIN2+ may have residual methylation levels from when they were severely immunosuppressed. 
Nadir CD4+ cell count data would be required to accurately assess this hypothesis. A second 
possible explanation is the potential for ART genetoxcity and the long term toxic effects of ART 
drugs are not yet known. Animal studies have shown that antiretroviral nucleoside analog drugs, 
such as zidovudine are incorporated into host DNA, where it causes mutations of genes associated 
with gene expression, cell cycle arrest and chromosomal abberations [455].  
10.5 Study limitations 
This study was constrained by its small sample size and its post-hoc design nested into the HARP 
parent study. While 94% of prevalent cases and 96% of incident cases from the parent HARP study 
were included, only a proportion of the controls (BF: 66/583 (11%), and in SA: 144/494 (29.1%)) were 
sampled because of limited resources and available samples. Therefore, the data might not be 
entirely generalizable to all women with ≤CIN1 in the HARP cohort. Furthermore, as the definition 
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for ‘high’ methylation was determined by the distribution of methylation values among the 
selected ≤CIN1 controls, this cut-off may not be reflective of the entire population without disease.   
The study was also limited in its ability to evaluate associations of HPV16 DNA methylation with 
CIN2+, due to the relatively small number of HPV16-positive samples included in the study. This 
study design favoured samples selected for evaluation of EPB41L3, and associations of HPV16 DNA 
methylation with HPV16 persistence could not be adequately assessed without the full set of HPV16 
persistent cases existing in the HARP study. The high co-infection rate of other HR types (35% in BF 
and 72% in SA) among the HPV16 positive samples and the immune evasion capabilities of HPV16 
[420] may have impacted the association of HPV16 methylation and CIN. Larger studies are 
required among both HIV positive and negative women using a variety of HPV methylation markers 
(which are available for HPV16, 18, 31 and 33) to investigate these associations. 
Other studies have restricted measurement of DNA methylation markers to HR-HPV positive 
women to evaluate their performance as triage tests. In this study, the EPB41L3 DNA methylation 
assay was performed irrespective of HR-HPV DNA status to describe the full range of 
epidemiological associations. A secondary sensitivity analysis restricted to HR-HPV positive women 
would help evaluate the performance of the assay as a possible triage test among WLHIV but 
would likely lack power.  
This study had only one prevalent ICC case, hence the study cannot verify the findings of studies 
that have shown even increased methylation EPB41L3 levels in ICC cases [256, 334].  
There was a higher proportion of particpants in SA with zero percentage methylation for EPB41L3 
compared to BF. It remains uncertain why this may be the case, but there are two possible reasons.  
The proportion of ART users in BF in this study was higher than that reported in the main HARP 
cohort (85% vs. 68.6%), and also higher than the proportion of ART users in SA. Given that ART users 
had higher levels of EPB41L3 methylation, this may partly explain why median percentage levels 
were higher overall among women in BF.  Secondly, there may be epigenetic differences between 
the two populations linked to different environmental exposures that cannot be fully investigated 
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in this study.  Others have reported that alcohol and dietary factors, such as folate, vitamin B6 and 
vitamin B12 which supply the methyl units for DNA methylation can modify the effects of DNA 
methylation, especially in combination with environmental carcinogens and infectious agents 
[456]. Although the study did not collect information on diet, WLHIV in BF reported similar alcohol 
intake as their counterparts in SA, and alcohol was found to be associated with an increase in HR-
HPV prevalence among women in BF. Others have shown that naturally occurring seasonal 
variations in food-consumption patterns, which vary by geographic region, have an effect on DNA 
methylation markers  [457]. A larger study enrolling both HIV-negative women and WLHIV would 
be required to test whether there are epigenetic differences between the two populations.  
 
The availability of an histological verification at both baseline and endline may have introduced a 
bias towards positive methylation (even in the absence of true disease) as women needed to have 
evidence of some abnormality in order to have been biopsied. In BF, 88% (58/66) of ≤CIN1 and 99% 
(143/144) of ≤CIN1 in SA were biopsied as they were positive for any one of the screening tests (the 
remainder were negative on all screening test and were considered CIN negative). This may had 
reduced the chances of discriminatory power of women with total absence of abnormalities.   
Despite these limitations, this study had several strengths, including its longitudinal design, the 
availability of a rigorously validated histological endpoint for the majority of women thereby 
minimizing disease ascertainment bias; and the availability of methylation data at both time points. 
Furthermore, the inclusion of women with prevalent CIN2/3 at baseline and followed, untreated, 
up to the endline visit allowed monitoring of methylation levels over time among women with 
varying severity and duration of lesions.    
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10.6 Summary of findings 
 Median methylation levels for EBP41L3 were significantly higher among prevalent 
CIN2/3 vs. ≤CIN1 in BF and SA (Mann-Whitney p<0.001 and Cuzick p-trend by CIN grade 
p<0.001 in both countries).  
 EPB41L3 DNA methylation distinguished women with CIN2/3 with an area under the 
curve (AUC) of 0.77 (95% CI 0.65-0.89) in BF and 0.68 (95%CI 0.62-0.74) in SA.   
 EPB41L3 methylation levels increased over time among the incident CIN2/3 at endline 
(Wilcoxon matched pairs test p=0.06 in BF, and p=0.11 in SA).  
 EPB41L3 methylation at endline generated an AUC of 0.80 (95%CI 0.63-0.97) in BF and 
0.60 (95%CI 0.47-0.73) in SA for incident CIN2/3 detection and 0.95 (95%CI 0.86-1.00) in 
SA for incident CIN3.  
 Among women with prevalent CIN2+ at baseline in SA, EPB41L3  median methylation 
levels at baseline were higher among women with persistent CIN3, or CIN2 which 
progressed to CIN3 compared to women who spontaneously regressed to ≤CIN1 
(Mann-Whitney p=0.016) 
 In both countries ‘high’ EPB41L3 methylation levels at baseline (>66.7 percentile point of 
distribution among ≤CIN1 controls) was associated with low CD4+ count ≤200 cells/mm3 
compared to CD4+ count >350 cells/mm3 (BF: adjusted Odds Ratio [aOR]=7.45, 95%CI 
1.53-36.22; SA: aOR=2.74, 95%CI 1.16-6.47; adjusted for HR-HPV and CIN status).   
 HPV16 L1 DNA methylation was similar between CIN2+ and ≤CIN1 in both countries 
(Mann Whitney p=0.61 in BF and 0.49 in SA; Cuzick p-trend=0.24 in BF and 0.72 in SA).   
 
Conclusion: Methylation of human biomarker gene EPB41L3 DNA is elevated in prevalent 
CIN2/3, and incident and persistent CIN3 cases, and independently associated with lower CD4 
count. 
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10.7 Findings in context 
DNA methylation assays show promise as an earlier indicator of precancer and cervical lesion 
progression in high risk populations, such as WLHIV, alongside existing screening tools with lower 
specificity, such as HPV DNA tests. EPB41L3 showed reasonable performance for the detection of 
CIN2/3. Given that DNA methylation markers in combination panels generate higher sensitivity and 
specificity compared to individual genes on their own (refer Chapter 4), multiplex DNA methylation 
assays including a combination of human genes may have a potential as primary screening of CIN2+ 
among WLHIV.   
An ideal bio-marker for progressive CIN2+ among WLHIV would therefore be sensitive enough to 
detect clinically relevant HPV (i.e. associated with CIN2+) but specific enough to rule out HPV-
positive women without evidence of disease (Test A). Furthermore, the ideal test (or a second test 
in triage; Test B) would be able to distinguish CIN2/3 that would persist from CIN2/3 that may 
spontaneously regress, thus prompting management for those most in need, but avoiding 
unnecessary management, use of resources and associated costs. Test B would be particularly 
useful for settings with limited resources for management, by prioritising women who are most 
likely to persist or progress to ICC for early management.  
The current screening modalities for cervical cancer screening in BF (visual inspection) and SA 
(≥HSIL on cytology) already have shown reasonable performance for Test A, but still result in over-
referral for colposcopy [446]. HPV DNA based testing would not entirely satisfy criteria for Test A 
given its low specificity (though high sensitivity) in this population [446].  Such triage strategies do 
not currently exist in either country. Human gene DNA methylation assays may have the potential 
to satisfy criteria for Test B, as they can be performed using the same clinician-collected or self-
collected sample used for cytology or HPV testing [458] and commercially-available kits are being 
developed but current platforms and the requirement for highly trained laboratory staff preclude 
their use for lower resource settings currently.  
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Figure 10.2. Study flowchart   
 
Case control 1
Cases
Prevalent CIN2+
n=152 
Controls 
≤CIN1 at baseline and 
endline
n=210
Case control 2
Cases
Incident CIN2+
n=26
Controls= 
≤CIN1 at baseline and 
endline
n=159
Histology at endline 
unavailable
n=25
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Figure 10.3. EPB41L3 methylation levels (percentages) by CIN status among 94 WLHIV in Burkina Faso (BF) 
and 268 in South Africa (SA) 
 
 
Table 10.5. EPB41L3 median methylation levels (%) among 94 WLHIV in Burkina Faso and 268 in South 
Africa by CIN grade 
 Burkina Faso South Africa Sites combined 
 N Median % (IQR) p1 N Median % (IQR) p1 N Median % (IQR) p1 
<CIN1 34 0.97 (0.0-2.60) Ref 85 0.0 (0.0-1.30) Ref 119 0.0 (0.0-1.50) Ref 
CIN1 32 1.42 (0.32-3.83) 0.25 59 0.0 (0.0-3.30) 0.05 91 0.87 (0.0-3.47) 0.02 
CIN2 17 6.40 (1.63-15.73) <0.001 73 1.60 (0.0-9.87) <0.001 90 1.80 (0.0-11.17) <0.001 
CIN3 11 8.93 (2.20-39.80) 0.003 51 2.97 (0.0-12.80) <0.001 62 3.85 (0.0-13.13) <0.001 
p-trend2   <0.001      <0.001 
1Mann-Whitney U test,  p-value for difference in median values of CIN2/3 relative to ≤CIN1;  
2Cuzick test for trend; p-value for trend in methylation levels by CIN grade
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Table 10.6. Sensitivity, specificity and area under the curve (AUC) for the detection of prevalent CIN2/3 
relative to ≤CIN1 among 94 WLHIV in Burkina Faso and 268 in South Africa; and incident CIN2/3 relative 
to ≤CIN1 at endline among 57 WLHIV in Burkina Faso and 128 in South Africa 
 Burkina Faso South Africa 
 AUC (95% CI) Sensitivity1 
(%) 
Specificity1 
(%) 
AUC (95% CI) Sensitivity1 
(%) 
Specificity1 
(%) 
       
Baseline EPB41L3  methylation      
Prevalent CIN2/3  0.77 (0.65-0.89) 60.7 72.7 0.68 (0.62-0.74) 58.9 70.8 
Prevalent CIN3  0.77 (0.57-0.97) 63.6 72.7 0.70 (0.62-0.78) 60.8 70.8 
       
Endline EPB41L3  methylation      
Incident CIN2/3  0.80 (0.63-0.97) 75.0 71.7 0.60 (0.47-0.73) 40.9 71.7 
Incident CIN3  0.62 (-)*   0.95 (0.86-1.00) 100.0 71.7 
      
Baseline HPV16 methylation       
Prevalent CIN2/3  0.57 (0.30-0.83) 50.0 73.3 0.45 (0.29-0.60) 16.7 71.4 
Prevalent CIN3  0.77 (0.56-0.99) 80.0 73.3 0.47 (0.30-0.65) 18.8 71.4 
1Sensitivity obtained from reading ROC curve for a set 70% specificity; *only 1 case of incident CIN3 in BF 
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Table 10.7. EPB41L3 median methylation levels (%) at baseline and endline for incident CIN2/3 over 16 months among 57 WLHIV in Burkina Faso and 128 in 
South Africa 
 Burkina Faso South Africa Sites combined 
 N Baseline values 
% (IQR) 
Endline values 
% (IQR) 
P2 N Baseline values 
% (IQR) 
Endline values 
% (IQR) 
P2 N Baseline values 
% (IQR) 
Endline values 
% (IQR) 
P2 
≤CIN1* 53 1.43 (0.73-2.63) 1.20 (0.63-3.63) 0.20 106 0.0 (0.0-1.43) 0.0 (0.0-1.10) 0.68 159 0.0 (0.0-1.9) 0.0 (0.0-2.37) 0.34 
Incident CIN2/3 4 2.45 (0.85-12.62) 5.35 (2.98-18.45) 0.06 22 0.0 (0.0-2.70) 0.0 (0.0-9.80) 0.11 26 0.0 (0.0-3.83) 0.85 (0.0-9.80) 0.02 
p-value1  0.42 0.05   0.68 0.07   0.85 
 
0.10  
≤CIN1* 53 1.43 (0.73-2.63) 1.20 (0.63-3.63) 0.20 106 0.0 (0.0-1.43) 0.0 (0.0-1.10) 0.68 159 0.0 (0.0-1.9) 0.0 (0.0-2.37) 0.34 
Incident CIN2 3 3.83 (0.63-21.4) 7.10 (3.60-29.80) 0.13 19 0.0 (0.0-2.70) 0.0 (0.0-3.77) 0.15 22 0.0 (0.0-3.83) 0.0 (0.0-7.10) 0.03 
p-value1  0.27 0.04   0.76 0.44   0.90 0.50  
Incident CIN3 1 1.07 (-) 2.35 (-) 0.50 3 0.0 (0.0-21.20) 14.2 (2.8-24.5) 0.50 4 0.53 (0.0-11.13) 8.50 (2.58-19.35) 0.31 
p-value1  0.77 0.67   0.71 0.001   0.85 0.005  
*≤CIN1 at both baseline and endline; 1Mann Whitney U p-value for difference in median values of incident CIN2/3 vs. ≤CIN1; 2one-sided Wilcoxon matched pairs test, where the alternative hypothesis is that the 
median of the difference between baseline and endline values is greater than zero 
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Table 10.8. EPB41L3 median methylation (%) at baseline and endline for CIN2/3 persistence, progression 
or regression over 16 months among 36 WLHIV not treated before final biopsy in South Africa  
 N Baseline values 
% (IQR) 
Endline values 
% (IQR) 
P** 
≤CIN1* 106 0.0 (0.0-1.43) 0.0 (0.0-1.10) 0.68 
     
Persistent CIN2 7 2.20 (0.0-3.10) 0.93 (0.0-5.5) 1.00 
Persistent CIN3a 5 11.35 (3.52-16.47) 13.67 (11.67-47.2) 0.31 
Progression CIN2 to CIN3 3 24.70 (3.13-24.83) 14.0 (0.0-18.53) 0.88 
CIN2/3 persistence/progression 8 15.67 (3.13-24.70) 13.82 (8.30-18.75) 0.50 
     
Regression CIN3 to CIN2 5 3.70 (0.0-5.40) 7.60 (2.70-9.50) 0.06 
     
Regression CIN2 to ≤CIN1b 13 0.43 (0.0-7.50) 0.0 (0.0-0.0) 0.997 
Regression CIN3 to ≤CIN1 3 0.0 (0.0-1.37) 4.57 (0.0-17.03) 0.50 
Any regression CIN2/3 to ≤CIN1  16 0.0 (0.0-3.83) 0.0 (0.0-0.0) 0.97 
*≤CIN1 at both baseline and endline; **one-sided Wilcoxon matched pairs test, where the alternative hypothesis is that the median of the 
difference between baseline and endline values is greater than zero; a1 case of persistent CIN3 with missing value at baseline; b1 case of CIN2 
regression to ≤CIN1 with missing values at baseline.    
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Table 10.9. Associations of HIV-related factors on ‘high’ EPB41L3 methylation among 94 WLHIV in Burkina Faso and 266 in South Africa 
  Burkina Faso South Africa 
  N n (%) aOR (95% CI) 1 aOR (95% CI) 2 N n (%) aOR (95% CI) 1 aOR (95% CI) 2 
All participants                 
CD4+ count (cells /mm3)  
  
  
  
 
         <200 15 10 (66.7) 7.45 (1.53-36.22)  - 32 22 (68.8) 2.74 (1.16-6.47)  - 
          201-350 16 7 (43.8) 1.79 (0.50-6.39)  - 73 38 (52.1) 1.52 (0.84-2.75)  - 
           >350 63 22 (34.9) 1.00  - 160 63 (39.4) 1.00  - 
ART status   
  
  
  
 
         >2 years 38 15 (39.5) 1.00 1.00 79 43 (54.4) 1.00 1.00 
        ≤2 years 42 20 (47.6) 1.13  (0.38-3.33)  0.70 (0.22-2.29) 83 43 (51.8) 0.64 (0.33-1.27) 0.48 (0.23-0.99) 
       ART-naive 14 4 (28.6) 0.40 (0.09-1.79) 0.32 (0.06-1.58) 104 37 (35.6) 0.37 (0.19-0.71) 0.38 (0.20-0.74) 
                  
ART users                 
HIV-1 viral suppression          
          <1000 copies/ml 64 27 (42.2) 1.00  129 68 (52.7) 1.00 1.00 
           ≥1000 copies/ml 13 7 (53.9) 2.34 (0.56-9.90) 1.29 (0.25-6.72) 32 18 (56.3) 1.19 (0.51-2.77) 0.94 (0.38-2.29) 
HIV-1 viral detection         
        ≤40 copies/ml 55 22 (40.0) 1.00 1.00 46 25 (54.4) 1.00 1.00 
         >40 copies/ml 22 12 (54.6) 2.40 (0.75-7.73) 1.49 (0.37-5.90) 115 61 (53.0) 1.10 (0.51-2.37) 1.12 (0.52-2.43) 
ART adherence  **  
  
  
  
 
       Low Adherence (<60%) 1 0 (0.0) 1.00 1.00 22 15 (68.2) 1.00 1.00 
      Moderate adherence (60-90%) 74 34 (46.0)  -  - 138 69 (50.0) 1.76 (0.63-4.92) 1.65 (0.58-4.66) 
CD4+ count (cells/mm3)  
  
  
  
 
         <200 13 8 (61.5) 4.88 (0.87-27.29)  - 30 21 (70.0) 2.42 (0.93-6.28)  - 
          201-350 13 7 (53.9) 2.15 (0.54-8.59)  - 45 26 (57.8) 1.80 (0.82-3.94)  - 
           >350 54 20 (37.0) 1.00  - 87 39 (44.8) 1.00  - 
                 
ART-naïve                  
CD4+ count (cells/mm3)   
  
  
  
 
         <200 2 2 (100.0)  -  - 2 1 (50.0) 2.35 (0.12-45.64)  - 
          201-350 3 0 (0.0)  -  - 28 12 (42.9) 1.15 (0.44-3.02)  - 
           >350 9 2 (22.2)  -  - 73 24 (32.9) 1.00  - 
Adjusted Odds Ratio (aOR) 1Model 1 adjusted for HR-HPV and CIN status in both countries, in addition to Candida albicans in BF; 2Model 2 is same as Model with additional adjustment for CD4+ cell count; 3 ART users 
with missing HIV-1 PVL in BF and 1 in SA; 5 participants with no data on adherence in BF and 2 in SA; 1 ART-naïve particiants with no CD4+ cell count in SA 
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11 DISCUSSION AND CONCLUSIONS 
 
In this chapter, I will present a summary of the key findings of the thesis, including a discussion of the 
factors found to be associated with HPV incidence and persistence and CIN2+ prevalence and incidence 
among WLHIV. I will illustrate how the potential interactions of cofactors with HR-HPV and with each 
other might facilitate the persistence of HR-HPV and the eventual incidence and progression of CIN2+. 
The role of ART on HPV and CIN2+ outcomes will be summarised and discussed. I will discuss the 
generalisability of these study findings to a wider population of WLHIV, and finally suggest 
recommendations for the control and prevention of HR-HPV infection and cervical lesions.  
    
11.1 Summary of findings in this thesis 
11.1.1 High levels of HR-HPV prevalence, incidence and persistence 
This study found a high prevalence of HR-HPV, of multiple HR-HPV types and high rates of 
persistence and incidence over a median 16-months follow-up, in both countries. The women 
included in this study did not report recent high-risk sexual behaviours, such as a high number of 
recent sex partners that might have explained the high incidence in these populations. Yet, while 
50% of all women in BF and 80% in SA had a single male sex partner at baseline, approximately half 
of these women in both countries self-reported using a condom all of the time and condom use all 
of the time was associated with a decrease in HR-HPV incidence.  However, around one-third of 
women in both countries had a HIV-positive male partner, and under half of male partners in SA 
were uncircumcised (limited data from BF). These parameters are indicative of an increased risk of 
HPV acquisition.  
HIV seroconcordance has been shown to be one of the strongest risk factors for HPV concordance 
between heterosexual couples [399]. Although this study found an inverse association in the cross-
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sectional study (women with HIV-positive partners had lower HR-HPV prevalence compared to 
women with HIV-negative partners), this was not verified in the prospective for HR-HPV incidence, 
and there may have been some misclassification bias or unmeasured confounding at baseline.  
Studies of heterosexual couples from Cape Town have shown that HPV concordance (penile-
cervical) between couples was significantly higher among HIV-infected couples than among HIV-
seronegative couples [400], and women with a high HPV viral load frequently shared HPV types 
with their male partners [117]. Because PLHIV are less likely to clear HPV infections, frequent re-
infection between partners may occur. It cannot be ruled out, that in this study, newly detected 
HPV DNA at endline could be re-activations of a latent infection, coinciding with periods of lack of 
HIV virological suppression and attendant immunosuppression in one of the partners.  There is a 
possibility of non-synchronous reactivation of infections over time within HIV-seroconcordant 
couples as viral loads of certain genotypes at one point may increase during HIV disease 
progression, thereby increasing transmission potential. The risk may further increase if condom 
use is low or inconsistent, and if male partners are uncircumcised.  
Male circumcision decreases HPV prevalence in both HIV-negative and HIV-positive men [108-113], 
and decreases transmission of HPV to female partners among HIV-negative men [85]. Although 
this study did not find a protective association of male circumcision with HR-HPV incidence, it was 
associated with lower CIN2+ prevalence among women in South Africa, and this may have 
indicated a HR-HPV infection which persisted. An association between male circumcision and HR-
HPV incidence could not be demonstrated in BF, due to the low number of responders to the 
question at enrolment (only 10 women in BF responded to the question), which may indicate the 
question was not well understood by the interviewer or by the woman. The prevalence of male 
circumcision in Burkina Faso is known to be high (83-97%), based on DHS surveys [459] and it is 
therefore less likely that we would find an association of MC with HR-HPV and CIN2+ outcomes.  
While data on HPV prevalence among men in Burkina Faso is unavailable, studies among men in 
Johannesburg report equally high prevalence of HPV and multiple HPV genotypes; among 304 HIV-
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positive men enrolled in a study in Johannesburg, 95% of whom identifying as heterosexual, the 
prevalence of penile HPV was 79%, of HR-HPV was 52% and of multiple HR-HPV was 27%.  [460]. 
 
11.1.2 Poor immunological response to HPV infection  
The women in this study had a very high exposure to HPV, which was not effectively cleared 
resulting in high rates of DNA persistence and CIN2+ prevalence and CIN2/3 incidence over 16 
months. The study has also shown that WLHIV in South Africa had very high HPV seroprevalence 
and seropersistence, with evidence of seroconversion over 16 months, however this did not 
protect against HPV DNA incidence and there is a possibility that seroconversion was a response 
to HR-HPV persistence. A decreased likelihood of seroconversion and DNA clearance and increased 
risk of HR-HPV persistence and CIN2+ prevalence were strongly associated with HIV-related 
factors, such as CD4+ cell count and ART.  In addition to these HIV-related factors which were 
discussed in detail in Chapter 7, the persistence of HR-HPV infection and CIN2+ prevalence were 
further influenced by inflammation linked to co-infection with other STIs and BV, as well as being 
facilitated by the potential carcinogenic effects of injectable contraceptive use.  
The possible interactions of the various cofactors in the pathway from HPV infection to CIN2+ are 
summarised in Figure 11.1. 
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Figure 11.1.Possible interactions of cofactors (injectable contraception and STIs) on the pathway from HPV acquisition to CIN2+   
A full description of the pathway from HR-HPV acquisition to ICC is reviewed in Chapter 2; section 1.4; Th1=T-helper 1 immune response; Th2=T helper 2 immune response; IL=interleukin; TSG=Tumour Suppressor Gene; cross-sectional view 
of cervix on bottom of diagram from [44]
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11.1.3 The role of immunity and inflammation  
In this study, the presence of other STIs, cervicitis and BV was associated with an increase in HR-
HPV incidence, HR-HPV persistence and CIN2+ prevalence.  
The inflammatory response to infection is part of the normal host response to eliminate foreign 
pathogens, however chronic inflammation caused by bacterial and viral infections can promote 
cancer development and progression. While HPV can subvert host immunity and establish 
persistent infection, the co-existence of other STIs can create an inflammatory environment in the 
cervical mucosa, resulting in 1.) inflammatory cytokine responses and 2.) increasing levels of nitric 
oxide that can facilitate the persistence of HR-HPV and allow for carcinogenic changes to occur. 
Figure 11.1 illustrates the interactions of the various cofactors for HPV persistence and cervical 
lesion development and progression which may occur among WLHIV.  
1. Specific cytokine profile involved in inflammation and tumour initiation  
Available evidence suggests that CIN2/3 lesions appear to be characterised by a reduction in the 
Th1 immune response, which stimulates cytokines in response to intracellular parasites such as 
bacteria and parasites, but an increase in the Th2 immune response which modulates antitumor 
responses.  Despite the inconsistency and variation in cytokine panels tested across a number of 
studies among women with CIN2+, increased levels of IL-8 and IL-10 have consistently been shown 
to be associated with CIN2+, while IL-2 and IFN-γ appear to be reduced.  There are however 
difficulties associated with interpretation of cytokine profiles for infection, particularly in blood 
and plasma samples, as HPV does not elicit a systemic response, and no cytokine profile has been 
identified that is specific to HPV infection.  
Higher levels of IL-2 in peripheral blood lymphocyte culture supernatants have been reported in 
women with normal pap smears compared to women with LSIL, HSIL and ICC [461], whilst lower 
concentrations of IL-2 and IFN-γ are been reported in some studies in blood samples of HIV-
negative women with CIN3+ [462, 463] compared to women without cervical disease.  
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By contrast, concentrations of IL-10 have repeatedly been shown to be increased in cervicovaginal 
lavage (CVL) [464, 465], blood [462], serum [466] and plasma [467] of HIV-negative women with 
CIN3 or ICC compared to women with no disease. However, IL-10 levels were similar among HR-
HPV positive and HR-HPV negative without cervical disease [466], suggesting that involvement of 
IL-10 is in the later stages of carcinogenesis rather than infection.   
Levels of IL-8 have also been shown to be elevated in biopsy specimens [468] and CVL samples 
[465, 469] of HIV-negative women with ICC, and were also higher in plasma of women with 
persistent HR-HPV compared to women who cleared infection [470]. Two recent studies among 
93 HIV-positive and 72 HIV-negative women in Cape Town, South Africa [471], and 45 HIV-positive 
and 27 HIV-negative women in Miami, Florida [472], have shown that IL-8 levels were higher among 
HIV-positive women compared to HIV-negative women. Furthermore, women who had presence 
of BV had higher levels of IL-8, after adjustment for HIV status and other confounders [472].  
A similar switch from the Th1 to Th2 immune response is also observed with HIV-disease 
progression. A small study among 13 HIV-positive women and 20 HIV-positive men initiating ART in 
Kigali, Rwanda [473] reported a negative correlation between CD4+ cell count and IL-10, but IL-10 
was positively correlated with HIV-1 plasma viral load (p<0.05). This is consistent with the 
observation that advanced HIV disease is associated with an increased risk of CIN2+.  
Both oral and injectable hormonal contraceptives can regulate cytokine and immunoglobulin 
expression [134] which may facilitate HPV persistence. The injectable hormonal contraceptive 
DMPA (used by 56% WLHIV in South Africa in this study) has been shown to facilitate mucosal 
inflammation, resulting in increases in the concentration of genital cytokines among HIV-negative 
women [474]. DMPA was also found to be associated with a suppressed Th1 response with lower 
levels of IFN-γ, IL-2, IL-4, IL-6, IL-12 and TNFα among HIV-negative women in the USA [475], and 
with increased levels of IL-8 in a cross-sectional analysis of 376 Kenyan and South African HIV-
negative women.  
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2. Elevated nitric oxide is associated with carcinogenesis 
Infections with Trichomonas vaginalis (TV), HSV-2 and BV have been associated with the production 
of nitric oxide and nitrosamine in cervical cells. Nitric oxide is a short-lived, endogenously produced 
free-radical gas that acts as a signalling molecule, induced by immunological stimuli, and is 
regulated by the Tumour Suppressor Gene p53 which inhibits production at elevated 
concentrations through negative feedback loop mechanism [476]. Tannenbaum et al first showed 
that infection resulted in increased levels of nitrite [477].  Nitric oxide is required to kill tumour 
cells, but in high levels, it can also form carcinogenic nitrosamines which can modify DNA or DNA 
repair proteins (Figure 11.1) [478].  Higher levels of nitric oxide have been reported in the serum of 
women with cervical cancer compared to healthy control [479, 480], in vaginal and endocervical 
swabs of women with CIN2+ [465] and increased expression of nitric oxide synthase (nitric oxide 
producing enzyme) was reported in HPV-infected epithelial and inflammatory cells from CIN 
lesions [481]. Nitric oxide has also been shown to act directly on the HPV virus causing earlier mRNA 
expression, silencing of Tumour Suppressor Genes (pRb and p53), resulting in increased survival of 
mutant cells leading to carcinogenesis [476].  
Oestrogen and progesterone can upregulate the nitric oxide production; studies have shown that 
oestrogen can stimulate release of nitric oxide synthase in breast tissue [482] and progresterone 
has been found to activate nitric oxide synthase expression [483].  
It is therefore possible that in this study, women with uncontrolled HIV disease, i.e. low CD4+ cell 
count and high HIV-1 plasma viral load may have higher levels of Th2 cytokines, further exacerbated 
by the presence of BV and injectable contraceptive use, which may have facilitated HR-HPV 
persistence and cervical lesion progression (Figure 11.1). Furthermore, elevated levels of nitric 
oxide associated with infection by other STIs including TV, HSV-2 and BV result in DNA damage, 
silencing of Tumour suppressor Genes and cell transformation. While there is no evidence that this 
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is the case for human gene EPB41L3, selected to be examined in this study, given that it is a TSG 
implicated in other cancers, it is plausible that similar mechanisms may be targeting EPB41L3.   
11.1.4 Role of antiretroviral therapy  
In this study, WLHIV taking ART for prolonged duration (>2 years) had the best outcomes in terms 
of burden of HR-HPV infection and CIN2+ prevalence and incidence. They had the lowest HPV DNA 
prevalence, incidence and persistence and CIN2+ prevalence and incidence when compared to 
short-duration (≤2 years) users or ART-naïve women in both countries. They also had the highest 
likelihood of clearing all HR-HPV infections (Table 11.1 and Table 11.2).  
By contrast, short duration ART users at baseline had the highest HR-HPV prevalence and 
incidence, and the highest CIN2+ prevalence possibly due to the cumulative effect of starting at a 
lower nadir CD4+ cell count. However, by endline, short-duration ART users had high HPV 
seroconversion rates and low CIN2/3 incidence in SA (equivalent to long-duration ART users). A 
longer duration on ART by endline with a corresponding increase in CD4+ cell count may have 
played a part in reducing the risk of CIN2/3 incidence over 16 months.  
ART-naïve participants appeared to have the worst outcomes over time. Although these women 
had a similar risk of HR-HPV prevalence and incidence, and CIN2+ prevalence as short-duration ART 
users (despite higher median CD4+ cell counts), they had the highest CIN2/3 incidence of all the 
groups in South Africa, and the highest persistence of HR-HPV in BF. While short-duration ART 
users appeared to recover their CD4+ T-cells over time and reduce their risk of HR-HPV persistence 
and CIN2/3 incidence, the risk remained elevated for ART-naive women (Table 11.1 and Table 11.2). 
This may be because ART-naïve WLHIV experience a continual decrease in mucosal immunological 
competence over time, despite maintaining a reasonable number of T-lymphocytes. By contrast, 
short-duration users, depending on the timing of ART initiation, may take a longer path to recovery, 
but will eventually restore some level of competence. In this study, the short-duration ART users 
appear to have similar risk of CIN2/3 incidence as long-duration ART users after 16 months duration.  
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These results confirm that there is a beneficial effect of ART initiation on HR-HPV and CIN lesion 
development, preferably early at a high nadir CD4+ cell count when a degree of competence is 
retained, but that positive effects may only appear over prolonged duration. It is unclear whether 
ART has a direct effect on the HPV virus; the most common classes of ARVs, nucleoside and non-
nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs) inhibit the transcription of HIV RNA 
into double-stranded HIV DNA [484] and it is not yet clear whether there may be some similar 
inihibition of the HPV virus. However the indirect effects of ART use include increases in CD4+ cell 
count with a certain degree of competence (perhaps not complete) needed to clear infection and 
prevent lesion progression, in addition to a decrease in other cofactors associated with HR-HPV 
persistence and CIN2+. Indeed, prolonged ART use is associated with a reduction in cervicovaginal 
HSV-2 shedding [142, 485] and regulation of the inflammatory environment [411]. ART use, 
accompanied by an increase in CD4+ cell count was associated with a decrease in IL-10 and an 
increase in IL-2 and IFN-γ among ART initiators in Kigali, Rwanda [473] and among ART initiators in 
in Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, the United States, and Zimbabwe as part 
of randomized controlled trial of ART regimens [486].  
A recent Brazilian study has shown that ART users have decreased nitric oxide compared to ART-
naïve participants. Soccal et al reported [487] among 18 HIV-positive ART-naïve participants, 49 
HIV-positive participants on ART (for at least 6 months) and 46 HIV-negative participants, that 
there was a statistically significant increase in nitric oxide levels in the ART-naïve group 
(164.0 ± 166.6 μmol/L), compared with both the ART users (71.7 ± 53.3 μmol/L) and the HIV-
negative group (98.9 ± 59.4 μmol/L), and the differences in nitric oxide levels were independent of 
gender and other covariates [487]. The similarities in nitric oxide levels between the ART users and 
the HIV-negative group suggest that ART somehow inhibits nitric oxide production among PLHIV, 
but whether this is a direct or indirect effect remains to be understood.   
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Table 11.1.  Summary of HPV and CIN2+ outcomes and their association with ART among WLHIV in Burkina Faso 
  ART-naïve 
Throughout FU 
Short-duration ART Long-duration ART Is association 
independent of CD4+ 
cell count?  
 Median CD4+ count at baseline (IQR) 414 (314, 604) 411 (276, 574) 478 (368, 639)  
 Median CD4+ count at endline (IQR) 586 (432, 888) 519 (368, 710) 627 (420, 829)  
HPV DNA HR-HPV Prevalence 60.1% 65.1% 52.1%  
aPR 1.12  (0.93-1.36) 1.21  (1.03-1.44) 1.00 Yes 
HR-HPV Incidence 47.2% 53.9% 45.5%  
aPR 1.03 (0.80-1.32) 1.20 (0.96-1.50)  No 
HR-HPV persistence 58.6% 33.3% 37.7%  
aOR 1.80 (1.21-2.66) 0.73 (0.45-1.21)  Yes 
HR-HPV complete clearance 17.6% 22.8% 28.2%  
 aPR 0.70 (0.41-1.22) 0.81 (0.50-1.33)  No 
CIN2+ CIN2+ Prevalence 4.2% 7.8% 5.5%  
aOR 1.20 (0.37-3.94) 1.22 (0.48-3.08) 1.00 No 
CIN2/3 Incidence 0.0% 1.0% 1.8%  
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Table 11.2. Summary of HPV and CIN2+ outcomes and their associations with ART among WLHIV in South Africa 
  ART-naïve 
throughout FU 
Short-duration ART Long-duration ART Is association 
independent of CD4+ cell 
count?  
 Median CD4+ count at baseline 
(IQR) 
448  (353, 614) 325 (207, 460) 478 (368, 639)  
 Median CD4+ count at endline 
(IQR) 
437 (346, 543) 427 (311, 509) 457 (326, 628)  
HPV DNA HR-HPV Prevalence 82.2% 82.1% 72.4%  
aPR 1.10 (1.00-1.22) 1.09 (0.98-1.22) 1.00 No (marginal) 
HR-HPV Incidence 47.6% 52.5% 48.6%  
aPR 0.95 (0.76-1.20) 1.01 (0.79-1.28) 1.00 No 
HR-HPV persistence 31.8% 35.2% 24.5%  
aOR 1.50 (0.94-2.40) 1.75 (1.17-2.64) 1.00 Yes 
HR-HPV complete clearance 21.1% 24.5% 33.3%  
 aPR 0.65 (0.42-0.99) 0.82 (0.53-1.26) 1.00 Yes (naïve only) 
HPV serology  HPV Seroprevalence 89.1% 94.3 94.6%  
aPR 0.98 (0.92-1.03) 0.98 (0.92-1.04) 1.00 No 
HPV Seroincidence 41.7% 61.3% 43.5%  
aPR 1.03 (0.83-1.29) 1.26 (1.01-1.56) 1.00 Yes (short vs. long) 
HPV Seroconversion 14.2% 24.6% 17.2%  
aOR 0.85 (0.41-1.75) 1.56 (0.72-3.40) 1.00 No 
 1.00 2.39 (1.02-5.62)  Yes (short vs. naïve) 
CIN2+ CIN2+ Prevalence 25.3% 29.2% 15.0%  
aOR 1.78 (1.06-2.99) 1.81 (1.03-3.17) 1.00 Yes 
CIN2/3 Incidence 9.6% 4.5% 4.5%  
 aOR 2.26 (0.80-6.41) 1.53 (0.43-5.46) 1.00 No (marginal) 
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11.1.5 Why were disease rates higher in South Africa?  
The rates of CIN2+ at baseline and endline were strikingly higher among WLHIV in South Africa 
compared to Burkina Faso, despite similar incidence and persistence rates of HR-HPV, and similar 
HPV genotype distribution and type-specific persistence. The difference in CIN2+ rates is possibly 
due to: a.) the difference in prevalence of co-factors associated with HR-HPV infection which may 
facilitate its persistence, and b.) poorer control of HIV disease among WLHIV in South Africa.  
The prevalence of STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and 
HSV-2) was consistently higher among women in South Africa at baseline, except for Candida 
albicans which was higher among women in Burkina Faso. In particular, nearly all the women 
(95.2%) enrolled in South Africa were HSV-2 seropositive compared to 74.9% in Burkina Faso. The 
resulting inflammation response associated with clinical recurrences and shedding [142, 411] and 
associated cytokine profile that accompany HSV-2 [141, 142, 488] may have facilitated cervical 
lesion progression.  
The prevalence of injectable contraceptive use was also far greater among WLHIV in South Africa 
compared to in Burkina Faso (72.2% vs. 20.0%, p<0.001), even though the proportion of oral 
contraceptive users was largely similar (31.3% vs. 26.8%, p=0.23).  
Women in South Africa were less likely to control HIV disease. Despite similar median CD4+ cell 
counts among ART users in Burkina Faso and South Africa at baseline, a greater proportion of 
women in South Africa had detectable HIV-1 PVL and also lower reported adherence to ART. Short 
duration ART users in South Africa had lower median CD4+ cell counts than their counterparts in 
Burkina Faso at baseline, and possibly started ART at a lower nadir CD4+ cell count, although this 
data was unavailable in this study.   
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11.2 Generalisability of study findings  
Women enrolled in the HARP study in Burkina Faso and South Africa represent the broad spectrum 
of WLHIV attending primary healthcare services in the cities of Ouagadougou and Johannesburg, 
however there may be differences that could affect the generalisability of these findings to the 
wider population of WLHIV. Table 11.3 summarises some of the key characteristics of the HARP 
study population, which were associated with HR-HPV or CIN2+ outcomes, and the known 
prevalence of these factors among a wider population of WLHIV in the respective countries, using 
national estimates, or individual studies when national estimates were unavailable. For some 
parameters, estimates are only available from the general population. The major differences 
between the HARP study participants and the wider population of WLHIV are age, stratification by 
ART and the exclusion of women who have already been treated for CIN.  
Age range 
The median age of women in the HARP study was 36 years (IQR: 31-41) in Burkina Faso and 34 years 
(IQR: 30-40) in South Africa. Women younger than 25 years were excluded from the study, as the 
aim was to evaluate cervical cancer screening strategies, including HPV DNA tests, which are not 
usually recommended for young women, and the exclusion of women <25 years in the HARP study 
may have influenced the overall prevalence of HR-HPV, which could be even higher had we 
included younger age groups. Mostly, persistence of HR-HPV in younger women is known to occur 
less frequently than in older women. Hence our lower age limit of 25 may have resulted in selection 
bias towards lower prevalence and higher persistence of HR-HPV. A population—based 
prospective case-control study in the UK reported that cervical screening in HIV-negative women 
<25 years (20-24 years) had no impact on ICC up to the age of 30 years [489]. 
However, others have shown a high rate of CIN2+ among WLHIV aged 20-25 years in Cape Town 
[397], suggesting that cervical lesions occur earlier among WLHIV compared to their HIV-negative 
counterparts, linked to increased HR-HPV persistence.  Women aged >50 years were excluded from 
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the HARP study due to the difficulty in interpretation of visual inspection in older age groups [490-
492]. Women are now living longer with HIV but increases in AIDS-defining illnesses, including ICC 
in older age are expected. This age exclusion in the HARP study limits the ability to extend findings 
to an older population with higher rates of CIN3 and ICC.  
Antiretroviral viral therapy use 
The proportion of ART users in Burkina Faso and South Africa in the HARP study is representative 
of the national percentage of WLHIV on ART in both countries, according to UNAIDS estimates 
from 2015 [10] although the proportion of ART users in SA is slightly higher than the national 
estimate (63% vs. 53%, respectively). However, the coming years may see an increase in ART use 
among WLHIV if the UNAIDS “90-90-90” strategy launched in 2014 is successful in its aims of 
ensuring that, by 2020, “90% of all people living with HIV will know their HIV status, 90% of all people 
with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people 
receiving antiretroviral therapy will have viral suppression” [493]. The feasibility of achieving these 
aims by 2020 remains uncertain; by the end of 2015, the greatest challenge to meeting the “90-90-
90” targets was in the provision of ART, with large disparities identified across countries [494].  
It would be expected that the increasing availability of ART, with earlier initiation, should 
contribute to lower rates of HR-HPV persistence and CIN2+ incidence among WLHIV, compared to 
what was observed in this study.  
Hormonal contraceptive use 
In both Burkina Faso and South Africa, a higher proportion of HARP participants reported ever 
having used injectable and oral contraception compared to other cohorts of WLHIV in the 
respective countries, which may have resulted in selection bias, making the study findings less 
generalizable to the wider population of WLHIV. This is especially relevant to women in South 
Africa, as this study found an increased risk of CIN2+ prevalence among injectable contraceptive 
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users. It is not clear why the proportion of WLHIV reporting hormonal contraceptive use in HARP 
was higher than other cohorts of WLHIV in South Africa.  In this study both past and current users 
were considered as a single group of ‘ever users’, whereas other studies may have restricted 
analyses to current users only, though it is not clear from the reports. In this study, current users 
had the highest risk of CIN2+ prevalence. The residual risk among past users justified their inclusion 
in the ‘ever users’ risk group. It is also surprising that other cohorts of WLHIV report such low use 
of hormonal contraception, when current prevalence of use in the general population of married 
and in-union women in SA in 2015 was 30.3% [122].  
Other potential sources of bias 
Few women in Burkina Faso provided a response to the question on whether their male partner 
was circumcised or not. The prevalence of male circumcision in Burkina Faso is high (83-97%), based 
on DHS surveys (Table 11.3), and it is therefore less likely that we would find an association of MC 
with HR-HPV and CIN2+ outcomes.  
The HARP study maximised the chances of obtaining histological results by basing biopsy decision 
on positivity of ANY of FOUR screening tests (Hybrid Capture 2 [HC2], cytology with any reading 
≥ASCUS, and abnormal findings on visual inspection [VIA/VILI] or colposcopy) to which ALL 
participants were subjected. This approach and the threshold to trigger biopsy for histology are in 
excess of usual recommendations, to minimise ascertainment bias in this study. Women negative 
by all tests were considered to be at extremely low risk of CIN2 since in particular HPV DNA and 
cytology have very high negative predictive values for CIN2 diagnosis [402]. Based on this biopsy 
algorithm, there is a potentially greater risk of ascertainment bias in BF as fewer women were 
biopsied and biopsy decision was largely based on HC-II test positivity. The CIN2+ prevalence and 
incidence estimates could be underestimated in BF. However, given the high sensitivity and NPV 
of HC-II [377, 402] it is unlikely that we would have missed many cases. In addition, the study built 
a strong review of histological results by consensus of 5 pathologists, which included all CIN1/2 and 
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CIN2+ cases and 10% of <CIN1 cases (among women who had been biopsied for at least one positive 
screening tests).  
As discussed in the limitations of the research Chapters 6 to 10, this study was constrained by the 
limited number of intermediate visits and overall follow-up duration. The definition of cumulative 
HR-HPV incidence over 16 months is of limited duration to assess the associations of risk factors 
with HR-HPV incidence. Furthermore, the study could not rule out type-specific clearance and 
reinfection when estimating persistence during the 16-months interval between HPV testing.  The 
evaluation of HPV at two time points only did not allow precise estimation of the duration of 
infections. Potential misclassifications of HR-HPV infection states could have led to inaccuracies in 
the description of the natural history of HPV and the associations of the risk factors with the 
different HR-HPV infection states. However in using a highly sensitivity genotyping assay (INNO-
LiPA), it is unlikely that persistent HR-HPV infections would have been missed, but HR-HPV 
clearance could have been missed in during the 16-months follow-up period. 
The lack of repeat testing for HIV-1 PVL may have resulted in misclassification of the effectiveness 
of ART use.  ART duration was used as a proxy measure for effective ART use in this study, but 
others have reported that sustained HIV-1 viral suppression over 40 months among ART users was 
associated with a decreased risk of HR-HPV persistence [209].  
Similarly, the lack of repeat testing for STIs at endline prevented further investigation of known 
risk factors for HR-HPV persistence at the time of detection. The use of baseline STI result have 
resulted in inaccuracies in the risk factor analyses for HR-HPV persistence and CIN2/3 incidence.  
Much of the behavioural and sexual behaviour factors were self reported (smoking, hormonal 
contraception, condom use, male partner circumcision and HIV status of male partner) , which can 
result in recall and social desirability bias,and this may have influenced the accuracy of the risk 
factor analyses.    
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Table 11.3. Generalizability of study findings to wider population of WLHIV, based on study population characteristics 
 Burkina Faso 
 
South Africa 
 Prevalence 
in HARP 
National estimates Generalizability to WLHIV 
population  
Prevalence 
in HARP 
National estimates Generalizability to WLHIV 
population?  
Proportion on ART 68.6% 66% [10] Comparable 65.2% 53% [10] Unclear, HARP slightly higher  
Possible selection bias  
HIV-1 viral suppression 
among ART users 
79.9% 81.8% among WLHIV (FSW) 
& 100% among WLHIV 
(non-FSW) [495]1 
Comparable 80.3% 87% among WLHIV* 
[496]  
Lower proportion with HIV-1 PVL 
suppression in HARP  
Measurement bias when using 
different PCR methods and cut-offs 
Smokers 0.8% 5% [497] among general 
population 
HARP is lower than general 
population 
Possible selection or 
information bias 
12.5% 7.3% [498] among 
general population 
Comparable to general population 
Male partner 
circumcision 
No precise 
estimate 
83-97% among general 
population [459] 
Difficult to ascertain as HARP 
data was mostly missing 
Possible Information bias 
48.5% 46 among general 
population [268] 
 
Comparable to general population 
Oral contraception use 26.8% 13.3% any HC among 
WLHIV [499] 
Higher than previous reports, 
but limited data  
Possible selection bias 
 
Not Comparable to generable 
population, but no available 
estimates among WLHIV 
31.3% 9% [500] to 14% [501] HARP is higher than other reports 
among WLHIV. 
Possible selection bias in HARP or 
in other reports 
Injectable 
contraception use 
20.0% 3.3% to 7.3% among general 
population [502, 503] 
72.2% Various from 8% [403], 
40% [501] to 45% [500] 
       
HSV-2 serology 74.9% 59.6% among WLHIV [502] HARP data Is higher, but only  1 
study 
95.2% 77% (mix of HIV 
positive and 
negative)[504] 
HARP data Is higher, but only  1 
study 
Bacterial vaginosis 34.6% 35.7% among WLHIV [499] 
[502] 
Comparable 41.6% 62.5% WLHIV aged 17-21 
years [505] 
HARP is lower but difference in age 
range with [52] 
Possible selection bias, or 
measurement bias for BV 
detection 
1HIV-1 PVL undetectable, defined as <300  copies/ml; FSW=female sex workers; *study combined WLHIV from  South Africa and Uganda for a single estimate
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11.3 Recommendations 
In considering the findings of this study, and taking into account the generalizability of the study 
population to a wider population of WLHIV in Africa, the following recommendations are discussed 
in four key areas: 1.) prevention of CIN through screening; 2.) monitoring and control of HIV disease 
for control of HPV-related disease; 3.) control of co-factors for HPV infection and cervical disease 
progression, including STI prevention and 5.) prevention of HPV infection through vaccination.  
11.3.1 Prevention of CIN through screening  
Cervical cancer screening tests for WLHIV 
Current international guidelines from WHO recommend that cervical cancer screening should be 
started in sexually active girls and women, as soon as they have tested positive for HIV, and if the 
screening test is negative, a repeat test is done within three years [278].  
Repeated screening of WLHIV is extremely important. This study has shown that even among 
previously screened CIN negative women, the incidence of CIN2/3 over a 16-month duration was 
1.2% among WLHIV in Burkina Faso and 5.8% among women in South Africa. It is unclear how many 
of the incident CIN2/3 may have persisted or progressed to higher grades beyond the end of this 
study, however 44% of women with CIN2+ at baseline had spontaneous regression to ≤CIN1 at 
endline.  
The suitability of screening tests for WLHIV is dependent upon: i.) resource requirements; and ii.) 
performance of the test for CIN2+ detection in this population.   
 Visual inspection by VIA/VILI has shown to be the most useful test in resource limited 
setting, requiring minimal equipment and training, and can be performed by trained nurse 
or midwife, however it has variable sensitivity and specificity for CIN2+ [229, 238]. Its 
potential benefit, however, is that frequent screening should be possible if integrated into 
HIV services.  A potential limitation is that it may result in a high number of unnecessary 
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colposcopy referrals; but VIA/VILI can also be coupled with immediate treatment by 
cryotherapy with good overall impact on the early management of CIN2+, as demonstrated 
in Cape Town, South Africa [227].  
 HPV testing is an increasingly recommended primary screening strategy. HPV DNA tests 
are now available in a format that can be easily adapted to resource-limited settings. The 
careHPV test (Qiagen) has shown good performance among HIV-negative women for the 
detection of CIN2+ [236] and in the HARP study [446], although it loses specificity when 
used among WLHIV given the high prevalence of HR-HPV in these populations. HPV testing 
may detect many transient infections, but as a repeat test over the duration of the HARP 
study, its specificity and PPV for detection of CIN2+ increased [446]. 
 There is a potential role for novel screening biomarkers, such as DNA methylation in this 
population, although DNA methylation based tests are not yet ready, nor would they be 
cost-effective as a primary screen for resource limited settings. Their utility as a triage test 
should be evaluated as it could reduce the number of colposcopy referrals, which would 
be valuable in resource-limited settings.  
Increase availability and uptake of cervical cancer screening  
Uptake of cervical cancer screening is still low in both countries; in Burkina Faso, 7.8% of all women 
aged 18-69 years in 2008 were screened within the previous 3 years [266], while in SA the uptake 
of cervical screening in 2014 was estimated to be 21.4% among women aged 30-39 [275]. 
Furthermore, the level of awareness of cervical cancer and HPV varies according to population. In 
this study, there was a high level of awareness of cervical cancer among women in Burkina Faso 
and South Africa (93% and 76%, respectively), despite the fact that a very low number of women 
were aware of HPV (6% and 20%, respectively). A lower proportion of women in Burkina Faso were 
worried about cervical cancer (28% vs. 42% in BF and SA, respectively).  However, a recent survey 
among 87 WLHIV aged 30-69 attending the Kisenyi Health Unit in Kampala, Uganda, found that 
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99% of WLHIV did not think it necessary to be screened for cervical cancer and 96% had never heard 
of HPV, despite the fact that 45% had tested positive for HR-HPV in that study [506].  
More efforts may be needed in emphasising the importance of cervical cancer screening in this 
population. Integration of cervical cancer screening within HIV care services could lead to 
continuity in primary prevention, favoring early detection and management of HPV-related cervical 
lesions with minimal loss to follow-up [507].  
 
11.3.2 Control of HIV disease to enhance the control HPV-related cervical disease  
Early initiation of antiretroviral therapy  (ART) 
CD4+ cell count is one of the strongest predictors of HR-HPV infection, persistence and SIL/CIN 
incidence and progression. But it has a limited effect on regression once lesions have established. 
Encouraging early ART initiation could have a significant impact on reducing CIN2+ incidence. The 
South African Department of Health announced the introduction of immediate ART initiation for 
those testing positive for HIV in the public sector in 2016, however the feasibility of wide-scale 
access with respect to financing, burden on healthcare facilities and access to ART, adherence 
forgiveness and potential risk of drug resistance strains in the community is uncertain.   
Cost-effectiveness studies weighing costs of drugs for all compared to the cost of lives lost or co-
morbidities requiring treatment including AIDS-related, non-AIDS-related cancers and 
opportunistic infection (cardiovascular, kidney and liver disease) are warranted [508].  
Routine screening for women starting ART at low or unknown CD4+ cell count 
ART users with low or unknown nadir CD4+ cell count should be screened frequently, although the 
optimal screening intervals remain unclear. Some authors have suggested that a screening interval 
triaged by CD4+ cell count may be of value considering the dose relationship observed in some 
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lesion progression studies [198]. However, such recommendation may become obsolete as more 
women become treated at higher CD4+ cell count. Of importance, maintaining a sustained viral 
suppression and stable high CD4+ cell count is required to reduce the risks of HR-HPV persistence 
and CIN/SIL development. This requires strong counseling on ART adherence and patience for the 
ART effects to take place.  
High levels of ART adherence 
Treatment success needs strict lifelong drug adherence. Reasons for non-adherence and 
interruption of treatment include the inconvenience of a daily regimen, and side effects associated 
with ART, including lipoatrophy (peripheral fat wasting), lipohypertrophy (central fat 
accumulation), insulin resistance, renal and bone dysfunction and increased risk of cardiovascular 
disease and hepatoxicity [509-513]. Suboptimal adherence allows HIV replication to continue in the 
presence of insufficient drug concentrations leading to drug resistance, which can be monitored 
using HIV genotyping.   Encouraging high adherence, especially among women who started ART 
at low nadir CD4+ cell count  is necessary to reduce the risk of cervical lesion incidence.   
Regular monitoring of CD4+ cell count and HIV plasma viral load 
ART-naïve women are at higher risk of HR-HPV infection and cervical lesion development when 
CD4+ cell count decreases. CD4+ cell count should be monitored closely and ART initiated at high 
CD4+ count. Starting ART early, coupled with rapid virological control, is likely to rapidly improve 
and maintain CD4+ at a higher level [408], leading to possibly more complete immune 
reconstitution at the systemic and mucosal levels, thereby reducing the risk of persistent HR-HPV 
infection and CIN incidence or progression.  
Continued access to ART treatment  
Urbans areas, such as Ouagadougou and Johannesburg attract a substantial migrant population,  
but migrants may not have equal access to healthcare. A recent study among attendees at a public-
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sector HIV care centre in Johannesburg reported that unconfirmed South Africa citizens (without 
national South Africa ID number) were more likely to die or become lost to follow-up after 1-year 
post-ART initiation compared to confirmed SA citizens (with national ID number) [514].  
Both Burkina Faso and South Africa depend on external donor funding for financing of HIV and 
sexual and reproductive health (SRH) services (refer Chapter 2, Table 2.6). Recent changes in 
political will may threaten continued financing of international programmes to provide these 
services to LMIC [515, 516].     
11.3.3 Influence of other co-factors for HPV infection and ICC 
 
Prevention of sexually transmitted infections (STIs) acquisition  
Condom promotion and male circumcision 
There was a high proportion of WLHIV in this study who had a regular male partner who was also 
HIV-positive (~40%), and there was a relatively higher proportion of injectable contraception users 
compared to condom users. While there are no data available to further understand low condom 
use, these women may be less concerned about HIV transmission risk if their partner is also HIV-
seropositive, but they remain at increased risk of acquiring HR-HPV types and other STIs from their 
male partners. Further efforts are required at the levels of service provision; a national evaluation 
to assess STI services in 50 public sector clinical sentinel surveillance facilities in nine provinces in 
South Africa reported using patient actors reported that 31% were offered condoms, 67% were 
offered HIV test, 61% were offered recommended syndromic treatment, and only 6% of providers 
discussed male circumcision with male patient actors [517]. Furthermore, men were more likely 
than women to be offered all services.  
The South African government introduced a Voluntary Medical Male Circumcision (VMMC) policy 
and programme in 2010 with a target of reaching 80% of HIV-negative men aged 15-49 years by 
2015, according to WHO targets [518]. The most recently available data on male circumcision 
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prevalence from 2012 in a survey by the Health Sciences Research Council (HSRC), reported that 
46.4% of men self-reported being circumcised, and this was highest among black men (52.4%) [268]. 
A recent household study has shown that male circumcision was highly acceptable among men 
aged 18 to 49 years in Orange Farm, South Africa and was further enhanced through motivational 
interviews with a male circumcision adviser [519].   
Screening for, and treatment of, sexually transmitted infections (STIs) 
The 2006 WHO guidelines for sexual and reproductive health care, treatment and support of 
WLHIV [520] recommend screening for STIs as part of the initial clinical evaluation of WLHIV, 
including genital examination to detect clinical signs of STIs and laboratory tests, and at each 
subsequent visit, careful attention should be paid to symptoms or examination findings suggesting 
a new or recurrent STIs. Early and effective treatment is recommended, in addition to counselling 
on safe sex practices and notifying and managing partners. The syndromic approach for STI case 
management has shown to be feasible and cost-effective in LMIC [521, 522].  
The prevalence of both bacterial vaginosis (BV) and HSV-2 are very high among WLHIV in this study. 
The underlying causes of BV are not well understood but hormonal changes during menstruation 
or due to hormonal contraception use, and hygiene practices (vaginal cleansing during 
menstruation and after sex) have been shown to cause alterations in vaginal flora. In addition, 
vaginal flora changes are known to occur in response to HIV [142, 523] and HSV-2 infection [524-
526]. Treatment of BV, combined with encouraging safe sex practices (condom use) and 
discouraging some harmful vaginal cleansing practices may contribute to a reduction in 
recurrences.  
Suppressive HSV-2 therapy using antiviral agents, such as acyclovir, reduces HIV-1 genital and 
systemic immune activation, which would lead to a reduction in the inflammatory mucosal 
environment, and balance in vaginal flora. HSV-2 is only partially reduced by ART use, but women 
with low CD4+ were reported to have higher genital HSV-2 DNA [499]. It is unclear whether 
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recurrent HSV-2 virus coinciding with high viral load is required to facilitate inflammatory responses 
and nitric oxide production associated with HR-HPV persistence and cervical lesion development, 
or whether these events also occur even when the virus is in a latent stage. ART initiation at a 
higher CD4+ cell count and maintaining a stable high CD4+ cell count could help reduce HSV-2 
recurrences among WLHIV [485, 527], but further studies are needed to fully investigate 
associations between HSV-2 and HPV virus among WLHIV.  
Hormonal contraception 
Levels of HC use among women in South Africa were very high in this study. A nationally 
representative survey of 6217 South African aged 15-24 year olds found that 52% reported using any 
form of contraception, among whom 67% reported hormonal contraception [528]. Depot 
medroxyprogesterone acetate (DMPA) was reported among 49% of women and has been reported 
to be as high as 90% in some areas [529]. A study among 349 sexually active, non-pregnant HIV-
positive women (18–44 years) matched with 214 HIV-negative women in Soweto, South Africa 
[500] reported that WLHIV were more likely than HIV-negative to report contraception use of any 
kind, which included hormonal, barrier and permanent methods (84% vs. 69%), but similar numbers 
used hormonal contraception (53% vs. 60%). Among the WLHIV, ART users were more likely than 
ART-naïve women to use injectable contraception (56% vs. 34%), possibly because a single dose is 
effective for months, which means fewer clinic visits and freedom from daily pills.  
As part of a technical statement on the use of hormonal contraception among WLHIV [530], the 
WHO reviewed the literature on its association with HIV disease progression and found no strong 
evidence that suggested that hormonal contraception was associated with negative HIV 
outcomes, although the included studies were was largely limited by high rates of contraception 
switching and loss to follow-up. In the technical statement, the WHO recommends that “Women 
living with HIV can continue to use all existing hormonal contraceptive methods without restriction”. 
It was not the purpose of this statement or review to consider the effects of hormonal 
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contraception on HPV infection and cervical lesion development and progression.  However, the 
role of hormonal contraception in cervical lesion development among high-risk women such as 
WLHIV should be considered. Given the high prevalence of injectable contraceptive use among 
WLHIV, the convenience and the benefits associated with its use (unwanted pregnancy avoidance) 
and the fact there is limited data available among WLHIV suggesting an unclear association with 
cervical lesions, a systematic review of the data is would complement this work.   
Smoking  
While smoking was not associated with cervical lesion progression in this study, it was associated 
with HR-HPV prevalence among women in South Africa. Smoking prevalence was low among 
women in Burkina Faso, but in South Africa, it was slightly higher than the national estimate for 
women in South Africa. The overall smoking prevalence is higher among PLHIV compared to the 
general population [531] and the consequences of smoking are greater among PLHIV due to the 
increase in risk of cancers, cardiovascular disease, inflammation and lung infections. Reported 
reasons for smoking among PLHIV include stress relief, coping with depression and anxiety, weight 
control, or habit [531]. Smoking cessation interventions for PLHIV are not widespread. Despite that 
fact that PLHIV were reported to engage in quitting smoking if an intervention is provided by a 
healthcare worker, healthcare workers report patient resistance to smoking cessation 
interventions, in addition to systemic barriers (access to pharmacotherapy, or lack of time) [531]. 
It is unclear whether smoking cessation remains a priority among South African women, however 
WLHIV could be counselled on the added risk of smoking for HIV related diseases.  
11.3.4 Primary prevention of HPV through vaccination among WLHIV 
HPV vaccination for PLHIV is recommended in very few countries (includes the US [532], Brazil 
[533] and the UK [534]), possibly due to the belief that PLHIV can no longer be protected because 
of multiple exposure to HPV types.  
308 
 
 
This study has shown that, while WLHIV mount an antibody response to infection, HPV antibodies 
did not protect against re-infection by the same type. This may be because immune responses are 
weak with low antibody titres that are insufficient to clear incident infections. But recent studies 
have shown that WLHIV seroconvert for HPV vaccine types following vaccination, and antibody 
titres are equivalent to those among HIV-negative women and are stable up to 12-months post-
vaccination [261, 440]. However there are yet no efficacy data against HPV persistence and CIN2+ 
outcomes.  
In this study, few women were infected by all of the bivalent (HPV16/18) and quadrivalent 
(HPV6/11/16/18) HPV types, and no woman was infected by all the nonavalent 
(HPV6/11/11/18/31/33/45/52/58) vaccine types.  WLHIV could potentially benefit from protection 
offered by a multivalent vaccine, such as the nonavalent vaccine, against types that have not yet 
acquired. This study found that up to 45% of CIN2/3 in Burkina Faso and 37% of CIN2/3 in South Africa 
could be prevented by the HPV16/18-targeting vaccines, and that a further 45% of CIN2/3 in Burkina 
Faso and 43% of CIN2/3 in South Africa could be prevented by the additional 5 types 
(HPV31/33/45/51/52) contained in the nonavalent vaccine. However, not all CIN2/3 develop into ICC, 
and not all HPV types found in CIN2+ have the same propensity to evolve towards ICC. At the same 
time, this data shows that vaccination could contribute to a reduction in screen-test positive 
women and subsequent colposcopy referral. Therefore, vaccination could also have an impact on 
screening and colposcopy services. Modelling studies would be required to more accurately 
quantify this impact.  
In 2014, South Africa introduced vaccination for school girls aged 9 years and older using the 
bivalent vaccine. HPV vaccination is expected to have some impact on HIV acquisition in this 
population, due to the fact that HPV infection is associated with increased HIV acquisition [165]. 
There could be a consequent reduction in HIV incidence among young women in the coming years 
as the first cohort of vaccinated girls reach adulthood and sexual debut.     
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Summary recommendations 
 
 Screening  
 Current methods of visual inspection in Burkina Faso and cervical cytology in 
South Africa appear to be feasible and have adequate performance but result 
in over-referral to colposcopy.  
 HPV DNA tests would not be suitable for a single round screening, but could be 
used as repeated screening. 
 There is scope for molecular based tests such as DNA methylation, in the 
future.   
 HIV care 
 Early ART initiation may provide strong benefits in terms of impact on HR-HPV 
and CIN, and these effects should be monitored by research.  
 All newly discovered infected women should be screened for cervical cancer, a 
rapid proactive approach is warranted for those women starting treatment 
late (at low nadir CD4+ cell count).    
 Encourage ART adherence  
 Gynaecologists should be aware of the importance of close monitoring of 
CD4+ T-lymphocyte count among ART naive and sustained HIV virological 
suppression among ART-treated women. 
 HIV treatment services should integrate cervical cancer screening and raise 
awareness among their staff to the needs of WLHIV. 
 Reduction in HPV transmission is of paramount importance 
 Condom promotion 
 Voluntary male circumcision services 
 Screening and treatment of STIs are essential services for WLHIV 
 HPV vaccination should be evaluated in these high-risk populations 
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11.4 Conclusions 
This thesis has described the natural history of HR-HPV infection and CIN2+ in a prospective cohort 
of WLHIV from two countries with different HIV epidemics, burdens of HPV infection and cervical 
cancer, and approaches to screening for cervical cancer. This allows the findings to be extended 
to a range of countries and settings in the region.   
The findings in this thesis confirm that women living with HIV have very high prevalence and 
persistence of HR-HPV, and high rates of CIN2+ prevalence and incidence over 16 months. Despite 
the similar rates of incident and persistent HR-HPV infection, women in South Africa had higher 
rates of CIN2+, which is linked with the poorer control of HIV disease and higher frequency of 
cofactors for CIN2+ in this population, but immune recovery over time corresponded with a 
reduction in risk of CIN2/3 incidence over 16 months. These findings are consistent with those of 
the meta-analysis which investigated the association of ART use on HR-HPV and CIN/SIL outcomes. 
The implications of these findings are that early ART initiation, prolonged use with sustained viral 
suppression and CD4+ cell count recovery is important in controlling HR-HPV and the development 
of CIN2+. 
Although WLHIV have high background rates of HPV infection, there is still scope for further 
prevention of infection. Women living with HIV are infected with a broad range of HPV genotypes, 
were multiply infected and had high HPV type seroprevalence, with limited evidence that HPV 
antibodies protect against same-type reinfection. WLHIV may benefit from vaccination using a 
multivalent vaccine. 
The control of HPV and CIN is important in WLHIV and this thesis explored the role of possible 
biomarkers to be evaluated in this context. DNA methylation of a tumour suppressor gene EPB41L3 
shows promise as a biomarker test for CIN2+ prediction among women living with HIV, although 
larger studies are required to accurately demonstrate this.    
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13 APPENDIX 
Appendix 1. The search strategy for systematic review of the association of ART on HR-HPV and 
cervical lesion outcomes 
Antiretroviral therapy, high-risk human papillomavirus and cervical intraepithelial 
neoplasia: a systematic review and meta-analysis  
 
Search performed using MEDLINE and EMBASE on 12 July 2016 
 
HPV STUDIES: 
HPV [Title/Abstract] OR Human papillomavirus [Title/Abstract] AND Antiretroviral therapy 
[Title/Abstract] OR ART [Title/Abstract] OR Antiretroviral therapy, highly active [MeSH Terms] AND 
Cervix Uteri [MeSH Terms] OR Uterine cervix [MeSH Terms] OR cervical  
CERVICAL LESION STUDIES: 
Intraepithelial neoplasia [Title/Abstract] OR Squamous intraepithelial neoplasia [Title/Abstract] OR 
Neoplasms [MeSH Terms] OR Precancer  [MeSH Terms] OR Intraepithelial lesion [Title/Abstract] OR 
Carcinoma, Squamous Cell [MeSH Terms] OR Precursor lesions [Title/Abstract] OR Cervical 
intraepithelial lesion [MeSH Terms] AND Cervical [Title/Abstract] OR Cervix uteri  [MeSH Terms] OR 
Uterine cervix  [MeSH Terms] AND Antiretroviral therapy [Title/Abstract] OR ART [Title/Abstract] OR 
Antiretroviral therapy, highly active [MeSH Terms]  
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Appendix 2. Quality assessment of studies reporting the effect of ART on HR-HPV prevalence, and other significant findings reported 
First author, 
year 
Participant selection HR-HPV test method Adjustment for confounding Other significant published findings related to HIV  
    Comparison groups Effect estimate, adjustment 
Africa      
Kelly, 2016 WLHIV attending HIV outpatient and treatment centres 
in Ouagadougou and Johannesburg invited to 
participate in a study comparing cervical cancer 
screening methods. Low risk 
PCR based (INNO-LiPA). Low risk In BF: alcohol, marital status, age at first 
pregnancy, cervicitis, CD4+ and ART 
duration. In SA: age, smoking, injectable 
contraception, genital warts, condom use, 
vaginal cleansing, Chlamydia trachomatis, 
BV, Trichomonas vaginalis, CD4+ and ART 
duration. Low risk 
Short duration ART 
(≤2yrs) vs. Long 
duration ART  
(≥2yrs)  
BF: aPR=1.24 (95%CI:1.04-1.47), 
adjusted for CD4+ 
CD4<200 vs. >500 
cells/µl  
BF: aPR=1.43 (95%CI:1.18-1.72), 
 SA: aPR=1.15 (95%CI:1.01-1.30) 
Zeier, 2015 Known HIV-positive women were approached for 
enrolment provided they were ART-naive. Decision to 
start ART based on South African guidelines. LTFU 
unclear. Selection bias of ART initiators. 
PCR based. Low risk Time dependent covariates: time on ART, 
HIV-1 PVL, age, sexual activity, months 
since excision. Low risk 
Months since ART 
initiation (per 
months analysis) 
aOR=0.95 (95%CI: 0.93-0.97), 
adjusted for time on ART, HIV-1 PVL, 
age, sexual activity, months since 
excision 
Ezechi, 2014 80% recruited from cervical cancer screening clinic; 20% 
from community cervical cancer screening outreach in 
urban and rural locations.  
HPV4A ACE PC. Unclear risk age, type of community, LTSP, marital 
status; no adjustment for ART duration or 
HIV-1 PVL or CD4+. High risk 
 
CD4 <200 vs. ≥500 
cells/mm3 
aPR=2.40 (95%CI:1.70-5.90), adjusted 
for age, type of community, LTSP, 
marital status 
Reddy, 2014 All women coming to clinic for routine ART or pre-ART 
care were given the opportunity to participate in the 
study. Large number on ART (82%) limits power to test 
association between ART and HR-HPV. Medium risk 
PCR based (MY09/MY11). Low risk Age, nadir CD4_, time since HIV diagnosis. 
Low risk 
- - 
De Vuyst, 
2012  
WLHIV attending Coptic Hope Centre for Infectious 
Diseases for HIV related conditions invited to participate 
in a study comparing cervical cancer screening methods. 
Low risk 
PCR based (GP5+/6+). Low risk Age, CD4 count and ART duration.  
Low risk 
Long duration ART  
(≥2yrs) vs. ART-naive 
aPR=0.77 (95%CI:0.61-0.96), 
adjusted for age 
 CD4<250 vs. ≥500 
cells/µl among ART-
naive 
aPR=1.51 (95%CI:1.02-2.25), adjusted 
for age 
Jaquet, 2012 Women with no cervical neoplastic lesion (determined 
by visual inspection), consecutively enrolled, attending 
HIV clinic and recruited through cervical cancer 
screening programme in Abidjan. Low risk 
 
Linear Array. Low risk Age, marital status, age at first sex, CD4+. 
Low risk 
CD4<200 vs. ≥500 
cells/µl 
aOR=2.8 (95%CI: 1.1-8.1), adjusted for 
age, marital status, age at first sex 
Veldhuijzen, 
2011 
 
 
‘High-risk’ women testing HIV positive as part of a HIV 
prevalence survey in Kigali, Rwanda were invited to 
participate in a survey for HPV prevalence. Women 
recruited via community meetings in three districts, 
study conducted in an international non-governmental 
organisation. Low risk.  
Linear Array. Low risk Unadjusted analysis undertaken by 
authors. High risk 
- - 
 
 
 
 
Asia 
     
Menezes, 
2015 
Consecutive women receiving care at Y.R. Gaitonde 
Center for AIDS Education and Research in Chennai, 
India. Low sample number (n=50). Medium risk 
PCR based (TS-E7-MPG). Low risk Unadjusted analysis due to small numbers. 
High risk 
- - 
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First author, 
year 
Participant selection HR-HPV test method Adjustment for confounding Other significant published findings related to HIV  
    Comparison groups Effect estimate, adjustment 
Zhang, 2014 Recruitment to HIV clinic  based on linkages with VCT 
centers and referrals of known HIV infected women 
from provincial and prefecture level CDC affiliated ART 
clinics. Representative of HIV-positive women seeking 
cervical cancer screening services. Low risk 
HC2; has good sensitivity for clinically 
relevant HR-HPV.  
Low risk  
Adjusted for age, CD4+ and ART duration.  
Low risk 
- - 
Mane, 2012 Women attending outpatient gynaecology clinic in 
tertiary care hospital in Pune, India, recruited 
consecutively. Low risk 
PCR based (Linear Array). Low risk age, marital status, education, family 
income, parity, age 1st sex, LTSP, past STI, 
smoking, CD4; Other typical confounding 
factors such as smoking, parity were not 
associated with HPV infection;  
Low risk. 
- - 
Aggarwal, 
2012 
HIV-positive women randomly enrolled from ARV clinic. 
Low risk 
Hybribio GenoArray. Low prevalence of HR-
HPV suggests poor sensitivity of test. 
Unclear risk 
Unadjusted analysis undertaken by 
authors. High risk 
- - 
 
 
Latin America 
    
Rocha-
Brischiliari, 
2014 
Women aged 18-66 yrs attending Specialized Assistance 
Service for STD/AIDS of Maringa city/Southern Brazil 
from April to Oct 2011. Low risk. 
PCR based (MY09/MY11/HypCH4V). Low 
risk 
Unadjusted analysis undertaken by 
authors. High risk 
- - 
Dames, 2014 HIV sero-positive women ≥18yrs consecutively enrolled 
from Infectious Disease Clinic at the Princess Margaret 
Hospital in New Providence, Nassau, Bahamas Feb-Sep 
2008. Clinic caters for all Bahaman islands, see 1500 HIV-
positive each year but at time of this study, there was  
no cervical cancer screening progamme (may explain 
high disease). Low risk 
PCR based (HC2+Linear Array). Low risk Unadjusted analysis undertaken by 
authors. High risk 
CD4 ≤200 cells/µl vs. 
>200 cells/µl 
aOR=7.27 (95%CI:1.41-37.53), 
adjusted for age, duration on ART, 
HIV PVL and cytological abnormality 
Grinsztejn, 
2009 
Prospective open cohort (IPEC-Fiocruz) established in 
1996, women followed up in a clinical research hospital 
in Rio de Janeiro. Low risk 
Not PCR based(HC2) but HC2 has good 
sensitivity for HR-HPV. Low risk  
Age, marital status, drug use, age at first 
sex, LTSP, history of HPV, condom use, 
nadir CD4+. Only Prevalence Ratio 
available.  HIgh risk 
Nadir CD4 <100 vs. 
≥250 cells/ µl 
aPR=1.56 (95%CI: 1.18-2.06), adjusted 
for age, marital status, drug use, 
age at first sex, LTSP, history of 
HPV, condom use 
 
 
Europe/North America 
    
Konopnicki, 
2013 
Women consecutively enrolled from cervical cancer 
screening program at AIDS reference centre in Saint-
Pierre University Hospital from 2002 to 2010. Those who 
developed lesions during study period were censored. 
84% of women were of SSA origin. Low risk 
Not PCR based (HC2) but HC2 has good 
sensitivity for HR-HPV. Low risk 
Age, current and nadir CD4+ count, CDC 
stage, duration of HIV follow-up, ART 
duration, HIV-1 viral suppression. Low risk 
Long duration ART  
(≥2yrs) vs. short 
duration (<2yrs) or 
ART-naive 
aPR=0.60 (95%CI:0.37-0.99), 
adjusted for age, current and nadir 
CD4+, CDC stage during HIV 
infection, ART status, HIV-1 viral 
suppression 
 HIV VL suppression 
≥2yrs vs. <2yrs 
aPR=0.28 (95%CI:0.17-0.49), , 
adjusted for age, current and nadir 
CD4+, CDC stage during HIV 
infection, ART status, ART duration 
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First author, 
year 
Participant selection HR-HPV test method Adjustment for confounding Other significant published findings related to HIV  
    Comparison groups Effect estimate, adjustment 
 Nadir CD4 <500 vs. 
≥500 cells/ µl 
aPR=3.31 (95%CI:1.51-7.24), , adjusted 
for age, current  CD4+, CDC stage 
during HIV infection, ART status, 
ART duration, HIV-1 viral 
suppression 
 Per 100 CD4 cells/µl 
increase 
aRR=0.89 (95%CI:0.85-0.93), , 
adjusted for age, current and nadir 
CD4+, CDC stage during HIV 
infection, ART status, ART duration, 
HIV-1 viral suppression 
Blitz, 2013 HIV-positive women recruited from community-based or 
tertiary care centres.  71% of women attended >1 follow-
up visit. Medium risk -significant LTFU 
PCR based (MY09/MY11/HNB01 & PGMY). 
Low risk 
Unadjusted analysis undertaken by 
authors. High risk 
- - 
Minkoff, 
2010 
Prospective follow-up of ART initiators in the Women’s 
Interagency HIV Study (WIHS). Selection bias of ART 
initiators. 
PCR based (MY09/MY11/HMB01). Low risk Treatment of CIN, CD4 pre- and post-
HAART. Women acted as their own 
comparator group. Minimises bias due to 
fact that women starting ART are sicker 
than those who do not yet need ART. Low 
risk. 
- - 
Fife, 2009 Subjects enrolled when they were about to begin ART; 
either in controlled clinical trial or by perscription. 18% 
LTFU at 6 months and 36% loss to follow-up at 24 
months. Hispanic subjects more likely to have HPV data 
at all time points. A higher rate of HR-HPV DNA 
detection at baseline associated (p=0.089) with with 
missing HPV data for at least one visit. Selection bias of 
ART initiators. High risk 
PCR based (Roche). Low risk Age, sexual activity at baseline and current, 
LSIL+ at baseline, CD4 count, HIV-1 PVL. 
Prevalence reported after compared to 
before - participants did not act as their 
own comparator group. High risk 
- - 
NR=not reported 
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Appendix 3. Quality assessment of studies reporting the effect of ART on high-grade cervical lesion prevalence, and other significant findings 
reported 
First author, year 
 
Participant selection 
 
Adjustment for 
confounding 
 
Endpoint determination & 
 Biopsy decision 
 
Other significant findings related to HIV 
Comparison groups Effect estimate, adjustment factors 
Africa      
Kelly, 2016 WLHIV attending HIV outpatient and 
treatment centres in Ouagadougou and 
Johannesburg invited to participate in a 
study comparing cervical cancer screening 
methods. Low risk 
In BF: age, BV, cervical 
ectopy, CD4+ and ART 
duration. In SA: age at first 
pregnancy, injectable 
contraception, LTSP, CD4+ 
and ART duration. Low 
risk 
All participants were referred for colposcopy performed by 
trained colposcopists. Systematic 4-quadrant cervical biopsy, 
including directed biopsy of any suspicious lesions, was 
performed for participants who had abnormalities detected 
by cytology, VIA/VILI or colposcopy, or who were HR-HPV DNA 
positive (Digene HC-II). Low risk 
 
Short duration ART 
(≤2yrs) vs. Long duration 
ART  (≥2yrs)  
SA: aPR=1.99 (95%CI:1.12-3.54), 
adjusted for CD4+ 
 ART-naive vs. Long 
duration ART  (≥2yrs)  
SA: aPR=1.87 (95%CI:1.11-3.17), 
adjusted for CD4+ 
Memiah, 2015 Consecutive enrolment of HIV positive 
women attending ART treatment clinic in 
Kiambu district, Kenya. Study site is a faith 
based hospital offering care and treatment 
to ~4000 HIV infected persons.  
Medium risk 
Unadjusted analysis 
undertaken by authors. 
High risk 
Women positive on VILI were indicated for biopsy. No details 
on histology readings or any QA involved. High risk. 
- - 
      
Huchko, 2014 Screening offered to women enrolled in 
care in two HIV clinics (Family AIDS Care 
and Education Services) in Kisumu, Kenya, 
no prior screening programmes were in 
place. Low risk. 
age and site. No 
adjustment for ART 
duration, HIV-1 PVL or 
CD4+. High risk. 
Screening in 3 clinics; 814 (25%) women were referred for 
colposcopy if: abnormal VIA (main clinic) ; abnormal VIA and 
VILI (staellite clinic 1);and cytology result of ≥ASCUS+ 
(satellite clinic 2) . Biopsies were taken when colposcopy 
abnormal or unsatisfactory (544 women (16.8% of all 
enrolled)). Histology results available for 15% of all enrolled 
women (n=488). High risk - only 15% have histology result; 
25% with colposcopy, remainder have combined VI/ cytology 
endpoint (possible underreporting of cervical disease) 
 
CD4 . ≥500  vs. <200 
among ART-naive 
aOR=0.42 (95%CI:0.22-0.80), 
adjusted for hormonal 
contraception 
Nadir CD4<500 vs. <200  
cells/μl 
aOR=0.61 (95%CI:0.38-0.97), 
adjusted for months in HIV care and 
hormonal contraception 
Months on HAART aOR=0.98 (95%CI: 0.95-1.01), 
adjusted for current CD4+, 
hormonal contraception 
De Vuyst, 2012 HIV positive women attending Coptic Hope 
Centre for Infectious Diseases for HIV 
related conditions invited to participate in 
a study comparing cervical cancer 
screening methods. Low risk 
Age, CD4+ and ART 
duration. Low risk 
All women biopsied (from most abnormal area of cervix, or if 
no lesion was visualised at 12 o clock). Cytology slides and 
biopsies read by single pathologist at Aga Khan University of 
Nairobi. No information on QA. All with histology result. 
Low risk 
CD4<250 vs. ≥500 among 
ART-naive 
aPR=4.23 (95%CI:1.27-14.0), adjusted 
for age 
Long duration ART  
(≥2yrs) vs. ART-naive 
aPR=0.88 (95%CI:0.57-1.35), 
adjusted for age 
Mabeya, 2012 Women recruited from waiting rooms of 
HIV clinics at Moi University school of 
Medicine in Eldoret, Kenya. Low risk 
Unadjusted analysis 
undertaken by authors. 
High risk 
All participants underwent VIA and cytology pap smear done 
by nurse. A single punch biopsy taken from visible abnormal 
lesion with aid of colposcope; if no visible lesion, a single 
punch biopsy taken from eith 6 or 12 oclock. Blinding 
screening and reading. 10% of pap smears and biopsies read 
by an external pathologist.  
All with histology result. Low risk 
- - 
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First author, year 
 
Participant selection 
 
Adjustment for 
confounding 
 
Endpoint determination & 
 Biopsy decision 
 
Other significant findings related to HIV 
Comparison groups Effect estimate, adjustment factors 
Ezechi, 2014 Participants recruited at cervical cancer 
screening clinic, NIMR, Lagos and 10 
communities of Lagos and Ogun States of 
Nigeria during community outreach 
programmes. Women who presented for 
cervical cancer screening at the NIMR clinic 
and during community outreach 
programmes were screened for eligibility 
for recruitment. Low risk 
Unadjusted analysis 
undertaken by authors. 
High risk. Original authors 
report the OR of HSIL+ vs 
Normal, and excludes 
those with ASCUS/LSIL 
from the analysis. 
Reported unadjusted 
analysis includes all 
women. High risk 
(unadjusted)  
 
Cytology only. Interpretation of pap at Anapath laboratory 
using Bethesda system. Second reading by senior pathologist 
of all abnormal cases and 15% normal cases (n=358 [31%] in 
total). In event of discrepency (5% -all ASCUS), slides sent to a 
second senior pathologist for independent review and final 
diagnosis attributed to this final review. Of 17 ASCUS cases, 1 
was upgraded and 5 were downgraded. Low risk. 
- - 
Firnhaber, 2010 Cross-sectional cohort recruitment from 
adult HIV outpatient clinic in teaching 
hospital affiliated with University of 
Witwatersand. Low risk 
Unadjusted OR 
undertaken by authors. 
High risk 
Cytology only, read and analysed according to Bethesda 
system. 10% of cytology sldes sent to University of North 
Carolina for blinded double reading on two occasions; high 
rate of concordance observed (81-85%). Of the 182 cases 
graded as HSIL+, 83 had pathology results; most HSIL cases 
were histologically confirmed as CIN2 (30%) ot CIN3 (47%); 
23% were classified as CIN1. Low risk. 
CD4 <200 vs. ≥500 aPR=2.4 (95%CI:1.4-4.2), adjusted 
for age and ART 
Mogtomo, 2009 Participants recruited in a day care centre 
at Bonassama hospital in Douala for HIV 
therapy. Low risk 
Unadjusted analysis 
undertaken by authors. 
High risk 
Cytology only, read by single pathologist. Unclear whether 
QA was used. High risk.  
- - 
Asia      
Feng, 2012 Recruitment through outreach to 
Women's and Children's Hospital of Luxi 
County in Mangshi, Dehong Perfecture by 
hospital personnel familiar to the local HIV-
infected population. Unpublished data. 
High risk.  
Age, CD4+ and ART 
duration. Low risk. 
Colposcopy performed on all. Biopsy performed on 
consenting participants with clinical evidence of cervical 
abnormalities (does not report N who had histology). Final 
diagnosis based on histology where biopsy was taken, and 
on colposcopic diagnosis where biopsy was not indicated or 
not taken. CIN2+ was 8.4% while HSIL+ was 1.1%. High risk 
- - 
Sahasrabuddhe, 2010 Study participation offered to consecutive 
HIV-infected women in a public-sector ART 
centre in hospital premises. Participants 
also recruited through outreach efforts. No 
participant had previously been screened 
or treated for cervical abnormality. Low 
risk 
Age, education, income, 
age at first sex, lifetime 
sex partners, parity, 
current CD4+, WHO stage 
of HIV disease, HR-HPV. No 
adjustment for ART 
duration or HIV-1 PVL. High 
risk. 
Colposcopy performed on all. Biopsy (cervical punch, ECC or 
LEEP) performed on consenting participants with clinical 
evidence of cervical abnormalities (24.1%). Final diagnosis 
based on histology where biopsy was taken, and on 
colposcopic diagnosis where biopsy was not indicated or not 
taken. Colposcopy results served as final diagnosis for 81.2% 
(246/303) participants. Final histopathology results were 
available for 18.8% (57/303). QA of colposcopic images by a 
senior experienced gynaecologist.  High risk - only 19% have 
histology result 
- - 
 
 
 
 
     
345 
 
 
First author, year 
 
Participant selection 
 
Adjustment for 
confounding 
 
Endpoint determination & 
 Biopsy decision 
 
Other significant findings related to HIV 
Comparison groups Effect estimate, adjustment factors 
Latin America 
De Andrade, 2011 Prospective open cohort at Evandro 
Chagas Clinical Research Institute, Oswaldo 
Cruz Foundation. Low risk 
Unadjusted (reported by 
original authors). High 
risk. 
Directed biopsies performed when minor colposcopic 
changes were observed but it was not possible to exclude 
CIN2+ and the pap test showed LSIL, ASC or normal. No 
information on how many had histology endpoint but 
authors report that all CIN2+/ICC were histopathologically 
reported. High risk 
Nadir CD4<350 vs. ≥350 
cells/μl 
aPR=6.03 (95%CI:1.50-24.3), 
adjusted for Age, smoking, VIN 
and/or VAIN 
Europe      
Patrellli, 2013  HIV-infected women admitted to the 
Department of Obstetrics and Gynaecology 
of the University of Parma, referred from 
Infectious Disease Clinic for early detection 
of HPV-related disease. No details on 
recruitment procedures or selection. 
Medium risk 
 Cytology by pap smear and colposcopy. Those with abnormal 
pap and colposcopy underwent targeted biopsy (48% of all 
women). All colposcopy performed by same examiner. 
Cytology and histology examined by gynaecological 
pathologists. No information on how many, or whether there 
was independent reading or QC. Medium risk. Authors 
mention bias could be attributed to period effect of cytology 
reporting over a 17 year period (frequency and reliability 
changed in subsequent years) and introduction of ASCUS 
class could have reduced number of high grade cases 
reported.   
- - 
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Appendix 4. Quality assessment of studies reporting the effect of ART on high-grade cervical lesion incidence, progression and regression and other 
significant findings reported 
First author, 
year 
Participant selection & ART status Statistical methods used Adjustment for 
confounding 
Endpoint assessment Other significant findings related to HIV 
(Outcome) 
Comparison groups 
Effect estimate, 
adjustment 
Africa (in alphabetical order)      
Adler, 2012 Operational cohort of treatment-naive HIV 
infected women set up to transition 
patients onto ARV, receiving a package of 
care between 2003-2010. Selection bias of 
ART initiators 
For incidence: Survival analysis 
using generalised estimating 
equation, accounts for changes 
over time. Low risk 
BMI, sex history, STI 
symptom, time since 
enrolment, current CD4+ 
count, time-varying CD4+ 
and ART. Low risk.  
Cytology on all women analysed at NHLS 
which is accredited by South African 
National Accreditation System. All smears 
verified by second reader. Low risk.  
(Incidence): Current 
CD4 ≤200 vs. >500 
aHR=1.73 (95%CI:1.15-2.61), 
adjusted for BMI, LTSP, 
STI, smoking, ART 
For progression/regression: 
marginal models which assumes no 
pattern in the correlation of 
observations within an individual; 
i.e. assess differences between 
individuals (a comparison of 
women on ART vs. women not on 
ART).  
 
The survival analysis was restricted 
to the women not on HAART at 
baseline who had a normal 
baseline cervical smear result 
(n=767) and assessed the risk of 
progression to any abnormal 
result. Women started on HAART 
during the study period were 
included in 
the survival analysis after they had 
been receiving treatment for 180 
days.  
 
(Progression): 
Current CD4 <200 
vs. >500 
aOR=2.50 (95%CI:1.67-3.73, 
adjusted for BMI, LTSP, 
STI, smoking, ART 
Kelly, 2016 WLHIV attending HIV outpatient and 
treatment centres in Ouagadougou and 
Johannesburg invited to participate in a 
study comparing cervical cancer screening 
methods. Low risk 
Logistic regression. Not included in 
the meta-analysis.  
Baseline CD4+ and lifetime 
number of sex partners. 
Medium risk 
All participants were referred for 
colposcopy performed by trained 
colposcopists. Systematic 4-quadrant 
cervical biopsy, including directed biopsy of 
any suspicious lesions, was performed for 
participants who had abnormalities 
detected by cytology, VIA/VILI or 
colposcopy, or who were HR-HPV DNA 
positive (Digene HC2). All histological slides 
from women with a local diagnosis of CIN2+ 
and approximately 10% of slides from 
women with ≤CIN1 histological findings 
were reviewed by the HARP Endpoint 
Committee of five pathologists, for 
consensus classification. 
Low risk 
 - 
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First author, 
year 
Participant selection & ART status Statistical methods used Adjustment for 
confounding 
Endpoint assessment Other significant findings related to HIV 
(Outcome) 
Comparison groups 
Effect estimate, 
adjustment 
Firnhaber, 
2012 
Observational longitudinal study included 
women 18-65yrs recruited from adult HIV 
outpatient clinic affiliated with teaching 
hospital in Johannesburg. Low risk.  
For both incidence and 
progression: Poisson regression 
reporting Incidence Rate Ratio. 
Intent-to-treat analysis, so no 
adjustment for change in ART 
exposure after baseline were 
considered -Low risk 
Age, CD4, age 1st sex, 
LTSP, history of STI, 
hormonal contraception, 
condom at last sex, 
employment, current 
smoking, snuff, education. 
No adjustment for change 
in ART exposure after 
baseline. Medium risk 
Cytology on all; 10% of cytology sldes sent 
to University of North Carolina for blinded 
double reading on two occasions; high rate 
of concordance observed (81-85%). Of the 
182 cases graded as HSIL+, 83 had 
pathology results; most HSIL cases were 
histologically confirmed as CIN2 (30%) or 
CIN3 (47%); 23% were classified as CIN1. 
Low risk.  
n/a n/a 
Omar, 2011 Operational cohort of treatment naive HIV 
infected women set up to transition 
patients onto ARV between 2003-2010. 
Although guidelines for annual screening 
have been established, implementation has 
been poor - authors do not think over-
diagnosis bias exists.  
Cox proportional hazards model. 
Low risk 
Age, baseline CD4, 
baseline smear result, 
smoking, baseline weight, 
time-varying ART. Low risk 
Cytology on all; performed at National 
Health Laboratory Service  - accredited by 
South Africa National Accreditation 
System. Women referred to colposcopy if 
cytology abnormal. Smear readers not 
blinded to previous smears which could 
have resulted in spuriously higher rates of 
premalignant lesions than if readers were 
blinded. Each smear was verified by second 
reader and all previous smears with 
higher/lower grade diagnosis to the 
current were then re-reviewed by a senior 
technologist.  For women diagnosed with 
ASCUS (n=16), their subsequent smear was 
used instead of their baseline smear in 
longitudinal analysis of progression and 
regression. ASCUS diagnosed at endline 
were excluded.Medium risk of 
overdiagnosis. 
(Progression): 
Baseline CD4 <200 
vs. >500 
aHR=1.96 (95%CI: 1.33-
2.88), adjusted for age, 
baseline smear result, 
smoking history and time-
varying ART 
Zeier, 2012 Retrospective cohort analysis of records 
from Colposcopy Clinic and Infectious 
Disease Clinic in Tygerberg Hospital, Cape 
Town, information collected from 2004-
2009. Authors identified 1960 cases that 
had LSIL at first abnormal smear, of these 
1720 had follow-up data available; only 
women with FU visit > 6mths after first LSIL 
detected were included, but they were 
included if they experienced progression 
event <6mths. Low risk 
 
Multivariable Cox proportional 
hazards regresion model. Low risk 
Age, CD4+ count at first 
LSIL, virological failure (2 
consecutive HIV VL 
measurements of >1000 
copies/ml at least 4 weeks 
apart) and excision 
treatment. ART 
considered as started 
before LSIL development 
(so no requirement for 
adjustment for duration). 
Low risk.  
Cytology on all; quality of cytology 
assessed by determining the percentage of 
smears with endocervical cells present. 
Cytology result read by pathologist and 
checked by a second pathologist. Low risk.  
n/a n/a 
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First author, 
year 
Participant selection & ART status Statistical methods used Adjustment for 
confounding 
Endpoint assessment Other significant findings related to HIV 
(Outcome) 
Comparison groups 
Effect estimate, 
adjustment 
Latin America 
Kreitchmann, 
2013 
Enrolled all WLHIV referred for 
gynaecological exam at reference center 
for STI/AIDS in Porto Algere, Brazil. Low risk 
Multivariable Cox proportional 
hazards regresion model. Low risk 
Age, CD4+ count, log viral 
load,  years at school. 
Medium risk. 
Cytology on all; all pap smears evaluated in 
one reference laboratory and interpreted 
by a certified cytopathologist. Approx. 10% 
of negative pap smears, chosen at random, 
and all positive smears for any cytologic 
abnormality were independenttly 
interpreted by another cytopathologist. 
Low risk 
(Incidence): Current 
CD4 ≤200 vs. >500 
aHR=3.0 (95%CI:1.2-7.2), 
adjusted for Age, ART, viral 
load, race, education 
(Incidence): Log 
viral load 
(copies/ml) 
aHR=1.4 (1.0-1.9), adjusted 
for Age, ART, CD4+, race, 
education 
 
EuropeNorth America (in alphabetical order) 
     
Blitz, 2013 Women recruited from 28 community 
based or tertiary care centres across 
Canada; 58% Canadian, 31% from HIV-
endemic country, from 1993-2002. There 
was 29% loss to follow-up after baseline 
visit. Medium risk of selection bias. 19% 
were on HAART at start of study; 64% by 
end of study -includes initiators 
Multistate time-homogenous 
Markov models used to model 
bidirectional transitions through 
different disease states by 
individuals over time; assumes that 
transition from one state to 
another is constant over timeand 
the probabilty of of transition 
depends on time between 
observations, rather than the 
overall time of observation. Low 
risk 
Unadjusted -univariate 
results presented only. 
High risk.  
Cytology on all. Women with abnormal 
findings referred for colposcopy and 
biopsy and treatment as necessary. Only 
cytology results used as endpoint. Medium 
risk of reporting bias. Sensitivity analysis 
which groups ASCUS with normal found 
similar results.  
n/a n/a 
Clifford, 2016 Swiss HIV cohort study (SHCS): nationwide 
prospective cohort enrolling PLHIV ≥16yrs. 
Case control study including cases of CIN2/3 
and ICC record in the SHCS and matched to 
≤CIN1 controls using incidence density 
sampling, matched on age, location, HIV 
transmission category and year of 
enrolment. Low risk  
Logistic regression. Not included in 
meta-analysis 
Nadir CD4+. Low risk NR (Incidence): per 100 
cell/µl decrease in 
nadir CD4+ 
OR=1.15, 95%CI: 1.08-1.22 
(Incidence): per 100 
cell/µl decrease in 
current CD4+ (at 
time of CIN2/3 
diagnosis) 
OR=1.10, 95%CI: 1.04-1.16 
Del Mistro, 
2004 
All HIV infected women attending the 
Infectious Disease Units of Vicenza and 
Padova City Hospitals were offered 
gynaecologic consultation from 1994-2002. 
HIV infection acquired by injection drug use 
or heterosexual contact (in near equal 
proportions). Mortality during FU was 9.5%, 
cause of death linked to HIV infection, 
except for 2 which were related by 
hysterectomy complictaions and breast 
cancer. Unclear Risk?  
 
Logistic regression was used to 
estimate odds of lesion regression. 
High risk- does not take into 
account changes over time.  
Unadjusted analysis 
undertaken by authors. 
High risk.  
Cytology on all; colposcopy driven biopsy 
for high grade SILs. Unclear if quality 
checks used for cytology reading. Unclear 
risk.  
n/a n/a 
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First author, 
year 
Participant selection & ART status Statistical methods used Adjustment for 
confounding 
Endpoint assessment Other significant findings related to HIV 
(Outcome) 
Comparison groups 
Effect estimate, 
adjustment 
Ellerbrock, 
2000 
Prospective cohort study of women 
enrolled in the New York Cervical Disease 
Study, recruited from HIV clinics between 
1991-1996. Women recruited from HIV 
clinics directly by health care provider, 
without regard of risk factors for cervical 
disease or clinical HIV status. Enrolled 
women likely to report history of 
prostitution (24%) and intravenous drug use 
(44%). Study conducted prior to 
introduction of protease inhibitors. High 
risk – possible bias given the population 
not generalizable and period effect (early 
ARV use).  
Cox proportional hazard model. 
Assumption of proportionality was 
tested and met in multivariate 
analysis. Low risk.  
Age, smoking, transient 
and persistent HPV, CD4 at 
enrolment. ART was 
included as a time-
dependent variable. Low 
risk 
Cytology on all, confirmed by histology  
(428 biopsies read). Low risk of 
misclassification.  
n/a n/a 
Heard, 2002 Prospective study among HIV positive 
women attending outpatient HIV clinics in 
Paris initiated in 1993, during period 1993-
1999. Period effect - unclear risk.  
Multivariate analysis of lesion 
regression and risj factors 
performed using Cox's 
proportional hazard model. Low 
risk 
HAART was considered as 
time-dependent variable 
using intention-to-
continue treatment 
approach. Women starting 
HAART during follow-up 
were classified as off-
HAART until time of first 
prescription and on-
HAART thereafter. Other 
adjustments for CD4+ 
count at detection, 
calender priod of CIN 
detection (1997-1999 vs. 
1996-1996), lesion grade. 
Low risk 
Cytology on all, standardised colposcopic 
exam with biopsy if necessary. Smears and 
biopsies read by same pathologist. CIN 
defined as high grade on basis of 
histologically confirmed high grade CIN or 
low grade CIN associated with smear 
showing HGSIL, similar for low grade. 
Normal smear and colposcopy, minor 
colposcopic changes associated with 
normal smear were considered as no 
evidence fo CIN. Biopsies taken for 57% of 
all participants. Reader bias?  
n/a n/a 
Heard, 2006 Prospective study enrolling women 
attending gynecology outpatient clinic of 
the HIV dept of Hopital Europeen Georges 
Pompidou and Hopital Cohin, Paris between 
1993-2005 .  Women with SIL diagnosed 
before or at time of enrolment were 
excluded, including those with abnormal 
colposcopic finding at enrolment. Low risk 
Multiple Cox regression model 
accounting for duration of follow-
up. Relative risk reported. Low risk 
Age, ethnicity, smoking, 
LTSP, contraception, 
condom use, CD4+ count, 
inclusion period. 
Hormonal contraception, 
condom use, CD4+ and 
HAART as time-dependent 
variables. Low risk 
Cytology on all; patients with major 
colposcopic abnormalities or high grade 
SIL underwent a biopsy, unless they 
refused or were not compliant for follow-
up. All smears and biopsies read by the 
same patholgist. Possible reader bias?  
n/a n/a 
Kim, 2013 20year Retrospective study among HIV 
infected women cared for at Strong 
Memorial Hospital AIDS Centre with ≥2 pap 
smears  between 1991-2011; 800-1061 
individuals with HIV were followed of which 
30% were women. Mean nadir CD4=206 
Cox proportional hazards 
modelallowing for the possibility of 
a patient having multiple events. 
Sandwich estimator used to adjust 
for the correlation. Low risk 
Time-dependent 
covariates assessed at visit 
prior to event or 
censoring:CD4+ count, 
duration of HIV infection, 
menopausal status, drug 
use, smoking . Low risk 
Cytology on all (Bethesda 1988 and 2001). 
Women with abnormal pap tests were 
referred to gynaecology clinic for 
colposcopy and further management. 
Unclear whether only cytology results 
used. Medium risk.  
(Progression): Per 
100 CD4 cells/mm3 
increase 
aHR=0.91 (95%CI: 0.86-
0.96), adjusted for ART, 
Duration of HIV infection, 
menopausal status, drug 
use, smoking 
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First author, 
year 
Participant selection & ART status Statistical methods used Adjustment for 
confounding 
Endpoint assessment Other significant findings related to HIV 
(Outcome) 
Comparison groups 
Effect estimate, 
adjustment 
Lehtovirta, 
2006 
Retrospective study of HIV positive women 
attending Dept of Obstetrics and 
Gynaecology in the University of Helsinki 
from 1989 to 2003, including all WLHA 
followed up with >1 visit; 65% of Finnish, 21% 
of African origin, origin. Low risk.  
Cox proportional hazard analysis 
used for calculating Relative Risk. 
Unclear risk. 
Age. No adjustment for 
ART duration during 
follow-up. High risk.  
Cytology on all; in event of LSIL+, patients 
had colposcopy and biopsy 
n/a n/a 
Lillo, 2001 HIV positive women recruited from a 
patient care program that included 
gynecologic monitoring from 1995-1997 
Odds Ratios estimated using 
logistic regression. High risk- does 
not take into account changes 
over time.  
CD4+ count, HIV RNA and 
gynecologic treatment. No 
adjustment for duration 
on ART- High risk 
Cytology on all; slides with abnormal 
smears were regularly seen by 2 
cytopathologists and 2 physicians. 53 
women (33%) had colposcopy driven 
biopsy at baseline: 68% had LSIL and 13% 
had HSIL. Low risk or reporting bias.  
n/a n/a 
Minkoff, 
2001 
HIV positive women enrolled in six clinical 
consortia: Bronx, Brooklyn, Chicago, Los 
Aneles, San Francisco, Washington between 
1994-1995 
Odds Ratios estimated using 
logistic regression. As each 
participant could contribute >1 pair 
of smears, inferences were based 
on robust statistical  methods that 
adjust for correlation inherent in 
such repeated measures. High risk- 
does not take into account 
changes over time.  
CD4+ count and pap smear 
status at baseline. No 
adjustment for ART 
duration. High risk 
Cytology (Bethesda 1994). All smears read 
by two cytotechnologists who were 
blinded to participants HIV status.All 
abnormal smears and 10% of all negative 
smears were confirmed by 
cytopathologist. Low risk 
n/a n/a 
Minkoff, 
2010 
Prospective follow-up of ART initiators in 
the Women’s Interagency HIV Study (WIHS) 
from 1994-2002; ≥2 semiannual visits during 
the 2.5 years just prior to HAART initiation 
and ≥2 semiannual visits during the 2.5 years 
immediately following HAART initiation. 
Selection bias of ART initiators.  
Within-woman analysis using 
random effects model -controlled 
for the fact that the data involved 
repeat observations of the same 
women over time and each woman 
acted as their own comparison 
group (after compared to before 
ART initiation). Low risk  
Adjusted for time-
dependent variable, CD4+ 
count pre- and post-
HAART. Low risk 
Cytology on all. Oncogenic SIL (SIL that 
was HR-HPV DNA positive) was used as 
endpoint. HPV DNA testing was performed 
using cervicovaginal lavage sample tested 
on PCR. There is a possibility that some SIL 
lesions could have been missed 
(incorrectly classified as HR-HPV negative). 
However, when analysis was repeated 
with any SIL, results were similar. Low 
risk.  
(Regression): 
Adherence vs. non-
adherence 
aHR=3.75 (95%CI: 1.43-
9.88), adjusted for 
treatment of CIN using a 
time-dependent variable, 
and CD4+ count at the 
start of each period 
Paramsothy, 
2009 
HIV Epidemiology Research Study (HERS): a 
prospective cohort study of women with 
HIV without AIDS–defining conditions were 
selected between 1996-2000; study sites in 
Bronx, Providence and Detroit and 
Baltimore. Low risk 
Cox proportional hazards model. 
Women never on HAART had time 
calculated from first until their last 
study visit. Women on HAART; first 
study visit when they report 
HAART use until their last study 
visit. Women on HAART were 
placed in the model for the time 
before they started HAART as pre-
HAART; measured from first study 
visit until visit before HAART use 
(pre-HAART combined with never 
HAART as comparison group). Low 
risk 
CD4+ count, HPV DNA 
status, baseline pap test 
result. Intent-to-treat 
analysis: once a woman 
reported HAART use, she 
was considered to be on 
HAART through her last 
visit; effect of 
discontinuation, changes 
in regimen or adherence 
were not evaluated. 
Adjusted for time-varying 
CD4+. Medium risk 
Cytology on all (Bethesda 1988). Women 
with abnormal pap in Bronx and 
Providence were referred for colposcopy. 
In Detroit and Baltimore, all women 
received colposcopy. No information 
about quality measures for reading. 
Unclear risk.  
n/a n/a 
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Endpoint assessment Other significant findings related to HIV 
(Outcome) 
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Effect estimate, 
adjustment 
Sirera, 2008 Retrospective cohort study including all 
patients in the database of the HIV Clinical 
Unit of the Germans Trias i Pujol University 
Hospital between 1997-2006, including only 
women with CD4+ >350 cells/mm3 at 
baseline. High selection bias.   
Multivariate proportional hazard 
regression (Cox regression) using 
log-rank test. Low risk 
CD4+ count. Not adjusted 
fir time-varying ART. 
Medium risk 
Cytology on all. Most samples were 
checked by two cytopathologists. When a 
patient was diagnosed with LSIL+, a 
colposcopy and biopsy were proposed to 
verify cytology result.  Low risk.  
n/a n/a 
Soncini, 2007 Screening data from pap smears and 
colposcopic exams were collected from HIV 
positive women at Colposcopy and Cervical 
Pathology Service at Parma University 
Hospital between 1993-2003 within a year 
of being admitted to a screening and early-
diagnosis program for cervical cancer. Only 
patients without prior diagnosis of CIN at 
first visit were enrolled. 81% of Italian orgin, 
14% of African origin. Low risk  
Cox regression model and log-rank 
test.  Low risk 
HAART was considered as 
time-dependent variable 
adjusted for CD4+ at first 
visit. Low risk 
Cytology and colposcopy (93% of visits had 
combined cytology and colposcopy, 
remainder were colposcopy only). If pap 
and/or colposcopy reveal abormality, 
targeted biopsy performed. Cytology and 
histology reviewed by gynecologic 
pathologists at the hospital. Colposcopy by 
two expert colposcopists, according to 
IFCPC classification. Low risk.  
(Incidence): Low vs. 
high CD4 at 
enrolment (unclear 
reporting) 
aHR=2.38 (95%CI:1.44-
3.96), adjusted for time-
dependent ART 
Schuman, 
2003 
HERS study: women 16-55yrs eligible if they 
reported injection use or high risk sex and 
no history of AIDS defining illness between 
1993-1995. Selection bias for a hIgh risk 
population. 
Discrete time survival analysis with 
complementary log-log model link 
allowing a Relative Risk 
interpretation of the coefficients. 
Repeated measures multivariate 
logistic regression models used for 
progression/regression, accounting 
for within-subject correlation. Low 
risk 
Cofactors permitted to 
have different values at 
each visit. Adjusted for 
time (visit), study site, age, 
race, education. Not 
possible to model ART 
duration ART; reported 
ART at each visit was 
considered; would not 
have taken into account 
new, intermittent or 
prolonged duration on 
ART. High risk 
Cytology (Bethesda 1988) on all. A senior 
cytopathologist read all tests originally 
classified as abnormal and 10% of the 
normal. Low risk.  
(Incidence): CD4 
<200 vs >500 at 
baseline 
aRR=2.13 (95%CI: 1.27-3.64), 
adjusted for time (visit), 
site and age 
(Progression): CD4 
<200 vs >500 at 
baseline 
aRR=1.76 (95%CI: 1.09-
2.84), adjusted for time 
(visit), site and age, race 
and education 
(Regression): HIV-1 
viral load (status at 
previous visit) 
aRR=0.78 (95%CI: 0.65-
0.94), adjusted for time 
(visit), site and age, race 
and education 
352 
 
 
 
Appendix 5. Funnel plots of publication bias among studies evaluating the association of ART with 
HR-HPV and cervical lesions 
A. HR-HPV Prevalence (OR=Odds Ratio) B. High-grade lesion prevalence (OR=Odds Ratio) 
  
 
C. Cervical lesion incidence D. Cervical lesion progression 
 
 
E. Cervical lesion regression  
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Appendix 6.Description of included studies for systematic review of DNA methylation and CIN2+ (by gene marker with most recent first)  
Author Methylation marker Country Study design Population Sample 
size 
Median age Sample HPV DNA Methylation  
CADM1/MAL/MIR          
Kim, 2016 CADM1, MAL, PAX1, 
ADCYAP1 
South Korea-
Seoul 
Case-control Samples collected at Cheil General Hospital & Women's 
Healthcare Centre ;HPV positive with concordant biopsy 
and pap result; biopsy-matched LBP sample and not 
population based screening  
170 NR Cervical 
scraping/Liquid 
based cytology 
sample 
Seeplex HPV4 
ACE/GG HPV 
genotyping Chip 
Kit 
PSQ 
VanBaars, 2016 CADM1, MAL Spain-
Barcelona 
Case-control Women aged ≥17y referred for colposcopy to Hospital 
Clinic, Barcelona because of abnormal cervical cytology. 
Random selection of 65 women with varying grades of 
CIN; irrespective of HPV positivity  
60 33 [range:19-92] Cervical 
scraping/Liquid 
based cytology 
sample 
SPF10-PCR-DEIA-
LIPA 
qMSP 
DeVuyst, 2015  CADM1, MAL, MIR Kenya-Nairobi Cohort HIV positive +HR-HPV positive recruited as part of a 
cervical screening study at Coptic Hope Center for 
Infectious Diseases, Nairobi, Kenya 
248 37 [33-42] Cytobrush PCR qMSP 
Verhoef, 2015  CADM1/MAL The 
Netherlands 
RCT HPV positive women from Dutch screening programme 
(PROHTECT3), cytology triage group, self-samples [non-
responder population]. Exclusion of previous 
hysterectomy, or CIN2+ or abnormal cytology in 
previous 2 yrs. All women from this group with HPV+ 
result and valid sample [28 CIN2; 56 CIN3; 6 ICC] 
364 42 [38-48] Cervical scrapes Diassay EIA HPV qMSP 
DeStrooper, 
2014  
CADM1/MAL The 
Netherlands 
Cohort   HR-HPV+ Women participating in population-based 
screening (similar to POBASCAM trial) 
234 34-40 Cervical scrapes PCR qMSP 
DeStrooper, 
2014 
CADM1/MAL/MIR124-
2 
The 
Netherlands 
Case-control Women participating in population based screening or 
attending gynaecological outpatient clinic [79 ICC, 16 
CIN3, 32 CIN2; 120 <CIN2] ; irrespective of HPV positivity 
247 37-48 Cervical scrapes  qMSP 
Hesselink, 2014  CADM1, MAL, MIR The 
Netherlands 
Cohort  HR-HPV+ Non-attending women from Dutch screening 
programme (PROHTECT1) using self-samples [20 CIN2; 
74 CIN3+, includes 4 SCC and 1 ADC] 
355 36-41 Cervical scrapes PCR qMSP 
Hesselink, 2011  CADM1, MAL The 
Netherlands 
Case-control 
(Training+ 
validation set) 
Cervical scraping of 300 of total 1102 HR-HPV+ women 
participating in intervention arm of the population-
based RCT POBASCAM; 51 women selected with CIN3 
detected within first screening + 224 women without 
evidence of CIN2 lesions after 2 screening rounds  
275  Cervical scrapes PCR qMSP 
Overmeer, 2011  CADM1, MAL The 
Netherlands 
Case-control Random selection of 40 cervical scrapings with HR-HPV+ 
normal cytology with no evidence of CIN disease + 30 
scrapings with moderate dyskaryosis or worse of HR-
HPV+ women with CIN3+ obtained from population-
based cervical screening trial POBASCAM 
70 32-34 Cervical scrapes PCR qMSP 
          
MAL/MIR          
Verhoef, 2014  MAL/MIR The 
Netherlands 
Prospective 
cohort 
HPV positive women from Dutch screening programme 
(PROHTECT3) returned self-samples and with study 
endpoint  
1019 43 [33-63] Cervical scrapes-self 
sample 
PCR qMSP 
FAM194A          
DeStrooper, 
2014  
FAM194A The 
Netherlands 
Case-control Validation set of samples comprised hrHPV-positive 
cervical scrapes of 52 women with CIN2+;  including 33 
CIN3+, 19 CIN2, and 166 women with CIN1. 
52 NR Cervical scrapes  PCR qMSP 
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Author Methylation marker Country Study design Population Sample 
size 
Median age Sample HPV DNA Methylation  
EPB41L3          
Lorincz, 2016  EPB41L3, HPV16-L1 UK-London Case-control Samples randomly selected from UK screening group 
(selection based on HR-HPV positivity, cytology results 
and CIN status) 
341 NR Exfoliated cervical 
specimen 
Aptima HPV 
positive +Abbott 
RT for genotyping 
PSQ 
Louvanto, 2015  EPB41L3, LMX1, 
HPV16 
Canada-
Montreal 
Case-control Women with abnormal pap referred for colposcopy and 
matched with women presenting for annual pap 
matched by age and site; irrespective of HPV positivity 
244 NR Exfoliated cervical 
specimen 
Linear Array PSQ 
Vasiljevic, 2014  EPB41L3, EDNRB, 
LMX1, DPYS, MAL, 
CADM1 
UK-London Populaton-
based 
screening 
study 
P1: HR-HPV positive women, Colposcopy referral 
sample, referred due to abnormal smear (Predictors) 
572 mean  Exfoliated cervical 
specimen 
Linear Array + BD 
HPV test 
PSQ 
Boers, 2014 EPB41L3, JAM3, 
TERT, C13ORF18 
The 
Netherlands 
Case-control HR-HPV positive women from Dutch screening 
programme (PROHTECT3b), self-sample. Sample 
selected based on false positive/false negative cytology 
vs. histology 
128 NR Physician collected 
cytobrush 
Diassay EIA HPV qMSP 
Eijinsk, 2012  EPB41L3, JAM3, 
TERT, C13ORF18 
The 
Netherlands-
Groningen 
Case-control Patients referred to colposcopy with abnormal smear 
irrespective of HR-HPV 
143 20-85 Cervical scraping PCR qMSP 
PAX1/SOX          
Xu, 2015  PAX1 China-Shanghai Case-control Women referred for colposcopy or known ICC at the 
central Hospital of Minhang District. Healthy women 
were included as healthy controls with pap test done at 
same time 
121 range of 
mean:36-44 
Cervical scrape PCR PSQ 
Kan, 2014  PAX1 Taiwan-Taipei Case-control 443 women were recruited from the Yuan's General 
Hospital 
96 NR Cervical scrape   
Lai, 2014  PAX1, SOX1 Taiwan Case-control Women aged ≥20y attending 11 medical centres in 
Taiwan, referred for low and high grade lesions 
identified by cytology and underwent biopsy; controls 
recruited from healthy women who underwent routine 
pap screening; final diagnosis made by histopathology 
for cases and cytology for controls 
346 Controls=46yrs Cervical scrape HC2 qMSP 
Wang , 2014  PAX1 China-Shan 
dong 
Case-control Women participating in screening programme at 
Weifang city people’s hospital and with an ASC-H 
diagnosis 
130 mean age 46 
years (range 25-
68) 
Cervical scrape  MS-HRM 
Lin, 2011  PAX1 Taiwan ASCUS triage 
sample set 
Women with ASCUS nested in multicentre study 
attending 11 medical centres in Taiwan, 
220 NR Cervical scrape HC2 MSP 
Huang, 2010  PAX1 Taiwan ASC-H triage Data extracted from an earlier meta-analysis [535] 73     
Lai, 2010  PAX1, SOX1, LMX1 Taiwan Case control Women referred for low and high grade lesions 
identified by cytology and underwent biopsy; controls 
recruited from healthy women who underwent routine 
pap screening; final diagnosis made by histopathology 
for cases an cytology for controls 
185 range of means 
by CIN: 40-54 yrs. 
Cervical scrape NR qMSP 
HPV16          
Bryant, 2015  HPV16-L1/L2/E2 Uk-Cardiff Case-control Women aged 20-22 attending first call for cervical 
screening as part of a cervical screening programme; 
this study included all women who screened positive 
for  HPV16 and were referred for colposcopy (n=267), a 
200 mean-21yrs LBC PCR PSQ 
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Author Methylation marker Country Study design Population Sample 
size 
Median age Sample HPV DNA Methylation  
further 22 who tested positive for HPV16 and with 
cytology normal 
Mirabello, 2015  HPV16-L1 USA-California Case-control Women aged 30 yrs. and older screening routinely using 
HC2 and cytology at Kaiser Permanente California; 
women aged <30 yrs. with ASCUS are triaged using HC2. 
HPV persistence and progression cohort is repository of 
residual cervical specimens; cases=women with HPV16 
at enrolment with CIN2/3 at enrolment; controls- HPV16 
positive at enrolment with <CIN2 and <LSIL during FU 
99 Cases: 33 
[range:22-68]; 
controls=34 
[range:21-64] 
Exfoliated cervical 
specimen in 
Specimen transport 
medium (STM) 
HC2 + PCR PSQ+NGS 
Qiu, 2015  HPV16-L1 China-
Zhengzhou 
Convenience 
sample 
Patients undergoing routine LBC test at Third Affiliated 
Hospital of Zhengzhou University; women with 
abnormal cytology referred for cervical biopsy; HPV16+ 
114 37 [range: 25-74] Cervical scrape PCR qPCR/MS-HRM 
(me-sensitive 
high-resolution 
melting 
Simanaviciene, 
2015  
HPV16-L1, LCR Lithuania-
Vilnius 
Case-control 
(unclear from 
the methods) 
Samples from a prior study estimating prevalence of HR-
HPV among Lithuanian women with cervical pathology. 
HPV16+ 
157 NR Cervical swab PCR Bisulfite 
sequencing 
Brandsma, 2014  HPV16-L1/L2/E2 Senegal-
Dakar/USA-
New Haven 
Case-control 
(unclear from 
methods) 
Two populations enrolled-21 women from routine ccx 
screening program in New Haven+12 women in Dakar 
never before screened attending community health 
clinic for reasons unrelated to ccx. All HPV+ 
33 African 
women=44 yrs 
(range:27-60); 
Usa-34 yrs (range: 
23-65) 
Cytology samples PCR Bisulfite 
sequencing 
Brentnall, 2014  HPV16, 18, 31 UK-London Population-
based 
Screening 
sample 
Colposcopy referral sample, referred due to abnormal 
smear; HPV16+ 
1493 NR Exfoliated cervical 
specimen 
Linear Array+ BD 
HPV test 
PSQ 
Bryant, 2014  HPV16-L1/L2/E2 UK-South 
Wales 
Population-
based 
screened 
sample 
HPV16+ samples from population based screening 37 26-31 LBC PCR 
 
Lorincz, 2013  HPV16-L1/L2/E6/URR UK-Wales Prospective HPV16+ Samples from clinical trial among women with 
newly diagnosed LG (borderline changes or mild 
dysplasia) cytological abnormalities; all women invited 
for colposcopy at 6 months with biopsy 
73 NR Exfoliated cervical 
specimen 
PCR PSQ 
Mirabello, 2013  HPV16 Costa-Rica-
Guanacaste 
Case-control Samples from population based cohort of 10,049 
individuals recruited for screening and followed up as 
part of natural history study of HPV among women >18 
yrs. Women referred to colposcopy if cytology 
abnormal. This study includes HPV16+ women; 100 with 
clearance in >2 yrs., 38 with persistence w/o CIN2+; 67 
with HR-HPV persistence and CIN2+ 
273 NR Cervical swab PCR PSQ 
Xi, 2011  HPV16-LCR USA Case-control Women (18-50 yrs.) attending Planned Parenthood 
clinics in Western Washington for routine 
Papanicolaou screening who were HPV16 positive at the 
screening and/or subsequent colposcopy visit 
211 NR Cervical swab PCR SequencerTM 
Hublarova, 2009  HPV16-E6 Promoter         NK Unclear 
(abstract only 
retrieved) 
Abstract only retrieved; cervical smears from 
asymptomatic women with no cytological and 
colposcopic abnormalities, 20.4% were HPV-16-positive. 
103 NR NR PCR specific restriction 
endonuclease 
McrBC 
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Appendix 7.Performance measures of CADM1 methylation assays for the detection of CIN2/3 and CIN3+ compared to ≤CIN1 in 7 studies 
Author Country Sample size Case definition N Cases Sensitivity  Specificity  PPV NPV AUC 
CIN2/3 
         
Kim, 2016 [329] South Korea-
Seoul 
170 CIN2/3 48 12.5% 95.9% 66.7% 62.8% 
VanBaars, 2016 [330] Spain-Barcelona 60 CIN2/3 25 20.0% 94.3% 71.4% 62.3% 
 
DeVuyst, 2015 [17] Kenya-Nairobi 248 CIN2/3 93 64.0% 70.0% 56.1% 76.4% 0.740 
 
CIN3 
         
VanBaars, 2016 [330] Spain-Barcelona 60 CIN3 12 33.3% 94.3% 66.7% 80.5% 
 
DeVuyst, 2015 [17] Kenya-Nairobi 248 CIN3 43 75.0% 70.0% 41.0% 91.0% 0.800 
Overmeer, 20114 [333] The Netherlands 70 CIN3 30 86.7% 92.5% 89.7% 90.2%  
          
CIN3+          
Hesselink, 20142 [331] The Netherlands 355 CIN3+  74 47.0% 70.0% 29.2% 83.4% 0.637 
Hesselink, 20113  [332] The Netherlands 275 CIN3+  38 79.0% 70.0% 36.0% 94.0% 0.682 
PPV=Positive Predictive Value; NPV=Negative Predictive Value; AUC=Area under the operating receiving characteristic (not reported by all studies);2includes 4 squamous cell carcinoma and 1 Adenocarcinoma; 
3includes 3 squamous cell carcinoma and 1 Adenocarcinoma in situ; 4 includes 2 cancer cases 
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Appendix 8.Performance measures of MAL methylation assays for the detection of CIN2/3 and CIN3+ compared to ≤CIN1 in 7 studies 
Author Country Sample size Case definition N cases Sensitivity Specificity PPV NPV AUC  
CIN2/3 
         
Kim, 2016 [329] South Korea-Seoul 170 CIN2/3 48 2.1% 91.9% 14.3% 59.1% 
 
VanBaars, 2016 [330] Spain-Barcelona 60 CIN2/3 25 32.0% 77.1% 50.0% 61.4% 
 
DeVuyst, 2015 [17] Kenya-Nairobi 248 CIN2/3 93 64.0% 70.0% 56.1% 76.4% 0.72 
Vasiljevic, 2014 [328] UK-London 572 CIN2/3 208 90.0% 12.0% 36.9% 67.7% 0.62 
          
CIN3 
         
VanBaars, 2016 [330] Spain-Barcelona 60 CIN3 12 41.7% 77.1% 38.5% 79.4% 
 
DeVuyst, 2015 [17] Kenya-Nairobi 248 CIN3 43 70.0% 70.0% 39.3% 89.4% 0.77 
Overmeer, 20114 [333] The Netherlands 70 CIN3 30 83.3% 87.5% 83.3% 87.5%  
          
CIN3+          
Hesselink, 20142 [331] The Netherlands 355 CIN3+ 74 67.0% 70.0% 37.0% 89.0% 0.77 
Hesselink, 20113  [332] The Netherlands 275 CIN3+ 38 60.0% 70.0% 29.9% 89.1% 0.57 
          
PPV=Positive Predictive Value; NPV=Negative Predictive Value; AUC=Area under the operating receiving characteristic curve (not reported by all studies);  2includes 4 squamous cell carcinoma and 1 
Adenocarcinoma; 3includes 3 squamous cell carcinoma and 1 Adenocarcinoma in situ; 4 includes 2 cancer cases
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Appendix 9.Performance measures of combination methylation panel assays of CADM1, MAL and MIR for detection of CIN2/3 and CIN3+ compared to 
≤CIN1 in 7 studies 
Author Country Sample size Case definition N cases Sensitivity Specificity PPV NPV AUC* 
          
CIN2/3          
CADM1/MAL          
VanBaars, 2016 [330] Spain-Barcelona 60 CIN2/3 25 36.0% 71.4% 47.4% 61.0%  
Verhoef, 2015 [351] The Netherlands 358 CIN2/3 84 57.1% 72.3% 38.7% 91.2%  
DeStrooper, 2014 [352]2 The Netherlands 234 CIN2+ 58 62.1% 78.4% 48.6% 86.3%  
Hesselink, 2011  [332] 3 The Netherlands 236 CIN2+ 58 62.1% 78.1% 48.0% 86.3%  
MAL/MIR          
Verhoef, 2014 [353] The Netherlands 1019 CIN2/3 212 30.7% 83.0% 32.5% 81.8%  
Hesselink, 2014 4 The Netherlands 355 CIN2+ 94 59.6% 70.0% 41.7% 82.8%  
CADM1/MAL/MIR          
DeVuyst, 2015 [17] Kenya-Nairobi 248 CIN2/3 93 65.0% 80.0% 66.0%  0.80 
DeStrooper, 2014 [354] The Netherlands 247 CIN2/3 48 47.9% 80.8% 50.0% 79.5%  
CIN3+          
CADM1/MAL          
VanBaars, 2016 [330] Spain-Barcelona 60 CIN3 12 50.0% 71.4% 37.5% 80.6%  
Verhoef, 2015 [351] The Netherlands 330 CIN3 56 66.1% 72.3% 32.7% 79.5%  
Overmeer, 2011 [333] The Netherlands 70 CIN3 30 90.0% 87.5% 84.4% 92.1%  
DeStrooper, 2014 [352] 2 The Netherlands 234 CIN3+ 38 68.4% 75.5% 35.1% 92.5%  
Hesselink, 2011  [332] 3 The Netherlands 236 CIN3+ 38 68.4% 75.3% 34.7% 92.5%  
MAL/MIR          
Verhoef, 2014 [353] The Netherlands 1019 CIN3 134 41.0% 83.0% 28.9% 89.3%  
Hesselink, 2014 The Netherlands 355 CIN3+ 74 64.9% 70.0% 36.3% 88.3%  
          
CADM1/MAL/MIR          
DeVuyst, 2015 [17] Kenya-Nairobi 248 CIN3 43 77.0% 80.0% 52.0%  0.85 
DeStrooper, 2014 [354] The Netherlands 247 CIN3 16 68.8% 80.8% 32.4% 95.9%  
DeStrooper, 2014 [354] 5 The Netherlands 247 CIN3+ 95 94.7% 77.0% 72.0% 95.9%  
PPV=Positive Predictive Value; NPV=Negative Predictive Value; AUC=Area under the operating receiving characteristic curve  (not reported by all studies); 2includes 3 squamous cell carcinoma (SCC) and 1 Adenocarcinoma in situ (AdCaIS); 
3includes 3 SCC and 1 AdCaIS; 4);  4includes 4 squamous cell carcinoma and 1 Adenocarcinoma; 5 includes 62 SCC, 12 AdCa, 2  Adenosquamous carcinoma and 3 undifferentiated carcinoma; *few studies provided AUC estimates
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Appendix 10.Performance measures of EPB41L3 methylation for the detection of CIN2/3 and CIN3+ compared to ≤CIN1 in 5 studies 
Author Country Sample size Case definition N cases Sensitivity Specificity PPV NPV AUC   
         
  
CIN2/3 
        
  
Louvanto, 20152 [334] Canada-Montreal 210 CIN2/3 94 60.0% 70.0% 76.7% 51.5% 0.67  
Boers, 20143 [254] The Netherlands 119 CIN2/3 40 60.0% 57.0% 41.4% 73.8%   
Vasiljevic, 20142 [328] UK-London 884 CIN2/3 323 61.0% 70.0% 55.6% 74.5%   
Eijinsk, 2012 [335] The Netherlands-Groningen 200 CIN2/3 66 50.0% 88.1% 67.3% 78.1%   
           
CIN2+           
Lorincz, 2016 [256]5 UK-London 341 CIN2+ 39 74.0% 65.0% 21.5% 95.1% 0.73  
Louvanto, 20152,4 [334] Canada-Montreal 210 CIN2+ 153 78.4% 35.1% 76.4% 37.7% 0.73  
Eijinsk, 2012 [335]6 The Netherlands-Groningen 200 CIN2+  65.0% 79.0%     
         
  
CIN3+ 
        
  
Boers, 20143 [254] The Netherlands 104 CIN3 25 84.0% 57.0% 38.2% 91.8% 0.88  
Eijinsk, 2012 [335] The Netherlands-Groningen 171 CIN3 37 67.6% 88.1% 61.0% 90.8%   
Eijinsk, 2012 [335]6 The Netherlands-Groningen 171 CIN3+   82.0% 73.0%     
Lorincz, 2016 [256]5 UK-London 341 CIN3+ 19 84.0% 63.0% 11.9% 98.5% 0.80  
PPV=Positive Predictive Value; NPV=Negative Predictive Value; AUC=Area under the operating receiving characteristic curve (not reported by all studies); 2Read from ROC curve for 70% specificity; 3Invasive 
cancer cases removed from analysis; 4includes 31 SCC and 28 ADC;  5in combination with HPV16, 18, 31 and 33; 6 in combination with TERT (telomerase reverse transcriptase), JAM3 (junctional adhesion 
molecule 3) and C13ORF18 (Chromosome 13 Open Reading Frame 18) 
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Appendix 11.Performance measures of PAX1 for the detection of CIN2/3 and CIN3+ in 8 studies 
Author Country Sample size Case definition Reference N cases Sensitivity Specificity PPV NPV  
          
 
CIN2/3          
 
Kim, 2016 [329] South Korea-Seoul 170 CIN2/3 ≤CIN1 48 14.6% 97.3% 77.8% 63.7%  
Xu, 2015 [336] China-Shanghai 121 CIN2/3 ≤CIN1 34 44.1% 95.0% 83.3% 75.0%  
Wang, 2014 [337]3 China-Shan dong 130 CIN2/3 ≤CIN1 29 79.3% 94.9% 82.1% 85.5%  
Lin, 2011 [338] Taiwan 220 CIN2/3 ≤CIN1 31 22.6% 90.4% 29.2% 87.0%  
           
CIN2+            
Lai, 2014 [339] 1 Taiwan 346 CIN2+ ≤CIN1 62 37.1% 89.8% 46.9% 85.4%  
Kan, 2014 [340] 2 Taiwan-Taipei 96 CIN2+ ≤CIN1 43 74.4% 88.7% 84.2% 81.0%  
Huang, 2010 [341] 4 Taiwan 73 CIN2+ ≤CIN1 39 56.4% 100.0% 100.0% 62.2%  
Lai, 2010 [342] 5 Taiwan 185 CIN2+ ≤CIN1 90 77.8% 100.0% 100.0% 72.2%  
          
 
CIN3          
 
Wang, 2014 [337]3 China-Shan dong 130 CIN3 ≤CIN1 12 91.7% 94.9% 68.8% 98.9%  
Lin, 2011 [338] Taiwan 220 CIN3 ≤CIN1 14 35.7% 90.4% 22.7% 93.1%  
           
CIN3+           
Kan, 2014 [340] 2 Taiwan-Taipei 89 CIN3+ ≤CIN1 36 86.1% 88.7% 83.8% 90.4%  
Lin, 2011 [338] Taiwan 220 CIN3+ ≤CIN1 25 52.0% 90.4% 43.3% 93.1%  
Huang, 2010 [341] 4 Taiwan 73 CIN3+ ≤CIN1 37 54.1% 99.9% 97.6% 41.4%  
Lai, 2010 [342] 5 Taiwan 185 CIN3+ ≤CIN1 73 94.5% 99.9% 99.3% 92.9%  
Lai, 2014 [339] 1 Taiwan 346 CIN3+ ≤CIN1 62 74.2% 89.8% 63.9% 89.8%  
PPV=Positive Predictive Value; NPV=Negative Predictive Value; AUC=Area under the operating receiving characteristic curve was not reported in any study; 1 Lai 2014 includes unknown carcinoma in situ (CIS); 2 
Kan includes 4 Adenocarcinoma (AC)/squamous cell carcinoma (SCC); 3 Wang includes 2 AC/SCC; 4Huang includes 14 AC/SCC; 5 Lai 2010 includes 27 AC/SCC; 
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Appendix 12.Performance measures of SOX1 for the detection of CIN2/3 and CIN3+ in 2 studies  
Author 
 
Country 
 
Sample size 
 
Case definition  
 
Reference 
 
N cases 
 
Sensitivity 
 
Specificity 
 
PPV 
 
NPV 
 
CIN2+          
Lai, 2014[339] 1 Taiwan 346 CIN2+ ≤CIN1 62 43.5% 79.9% 34.6% 85.3% 
          
CIN3+          
Lai, 2014 [339] 1 Taiwan 346 CIN3+ ≤CIN1 62 80.6% 79.9% 49.5% 90.2% 
Lai, 2010 [342] 2 Taiwan 185 CIN3+ ≤CIN1 73 87.7% 81.6% 77.2% 90.3% 
          
PPV=Positive Predictive Value; NPV=Negative Predictive Value; AUC=Area under the operating receiving characteristic curve was not reported by any study; 1 Lai 2014 includes unknown carcinoma in situ (CIS); 
2Lai 2010 includes 27 AC/SCC; 
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Appendix 13.Summary of studies reporting performance estimates of methylation of HPV16 L1, L2, E2 and LCR regions for detection of CIN2/3, CIN2+ 
and CIN3+ relative to ≤CIN1, in 10 studies 
Author HPV Country Sample 
size 
Case 
definition 
N cases Sensitivity Specificity PPV NPV AUC 
L1/L2 regions           
CIN2/3           
Louvanto, 2015 [334] 1 HPV16-L1 Canada-Montreal 244 CIN2/3 94 62.5% 70.0% 77.5% 53.1%  
Mirabello, 2015 [343] HPV16-L1 USA-California 99 CIN2/3 59 92.5% 73.1% 83.5% 86.9%  
Simanaviciene, 2015 [344] HPV16-L1 Lithuania-Vilnius 157 CIN2/3 87 20.7% 97.4% 94.7% 35.5%  
Brentnall, 2014 [345] HPV16 -L1/L2 UK-London 556 CIN2/3 323 90.0% 38.0% 66.8% 73.3%  
Brandsma, 2014 [346] HPV16-L1/L2/E2 Senegal-Dakar/USA-New Haven 33 CIN2/3 12 75.0% 75.0% 69.2% 80.0%  
Lorincz, 2013 [347] HPV16-L1/L2 UK-Wales 73 CIN2/3 25 92.0% 40.0% 44.4% 90.6%  
Lorincz, 2013 [347] HPV16-L1/L2/E6/URR UK-Wales 73 CIN2/3 25 92.0% 40.0% 44.4% 90.6%  
           
CIN2+           
Lorincz, 2016 [256] HPV16-L1 UK-London 99 CIN2+ 39     0.69 
Mirabello, 2013 [348] HPV16-L1 Costa-Rica-Guanacaste 93 CIN2+ 57 91.1% 60.2% 78.4% 81.0% 0.82 
Qiu, 2015 [349] HPV16-L1 China-Zhengzhou 114 CIN2+ 72 91.7% 59.5% 79.5% 80.7% 0.978 
Lorincz, 2016 [256] HPV16-L2 UK-London 99 CIN2+ 39     0.69 
Bryant, 2015 [350] HPV16-L1/L2 UK-Cardiff 200 CIN2+ 145 61.9% 66.0% 82.8% 39.7%  
Bryant, 2015 [350] HPV16-L1/L2/E2 UK-Cardiff 200 CIN2+ 145 60.3% 61.7% 80.6% 37.1%  
           
CIN3/CIN3+           
Lorincz, 2016 [256] HPV16-L1 UK-London 99 CIN3+ 19     0.72 
Lorincz, 2016 [256] HPV16-L2 UK-London 99 CIN3+ 19     0.73 
Bryant, 2015 [350] HPV16-L1/L2 UK-Cardiff 200 CIN3+ 145 60.5% 70.3% 84.3% 40.3%  
Bryant, 2015 [350] HPV16-L1/L2/E2 UK-Cardiff 200 CIN3+ 145 60.5% 65.9% 82.4% 38.8%  
Brandsma, 2014 [346] HPV16-L1/L2/E2 Senegal-Dakar/USA-New Haven 33 CIN3 5 80.0% 75.0% 50.0% 80.0%  
 
           
PPV=Positive Predictive Value; NPV=Negative Predictive Value; AUC=Area under the operating receiving characteristic curve (not reported by all studies) 1 read from ROC curve  
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Appendix 14. Table of denominators for all analyses in Chapters 6, 7, 8, 9 and 10 
Outcome Analysis Obj. Chap. Table/fig Denominator  
(N women) 
Reason for exclusions 
Total BF SA 
STUDY 1: Epidemiology of HR-HPV and cervical lesions in WLHIV in BF and SA 
Population 
characteristics 
Description of study population at baseline n/a 6 Table 6.2 
Fig. 6.1 
1,238 615 623 No exclusions 
HR-HPV 
prevalence 
HR-HPV prevalence description 2.1 6 Table 6.2 1215 594 621 All women with genotyping data at baseline 
Risk factor analysis for HR-HPV prevalence 2.3 6 Table 6.5 1183 570 613 All women with genotyping data available; 32 
women who were ART-naive and with undetectable 
HIV-1 PVL were excluded from analysis 
HIV-related factors associated with HR-HPV 
prevalence 
2.4 7 Table 7.2 1183 570 613 As above 
CIN2+  
prevalence 
CIN2+ prevalence description 2.2 6 Table 6.2 1128 554 574 All women with histology data at baseline 
Risk factor analysis for CIN2+ prevalence 2.3 6 Table 6.9 1096 530 566 All women with histology data available; 32 women 
who were ART-naive and with undetectable HIV-1 
PVL were excluded from analysis 
HIV-related factors associated with CIN2+ prevalence 2.4 7 Table 7.6 1096 530 566 As above 
Population 
characteristics 
Description of study population at endline 2.1 6 Table 6.3 
Fig 6.1 
963 512 451 Women with ≤CIN1 at baseline who returned for 
endline visit 
HR-HPV 
incidence 
HR-HPV incidence description 2.1 6 Table 6.3 
Fig 6.1 
922 476 446 Women with ≤CIN1 at baseline with genotyping at 
baseline and endline at risk for acquiring any HR-
HPV (no woman was positive for ALL HR-HPV types) 
Risk factor analysis for HR-HPV incidence 2.3 6 Table 6.6 900 460 440 As above, but excluding 22 women who were ART-
naive and with undetectable HIV-1 PVL at baseline 
HIV-related factors associated with HR-HPV incidence 2.3 7 Table 7.3 900 460 440 As above 
HR-HPV 
persistence 
HR-HPV type-specific persistence description 2.1 6 Table 6.3 
Fig 6.1 
610 270 340 Women with ≤CIN1 and HR-HPV positive at baseline  
Risk factor analysis for HR-HPV persistence 2.3 6 Table 6.7 597 263 334 As above, but excluding 13 women who were ART-
naive and with undetectable HIV-1 PVL at baseline 
HIV-related factors associated with HR-HPV 
persistence 
2.4 7 Table 7.4 1002 404 598 Same number of women as above, but total number 
of infections was used as denominator 
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Outcome Analysis Obj. Chap. Table/fig Denominator  
(N women) 
Reason for exclusions 
Total BF SA 
HR-HPV 
complete 
clearance 
HR-HPV complete clearance description 2.1 6 Table 6.3 
Fig 6.1 
610 270 340 As above 
Risk factor analysis for HR-HPV complete clearance 2.3 6 Table 6.8 597 263 334 As above, but excluding 13 women who were ART-
naive and with undetectable HIV-1 PVL at baseline 
HIV-related factors associated with HR-HPV complete 
clearance 
2.4 7 Table 7.5 597 263 334 As above 
CN2+ Incidence Incidence of CIN2+ description 2.2 6 Table 6.3 
Fig 6.1 
809 430 379 Women with ≤CIN1 at baseline who returned for 
endline visit with histology data at both baseline 
and endline 
Risk factor analysis for CIN2+ incidence 2.3 6 Table 6.10 785 412 373 As above but excluding 24 women who were ART-
naive and with undetectable HIV-1 PVL at baseline 
HIV-related factors associated with CIN2+ incidence  2.4 7 Table 7.7 785 412 373 As above 
 
STUDY 2: HPV type-specific infection and serodynamics among WLHIV in Burkina Faso and South Africa   
HPV-type 
specific 
infection 
HPV genotype prevalence 3.1 8 Table 8.1 1215 594 621 All women with genotyping data at baseline 
The association of prevalent HPV genotypes with 
prevalent CIN2+ 
3.2 8 Figure 8.1 
Figure 8.2 
Figure 8.3 
Figure 8.4 
1119 546 573 All women with genotyping and histology data at 
baseline 
HPV type incidence  3.1 8 Table 8.1 922 476 446 Women with ≤CIN1 at baseline with genotyping at 
baseline and endline at risk for acquiring any HR-
HPV  
HPV type persistence 3.1 8 Table 8.1 610 270 340 Women with ≤CIN1 and HR-HPV positive at baseline  
HR-HPV type persistence associated with incidence 
CIN2/3 
3.2 8 Table 8.3 780 405 375 Women with ≤CIN1 at baseline who returned for 
endline visit with histology and genotyping data at 
both baseline and endline 
Association of HIV-related factors with HR-HPV type 
prevalence 
3.3 8 Table 8.4 
Table 8.5 
1183 570 613 All women with genotyping data available; 32 
women who were ART-naive and with undetectable 
HIV-1 PVL were excluded from analysis 
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Outcome Analysis Obj. Chap. Table/fig Denominator  
(N women) 
Reason for exclusions 
Total BF SA 
STUDY 2: HPV type-specific infection and serodynamics among WLHIV in Burkina Faso and South Africa   
HPV serology HPV seroprevalence description 3.4 9 Fig 9.2/9.3 604 - 604 All women enrolled in SA with matched genotyping 
and serology data at baseline 
Correlation of HPV DNA and serology at baseline 3.4 9 Table 9.1 604 - 604 As above 
Risk factors associated with HPV seroprevalence 3.4 9 Appendix 
(App.) 13 
600 - 600 As above, but excluding 4 women who were ART-
naive and with undetectable HIV-1 PVL at baseline 
HPV seroincidence description 3.5 9 Narrative 433 - 433 Women with ≤CIN1 at baseline who returned for 
endline visit and with genotyping and serology data 
at both baseline and endline 
Risk factors associated with HPV seroincidence, 
including HIV-related 
3.5 9 Not shown 425 - 425 As above, excluding 4 women who had 
seropositivity for all 15 types at baseline, and 4 
women who were ART-naive and with undetectable 
HIV-1 PVL at baseline 
HPV seroconversion description 3.5 9 Table 9.2 219 - 219 Women with ≤CIN1 at baseline who returned for 
endline visit ; who were HV DNA positive and same 
type seronegative at baseline 
Risk related factors associated with HPV 
seroconversion 
3.5 9 App.14 214 - 214 As above, excluding 4 women who were ART-naive 
and with undetectable HIV-1 PVL at baseline 
HIV related factors associated with HPV 
seroconversion 
3.5 9 Table 9.3 319 - 319 As above but using total baseline infections as 
denominators (319 baseline infections among 214 
women)  
Risk of type-specific re-infection following same-type 
seropositivity at baseline 
3.6 9 Table 9.4 433 - 433 Women with ≤CIN1 at baseline with genotyping and 
serology at baseline and endline at risk for acquiring 
any HR-HPV (no woman was positive for ALL HR-
HPV types) 
Risk of type-specific DNA persistence following same-
type seropositivity at baseline 
3.6 9 App.15 148 - 148 Women with ≤CIN1 at baseline with genotyping and 
serology at baseline and endline at risk and positive 
for any HPV at baseline – includes a total of 577 
infections 
Association of baseline seropositivity and 
seropositivity at endline with CIN2/3 incidence 
- 9 App.16 365  365 Women with ≤CIN1 at baseline with histology and 
serology at baseline and endline  
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Outcome Analysis Obj. Chap. Table/fig Denominator  
(N women) 
Reason for exclusions 
Total BF SA 
 
STUDY 3: Association of DNA methylation with prevalent and incident CIN2+ among WLHIV in Burkina Faso and South Africa 
DNA 
methylation 
Determining the association of DNA methylation of a 
human gene EPB41L3 with CIN2+ prevalence  
4.1 11 Fig 10.4, 
Table 10.4  
Table 10.5 
App. 17 
App. 18 
362 94 268 All CIN2+ cases at baseline matched 1:1 with ≤CIN1 in 
each country for EPB41L3 DNA methylation 
Evaluating the role of socio-demographic, behavioral 
and HIV-related factors on the EPB41L3 DNA 
methylation at enrolment 
4.2 11 Table 10.8 
App. 19 
App. 20 
360 94 266 As above excluding 2 ART-naïve women with 
undetectable HIV-1 PVL 
Determining the association of baseline and endline 
EPB41L3 DNA methylation with CIN2+ incidence  
4.1 11 Table 10.5 
Table 10.6 
185 57 128 All ≤CIN1 controls at baseline with histology and 
EPB41L3 DNA methylation at endline 
Monitoring the change in EPB41L3 DNA methylation 
levels over time among CIN2+ that progress vs. 
regress 
4.3 11 Table 10.7 36 - 36 All prevalent CIN2+ in SA that did not receive 
treatment by endline visit 
Determining the association of DNA methylation of a 
HPV16 L1 with CIN2+ prevalence  
4.1 11 App. 21 81 23 58 All HPV16-positive CIN2+ cases at baseline matched 
1:1 with HPV16-positive ≤CIN1 in each country  
   
367 
 
 
Appendix 15. Multivariate analysis of HPV seroprevalence among 600 WLHIV1 in South Africa: 
associations with baseline sociodemographic factors, behavioural factors, HIV-related factors, 
clinical symptoms/signs and STIs  
 
  
 
Univariate analysis 
  
Multivariate analysis 
  N n (%) PR (95%CI) p-value aPR (95%CI)* p-value 
Ever used injectable contraceptives 
  
    
  
Never 165 146 (88.5) 1   1 
 
Past 322 305 (94.7) 1.07  (1.01-1.14) 0.03 1.07  (1.01-1.13)      0.03 
Current 113 109 (94.5) 1.09  (1.02-1.16) 0.01 1.09  (1.03-1.16)        0.01 
   
    
  
ART status 
  
    
  
ART >2 years 224 216 (94.6) 1   1 
 
ART ≤2 years 174 164 (94.3) 0.98  (0.93-1.02)    0.32 0.98  (0.92-1.04)   0.412 
ART-naïve 202 180 (89.1) 0.92  (0.88-0.98)  0.004 0.98  (0.92-1.03)     0.412 
   
    
  
HIV-1 viral suppression 
  
    
  
<1000 copies/ml 342 331 (96.8) 1   1 
 
≥1000 copies/ml 258 229 (88.8)  0.92  (0.87-0.96)    <0.001 0.93  (0.87-0.99)   0.02 
   
    
  
CD4+ count (cells/mm3) 
  
   
  
>500 220 206 (93.6) 1   1 
 
351-500 181 174 (96.1) 1.03  (0.98-1.07)  0.25 1.03  (0.99-1.08)     0.17 
200-350 143 127 (88.8) 0.95  (0.89-1.01)     0.13  0.96  (0.90-1.03)  0.27 
<200 56 53 (94.6) 1.01  (0.94-1.09)     0.77 1.02  (0.95-1.10)   0.58 
Adjusted Prevalence Ratio (aPR); *All factors in table adjusted for each other; 14 women excluded from analysis as they were ART-
naïve but had detectable HIV-1 PVL 
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Appendix 16. HPV DNA persistence among 148 WLHIV, measured over 16 months follow-up, stratified by same type seropositivity at baseline 
                 All participants Seronegative at baseline Seropositive at baseline aOR (95%CI)2 Seropersistence at endline Seroreversion at endline 
  N1  n (%) N1 n (%) N1  n (%)   N1 n (%) N1 n (%) 
Any Alpha-9 HR-HPV types                  
HPV16 67 22 (32.8) 41 11 (26.8) 26 11 (42.3) 2.35 (0.74-7.75) 23 8 (34.8) 3 3 (100.0) 
HPV31 39 5 (12.8) 13 2 (15.4) 26 3 (11.5) 0.76 (0.10-5.76) 24 3 (12.5) 2 0 (0.0) 
HPV33 25 4 (16.0) 15 1 (6.7) 10 3 (30.0) 4.50 (0.25-80.57) 9 3 (33.3) 1 0 (0.0) 
HPV35 59 24 (40.7) 26 11 (42.3) 33 13 (39.4) 1.00 (0.34-2.95) 30 
12 
(40.0) 
3 1 (33.3) 
HPV52 106 38 (35.9) 63 21 (33.3) 43 17 (39.5) 1.49 (0.64-3.50) 39 16 (41.0) 4 1 (25.0) 
HPV58 29 11 (37.9) 12 4 (33.3) 17 7 (41.2) 1.35 (0.29-6.40) 15 7 (46.7) 2 0 (0.0) 
            
Any Alpha-7 HR-HPV types            
HPV18 66 22 (33.3) 41 14 (34.2) 25 8 (32.0) 0.94 (0.31-2.86) 18 6 (33.3) 7 2 (28.6) 
HPV39 36 8 (22.2) 19 2 (10.5) 17 6 (35.3) 4.75 (0.70-32.19) 10 3 (30.0) 7 3 (42.9) 
HPV45 30 11 (36.7) 25 8 (32.0) 5 3 (60.0) 2.00 (0.20-20.08) 1 0 (0.0) 4 3 (75.0) 
HPV59 9 2 (22.2) 4 1 (25.0) 5 1 (20.0) 0.77 (0.03-18.30) 3 0 (0.0) 2 1 (50.0) 
HPV68 21 4 (19.1) 13 3 (23.1) 8 1 (12.5) 0.16 (0.01-2.83) 8 1 (12.5) 0 0 (0.0) 
            
Other HPV types            
HPV56  37 9 (24.3) 26 4 (15.4) 11 5 (45.6) 12.79 (1.14-143.23) 8 5 (62.5) 3 0 (0.0) 
            
LR-HPV            
HPV6 23 2 (8.7) 13 0 (0.0) 10 2 (20.0) - 10 2 (20.0) 0 0 (0.0) 
HPV11 25 4 (16.0) 13 3 (23.1) 12 1 (8.3) 0.16 (0.09-2.91) 11 1 (9.1) 1 0 (0.0) 
HPV73 5 0 (0.0) 2 0 (0.0) 3 0 (0.0) - 3 0 (0.0) - - 
            
Any HPV type 577 166 (28.8) 326 85 (26.1) 251 81 (32.3)  212 67 (31.6) 39 14 (35.9) 
                        
1Denominator is total number of infections detected at baseline; 2adjusted Odds Ratio (OR) for DNA persistence among same-type seropositive vs. seronegative at baseline, adjusted for ART status at baseline 
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Appendix 17. Risk of incident CIN2+ according to HPV seropersistence over 16 months among 365 WLHIV in South Africa   
 
Seronegative at baseline Seropositive at baseline aOR (95%CI)1 
Seroreversion or 
seronegative at baseline 
Seropersistence aOR (95%CI)2 
 N n (%) N n (%)  N n (%) N n(%)  
Any Alpha-9 HR-HPV types      
 
    
HPV16 207 10 (4.8) 158 12 (7.6) 2.20 (0.88-5.49) 234 13 (5.6) 131 9 (6.9) 1.76 (0.69-4.48) 
HPV31 152 5 (3.3) 213 17 (8.0) 3.45 (1.19-10.07) 171 6 (3.5) 194 16 (8.3) 3.32 (1.21-9.11) 
HPV33 223 11 (4.9) 142 11 (7.8) 1.93 (0.79-4.73) 238 14 (5.9) 127 8 (6.3) 1.23 (0.49-3.08) 
HPV35 212 13 (6.1) 153 9 (5.9) 1.07 (0.43-2.67) 245 15 (6.1) 120 7 (5.8) 1.03 (0.39-2.71) 
HPV52 247 15 (6.1) 118 7 (5.9) 1.09 (0.42-2.85) 261 16 (6.1) 104 6 (5.8) 1.04 (0.38-2.85) 
HPV58 158 3 (1.9) 207 19 (9.2) 6.60 (1.85-23.51) 183 3 (3.3) 182 16 (8.8) 3.53 (1.30-9.58) 
 
     
 
    
Any Alpha-7 HR-HPV types      
 
    
HPV18 231 15 (6.5) 134 7 (5.2) 0.94 (0.36-2.47) 279 18 (6.5) 86 4 (4.7) 0.79 (0.25-2.49) 
HPV39 229 14 (6.1) 136 8 (5.9) 1.14 (0.45-2.85) 288 17 (5.9) 77 5 (6.5) 1.33 (0.46-3.88) 
HPV45 297 17 (5.7) 68 5 (7.4) 1.47 (0.50-4.27) 331 19 (5.7) 34 3 (8.8) 1.81 (0.49-6.74) 
HPV59 238 10 (4.2) 127 12 (9.5) 2.81 (1.14-6.91) 270 14 (5.2) 95 8 (8.4) 1.94 (0.77-4.91) 
HPV68 262 12 (4.6) 103 10 (9.7) 2.71 (1.09-6.77) 284 16 (5.6) 81 6 (7.4) 1.61 (0.58-4.50) 
 
     
 
    
Other HR-HPV types      
 
    
HPV56  247 9 (3.6) 118 13 (11.0) 3.79 (1.53-9.39) 274 10 (3.7) 91 12 (13.2) 4.58 (1.85-11.37) 
           
LR-HPV           
HPV6 213 15 (7.0) 152 7 (4.6) 0.75 (0.29-1.94) 238 18 (7.6) 127 4 (3.2) 0.49 (0.16-1.52) 
HPV11 236 14 (5.9) 129 8 (6.2) 1.31 (0.51-3.37) 255 14 (5.5) 110 8 (7.3) 1.81 (0.69-4.75) 
HPV73 277 17 (6.1) 88 5 (5.7) 1.17 (0.40-3.45) 301 20 (6.6) 64 2 (3.1) 0.55 (0.12-2.52) 
 
     
 
    
Any HPV 28 0 (0.0) 337 22 (6.5)  45 0 (0.0) 320 22 (6.9) - 
1adjusted Odds Ratio (OR) for CIN2/3 incidence among seropositive vs. seronegative at baseline; 2adjusted OR for CIN2/3 incidence among seropersistent vs. seroreverted or seronegative at baseline, adjusted 
for injectable contraception, cervicitis, ART status (associated with incident CIN2/3, Chapter 7) and same-type DNA detection at baseline
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Appendix 18. Multivariate risk factor analysis for ‘high’ methylation among 94 WLHIV in Burkina Faso 
  Low methylation High methylation aOR (95%CI) 
 N n (%) n (%)  
Education     
Primary or less 60 44 (73.3) 16 (26.7) 1 
More than primary 33 11 (33.3) 22 (66.7) 3.89 (1.20-12.62) 
     
Partner status     
Never married 11 3 (27.3) 8 (72.7) 1 
Divorced/separated/widowed 46 32 (69.6) 14 (30.4) 0.38 (0.04-3.34) 
Married/cohabiting 36 20 (55.6) 16 (44.4) 0.75 (0.09-6.06) 
     
CD4+ count (cells/mm3)     
350+ 63 41 (65.1) 22 (34.9) 1 
201-349 16 9 (56.3) 7 (43.8) 1.84 (0.45-7.48) 
≤200 15 5 (33.3) 10 (66.7) 8.29 (1.30-52.79) 
     
Candida albicans     
Negative 73 42 (57.5) 31 (42.5) 1 
Positive 13 11 (84.6) 2 (15.4) 0.08 (0.01-0.99) 
     
HR-HPV (by INNO-LiPA)     
Negative 16 12 (75.0) 4 (25.0) 1 
Positive 77 43 (55.8) 34 (44.2) 2.18 (0.39-12.11) 
     
CIN status     
<CIN1 34 24 (70.6) 10 (29.4) 1 
CIN1 32 21 (65.6) 11 (34.4) 0.75 (0.19-2.98) 
CIN2 17 7 (41.2) 10 (58.8) 1.14 (0.225.94) 
CIN3 11 3 (27.3) 8 (72.7) 2.94 (0.34-25.48) 
1adjusted Odds Ratio (aOR); adjusted for all covariates in table  
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Appendix 19. Multivariate risk factor analysis for ‘high’ methylation among 266 WLHIV* in 
South Africa 
  Low methylation High methylation aOR (95%CI) 
 N n(%) n(%)  
Education     
Less than complete secondary 145 70 (48.3) 75 (51.7) 1.00 
Minimum secondary 112 69 (61.6) 43 (38.4) 0.48 (0.21-1.10) 
     
Age at 1st pregnancy     
<20 years 135 67 (49.6) 68 (50.4) 1.00 
≥20 years 117 69 (59.0) 48 (41.0) 1.07 (0.46-2.51) 
     
ART status     
 >2 years 79 36 (45.6) 43 (54.4) 1.00 
 ≤2 years 83 40 (48.2) 43 (51.8) 0.26 (0.10-0.67) 
ART-naïve 104 67 (64.4) 37 (35.6) - 
     
ART adherence     
60-90% 138 69 (50.0) 69 (50.0) 1.00 
<60% 22 7 (31.8) 15 (68.2) 1.68 (0.48-5.89) 
     
HIV-1 Viral suppression      
≥1000 copies/ml 127 75 (59.1) 52 (40.9) 1.00 
<1000 copies 139 68 (48.9) 71 (51.1) 1.02 (0.33-3.14) 
     
CD4+ count (cells/mm3)     
>350 160 97 (60.6) 63 (39.4) 1.00 
201-349 73 35 (48.0) 38 (52.1) 1.66 (0.58-4.75) 
≤200 32 10 (31.3) 22 (68.8) 3.18 (0.95-10.69) 
     
Chlamydia trachomatis     
Negative 253 132 (52.2) 121 (47.8) 1.00 
Positive 13 11 (84.6) 2 (15.4) - 
     
Anogenital warts     
No 243 135 (55.6) 108 (44.4) 1.00 
Yes 23 8 (34.8) 15 (65.2) 1.55 (0.37-6.40) 
     
CIN status     
<CIN1 84 62 (73.8) 22 (26.2) 1.00 
CIN1 59 36 (61.0) 23 (39.0) 2.68 (0.94-7.64) 
CIN2 72 28 (38.9) 44 (61.1) 19.28 (5.47-68.03) 
CIN3 51 17 (33.3) 34 (66.7) 9.31 (2.77-31.29) 
*2  WLHIV  who were ART-naïve and with undetectable HIV-1 PVL were excluded from the analysis; adjusted Prevalence Ratio (aPR); 
adjusted for all covariates in table 
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Appendix 20. Median methylation levels (%) for HPV16 L1 among 23 HPV16 positive WLHIV in BF and 58 in SA, by CIN grade.  
 Burkina Faso South Africa Sites combined 
 N Median % (IQR) p1 N Median % (IQR) p1 N Median % (IQR) p1 
<CIN1 6 6.88 (2.65-22.5) Ref 14 9.95 (0.0-19.15) Ref 20 8.68 (0.78-20.83) Ref 
CIN1 9 7.20 (4.90-14.60) 0.77 14 9.28 (3.3-33.40) 0.50 23 8.40 (3.30-20.75) 0.59 
CIN2 3 3.75 (4.45-4.60) 0.30 14 5.28 (2.60-8.00) 0.64 17 4.95 (2.60-7.85) 0.44 
CIN3 5 39.90 (14.70-46.85) 0.20 16 7.83 (3.28-14.40) 0.97 21 8.90 (4.80-26.55) 0.44 
p-trend2   0.24   0.79   0.72 
1Mann-Whitney U test,  p-value for difference in median values of CIN2/3 relative to <CIN1;  
2Cuzick test for trend; p-value for trend in methylation levels by CIN grade  
 
